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Abstract 
 
 
  Weibel‐Palade bodies (WPBs) are large rod‐shaped secretory organelles found 
exclusively in endothelial cells. In response to the activation of the endothelium by chemical 
or mechanical stimulation they undergo regulated exocytosis and release their contents into 
the bloodstream. Their primary cargo proteins are the large pro‐thrombotic glycoprotein von 
Willebrand Factor (VWF) and the leukocyte adhesion receptor P‐selectin. Hence, the 
principal function of WPBs is to act as a storage compartment for molecular mediators of 
thrombosis and inflammation. It is known that the exocytosis of WPBs is induced by 
increasing levels of free Ca
2+
 ions in the cytosol. However, the molecular machinery which 
drives exocytosis is currently unclear. The aim of my PhD was to determine the identity of 
the Ca
2+
 sensor responsible for the regulation of WPB secretion and it is my hypothesis that 
this process is driven by one or more members of the synaptotagmin (SYT) family. SYTs are 
the most well-characterized family of calcium sensors and have established roles in mediating 
the Ca
2+
-driven exocytosis of large secretory organelles from a range of cell types. However 
the expression, subcellular distribution, and function of SYTs in endothelial cells remains 
largely unknown. Here, I show by RT-PCR and Western blotting that SYTs I, III, V, VI, VII, 
VIII, XI, and XVII are expressed in Human Umbilical Vein Endothelial Cells (HUVECs). 
Additionally, I constructed fluorescent fusion proteins of these endothelial-expressed SYTs 
and have demonstrated by over-expression that SYTs V, VII, VIII, and XVII are trafficked to 
the WPBs in HUVECs. The use of a novel dose-response assay has revealed that the up-
regulation of SYT VII modulates the calcium sensitivity of WPB exocytosis and thus this 
raises the intriging possibility that SYT VII may be a principle component of the Ca
2+
-
sensing complex on the organelle membrane.  
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Chapter One 
Introduction 
 
1.1 The Endothelial Cell: A Brief Introduction 
 
 1.1.1 Endothelial Cells are Heterogeneous Secretory Systems: 
 
 Endothelial cells line the vasculature and the lymphatic system and are essentially the 
gatekeepers between tissue and blood. These cells are highly-metabolically active secretory 
systems which play a pivotal role in the maintenance of healthy blood vessels. Under 
unstimulated, resting conditions endothelial cells promote vasodilatation and inhibit 
coagulation through the secretion of a wide range of vasoregulatory factors. However, once 
activated by injury or infection they become pro-thrombotic and promote vasoconstriction 
and inflammation. The dysregulation of the equilibrium between pro- and anti-thrombotic 
states contributes to the pathogenesis of many diseases which affect the vasculature including 
atherosclerosis, diabetes, and malaria (reviewed in Cines et al. 1998).  
Endothelial cells originate in the splanchnopleuric mesoderm from hemangioblasts 
which are also the precursors of hematopoietic cells (Choi et al. 1998). They constitute a 
highly heterogeneous population of cells which can be differentiated by their size, shape, 
secretory repertoire, solute permeability, and glycocalyx thickness (reviewed in Aird, 2007). 
The final phenotype of an endothelial cell is influenced by a number of factors such as its 
exposure to growth factors, cytokines, hormones, antibodies, microbes and is also modulated 
by local blood flow dynamics, interactions with surrounding smooth muscle cells, and the 
composition of the extracellular matrix (van Hinsbergh, 2012). Indeed, it is difficult to 
provide a precise definition of an endothelial cell as there are few phenotypic properties 
which are shared across the vasculature tree and which are unique to this cell type. Features 
which are generally considered to be universal such as the presence of the secretory 
organelles Weibel-Palade bodies are not common to all endothelial cells (Turner et al. 1985, 
Kumar et al. 1987). Additionally, the plasma membrane protein PECAM-1 is a commonly-
used endothelial marker but this molecule is not expressed by sinusoidal intrahepatic 
endothelial cells (Morin et al. 1984).  
The most obvious and fundamental function of endothelial cells is to provide a 
selectively-permeable barrier between the blood and underlying tissue. Therefore it is 
essential that these cells engage in both regulated exocytosis and endocytosis to allow the 
controlled uptake and release of material from both sides of the vasculature. Endothelial cells 
engage in the process of transcytosis whereby material is removed from the bloodstream by 
endocytosis and expelled into the basal lamina from the opposite pole of the cell through the 
process of regulated exocytosis (Simionescu et al. 2002). These transcytotic events occur 
through the formation of caveolae and vesiculo-vacuolar organelles (VVOs), two structures 
which are commonly seen features of endothelial cells but which are rare in most other cell 
types. Indeed, caveolae are more common than clathrin-coated pits in endothelial cells 
(Gratton et al. 2004). VVOs are aggregations of intracellular vesicles which are thought to 
result from fusion events between caveolae and which have been linked with the vascular 
leakage associated with tumour angiogenesis and allergic reactions (Pober and Sessa, 2007).  
In the skin venules, where endothelial cells are unusually long, VVOs consisting of over 100 
individual vesicles occupying 20% of the cytoplasm have been reported (Dvorak et al. 2001). 
Clearly, endothelial cells do not constitute an inert, metabolically inactive barrier but rather 
are specialized secretory cells responsible for regulating the constant movement of material 
between the bloodstream and tissues whilst maintaining the integrity of the vessel wall.  
 
1.1.2 The Primary Functions of Endothelial Cells:  
 
1.1.2.1 The Resting State: Vasodilation and Fibrinolysis 
   
 Endothelial cells are responsible for the maintenance of healthy, non-thrombogenic 
blood vessels through the secretion of a range of molecular mediators which act on platelets, 
leukocytes, and surrounding smooth muscle cells (reviewed in Cines et al. 1998). Firstly, 
when in the unperturbed resting state endothelial cells promote the dilation of blood vessels 
through the secretion of the eicosanoid prostacyclin (PGI2) (Egan and FitzGerald, 2006) and 
the gas nitric oxide (NO) (Moncada and Higgs, 2006), both of which act on smooth muscle 
cells to dilate the vessel. PGI2 and NO are released by endothelial cells following their 
exposure to agonists including ADP and thrombin or in response to physical stimulation such 
as exposure to shear stress (Pober and Sessa, 2007). NO inhibits platelet aggregation, 
adhesion, activation, and secretion and also inhibits leukocyte adhesion to the endothelium 
(Moncada and Higgs, 2006). The secretion of endothelium-derived hyperpolarizing factor 
(EDHF) results in smooth muscle relaxation and is released by endothelial cells in response 
to muscarinic agonists (Garland et al. 1995). 
 In addition to promoting vasodilation, endothelial cells are responsible for the 
maintenance of an anti-thrombotic environment which is essential for the prevention of 
potentially-fatal blood clots. The two most common fribrinolytic agents secreted by 
endothelial cells are tissue plasminogen activator (tPA) and urokinse-type plasminogen 
activator (uPa). The serine protease tPA is primarily expressed by microvascular endothelial 
cells and promotes the breakdown of blood clots by converting plasminogen to plasmin 
(Medcalf, 2007). Endothelial cells also secrete the t-PA inhibitor PAI-I (plasminogen 
activator inhibitor), thus providing a negative-feedback mechanism which prevents excessive 
fibrinolysis (van Hinsbergh, 2012). uPA is expressed by endothelial cells which are involved 
in tissue repair following injury and aids the breakdown of plasminogen (Bacharach et al. 
1992). The uPA knock-out mouse develops inflammation-induced thrombi and when exposed 
to LPS suffers thrombosis and tissue damage due to unchecked coagulation and inflammation 
(Carmeliet et al. 1994, Yamamoto et al. 1996). 
Endothelial cells secrete thrombomodulin which binds to thrombin, resulting in the 
activation of the anti-coagulant protein C (Pober and Sessa, 2007).  The 
thrombin:thrombomodulin complex is then internalized and destroyed (Esmon et al. 1993). 
Cytokine exposure decreases the expression of thrombomodulin and encourages its 
internalization, thus converting endothelial cells from the resting, anti-thrombotic state to an 
activated pro-thrombotic one (Mantovani et al. 1997). Lastly, in response to heparin 
stimulation endothelial cells secrete tissue factor pathway inhibitor (TFPI) which binds to 
factor Xa and thereby inhibits coagulation (van Hinsbergh, 2001). Thus, in order to maintain 
an anti-thrombotic, anti-inflammatory environment endothelial cells secrete a range of 
molecules including those which directly degrade and remove fibrin clots (thrombomodulin, 
tPA, uPA, TFPI), those which relax smooth muscle cells (PGI2, EDHF, NO), and those which 
act on platelets and leukocytes to prevent their activation (NO). The actions of these 
substances are summarized in Figure 1.1. 
 
1.1.2.2 The Activated State: Vasoconstriction and Coagulation 
 
 Following their activation by injury or inflammation endothelial cells alter their 
secretory repertoire to promote vasoconstriction and coagulation at the expense of 
vasodilation and fibrinolysis. Firstly, vasoconstriction is achieved by the release of the 21-
residue protein endothelin-1 (ET-1) following endothelial activation by molecular mediators 
such as thrombin, histamine, and adrenaline (Levin, 1996). ET-1 binds to ET-A receptors on 
smooth muscle cells, resulting in a signalling cascade which ultimately raises cytosolic Ca
2+
 
levels and induces vessel constriction (Simonson and Dunn, 1990). The consequences of ET-
A activation are long-lasting and Ca
2+
 levels only return to baseline following smooth muscle 
cell exposure to counteracting signals such as NO and PGI2 secreted by surrounding 
endothelial cells. Therefore, a delicate balance exists between vasodilatation and 
vasoconstriction and the dysregulation of this equilibrium has clinical implications. For 
example, in patients suffering from atherosclerosis the level of secreted NO is lower than 
normal whereas ET-1 levels are abnormally high (Hansson and Libby, 2006). This suggests 
that the regulation of vascular tonicity is disrupted in these patients, resulting in smooth 
muscle proliferation and contraction which ultimately contribute to the development of 
atherosclerotic plaques.  
 Endothelial cells secrete the vasoregulatory agent platelet activating factor (PAF) 
following thrombin or histamine exposure (Whatley and Zimmerman, 1996). PAF is a cell-
surface endothelial phospholipid which acts by binding to G-protein-linked receptors on 
leukocytes, resulting in juxtacrine signalling between the two cell types which ultimately 
induces leukocyte extravasation to underlying tissue (Lorant et al. 1991). Like ET-1, PAF is 
not stored within resting endothelial cells but instead is synthesized following their 
activation. PAF can also induce vasodilation and the exact consequences of its synthesis 
depend on its concentration in the endothelial cell membrane (Campbell et al. 1996).  
 In addition to inducing vasoconstriction endothelial cells protect against injury by 
driving thrombosis. The expression of Tissue Factor following endothelial activation by, for 
example, thrombin, cytokines, endotoxin, or hypoxic conditions is fundamental in bringing 
about the pro-thrombotic state (Pober and Sessa, 2007). Tissue Factor induces the activation 
of factors X and IX through an interaction with Factor VIIa (Drake et al. 1989) and its  
importance is demonstrated by mice lacking this protein which show increased ferric 
chloride-induced arterial thrombosis (White et al. 2010). Additionally, the up-regulation of 
Tissue Factor has clinical importance as its expression is seen in endothelial cells lining 
atherosclerotic plaques and in blood vessels surrounding tumors (van Hinsbergh, 2012). 
As well as being involved in vasoregulation PAF also acts as a pro-coagulant 
molecule by inducing both platelet adhesion to the vessel wall and the formation of fibrin 
clots. The mechanism behind PAF’s action is complex and poorly understood but ultimately 
it induces the expression of platelet-binding adhesion molecules on the endothelium, the 
increased secretion of Tissue Factor, and the release of the pro-thrombotic protein von 
Willebrand Factor (VWF) from Weibel-Palade bodies (reviewed in Cines et al. 1998).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Endothelial cells secrete a range of molecular mediators.  
Endothelial cells in the resting state induce vasodilation and fibrinolysis. Once activated by 
injury or infection they induce vasoconstriction and coagulation. The ability of an endothelial 
cell to influence vascular tonicity and the coagulatory state depends on the regulated secretion of 
a range of molecular mediators, as shown. Note that this is by no means an exhaustive list of the 
molecules secreted by endothelial cells.  
 Lastly, endothelial cells secrete the highly-thrombogenic serine protease thrombin 
which results in the activation of platelets and the coagulation cascade. Thrombin binds to the 
well-characterized G-protein-linked PAR (Protease-Activated Receptor) proteins on platelets 
and endothelial cells (Woolkanis et al. 1995). Following thrombin binding, an N-terminal 
fragment of the receptor is cleaved resulting in the generation of signalling pathways which 
ultimately induce the expression of intercellular adhesion proteins and Tissue Factor 
(Kanthou and Benzakour, 1995). Thus, following their activation by inflammation or injury 
endothelial cells adopt a strongly pro-thrombotic and vasoconstrictive state. The molecules 
which drive these processes are summarized in Figure 1.1. 
 
1.1.3 The Role of Endothelial Cells in Inflammation and Disease: 
 
Following the activation of the immune system by injury or invasion endothelial cells 
contribute to the inflammatory state through interactions with circulating leukocytes. Firstly, 
in response to cytokine or LPS exposure endothelial cells express a variety of adhesion 
molecules which bind to complementary proteins on circulating leukocytes to induce their 
migration to underlying tissue through the process of extravasation (reviewed in Cines et al. 
1998, Wagner and Frenette, 2008). Extravasation can be considered as a series of steps which 
are illustrated in Figure 1.2. Initially, a reversible attachment is formed between the leukocyte 
and the endothelium, mediated in part by the endothelial protein P-selectin which binds to 
Glycoprotein Ligand 1 (PSGL‐1) on leukocytes.  This initial interaction is weak and so the 
surrounding blood flow drives the rolling of the leukocyte along the vessel wall. As the 
inflammatory state increases, both endothelial cells and leukocytes become activated and this 
is assisted by the secretion of PAF which induces the up-regulation of the β2 integrins LFA 
(Leukocyte Function-associated Antigen-1) and MAC-1 (Macrophage-1) on leukocytes (Huo 
et al. 2000). Activation also induces the expression of VCAMs (Vascular Cell Adhesion 
Molecules), ICAMs (Intercellular Adhesion Molecules) and E-selectin on endothelial cells 
which bind with high-affinity to their complementary partners on leukocytes (Sumpio et al. 
2002). This strong interaction causes the firm attachment of the leukocyte to the vessel wall 
and allows its ultimate extravasation. The precise molecular mechanisms controlling 
leukocyte extravasation to underlying tissues are poorly understood but are thought to depend 
on a chemokine gradient, β2 integrin and myosin light chain kinase activation, and the 
activity of the transmembrane proteins PECAM-1, CD99, and Junctional Adhesion Molecule 
(JAM)-A (Schenkel et al. 2002, Aird, 2012, Dejana, 2004).  
  
 
 
 
 
 
 
 
 
 
Endothelial cells are immunocompetent in that they express MHC markers and 
present antigens to T-cells in peripheral tissues (Pober et al. 1996). Most endothelial cells, 
including those grown in culture, express MHC class I molecules and IFN-γ exposure induces 
the expression of MHC class II molecules (Shiao et al 2005). Thus, endothelial cells play a 
direct role in cell-mediated immunity. Additionally, T-cells express CD40 ligand which binds 
to CD40 on endothelial cells, inducing the expression and secretion of mediators of 
vasoconstriction, chemokines, and adhesion proteins (van Hinsbergh, 2012). 
Endothelial cells which are exposed to cytokines for an extended period of time 
drastically alter their phenotype and can in some circumstances suffer adverse effects. Within 
a few hours of continuous cytokine exposure, the intercellular junctions between 
neighbouring endothelial cells disassemble to induce maximum lymphocyte extravasation 
(Frangogiannis, 2006). Ultimately very long-term exposure to inflammatory stimuli as is 
experienced during chronic disease results in the induction of endothelial cell proliferation 
and angiogenesis (Pober and Sessa, 2007). These processes occur over a period of months 
Figure 1.2. Endothelial cells mediate leukocyte extravasation. 
Endothelial cells regulate the migration of leukocytes from the bloodstream to underlying 
tissues (extravasation) through the expression of a range of adhesion proteins which bind 
to complementary ligands on leukocytes. Extravasation can be considered as a series of 
steps requiring the tethering, rolling, activation, adhesion, and migration of leukocytes. 
Each step is regulated by the expression of a unique set of adhesion molecules on both the 
endothelial cells and leukocytes.  
Figure taken from Cines et al. 1998 with permission from Blood journal. 
and, in some cases, years. Organ transplantation, atherosclerosis, and cancer are examples of 
conditions which can lead to serious damage of the endothelium as over-stimulated T-cells 
attack and destroy endothelial cells (Cines et al. 1998, Jutte et al. 1996, Taflin et al. 2011). 
Indeed LAK (Lymphokine-Activated Killer) cells may be responsible for vascular leak 
syndrome which is often seen in cancer patients undergoing IL-2 and LAK therapy (Damle et 
al. 1987).  
 A detailed discussion of the relationship between the endothelium and disease 
progression is beyond the scope of this thesis. However, it is clear that endothelial cells play a 
fundamental role in the maintenance of the healthy vasculature and are heavily involved in 
tissue repair, coagulation, and the inflammatory response. It is therefore essential that we 
develop a complete understanding of their biology as the dysregulation of endothelial activity 
contributes to the pathology of a number of diseases including diabetes, sickle-cell anemia, 
atherosclerosis, malaria, and the thrombotic disorders Thrombotic Thrombocytopenic 
Purpura (TTP) and Hemolytic Uremmic Syndrome (HUS) (reviewed in Cines et al. 1998). 
Endothelial cells also play a key role in the biology of transplant rejection and tumor-induced 
angiogenesis (van Hinsbergh, 2012, Taflin et al. 2011).  
 
1.1.4 Endothelial Cells in Culture: 
 
 Endothelial cells were first successfully grown in culture in the 1970s and have a 
characteristic ‘cobblestone’ morphology when viewed through a light microscope (Gimbrone 
et al. 1974). They are typically grown in confluent monolayers although they can form 
vessel-like tubes when cultured in fibrin or collagen gels in the presence of the appropriate 
growth hormones (Mueller-Klieser, 1997). Additionally, when cultured cells are exposed to 
perfusion systems aiming to mimic the bloodstream they adopt an elongated shape orientated 
in the direction of flow (Bachetti and Morbidelli, 2000, Wagner and Frenette, 2008). Hence, 
although endothelial cells are typically grown in single inert monolayers it is possible to 
create vessel-like environments with the aim to approximate the conditions experienced by 
endothelial cells in vivo.  
Human Umbilical Vein Endothelial Cells (HUVECs) are considered to be model 
endothelial cells because they show features common to most of the vasculature and are 
readily available. As their name suggests, HUVECs are derived from the human umbilical 
vein by collagenase treatment which isolates individual cells from the basal lamina 
(Gimbrone et al. 1974). This approach is efficient and results in little contamination from 
non-endothelial cells. Other possible isolation methods include vessel mincing and enzymatic 
digestion or physically disrupting cells by scraping from the vessel wall (Gospodarowicz et 
al. 1976, Schelling et al. 1988). In both cases endothelial cells must be purified by cell 
sorting with endothelial-specific antibodies and the yield is generally lower than that 
achieved following collagenase digestion (Bachetti and Morbidelli, 2000). 
 The major difficulty with using cultured cells as a model for the endothelium is that 
endothelial cells in vivo replicate at a rate of 0.1% per day whereas in culture this increases to 
1-10% per day (Bachetti and Morbidelli, 2000). Although this might be considered a 
hindrance when studying the function of healthy cells it is beneficial when examining the 
mechanisms of wound healing and cancer development as this rapid rate of division mimics 
the phenotype shown by endothelial cells mediating tissue repair and angiogenesis. An 
additional consideration when culturing endothelial cells is that functions specific to certain 
parts of the vasculature will be lost over time (Aird 2012, Burridge and Friedman 2010) and 
for this reason cultured cells are generally derived from primary sources and rarely used 
above passage 6 or 7. Finally, endothelial cells are a highly heterogeneous population and 
therefore observations made from cells derived from one source cannot be assumed to be 
valid for all endothelial cell types. Although it is necessary to be aware of the inherent 
limitations with using cultured endothelial cells as a model system, the ability to grow cells in 
vitro has proved invaluable to our understanding of endothelial cell biology.  
   
1.2 Regulated Exocytosis and the Molecular Mediators of Secretion: 
 
 1.2.1 An Overview of Regulated Exocytosis: 
 
 Proteins destined for secretion to the extracellular milieu are first synthesized in the 
endoplasmic reticulum and then transported to the Golgi apparatus where they are modified 
by glycosylation and sulfation. In the trans Golgi network (TGN), secretory proteins are 
packaged into vesicles which are then directed to either the constitutive or regulated secretory 
pathway. The constitutive pathway mediates the stimulus-independent release of material 
whereas vesicles secreted by the regulated pathway are held at the plasma membrane until an 
appropriate signal induces their temporally-controlled and highly-ordered release. In both 
cases, once vesicles have undergone exocytosis their membranes are internalized by 
endocytosis in order to maintain a constant cell surface area and allow the recycling of 
membrane proteins.  
 Regulated exocytosis is a tightly-controlled process which can be considered as a 
series of steps (reviewed in Gerber and Sudhof, 2002). Firstly, secretory vesicles are recruited 
to and tethered at the plasma membrane. These vesicles are then primed for fusion, thus 
creating what is called the ‘readily-releasable pool’ (RRP). Lastly, fusion is induced by a 
specific stimulus which is usually the influx of Ca
2+
 ions into the cytosol and the contents of 
the granules are expelled by exocytosis.  
 
1.2.2 The Fusion Pore: 
 
 The defining step in the initiation of fusion between two membranes is the formation 
of the fusion pore. This structure is a narrow fluid-filled channel formed by the mixing of the 
two outer leaflets of opposing membranes (reviewed in Jackson and Chapman, 2008). It 
functions to provide a physical connection between two structures which are on the cusp of 
undergoing fusion such as a secretory vesicle and the plasma membrane and its formation 
represents the final crucial step in the pathway of regulated exocytosis. Although the exact 
structure of the fusion pore is currently unclear it is most likely formed following the Ca
2+
-
induced oligomerization of proteins which mediate the final stage of exocytosis (the fusion 
apparatus, see 1.2.3 The Molecular Mediators of Regulated Exocytosis). Indeed, in PC12 
cells mutations which introduce bulky tryptophan residues into the transmembrane α-helix of 
the t-SNARE syntaxin result in reduced pore sizes (Han et al. 2004). Based on this study it 
has been predicted that between five and eight syntaxin transmembrane domains line the wall 
of the fusion pore and determine its physical structure.  
 The formation of the fusion pore (also called hemifusion) is a reversible process. A 
fusing granule can undergo full fusion and release its contents into the opposing lumen or 
alternatively the fusion pore can collapse and the membranes re-seal. This process is now 
referred to as ‘kiss-and-run’ and was first described following capacitance measurements of 
degranulating rat peritoneal mast cells (Fernandez et al. 1984). Kiss-and-run events result in 
the secretory vesicle remaining intact with larger proteins sequestered inside but during the 
time when the pore is open smaller molecules can escape and hence a degree of exocytosis 
does occur through a size-exclusion mechanism (Fulop et al. 2005). Additionally, kiss-and-
run events at the synapse may regulate the kinetics and amplitude of the synaptic current and 
hence function to fine-tune synaptic transmission (He et al. 2006). 
 
 1.2.3 The Molecular Mediators of Regulated Exocytosis: 
  1.2.3.1 SNAREs: 
 
 The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) 
proteins constitute a family of 36 members in mammals and are defined by a 60-70 residue 
coiled-coil SNARE motif (reviewed in Jahn and Scheller, 2006, Sudhof and Rothman, 2009, 
Kreyet and Sollner, 2008, Jahn and Fasshauer, 2012). SNAREs function to physically tether 
vesicles together as their coiled-coil motifs spontaneously form an extremely stable four-
helix structure called the SNAREpin or trans-SNARE complex. The formation of this 
SNAREpin likely provides the energy needed to force opposing membranes together and 
thereby promotes fusion pore formation.  
For fusion events which occur at the plasma membrane the SNAREpin is made up of 
two plasma-membrane SNAREs (t-SNAREs) and one vesicular SNARE (v-SNARE). There 
are two classes of t-SNAREs: the syntaxins and SNAP-25 (synaptosomal-associated protein 
of relative molecular mass 25 kDa). Syntaxins contain a C-terminal SNARE motif, a 
transmembrane domain, and an N-terminal sequence which folds to form a three-helix 
structure known as the Habc domain (Fernandez et al. 1998). This domain is inhibitory and 
when not in a complex with SNAP-25 folds back onto syntaxin and blocks the SNARE motif 
(Nicholson et al. 1998).  Hence, syntaxin can exist in either an open or closed conformation 
depending on the position of the Habc domain. SNAP-25 is not a transmembrane protein but 
instead is tethered to the membrane by multiple palmitoylated cysteine residues (Oyler et al. 
1989). This protein contains two SNARE motifs connected by a linker region and hence 
contributes two coiled-coils to the SNAREpin. It is thought that, in the plasma membrane, 
syntaxin and SNAP-25 form a complex which functions as the receptor for the v-SNARE of 
which there is only one class, the VAMPs (vesicle-associated membrane proteins, also called 
synaptobrevins) (Sutton et al. 1998). 
The accepted model of SNARE function states that when opposing SNAREs are in 
close proximity they form the SNAREpin complex which consists of two SNARE motifs 
from a SNAP-25 molecule and one each from syntaxin and VAMP. The spontaneous 
formation of this complex forces the membranes together and provides the activation energy 
necessary for membrane fusion. Additionally, as has been discussed (see 1.2.2 The Fusion 
Pore) the syntaxins may be essential for the formation of the fusion pore. However, other 
proteins are required for fast secretory events, and it is likely that SNAREs and members of 
the synaptotagmin family (see below) function cooperatively to induce membrane merging 
during fusion. 
Lastly, NSF (N-ethylmaleimide-sensitive factor) is a highly-conserved hexameric 
ATPase which binds to SNARE complexes post-fusion via the adaptor protein SNAP (no 
relation to SNAP-25) (Sollner et al. 1993). This protein is an essential component of the 
fusion apparatus and functions to recycle SNAREs following membrane fusion by 
dismantling the cis-SNARE (post-fusion) complex through repeated cycles of ATP 
hydrolysis (Jahn and Scheller, 2006). 
 
1.2.3.2 Sec1/munc18-like Proteins: 
 
 Sec1/munc18-like (SM) proteins are small (60-70 kDa) arch-shaped cytosolic proteins 
which interact with SNARE proteins and have been shown to have a fundamental and 
increasingly diverse role in the regulation of exocytosis (Jahn and Scheller, 2006, Kreye and 
Sollner, 2008). There are 7 members of the SM protein family in humans and the most well-
characterized member to-date is Munc18-1 (Kreye and Sollner, 2008). It was originally 
believed that Munc18-1 acts as an inhibitor of exocytosis by binding to the N-terminal Habc 
domain of syntaxin and stabilizing its ‘closed’ conformation (Misura et al. 2000). Although 
this mechanism of action of Munc18-1 is still largely accepted it is now known that SM 
proteins also bind to the trans-SNARE complex, again via the N-terminal region of syntaxin, 
and are likely to be involved in SNARE priming prior to fusion (Dulubova et al 2002, Shen et 
al. 2007). Indeed, SM proteins are absolutely required for fusion to proceed as the ablation of 
Munc18-1 completely blocks synaptic exocytosis (Verhage et al. 2000). Thus SM proteins 
have been proposed to act as catalysts for SNAREs by stabilizing the trans-SNARE complex 
and may be involved in determining the spatial and temporal organization of fusion (Sudhof 
and Rothman, 2009, Jahn and Fasshauer, 2012).  
In addition to their roles as both inhibitors and activators of fusion, SM proteins have 
been shown to have a number of accessory functions essential for vesicle exocytosis. Firstly, 
SM proteins mediate the specificity of SNARE pairings as their inclusion in liposome fusion 
assays decreases the extent of promiscuity among SNARE binding partners (Shen et al. 
2007). SM proteins also act as chaperones for syntaxin as it traverses through the secretory 
pathway by protecting it from degradation (Braun and Jentsch, 2007) and inhibiting the 
formation of inappropriate SNARE complexes (Bryant and James, 2001). Lastly, SM proteins 
are likely to be involved in vesicle docking, as shown by the observation that mouse 
chromaffin cells deficient in Munc18-1 show an increased number of undocked vesicles 
(Voets et al. 2001). This function of SM proteins may be achieved through their ability to 
interact directly with Rab tethering complexes (see later) at the plasma membrane (van 
Weering et al. 2007). 
 Munc13 is not strictly an SM protein but instead belongs to the CATCHR protein 
family (Jahn and Fasshauer, 2012). However, this protein acts synergistically with Munc18-1 
by displacing it from syntaxin, thus allowing the t-SNARE to adopt the ‘open’ conformation 
and the initiation of fusion (Richmond et al. 2001, Ma et al. 2011). The Munc13-deficient 
mouse shows impaired spontaneous and evoked fusion with a notable reduction in the size of 
the RRP (Augustin et al. 1999, Varoqueaux et al. 2002). Lastly, the CAPS (Ca
2+
-dependent 
activator protein for secretion) family shows sequence homology to Munc13 proteins (Walent 
et al. 1992). These molecules are thought to be involved in vesicle priming and convert 
syntaxin to its open conformation via an interaction with PIP2 and Ca
2+
 ions (Grishanin et al. 
2004). 
 
 1.2.3.3 Complexins: 
 
Complexins are small 15-kDa helical proteins which associate with partially-
assembled SNARE complexes (Jahn and Scheller, 2006, Chen et al. 2002). Their primary 
function is to act as a ‘fusion-clamp’ through the insertion of a central α-helix into the trans-
SNARE complex, an interaction which impairs full SNAREpin formation (Giraudo et al. 
2009, Chen et al. 2002). Indeed, complexin-deficient synapses show increased spontaneous 
synaptic fusion events (Maximov et al. 2009). The activity of complexin results in the 
generation of a pool of vesicles which are docked, primed, and on the verge of undergoing 
full fusion. Increasing Ca
2+
 levels in the cytosol results in the displacement of complexin 
from the trans-SNARE complex by the pro-fusogenic protein synaptotagmin (see below) and 
the initiation of exocytosis (Fernandez-Chacon et al. 2001, Sudhof and Rothman, 2009). 
Interestingly, complexin may be involved in priming the trans-SNARE complex in addition 
to its role as an inhibitor of fusion as complexin-deficient neurons show a loss of Ca
2+
-
mediated synchronous exocytosis (Reim et al. 2001). Thus, these proteins are likely to have 
dual functions as both activators and inhibitors of regulated exocytosis.  
 
  1.2.3.4 The Rab Family: 
 
 Rab proteins are monomeric GTPases of the Ras superfamily which play an essential 
role in all aspects of regulated exocytosis including vesicle budding, trafficking, docking, 
priming, and fusion (reviewed in Fukuda, 2008). They are GTP-binding proteins which cycle 
between an active GTP-bound state and an inactive GDP-bound state. In mammalian cells, 
Rab proteins constitute a family of more than 60 members (Bock et al. 2001). However, the 
role of individual Rabs is relatively specific and most show a limited subcellular distribution. 
For example, Rabs 5 and 21 are endosomal proteins whereas Rabs 1 and 2 can be found as 
components of the Golgi apparatus (Fukuda, 2008). The Rab27 family consists of Rab27a 
and Rab27b and these two isoforms have particular importance in regulated exocytosis as 
they play general roles in mediating the fusion of secretory vesicles (Tolmachova et al. 2007, 
Mizuno et al. 2007, Munafo et al. 2007). These proteins are found on a range of secretory 
granules and Rab27 
-/-
 animals show a variety of secretory defects (Menasche et al. 2000, 
Wilson et al. 2000). It is now known that the primary purpose of Rab27 proteins is to regulate 
the docking of secretory vesicles at the plasma membrane (Tsuboi and Fukuda, 2006). They 
may also function to regulate the size and shape of vesicles as the number of dense granules 
in platelets derived from Rab27b 
-/-
 mice is diminished compared with those from wild-type 
mice (Tolmachova et al. 2007).  
 Rab proteins regulate vesicle trafficking and fusion via a large family of effector 
proteins which are characterized by the presence of a Rab-binding domain (RBD) at their N-
terminus (Fukuda, 2008). Effector proteins generally function to provide a physical link 
between vesicle-associated Rabs and molecules found on target structures such as SNAREs, 
phospholipids, and components of the cytoskeleton. Examples of Rab effectors include the 
synaptotagmin-like proteins 1-5 (Slps 1-5), rabphilin, Noc2, Munc13-4, and Rim (Fukuda, 
2008) and indeed the effector proteins for Rab27 (Slp2-a, Slp4-a/granuphilin-a, and 
rabphilin) are known to mediate the tethering of secretory vesicles to the plasma membrane in 
neuroendocrine and gastric surface mucous cells (Gomi et al. 2005, Saegusa et al. 2006). In 
some cases, additional tethering proteins consisting of large complexes or coiled-coil 
structures connect Rab effectors with components of the SNARE apparatus, and the classic 
example of this is the yeast exocyst complex (Whyte and Munro, 2001). Lastly, the activation 
state of the Rabs is governed by a further set of proteins, the GEFs (guanine nucleotide 
exchange factor) and GAPs (GTPase activating protein), although little is known concerning 
the tissue distribution and activity of these enzymes (Fukuda, 2008).  
 
1.2.3.5 The Core Complex in the Regulation of Exocytosis: 
 
The process of regulated exocytosis is orchestrated by the coordinated action of a 
number of protein families including the SNAREs, SM proteins, complexins, and Rabs. 
Indeed, the precise repertoire of these proteins which are expressed by a cell determines its 
specific secretory properties. The ‘core’ complex required for the final stage of vesicle fusion 
at the plasma membrane is thought to consist of v- and t-SNAREs, complexins, and SM 
proteins. The Rabs generally play a pre-fusion role in either vesicle trafficking or docking. A 
model depicting how the components of the core complex interact to mediate the final stages 
of regulated exocytosis is shown in Figure 1.3. Note that, in addition to the proteins described 
thus far, Ca
2+
-mediated exocytosis also requires a calcium sensor which is generally a 
member of the SYT family. 
 
1.2.3.6 Molecular Mediators of Regulated Exocytosis in Endothelial Cells: 
 
 SNARE proteins and their binding partners will undoubtedly play a fundamental role 
in mediating vesicle trafficking and regulated exocytosis in endothelial cells as they do in all 
other eukaryotic cell types.  However, the identity of the SNAREs, SM proteins, complexins, 
and Rabs which are expressed in endothelial cells is currently unclear. It is known that the 
Golgi/endosomal t-SNARE syntaxin-6 plays a crucial role in endothelial cell biology as its 
inhibition disrupts both cell migration and angiogenesis through the impaired trafficking of 
two essential signaling molecules, integrin α5β1 and vascular endothelial growth factor 
receptor 2 (VEGF2) (Tiwani et al. 2011, Manickan et al. 2011). Equally, it has been shown 
that the process of caveolae formation is regulated by the v-SNARE VAMP2 (McIntosh and 
Schnitzer, 1999) and caveolae fusion with the basolateral membrane is regulated by the t-
SNAREs syntaxin-4 and SNAP-23 (Preduscu et al. 2005). Lastly, the exocytosis of 
lysosomes following death receptor activation in aortic endothelial cells is regulated by 
syntaxin-4 and VAMP2 (Han et al. 2011), whereas the process of WPB exocytosis is 
mediated by a complex consisting of syntaxin-4, VAMP3, and SNAP-23 (Pulido et al. 2011). 
 Although our knowledge concerning the roles of individual SNAREs in the 
endothelium is becoming more detailed there is still very little known regarding the 
expression and function of the SNARE-binding partners, SM proteins and complexins, in 
endothelial cells. Thus far, it has been reported that Munc18c is expressed in human lung 
microvascular endothelial cells (Fu et al. 2005) and Munc13-4 is expressed in HUVECs 
(Zografou et al. 2012). Both proteins are known to play an as-yet unclear role in the  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. A core complex of proteins regulates exocytosis 
A likely model explaining the action of the core complex in regulated exocytosis at the plasma 
membrane is shown. In resting cells, the plasma membrane-associated SNARE syntaxin is 
found in a ‘closed’ complex with Munc18-1. Following cell stimulation, Munc18-1 dissociates 
from syntaxin, allowing it to adopt the ‘open’ state and bind to SNAP-25. Following the 
docking of VAMP-containing vesicles at the plasma membrane a SNAREpin is formed by the 
binding of the syntaxin:SNAP-25 complex to the v-SNARE VAMP (synaptobrevin). This is 
thought to pull the opposing membranes together and may provide the activation energy 
required to drive fusion pore formation. Following fusion, NSF and its adaptor protein SNAP 
dissociate the cis-SNARE complex, allowing all components to be recycled for future events.  
 
Taken from Gerber and Sudhof, 2002.  
Copyright 2002 American Diabetes Association  
From Diabetes®, Vol. 51, 2002; S12-S18  
Reprinted by permission of The American Diabetes Association. 
regulation of WPB exocytosis (see 1.5.3.3 The Fusion Apparatus Mediating WPB 
Exocytosis).  
Considering the central importance of the Rab family in eukaryotic cell biology as 
well as its size and diversity it stands to reason that these proteins are widely expressed in the 
endothelium. As expected, endothelial cells express a range of Rab family members and 
indeed the plasma membrane/early endosome protein Rab5b was initially identified and 
characterized in HUVECs (Wilson and Wilson, 1992). An early study determined that Rabs 
2, 4b, 7, 9, 15, and 30 are expressed in HUVECs (de Leeuw et al. 1998) and functions have 
slowly been assigned to each of these endothelial-expressed Rabs. It is known that Rab5a and 
Rab7a function synergistically to mediate VEGFR2 trafficking and degradation (Jopling et al. 
2009). Additionally, Rab5a and Rab11 have been shown to play a role in the internalization 
and trafficking of Factor VIII in HUVECs (Nayak et al. 2013). Lastly, a recent study has 
shown that Rabs 3, 27, 15, 30, and 37 associate with WPBs in HUVECs, and the central role 
of Rab27a in mediating WPB trafficking is well-established (Bierings et al. 2012, Pulido et 
al. 2011, Nightingale et al. 2009).  
 
1.3 The Synaptotagmins:  
 
 1.3.1 An Overview of the SYTs: 
 
In order for regulated exocytosis to proceed in response to increasing Ca
2+ 
levels there 
must be a molecule associated with the core complex which can in some way ‘sense’ and 
respond to cytosolic Ca
2+ 
ions.
 
The synaptotagmin (SYT) family is the most well-
characterized family of calcium-sensing proteins and these molecules are thought to mediate 
secretory events by providing the physical link between rising Ca
2+
 concentrations in the 
cytosol and the fusion apparatus (for reviews see Yoshihara and Montana 2004, Tucker and 
Chapman 2002, and Sudhof, 2002).  
There are currently 17 reported mammalian SYT family members. They are all type I 
integral membrane proteins which share a common basic structure consisting of a short, 
highly-variable N-terminal region, a transmembrane domain, a linker region, and two C- 
terminal C2 domains (Perin et al. 1991). The structure of a typical SYT is shown in Figure 
1.4. Although SYTs are defined by the presence of these five domains they do show 
significant diversity within the family. For example, the length of the transmembrane domain 
varies considerably between SYTs, ranging from 43 residues for SYT VIII to 417 residues  
  
 
 
 
 
 
 
 
 
for the longest variant of SYT VII (Sudhof, 2002). The linker region is an additional source 
of variability and is also the target for extensive gene splicing, leading to the generation of 
multiple isoforms of the same SYT family members (Gauthier et al. 2007, Fukuda and 
Mikoshiba, 1999). Indeed, the majority of the SYTs exist as multiple splice variants which 
can have their own unique properties and subcellular distributions. It is currently unclear how 
many variants exist for each SYT and in which cell types they are specifically expressed. 
The crucial Ca
2+
-binding regions of the SYTs are the two C2 domains, so called 
because they are highly homologous to the second constant sequence of protein kinase C 
(Perin et al. 1990). The C2 domains consist of an eight-stranded β-sandwich surrounding a 
conserved 60-residue four-stranded motif known as the C2 key (Sutton et al. 1995). A 
polybasic region comprising four lysine residues is found in a hairpin loop connecting β-
strands 3 and 4, and this region is most likely involved in mediating interactions with anionic 
phospholipids and protein binding partners (Sutton et al. 1995). 
Figure 1.4. SYTs share a common structure consisting of five domains.  
A simple schematic describing the general structure of the SYT proteins is shown. All 
isoforms are type I integral membrane proteins containing five distinct domains: the N-
terminus, the transmembrane domain (shown in black), the linker region, and two C2 
domains (shown in red). Note that the size of the transmembrane domain and the linker 
region can vary considerably depending on the SYT isoform.  The C2 domains have a 
number of binding partners which are essential for the function of the SYTs, as indicated. 
The C2A domain of SYT I binds three Ca
2+
 ions while the C2B domain binds two 
although variations do exist within the family (Sutton et al. 1995, Fernandez et al. 2001). The 
crystal structure of the SYT I C2A domain has revealed that the Ca
2+
 binding pocket is found 
in a cluster spanning 6Å at the tips of flexible loops protruding from the β-sandwich (Ubach 
et al. 1998). Binding requires one serine residue, five aspartate residues, and three backbone 
carbonyl groups. The conformation of the domain is stabilized by Ca
2+
-binding. The structure 
of the C2B domain is similar to the C2A domain although two additional α-helixes are 
present, one between the 7
th
 and 8
th
 β-strands (helix A) and the other in the C-terminal region 
(helix B) (Fernandez et al. 2001). The physiological implications of these motifs are currently 
unknown although they may be related to the specific role of the C2B domain in mediating 
endocytosis by binding to AP2 and clathrin (see Figure 1.4 and Section 1.3.3.2). Ca
2+
 
coordination by the C2B domain is achieved by five aspartate residues and two carbonyl 
groups (Fernandez et al. 2001). Interestingly, the C2A and C2B domains function 
cooperatively in that the physical presence but not necessarily the functional activity of the 
C2A domain is required for the activation of the Ca
2+
-binding site of the C2B domain (Bai et 
al. 2002). 
Importantly, the SYT family can form hetero- and homo-oligomers and normally 
function in an oligomeric state (Fukuda et al. 2000). Oligomerization can be both Ca
2+
-
dependent and Ca
2+
-independent, with Ca
2+
-dependent oligomers forming as a result of 
interactions between the cytoplasmic domains and Ca
2+
-independent oligomers resulting 
from the aggregation of the N-terminal domains. Mutations which abolish the ability of SYTs 
to undergo oligomerization often render them non-functional (Fukuda et al. 2000). 
 
1.3.2 The Classification of the SYT Family Members: 
 
SYTs are generally classified based on their Ca
2+
-dependency as approximately half 
of the family (SYTs IV, VIII, and XI – XVII) does not bind Ca2+ ions due to an evolutionary-
conserved mutation whereby serine is found in place of one of the crucial Ca
2+
-coordinating 
aspartate residues in the C2A domain (von Poser et al. 1997). Therefore these SYTs are 
considered to be ‘Ca2+-independent.’ Indeed, it has been shown that mutating this serine back 
to aspartate restores the Ca
2+
-dependency of SYTs IV and XI (von Poser et al. 1997). Clearly 
some SYT family members have Ca
2+
-independent functions which are more valued than the 
conventional SYT Ca
2+
-dependent activities. It is likely that the Ca
2+
-independent SYTs 
function to modulate secretion by competing with Ca
2+
-dependent SYTs for oligomer  
SYT [Ca
2+
]50 Group 
I 10 Fast 
II 20 Fast 
III 2 Medium/Fast 
V 2.5 Medium 
VI N/A Medium 
VII 1.5 Slow 
IX N/A Medium 
X 8 Medium 
 
 
formation and therefore the ratio of expression of Ca
2+
-dependent and -independent SYTs 
may provide a mechanism for fine-tuning the calcium sensitivity of secretory events.  
The Ca
2+
-dependent SYTs can be further classified into three distinct kinetic groups 
based on their Ca
2+
 binding properties. The Ca
2+
 affinity of the SYTs is determined from in 
vitro assays which measure the disassembly kinetics of the cytoplasmic domains following 
liposome binding (Sugita et al. 2002, Hui et al. 2005). From this, SYTs I, II, and III have 
been found to comprise the ‘fast’ group, SYTs V, VI, IX, and X constitute a group with 
medium binding kinetics, and finally SYT VII is considered to be the ‘slowest’ SYT family 
member (Hui et al. 2005). The precise Ca
2+ 
binding affinities of the C2A domains of the 
SYTs are shown in Table 1.1 (information derived from Sugita et al. 2002). However, it 
should be noted that these figures, although a good estimate of the relative Ca
2+
 affinities of 
the SYT family members, are unlikely to represent the true values seen in vivo because the 
phospholipid composition of target membranes is known to affect the Ca
2+
 binding abilities 
of the SYTs and full-length molecules most likely have a higher Ca
2+
 affinity than individual 
C2 domains (Sugita et al. 2002).  
 A further criteria which is often used to classify the SYT family members is whether 
or not they bind to inositol 1,3,4,5-tetrakisphosphate (IP4). The putative IP4 binding site 
consists of a series of lysine residues found in the C2B domain which are not present in the 
C2A domain (Ibata et al. 1998). SYTs III, V, VI, and X show no significant IP4 binding 
ability although they contain putative IP4 binding sequences whereas SYTs I, II, IV, VII, 
VIII, IX, and XI show strong IP4 binding activity (Ibata et al. 1998). The deletion of the C-
terminus restores the ability of SYTs III, V, VI, and X to bind IP4, indicating that this region 
Table 1.1 SYTs can be classified 
according to their Ca
2+
 binding 
kinetics. 
The estimated Ca
2+
 concentrations 
which induce half-maximal binding 
([Ca
2+
]50) are listed for the C2A 
domains of each Ca
2+
-dependent 
SYT along with the kinetic group to 
which they belong.  
masks the binding site. The functional significance of IP4 binding to the SYT family members 
is currently unclear although it may act to inhibit secretion as inositol polyphosphates are 
known to prevent neurotransmitter release (Llinas et al. 1994). 
Lastly, the SYTs show considerable variability in certain aspects of their structure 
which can be used to differentiate between family members. For example, the N-terminals 
are highly variable with only SYTs I and II displaying N-linked glycosylation in this region 
and only SYTs III, V, VI, and X having the ability to undergo disulphide bonding (Sudhof, 
2002). Additionally, there is little similarity between the transmembrane domains (TMDs) 
although all except SYT XII contain a series of cysteine residues in the cytoplasmic region 
directly adjacent to the TMD. This region is palmitoylated in SYTs I and VII (Sudhof, 2002). 
 
1.3.3 An Overview of the SYT Binding Partners: 
 
As shown in Figure 1.4 the SYTs have a number of binding partners, many of which 
are components of the exocytic machinery. The interactions between SYTs and these proteins 
are thought to be essential for mediating regulated secretion by providing a physical link 
between rising Ca
2+
 levels in the cytosol and the initiation of fusion pore formation following 
the activation of the exocytic core complex. Equally, as a consequence of their ability to 
interact with the endocytic proteins clathrin, AP-2, and stonin 2 SYTs most likely play a 
fundamental role in the regulation of endocytosis as well as exocytosis.  
 
 1.3.3.1 SNAREs: 
 
 SYTs bind to the C-terminal region of syntaxins in a Ca
2+
-dependent manner. This 
ability is not disrupted by mutations which abolish the Ca
2+
-dependency of SYT I suggesting 
that SNARE binding is an intrinsic property of all SYTs regardless of their Ca
2+
-dependency 
(Chapman et al. 1995).  The C2A domain of SYTs can also bind to an acidic region in the N-
terminal Habc domain of syntaxin in a Ca
2+
-dependent manner (Fernandez et al. 1998). The 
binding of SYT to syntaxin is now known to be dependent on the ability of Ca
2+
 ions to 
neutralize basic residues surrounding the Ca
2+
-binding site in the SYT C2A domain, and 
hence calcium binding results in an electrostatic switch within the SYT molecule which 
allows syntaxin binding and possibly the initiation of vesicle fusion (Shao et al. 1997). 
The affinity of the SYT:syntaxin interaction varies depending on the SYT family 
member under investigation. For example, SYTs I, II, and V bind syntaxins at Ca
2+
 
concentrations greater than 200 µM, whereas SYTs III and VII can bind syntaxins at 
concentrations less than 10 µM (Li et al. 1995). Interestingly, when SYTs and syntaxins are 
present at artificially high levels the binding between the two protein families is relatively 
non-specific as SYTs I, VI, and VII can bind to syntaxins I - IV in any combination. 
However, at physiological concentrations SYT I binds specifically to syntaxin I and so the 
SYT:syntaxin interaction in vivo is likely to be specific (Li et al. 1995).   
 In addition to its established ability to bind syntaxin in a Ca
2+
-dependent manner SYT 
also binds to the second t-SNARE, SNAP-25 (Gerona et al. 2000). Indeed, this interaction is 
thought to enhance the ability of SYT to bind to syntaxin and so possibly promotes the 
formation of syntaxin/SNAP25 heterodimers (Gerona et al. 2000). Chemical cross-linking 
experiments have demonstrated that SYT proteins bind to three aspartate residues found in 
the C-terminal helix of SNAP-25 in a Ca
2+
-dependent manner (Zhang et al. 2002). If this 
region of SNAP-25 is mutated then the exocytosis of LDCVs from PC12 cells is severely 
inhibited, indicating that the binding of SYT to SNAP-25 plays an essential role in Ca
2+
-
mediated exocytosis, possibly through the stabilization of the SNAREpin. 
 
  1.3.3.2 AP2 and Other Components of the Endocytic Machinery: 
 
 Clathrin-mediated endocytosis is the primary pathway through which the cargo 
proteins of fused vesicles are removed from the plasma membrane and returned to 
intracellular organelles for recycling or degradation. The main constituents of this pathway 
are the coat protein clathrin, the adaptor complex AP2, and the fission-driving enzyme 
dynamin.  The SYTs bind clathrin and AP2 via their C2B domains in a Ca
2+
-independent 
manner and so are likely to play a role in the facilitation of endocytosis as well as exocytosis 
(Zhang et al. 1994, Li et al. 1995). Indeed, the expression of mutant SYTs I and VII lacking 
the C2B domain in HeLa cells inhibits the formation of cell surface clathrin-coated pits (von 
Poser et al. 2000). The interaction between SYT and AP2 is stimulated by the activity of 
phospholipase D and the presence of tyrosine-based endocytoic motifs similar to those found 
in cargo proteins (Haucke and De Camilli, 1999). Additionally, endocytosis is dependent on 
the oligomerization ability of SYTs as over-expressed proteins with truncated transmembrane 
domains containing mutated cysteine residues are unable to act as dominant-negative 
inhibitors of endocytosis unlike wild-type truncated proteins (von Poser et al. 2000).  
SYTs can also interact with the ubiquitous endocytoic protein stonin 2 which 
facilitates the uncoating of vesicles following their budding from the plasma membrane. 
Indeed stonin 2 competes with AP2 for the same binding site in the C2B domain of the SYT 
protein (Martina et al. 2001, Walther et al. 2001). Particularly, the mutation of two residues 
(W719 and K721) in the µ2 homology domain of stonin 2 impairs its ability to bind to SYT I.  
Therefore it is likely that stonin 2 functions to displace AP2 from SYTs following vesicle 
budding and thereby stimulates the disassembly of the clathrin coat.  
Following exocytosis SYTs play a direct role in mediating endocytosis and therefore 
are required for granule recycling.  Indeed, C. elegans with mutant SYT C2B domains show 
defective recycling of synaptic vesicles at their neuromuscular junctions, leading to reduced 
quantities of plasma membrane-associated vesicles and impaired neurotransmission 
(Jorgensen et al. 1995). 
 
  1.3.3.3 Additional SYT Binding Partners: 
 
 SYT I is known to associate with ω-conotoxin-sensitive calcium channels as both 
proteins co-precipitate in rat brain synaptic membrane preparations (Leveque et al. 1992). 
Additionally, the C-terminus of SYT I binds to the cytoplasmic domains of α- and β-
neurexins in a Ca
2+
-independent manner and this interaction inhibits the phosphorylation of 
SYT (Petrenko et al. 1991, Hata et al. 1993, Perin, 1994). Neurexins are brain-specific 
transmembrane adhesion proteins which were initially identified as the receptors for α-
latrotoxin, a component of black widow spider venom. Hence, the interaction between the 
cytoplasmic portions of the synaptic vesicle protein SYT and a neuronal plasma membrane 
protein suggests that SYTs play a role in mediating synaptic vesicle tethering.  
 
1.3.4 A Model for the Mechanism of Action of the SYTs: 
 
It is currently unclear exactly how SYTs induce fusion pore formation and vesicle 
exocytosis following Ca
2+
 binding. However, as a result of the many investigations of recent 
years examining the mechanism of SYT binding to target membranes and components of the 
exocytic machinery, a generally-accepted model has been proposed (Tucker and Chapman, 
2002). This is shown in Figure 1.5.  It is thought that in resting cells vesicle-associated SYTs  
are in close contact with the plasma membrane syntaxin:SNAP-25 complex. Following cell 
stimulation SYTs bind Ca
2+
 ions in a coordination sphere which requires negatively-charged 
molecules contributed from both the SYT C2 domains and anionic phospholipids in the target 
membrane. Ca
2+
 binding does not cause a large conformational change in the SYT protein but  
  
 
 
 
 
 
 
 
 
 
 
 
 
rather results in an electrostatic switch which neutralizes acidic residues and allows the 
insertion of the SYT into the target membrane. This is thought to disrupt the integrity of the 
membrane, decreasing the activation energy required for fusion pore formation (Sollner, 
2003). At the same time, Ca
2+
-binding allows SYTs to bind to SNAREs which assists in 
vesicle tethering and SNAREpin formation. This model was supported by the observation 
that following Ca
2+
 binding SYT I binds simultaneously to phospholipids in the target 
membrane and to the ternary SNARE complex with kinetics which are rapid enough to 
satisfy the requirements for synaptic transmission (Davis et al. 1999). 
Crucially, it is now thought that the oligomerization of members of the SYT family 
into ring-like structures, possibly in combination with SNARE proteins, contributes to fusion 
pore formation by providing physical support for the wall of the aqueous stalk (Tucker and 
Chapman, 2002). Indeed, mutations which increase the length of the 9-residue linker region 
connecting the SYT C2A and C2B domains result in a progressive disruption of both the 
Figure 1.5. A Model Explaining the Mechanism of Action of the SYTs.  
In resting cells (1), vesicle-associated SYTs are in close proximity to the target membrane 
and may form a weak interaction with t-SNAREs. Following Ca
2+
 binding (2), an 
electrostatic switch in the SYT proteins drives them into the target membrane (3), enhancing 
their binding affinity to the SNARE complex and physically disrupting the membrane. 
Hemifusion proceeds (4 and 5) assisted by the oligomerization of the SYTs and SNARE 
complex formation. Full fusion then occurs and the vesicle’s cargo is expelled into the 
opposing lumen (6).  
Figure taken from Tucker and Chapman, 2002  
Reproduced, with permission, from Tucker and Chapman, 2002 (Biochemical Journal, 366 (1) 1-13 
© the Biochemical Society. 
 
 
syntaxin:SNAP-25 interaction and the stability of the fusion pore (Bai et al. 2004). 
Additionally, an elegant single-vesicle content-mixing assay has shown that SNARE proteins 
alone can drive membrane hemifusion but full pore formation and expansion requires the 
cooperative action of SYT I and Ca
2+
 (Lai et al. 2013). 
Lastly, SYTs are likely to play a role in mediating vesicle docking and clustering at 
the plasma membrane as a consequence of their ability to bind to SNARE proteins. SYT I 
plays an essential role in the docking of LDCVs in adrenal chromaffin cells via a direct 
interaction with SNAP-25, as both SNAP-25- and SYT 1-deficient cells show a significantly 
reduced number of docked vesicles at the plasma membrane (de Wit et al. 2009). The over-
expression of wild-type, but not a mutant variant of SYT I with impaired SNAP-25 binding 
ability, was able to rescue docking in SYT I-deficient chromaffin cells. Therefore it is likely 
that SYT I mediates vesicle docking through a physical interaction with the syntaxin:SNAP-
25 acceptor complex in the plasma membrane. This hypothesis has been supported by more-
recent studies which have shown that SYT I mediates the rapid docking of synaptic vesicles 
in a reconstituted membrane fusion system through a mechanism which requires the 
polybasic region of the SYT C2B domain and the presence of PIP2 in the target membrane 
(Wang et al. 2011). Lastly, it has been shown that vesicle docking mediated by SYT I is a 
prerequisite for SNAREpin assembly which is in turn driven by munc18-1 (Parisotto et al. 
2012). Munc18-1 in isolation cannot drive efficient vesicle docking, demonstrating that SYT 
is the major docking protein at the plasma membrane. Therefore, on the basis of these studies 
a model for vesicle docking has been proposed whereby the C2B domain of SYT I binds to 
SNAP-25 and PIP2 in the target membrane. This step in the secretory pathway is an essential 
prerequisite for vesicle fusion.   
Therefore, SYTs regulate Ca
2+
-mediated exocytosis through a coordinated interaction 
with phospholipids and SNAREs in the target membrane. They are likely to be crucial for the 
formation of the fusion pore and for vesicle tethering prior to fusion. However the true 
mechanism of action of the SYT proteins is likely to be more complicated than the model 
shown in Figure 1.5. Indeed, evidence has been provided suggesting that in resting cells 
SYTs form a weak Ca
2+
-independent interaction with SNAREs and phospholipids in the 
target membrane and this pre-fusion complex prevents spontaneous premature SNAREpin 
formation (Tucker and Chapman, 2002). It is possible that Ca
2+
 binding then forces the SYTs 
deeper into the target membrane, thus liberating the transSNARE complex and allowing 
fusion to proceed.  
 
1.4 Ca
2+
 Signalling and Regulated Exocytosis: 
 
 The first indication that regulated exocytosis is initiated by Ca
2+
 ions was provided in 
1967 by the pivotal observation that extracellular Ca
2+
 ions are required for synaptic vesicle 
exocytosis (Katz and Miledi, 1967). It is now known that increasing Ca
2+
 levels in the cytosol 
act as the crucial trigger for a wide range of secretory events from the rapid release of small 
synaptic vesicles in neurons to the slower secretion of Large Dense-Core Vesicles (LDCVs) 
from endocrine cells. These Ca
2+
-mediated secretory events differ in their kinetics and 
calcium sensitivity of exocytosis and are regulated by a diverse array of calcium sensors with 
varying Ca
2+
 affinities (reviewed in Pang and Sudhof, 2010).  
 In neurons, synaptic vesicles are tethered in the immediate vicinity of plasma 
membrane Ca
2+
-channels and so Ca
2+
 influx into the cell from the extracellular medium 
following the generation of the action potential directly triggers synaptic transmission. 
However, in non-neuronal cells the Ca
2+
 ions which act as the initial trigger for exocytosis are 
generally derived from internal sources. In endothelial cells, the binding of a suitable agonist 
such as histamine or thrombin to cell-surface G-protein-linked receptors results in the 
activation of a GTP-binding protein which in turn activates phospholipase C-β-1. This 
enzyme hydrolyses phopsphatidylinositol-4,5-bisphosphate (PIP2), generating the second 
messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (reviewed in Berridge, 2009). 
Mechanical stimulation also activates IP3 production, providing a mechanism whereby 
wounding can activate endothelial cells and induce the secretion of pro-thrombotic and 
vasoconstrictive substances.  
Once formed, IP3 binds to IP3 receptors (IP3R) on the surface of the endoplasmic 
reticulum, leading to the activation and opening of IP3R Ca
2+
 release channels (Streb et al. 
1983). Ca
2+
 ions sequestered in the ER then flood the cytoplasm and eventually trigger 
regulated fusion events at the plasma membrane. In endothelial cells, the mitochondria also 
constitute a major source of free Ca
2+
 ions which are released following the stimulation of 
mitochondrial permeability transition pores (PTPs) in the inner membrane (Wood and 
Gillespie, 1998). Mitochondrial activation is critical for the formation of the Ca
2+
 oscillation 
patterns which are regularly seen following endothelial stimulation (Falcke et al. 1999).   
Once internal supplies of Ca
2+
 have been depleted transplasmalemmal Ca
2+
 channels 
open, allowing the influx of Ca
2+
 ions into the cell from the extracellular medium (Schilling 
et al. 1992). Equally, stimulation of the cell results in the activation of phospholipase A2 
which generates arachidonic acid. This lipid induces Ca
2+
 entry into the cell across the 
plasma membrane through a mechanism which is independent of store depletion 
(Shuttleworth, 1997). Hence, in endothelial cells most agonists trigger a biphasic rise in 
cytosolic Ca
2+
 whereby the first component is transient and mediated by the release of stored 
intracellular Ca
2+
 ions. The second component of the Ca
2+
 signalling pattern is larger and 
more sustained, resulting from the influx of Ca
2+
 across the plasma membrane. Lastly, it is 
noteworthy that certain endothelial agonists such as thrombin, serotonin, and ATP activate 
non-selective plasma membrane cation channels which allow the direct entry of Ca
2+
 ions 
into the cell and so are able to by-pass the requirement for phosphoinositols and internal Ca
2+
 
supplies (Brauneis et al. 1992, Popp and Gogelein, 1992). 
 
1.5 Weibel-Palade Bodies: A Model System for Regulated Exocytosis 
 
 1.5.1 An Introduction to WPBs: 
 
The distinctive rod-shaped secretory organelles which are now referred to as Weibel-
Palade bodies (WPBs) were first observed in 1958 by Hibbs and colleagues following an 
investigation examining the heterogeneity of the endothelium of human skin (Hibbs et al. 
1958). These investigators reported the presence of ‘groups of very dense, rod-shaped 
granules, varying from 0.1 to 0.3 µ in diameter and 0.3 to 0.6 µ in length,’ but did not hazard 
to guess the function of these novel organelles.  Subsequently, in 1964 Edward Weibel and 
George Palade described a ‘hitherto unknown rod-shaped cytoplasmic component’ during an 
electron micrographic study of rat vascular tissue (Weibel and Palade, 1964). They also 
observed that the bodies contained regularly-spaced fibrous tubules which were 
approximately 150 Å thick and embedded in a dense matrix. This paper was the first to 
characterize the structural features of these new organelles and as a result they became known 
as Weibel-Palade bodies.  
In 1982, Wagner and colleagues determined by immunohistochemistry and electron 
microscopy that the tubular structures seen in WPBs are made up of von Willebrand Factor 
(VWF) (Wagner et al. 1982). VWF is a large multimeric glycoprotein which is synthesized 
exclusively in megakaryotcytes and endothelial cells and stimulates thrombosis upon its 
release. The leukocyte receptor P‐selectin was subsequently identified as a WPB membrane 
protein (Bonfanti et al. 1989), providing evidence that these organelles are involved in the 
regulation of both inflammation and thrombosis. In later years, additional WPB cargo 
proteins and the ability of these organelles to undergo regulated secretion following the 
stimulation of the endothelium by suitable agonists would be described.  
In short, WPBs are large rod-shaped secretory organelles found exclusively within 
endothelial cells (for reviews see Valentijn et al. 2011, Rondaij et al. 2006, Michaux and 
Culter, 2004). Their primary function is to act as a storage compartment for VWF although 
they do contain a range of additional cargo proteins including many which regulate 
inflammation, angiogenesis, and vascular tonicity. A representative immunofluorescence 
image of a HUVEC teaming with these organelles is shown in Figure 1.6.  
 
1.5.2 The Contents of WPBs:  
 
WPBs contain a range of proteins which regulate diverse biological processes 
including haemostasis, inflammation, vascular tonicity, and angiogenesis. Table 1.2 provides 
a comprehensive list of the molecules which have been detected in WPBs thus far and their 
putative functions. The principal WPB cargo protein is the pro‐thrombotic glycoprotein VWF 
and indeed this molecule and its cleaved peptide make up 95% of the protein content of 
WPBs (Ewenstein et al. 1987). Following the stimulation of the endothelium VWF is rapidly 
released into the bloodstream where it mediates platelet aggregation by forming long strings 
which adhere strongly to both the vessel wall and circulating platelets (Dong et al. 2002).  
Monomeric unprocessed VWF (proVWF) is a large protein of 250 kDa which 
contains a 22-residue signal sequence and a pro-peptide of 741 residues (Bonthron et al. 
1986). The pro-peptide is cleaved from the main protein in the TGN by an unknown protease 
and remains with the mature protein in a 1:1 stoichiometry until the point of WPB fusion at 
the plasma membrane (Ewenstein et al. 1987). Indeed, despite being physically separated 
from the mature protein the propeptide is essential for its correct multimerization and WPB 
formation (Journet et al. 1993, Leyte et al. 1991). From herein the pro-peptide will be 
referred to as ‘proregion’ and this terminology has relevance for the biochemical assays 
described at a later point (see 2.7.3 Proregion ELISAs). 
VWF is instrumental in driving the formation of WPBs and is solely responsible for 
their distinctive rod‐shaped morphology. The importance of VWF for WPB formation is 
demonstrated by studies which show that when VWF cDNA is expressed in non‐endothelial 
cells such as the mouse pituitary cell line AtT‐20 and the rat insulinoma cell line RIN5F 
VWF-containing rod‐shaped storage granules are produced by these cells (Wagner et al.  
  
 
 
 
 
 
Figure 1.6. Weibel-Palade bodies are large rod-shaped secretory organelles. 
A representative image of a HUVEC stained with an antibody specific for the major WPB 
cargo protein VWF. Numerous rod-shaped WPBs distributed throughout the cytoplasm of 
the cell have been identified. The scale bar is 20 µm. 
 Table 1.2. WPBs store a wide range of molecules with diverse physiological functions.  
A full list of the cargo proteins reported to be resident within WPBs is provided along with 
each molecule’s primary function.  
 
1991). These granules are morphologically identical to endogenous WPBs. Conversely, 
humans and animals which suffer from severe forms of von Willebrand disease (VWD) and 
therefore synthesize no functional VWF fail to produce WPBs (Castaman et al. 2010, Sadler, 
1998). In addition to driving the formation of WPBs, VWF is responsible for the recruitment 
of a number of other cargo molecules to the forming vesicles such as P‐selectin, 
osteoprotegrin, and IL‐8 (Metcalf et al. 2008). 
P‐selectin is found exclusively in platelets, megakaryocytes, and endothelial cells and 
is the most well‐characterized membrane protein found on WPBs. P‐selectin is a highly‐
glycosylated adhesion molecule which binds to P‐selectin Glycoprotein Ligand 1 (PSGL‐1) 
on leukocytes, triggering their extravasation to underlying tissues. It is therefore involved in 
the inflammatory response and may also play a role in mediating thrombosis as it is thought 
to activate microparticle production (Cambien and Wagner, 2004). Mice which are deficient 
in P‐selectin show a decreased efficiency of leukocyte adherence to the vessel wall following 
endothelial stimulation (Mayadas et al. 1993).  
WPBs are heterogeneous organelles and their contents vary depending on the location 
of a particular endothelial cell within the vasculature and the prevailing environmental 
conditions. IL‐8, for example, is only stored in WPBs following exposure to inflammatory 
mediators such as TNF‐α and IL‐1β (Utgaard et al. 1998). Exotaxin‐3 likewise is only found 
Cargo Function Reference 
VWF Thrombosis Wagner et al. 1982 
P-selectin Inflammation Bonfanti et al. 1989; McEver et al. 1989 
Factor XIIIa Thrombosis Schaumburg-Lever et al. 1994 
tPA Fibrinolysis Rosnoblet et al. 1999 
IL-8 Inflammation (neutrophil activation) Utgaard et al. 1998 
Exotaxin-3 Inflammation (eosinophil attraction) Oynebraten et al. 2004 
α–1,3-fucoysyltransferase VI Glycosylation Schnyder-Candrian et al. 2000 
CD63 Adhesion / Membrane Organization Vischer and Wagner 1992 
Endothelin-1 Vasoconstriction Ozaka et al. 1997, Russell et al. 1998a 
Endothelin Converting Enzymes Vasoconstriction Russell et al. 1998a 
Calcitonin-gene-related Peptide Vasodilatation Ozaka et al. 1997 
Angiopoietin-2 Inflammation Fielder et al. 2004 
Osteoprotegerin Bone Growth / Cell Survival Zannettino et al. 2005 
IL-6 Inflammation Knipe et al. 2010 
MCP-1 Inflammation  Knipe et al. 2010 
Gro-α Inflammation Knipe et al. 2010 
Factor VIII Coagulation Rosenberg et al. 1998 
IGFBP7 Angiogenesis van Breevoort et al. 2012 
in WPBs following their exposure to IL‐4 (Oynebraten et al. 2004). Interestingly, P‐selectin 
and angiopoeitin‐2 are never found within the same organelles, suggesting that the trafficking 
of these two proteins to WPBs is mutually exclusive although the mechanisms governing this 
are currently unclear (Fiedler et al. 2004). The ability to regulate the exocytosis of certain 
subsets of WPBs at a given time could impart endothelial cells with considerable flexibility 
when responding to different environmental stimuli. 
Lastly, WPBs contain the tetraspanin CD63 on their limiting membranes which is a 
marker protein for late endosomes and lysosomes (Vischer and Wagner 1993). The role of 
CD63 on WPBs is currently unclear although it may function to organize proteins into 
specific domains within the membrane. Importantly, its presence on WPBs as well as the fact 
that they require the adaptor protein AP‐3 for full maturation has led to the argument that 
WPBs should be classified as lysosome‐related organelles (LROs) rather than simply 
secretory organelles (Hannah et al. 2002). LROs are storage granules which have features in 
common with lysosomes such as a low internal pH and access to proteins from the endocytic 
pathway, hence their requirement for AP‐3 (Cutler 2002). These organelles include 
melanosomes, T‐cell lytic granules, platelet α‐granules, and the secretory granules found in 
basophils and azurophils. The idea that WBPs may be classified as LROs is important to 
consider when identifying potential candidate proteins for the regulation of their biogenesis 
and secretion. 
 
1.5.3 The Biosynthesis, Trafficking, Docking, and Secretion of WPBs: 
 
1.5.3.1 The Formation of WPBs at the TGN: 
 
 WPBs develop at the TGN through a process which requires the coat protein clathrin 
and the adaptor protein AP1. Indeed, both these molecules are seen to coat immature WPBs 
as they emerge from the TGN, and in some cases cover the entire organelle (Lui-Roberts et 
al. 2005). Disrupting the clathrin coat by over-expressing a dominant-negative version of 
AP180 inhibits WPB formation and increases the quantity of VWF which undergoes 
constitutive secretion from HUVECs. In place of wild-type rod-shaped WPBs, small punctate 
vesicles which do not undergo regulated secretion are formed. The same effect is seen 
following the knock-down of AP1. As VWF tubulation is responsible for the distinctive rod-
shaped morphology of WPBs, it has been proposed that the AP1/clathrin coat provides a 
physical scaffold on which VWF can begin folding into tubules. It may be that the coat 
proteins hold the membrane in an elongated shape allowing time for the VWF subunits to 
tubulate (Lui-Roberts et al. 2005). It is unusual for clathrin to be involved in the biosynthesis 
of a large secretory granule as this coat protein is generally required for the formation of 
small vesicles or for the recycling of material back to the TGN. It is probable that the 
distinctive shape of the WPB requires an unusual coat protein for its biosynthesis. Once the 
forming WPBs have budded from the TGN, clathrin is no longer necessary for the 
maintenance of their morphology as brefeldin-A treatment has no effect on the shape of the 
immature granules (Lui-Roberts et al. 2005). However, clathrin-coated buds are seen on 
newly-formed WPBs, and presumably these are involved in the recycling of unwanted cargo 
back to the TGN.  
It is currently unclear which AP1-interacting proteins are involved in the formation of 
WPBs at the TGN. However, the inhibition of the AP1 effector proteins γ-synergin and 
aftiphilin disrupts the ability of mature WPBs to undergo regulated secretion (Lui-Roberts et 
al. 2008). Aftiphilin and γ-synergin are members of the AP1-interacting aftiphilin/γ-
synergin/p200 complex which has been reported to be present on both forming WPBs at the 
TGN and on immature granules in the perinuclear area. The treatment of HUVECs with 
siRNA for either γ-synergin or aftiphilin results in the production of WPBs which are 
morphologically normal, have a high electron density, and are positive for Rab27A. 
However, siRNA-treated HUVECs show an increased quantity of constitutively-secreted 
VWF while the quantity of VWF which undergoes regulated secretion is only 20% of that 
seen from control cells.  The multimeric state of the VWF released from treated HUVECs is 
equivalent to that released from control cells, suggesting that the knock-down of aftiphilin 
and γ-synergin allows the unregulated release of mature WPBs rather than increasing the 
quantity of VWF directed to the constitutive pathway. Therefore, it appears that aftiphilin and 
γ-synergin are essential for determining the regulated nature of WPB secretion, and indeed it 
is possible that these effector proteins function to recruit other components of the fusion 
apparatus to the forming vesicles (Lui-Roberts et al. 2008). 
Recently, an AP1 interactor screen performed in C. elegans has implicated Rab10 and 
Rab8a as having key roles in the formation of WPBs (Michaux et al. 2010). Both Rab10 and 
Rab8a are found in the TGN of HUVECs although they are not seen to co-localize with 
VWF. However, the knock-down of either Rab10 or Rab8a inhibits the secretion of VWF 
following PMA stimulation by up to 40% (Michaux et al. 2010). Interestingly, this inhibition 
is specific for the immediate secretion of VWF following stimulation and so Rab10 and 
Rab8a are most likely involved in the formation or secretion of the RRP. The WPBs in 
treated cells are morphologically normal and are positive for CD63 and MyRIP as expected, 
indicating that these two Rabs are involved in WPB formation at the TGN. An identical effect 
on VWF secretion is seen if Rab10 and Rab8a are knocked-down singularly or together 
suggesting that these two proteins play a functionally-equivalent role within the cell. 
 The mechanism by which cargo proteins are targeted to forming WPBs at the TGN is 
currently unclear. Both osteoprotegrin and IL-8 are retained within WPBs via a direct 
interaction with VWF. Indeed, if VWF-GFP is expressed in the non-WPB-containing 
endothelial cell line EC0RF24, IL-8 is recruited to the fluorescent WPBs (Romani de Wit et 
al. 2003). CD63 is recruited to WPBs after they have budded from the TGN via a mechanism 
which is dependent on AP3 and the tyrosine-based AP3-binding motif, GYEVM (Harrison-
Lavoie et al. 2006). The mutation of this motif inhibits the recruitment of CD63 to WPBs. As 
a result of its absence on newly-formed WPBs, CD63 is considered to be one of the markers 
of mature granules.  
The targeting of P-selectin to WPBs is more complicated because it is derived from 
two pools; newly synthesized protein and protein which has been recycled from the cell 
membrane. Like IL-8 and osteoprotegrin, P-selectin is able to bind directly to VWF, as 
shown by the observation that when VWF is over-expressed in epithelial cells P-selectin is 
found within the VWF-positive organelles formed (Hop et al. 2000). This interaction is 
dependent on the D’-D3 domains of VWF, as when truncated forms of VWF are expressed in 
HEK-293 cells P-selectin is able to bind only to variants which contain the D’-D3 domains 
(Michaux et al. 2006). These findings have functional consequences for VWD sufferers who 
have mutations in the D’-D3 domains of VWF and therefore are unable to recruit P-selectin 
to their WPBs. Newly-synthesized P-selectin arrives in WPBs at the TGN in an AP3-
independent manner and efficient trafficking requires its luminal domain and a YGVF motif 
(Harrison-Lavoie et al. 2006). When the luminal domain of P-selectin is expressed in 
isolation, the peptide does enter WPBs as a result of its interaction with VWF. However, 
replacing the luminal domain with horseradish peroxidase does not prevent the recruitment of 
P-selectin to WPBs. Therefore it is likely that the mechanism whereby the cytoplasmic tail of 
P-selectin mediates its trafficking is indirect. If the luminal domain is deleted leaving only the 
cytoplasmic domain, recruitment does still occur but is very slow. The YGVF motif is 
involved in the trafficking of newly-synthesized P-selectin to forming WPBs, as following its 
deletion mutated P-selectin is trafficked to the lysosomes and endosomes but not to WPBs. It 
is likely that the loading of P-selectin into WPBs is AP1-dependent as when this protein is 
knocked-down in HUVECs P-selectin is absent from the small spherical VWF-containing 
vesicles which are the by-product of AP1 deletion (Harrison-Lavoie et al. 2006). The 
recruitment of recycled P-selectin back to the WPBs is dependent on two cytoplasmic motifs 
and the adaptor protein AP3. The KCPL motif contains a key lysosine which mediates AP3 
binding, and this regulates the movement of P-selectin from the early to late endosomes. The 
YGVF motif controls movement from the endosome to the TGN (Harrison-Lavoie et al. 
2006). 
It is currently unclear how the biosynthesis, content, morphology, and secretion of 
WPBs is regulated at the genomic level. However, the shear-stress induced transcription 
factor Krüppel-like factor 2 (KLF2) is known to influence the number, morphology, and 
content of WPBs by inducing an atheroprotective phenotype. When KLF2 is expressed in 
HUVECs, the result is a quiescent endothelial phenotype which shows anti-inflammatory 
properties, delayed wound healing, and stress-fibre formation (Dekker et al. 2006). 
Additionally, KLF-2 attenuates the thrombin-induced release of WPBs from HUVECs but 
does not affect secretion following stimulation by epinephrine.  When KLF2 expression is 
induced in blood outgrowth endothelial cells (BOECs) the result is a 4.5-fold increase in the 
number of WPBs per cell and these organelles, although rod-shaped, are significantly shorter 
than those in mock-transfected cells (van Agtmaal et al. 2012). The increase in WPB number 
per cell is most likely a consequence of increased VWF synthesis, as it is known that KLF2 
expression increases the quantity of VWF mRNA found within HUVECs (Dekker et al. 
2006). KLF2 also influences the content of WPBs as granules in transfected BOECs do not 
contain angiopoietin-2 (ANG-2) and also show reduced levels of IL-8 storage after IL-1β 
treatment. Following stimulation, virtually no ANG-2 is released from KLF2-treated cells 
and the level of IL-8 secretion is significantly reduced. Hence, the exposure of the 
endothelium to shear stress results in an up-regulation of KLF2 which in turn induces WPBs 
to display an anti-inflammatory, atheroprotective phenotype.  Sites of low shear stress such as 
arterial branch points may be prone to developing atherosclerotic plaques due to a lack of 
expression of KLF2.  
 
1.5.3.2 The Trafficking of WPBs to the Plasma Membrane: 
 
The first indication that Rab proteins may be involved in the regulation of WPB 
trafficking and exocytosis came from the observation that non-hydrolysable GTP analogues 
stimulate VWF exocytosis from endothelial cells (Fayos and Wattenberg, 1997). A number of 
specific Rab proteins have since been implicated in regulating WPB secretion. Firstly, 
Rab27a is recruited to WPBs both in endothelial cells and in non-endothelial cells types 
where VWF expression has been induced (Hannah et al. 2003). This suggests that the 
recruitment of Rab27a to granules is due to either a direct or indirect association with VWF. 
Interestingly, Rab27a is not associated with newly-formed perinuclear WPBs but instead is 
found on peripheral WPBs which are several hours old. This population of peripheral WPBs 
makes up the RRP which is docked to the actin cortex. The majority of WPBs are associated 
with microtubules which are then transferred to the actin cortex to replenish the RRP. It is 
thought that Rab27a may function to transfer WPBs to the actin cortex, as in melanocytes 
Rab27a is essential for the transfer of melanosomes from the microtubules to the actin cortex 
prior to their exocytosis (Wu et al. 2001). Indeed, if Rab27a is over-expressed in HUVECs 
the result is an increased number of WPBs in the periphery (Hannah et al. 2003).   
Immunofluorescence and PCR has revealed that the Rab27a effector protein MyRIP 
(myosin and Rab27a interacting protein) is localized to mature WPBs where it concentrates at 
one pole of the granule (Nightingale et al. 2009). The recruitment of MyRIP is temporally 
coupled to that of Rab27a. The knock-down of either Rab27a or MyRIP in HUVECs results 
in the loss of peripheral WPBs, a 2-fold increase in basal secretion, and a 3.5-fold increase in 
regulated secretion. The VWF released from transfected cells is less highly-multimerized 
than that released from mock-transfected HUVECs and following secretion generates VWF 
strings which are shorter and more numerous. This work suggests that the function of Rab27a 
and MyRIP is to anchor the WPBs in the actin cortex, allowing time for VWF to multimerize 
fully. It is noteworthy that patients suffering from Griscelli type II disease who lack a 
functional Rab27a protein and the naturally occurring Rab27a-negative ashen mouse both 
show a bleeding phenotype (Nightingale et al. 2009). The cause of this unregulated bleeding 
has not been investigated in any great detail although it is tempting to speculate that the lack 
of Rab27a may impair regulated WPB secretion and therefore thrombosis in these cases.  
A recent paper has demonstrated that myosin Va is found on mature WPBs located in 
the periphery of the cell and forms a triple complex with Rab27a and MyRIP (Pulido et al. 
2011). Myosin Va is a member of the myosin V family and HUVECs express both the exon-
D-containing isoform and the exon-D-lacking isoform. If either isoform is knocked-down or 
inhibited by the expression of a dominant-negative variant the result is increased WPB 
clustering in the perinuclear area and the secretion of less highly-multimerized VWF (Pulido 
et al. 2011).  These results suggest that myosin Va functions to inhibit the secretion of 
immature WPBs from endothelial cells.  
A second Rab protein, Rab3D, is found on mature WPBs in the GTP-bound state 
following its over-expression and functions to regulate WPB formation (Knop et al. 2004). If 
a constitutively-active form of Rab3D is expressed in HUVECs the result is larger and 
rounder WPBs. In contrast, if a constitutively-inactive version of Rab3D is over-expressed no 
WPBs are formed. Therefore, Rab3D is essential for WPB formation and most likely 
functions to regulate the size and shape of mature granules. However, the over-expression of 
wild-type Rab3D, constitutively-active Rab3D, or constitutively-inactive Rab3D leads to 
reduced VWF secretion and so its precise role in WPB biogenesis is currently unclear.  
Recent work has shown that Rab27 functions cooperatively with Rab15 through a 
mutual effector protein, Munc13-4, to regulate WPB exocytosis (Zografou et al. 2012). 
Endogenous Munc13-4 localizes to WPBs and its knock-down in HUVECs results in the 
inhibition of VWF secretion. Rab15 is commonly associated with the endosomal pathway 
and so many be involved in the recycling of components of the fusion apparatus to newly-
synthesized WPBs following endothelial stimulation. The importance of Rab27a and its 
effectors in the regulation of WPB exocytosis was further demonstrated by the observation 
that the two Rab27a effectors MyRIP and Slp4-a/granuphilin function cooperatively to 
mediate the probability of WPB release, with MyRIP acting to inhibit secretion and Slp4-a 
acting to induce fusion (Bierings et al. 2012). It has been proposed that the interplay between 
these two proteins through Rab27a determines WPB tethering and fusion at the plasma 
membrane.  
 
1.5.3.3 The Fusion Apparatus Mediating WPB Exocytosis: 
 
It is currently unclear which proteins constitute the fusion apparatus of WPBs. It is 
known that human aortic endothelial cells express syntaxin-4, VAMP-3, syntaxin-2, and 
SNAP-23, and thus far evidence has been provided to suggest that syntaxin-4 is the t-SNARE 
controlling WPB exocytosis on the plasma membrane (Matsushita et al. 2003). Indeed, if 
syntaxin-4 is inhibited with α-syntaxin-4 antibodies WPB exocytosis is decreased by 75% 
compared with control cells. Recent evidence has shown that VAMP3 and VAMP8 are found 
on the WPB membrane although only VAMP3 participates in Ca
2+
-dependent exocytosis 
(Pulido et al. 2010).  Cytoplasmic fragments of VAMP3 but not VAMP8 are able to inhibit 
VWF secretion by approximately 30% compared with untreated cells.  As VAMP8 is present 
on WPBs but does not regulate their fusion it is possible that this SNARE may be involved in 
the biogenesis of the organelle. VAMP3 can be precipitated from endothelial cells as a 
complex with syntaxin-4 and SNAP-23, and so these three SNAREs are likely to be 
responsible for mediating WPB secretion through the formation of the SNAREpin. However, 
it is difficult to verify this hypothesis due to the high level of redundancy between SNAREs 
and the low level of protein needed to facilitate fusion. Indeed, siRNA studies generally fail 
to detect any significant effects following the knock-down of individual SNAREs.  
The expression of Munc18c has been identified in human lung microvascular 
endothelial cells and following thrombin stimulation both syntaxin-4 and Munc18c are 
phosphorylated (Fu et al. 2005). This modification has been proposed to disrupt the 
Munc18c:syntaxin-4 interaction, allowing exocytosis to proceed. Hence, Munc18c may have 
an inhibitory effect on WPB exocytosis.  
Finally, it is now known that the annexinA2/S100A10 complex is required for WPB 
secretion (Knop et al. 2004). This heterotetrameric complex is not found on WPBs but 
instead is localized to the plasma membrane and cytoplasm where it binds to phosphatidic 
acid in the membrane.  The inhibition of annexin-A2 by the treatment of HUVECs with either 
siRNA or blocking peptides leads to reduced VWF secretion (Knop et al. 2004). The annexin 
A2/S100A10 complex has been implicated in forming actin-rich membrane domains in other 
cell types and so it may be involved in organising the plasma membrane to allow WPB 
fusion. 
 
1.5.3.4 Signalling Mechanisms Governing WPB Exocytosis:  
 
Mature WPBs are held at the plasma membrane and undergo regulated secretion in 
response to stimulation of the endothelium by a wide range of agonists, most of which are 
associated with tissue injury or inflammation. A number of WPB agonists are proteins 
associated with the coagulation cascade and include thrombin and fibrin (Levine et al. 1982, 
Ribes et al. 1987). Others are released from activated platelets such as ATP, serotonin, and 
sphingosine-1-phosphate (Vishcer and Wollheim 2000, Schluter and Bohnensack, 1999, 
Matsushita et al. 2004). Others still are associated with inflammation including IL-4 and the 
complement proteins (Inomata et al. 2009, Hattori et al. 1989). Indeed, WPB exocytosis can 
be initiated by the direct contact of endothelial cells with bacterial constituents such as LPS 
and lipoteichoic acid (Schorer et al. 1987, Into et al. 2007). Exocytosis can also be induced 
by environmental conditions such as exposure to hypoxic conditions and radiation (Pinsky et 
al. 1996, Sporn et al. 1984). The list of substances which induce WPB exocytosis is large and 
growing. The most recent observation is that WPB secretion is stimulated by silica 
nanoparticles which are used extensively in medical procedures for drug delivery, cancer 
therapy, and are often added to cosmetics and paint (Bauer et al. 2011).  
Stimulants which trigger WPB secretion do so either through Ca
2+‐ or cAMP‐
dependent signalling, with the pathway utilized determined by the particular agonist. 
Thrombin is currently the most well-characterized Ca
2+‐dependent agonist and its application 
to endothelial cells causes a rapid localized increase in the intracellular free Ca
2+
 
concentration (Vischer et al. 2000). The Ca
2+
 sensitivity of WPB exocytosis is currently 
unclear although a number of studies have reported that secretion requires the prolonged 
exposure of endothelial cells to high Ca
2+ 
concentrations of between 10-20 µM (Birch et al. 
1992, Carter et al. 1998, Zupancic et al. 2002). It is assumed that, as with classical models of 
regulated secretion, free Ca
2+
 ions bind to an as‐yet unidentified calcium sensor which then 
drives the fusion of WPBs with the plasma membrane. Based on the estimated Ca
2+
 
sensitivity of WPB exocytosis, it is likely that this protein is a low-affinity Ca
2+
 sensor. For 
example, the well-characterized calcium sensors SYTs I and II show Ca
2+
 binding kinetics 
which match the secretion profile of WPBs (see Table 1.1). However, it is important to 
consider that the true Ca
2+
 threshold required for WPB exocytosis following receptor 
stimulation in vivo is likely to differ from the estimates provided thus far as these studies do 
not account for the spatial control of Ca
2+
 increases within the cell. Additionally, the 
optimum Ca
2+
 levels required for WPB exocytosis vary depending on the stimulation 
technique employed. For example, flash photolysis of caged Ca
2+
 results in maximal WPB 
exocytosis at 20 µM Ca
2+
 whereas this occurs at 7.1 ± 1.5 µM Ca
2+ 
following the direct 
stimulation of HUVECs with thrombin (Zupancic et al. 2002). Hence the true calcium 
sensitivity of WPB secretion is currently debatable and requires further investigation, ideally 
with the aim to mimic physiological conditions.  
The mechanisms regulating cAMP signalling in endothelial cells are unclear although 
they are known to be blocked in vitro by the inhibition of PKA (Vischer et al. 1997). An 
interesting feature of cAMP‐dependent secretion is that in response to increased levels of 
cAMP in the cell WPBs congregate in the perinuclear region in what is thought to be the 
centrosome (Rondaij et al. 2006). It is likely that this is a mechanism to limit the number of 
organelles secreted at once as only WPBs in the periphery of the cell undergo exocytosis. 
This clustering may also result in only a subset of WBPs being released, hence allowing a 
more tailored response to specific agonists.  
The stimulation of endothelial cells by increasing levels of either Ca
2+
 or cAMP leads 
to cytoskeletal rearrangements which increase or decrease endothelial cell permeability and 
hence impact the vascular tonicity of blood vessels. The precise effect depends on the nature 
of the stimulant. For example, exposure to thrombin leads to RhoA activation and this results 
in the formation of stress fibres which in turn causes endothelial permeability to increase as 
tight junctions disassemble (van Nieuw Amerongen et al. 2000). Conversely, cAMP‐induced 
signalling results in Rap1 activation and decreased permeability of the endothelium as 
adherens junctions are strengthened (Cullere et al. 2005). In both cases, WPBs are released 
but this is accompanied by opposing effects on endothelial permeability. Therefore, it is 
likely that different agonists result in varying degrees of inflammation as stimulation which 
increases levels of cAMP results in thrombosis but minimized leukocyte extravasation 
whereas stimulants which raise calcium levels lead to a more pronounced inflammatory 
response. 
 
 1.5.4 The Clinical Importance of WPBs: 
 
As is apparent from Table 1.2, WPBs secrete a wide range of proteins which regulate 
diverse biological processes including thrombosis, vascular tonicity, angiogenesis, and 
inflammation. It is not surprising therefore that the errant secretion of WPBs from 
chronically-activated endothelial cells has been implicated in the pathogenesis of many 
human diseases. The most well-characterized example of this is the established link between 
WPB exocytosis and the development of atherosclerotic plaques. Indeed, VWF
 -/-
 mice show 
a reduced number and size of atherosclerotic plaques (Methia et al. 2001). Equally, pig 
models for VWD show a resistance to developing atherosclerosis (Fuster et al. 1978). It is 
thought that the excessive release of VWF in the vicinity of atherosclerotic lesions promotes 
thrombosis and exacerbates the condition.  
 A number of infectious diseases which attack the endothelium such as malaria, 
dengue fever, and sickle cell anaemia induce the release of WPBs. It is highly likely that this 
results in severe clinical consequences by contributing to the obstruction of small blood 
vessels which is often the cause of death in these conditions. Additionally, the increased level 
of VWF and proregion in the plasma of infected people can be used as a useful biomarker for 
disease progression. For example, numerous studies have demonstrated that the plasma levels 
of VWF and proregion are considerably elevated in children with malaria and correlate with 
the level of plasma lactate, an established biomarker for disease severity (Hollestelle et al. 
2006, Larkin et al. 2009, de Mast et al. 2009, Phiri et al. 2011). The levels of these proteins 
decrease as treatment commences and clinical symptoms improve. Additionally,  a recent 
study has demonstrated that Indonesian children suffering from dengue haemorrhagic fever 
show increased plasma levels of highly-multimerized VWF, proregion, and osteoprotegrin 
compared with healthy controls (Djamiatun et al. 2012). 
 Recently, the release of WPBs has been linked to the development of the degenerative 
neurological condition multiple sclerosis and to the recruitment of stem cells. Firstly, mice 
models for multiple sclerosis which are deficient in VWF show an earlier onset of 
encephalomyelitis, a greater number of lesions, and a more severe disease phenotype 
characterized by increased demyelination and neutrophil infiltration into the brain (Noubade 
et al. 2008). Therefore VWF may protect against the development of multiple sclerosis 
although the rationale behind this is currently unclear as it was initially anticipated that the 
release of WPBs would exacerbate the condition by increasing the permeability of the blood-
brain barrier and allowing the extravasation of leukocytes into the brain. WPBs have also 
been loosely linked to the process of stem cell recruitment as they are released following 
exposure to the stem cell mobilizing agent uric acid (Kuo et al. 2008). The WPB cargo 
protein angiopoeitin-2 also stimulates the rapid mobilization of hematopoietic stem cells, 
indicating that the release of WPBs may provide a positive-feedback mechanism ensuring the 
rapid recruitment and activation of stem cells following tissue injury.  
 Lastly, it has always been anticipated that the endothelium would play a role in the 
development of tumours and their metastasis as both processes require increased 
angiogenesis which is governed by endothelial cells. It is now known that VWF adheres 
directly to the murine melanoma cells B16-BL6 in vitro via its RGD domain (Terraube et al. 
2006). Additionally, VWF 
-/-
 mice injected with B16-BL6 cells show a significantly greater 
occurrence of metastatic foci compared with wild-type mice due to the increased survival rate 
of tumour cells in the lungs of VWF-deficient animals. Hence VWF plays a protective role in 
metastasis by inducing the destruction of cancerous cells.  
 Therefore, in addition to providing a useful model for regulated exocytosis WPBs 
have considerable clinical importance in their own right. Our understanding of the control of 
WPB exocytosis at the molecular level is however lacking and therefore further studies 
attempting to identify the components of the signalling pathways and fusion apparatus which 
mediate the release of these organelles from endothelial cells are necessary. Information 
derived from these investigations may aid in our understanding of how the errant release of 
WPBs contributes to the pathogenesis of human disease.  
 
1.6 SYTs and WPB Exocytosis in Human Endothelial Cells: Thesis Aims 
 
 As has been discussed thus far, endothelial cells are metabolically active specialized 
secretory cells and their major defining feature is the presence of the large rod-shaped 
organelles WPBs. These granules are not only useful models for regulated secretion but they 
are also clinically important. Our knowledge concerning the physical structure, molecular 
composition, and synthesis of WPBs has become more detailed in recent years. However, the 
signalling pathways which govern their release and the molecules which make up the WPB 
fusion apparatus are currently unclear. Specifically, it is unknown which protein or group of 
proteins constitute the calcium sensor regulating WPB fusion with the plasma membrane. 
SYTs are the most well-characterized family of calcium sensors and have an established role 
in mediating the Ca
2+
-dependent exocytosis of a large number of vesicles and organelles from 
a range of cell types. Therefore, it is my hypothesis that the Ca
2+
-mediated release of WPBs 
from endothelial cells is regulated by one or more members of the SYT family. This thesis 
describes my efforts to test this hypothesis by determining which SYTs are expressed in 
HUVECs and attempting to assign functional roles to these endothelial-expressed SYTs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Two 
Materials and Methods 
 
2.1 Reagents: 
 
 The SYTVII-YFP and SYTVII-YFP-D/N constructs were a kind gift from Professor 
Norma Andrews (University of Maryland). The CLB proregion-35 antibody was a kind gift 
from Professor M.J.A van Mourik (Sanquin Research, Amsterdam). The full details of all 
commercial antibodies used for Western blotting and ICC are listed in Table 2.1 (for α-SYT 
antibodies) and Table 2.2 (for all other antibodies).  
 
2.2 Tissue Culture and Nucleofection™: 
 
2.2.1 The Culture of HUVECs: 
 
 Passage 1 Human Umbilical Vein Endothelial Cells (HUVECs) were purchased from 
PromoCell GmbH (Heidelberg, Germany).  Initially, passage 1 HUVECs were grown on a 
14-cm dish and once confluent were expanded to 4 x 14-cm dishes. These cultures were 
grown to confluency prior to collection into vials (3 per dish) which were then frozen at          
-80°C. The vials (now passage 3) were used as stocks for individual experiments (e.g. for 
ELISAs each individual assay was performed with a separate vial of stock cells). HUVECs 
are primary human cells and as such are inherently heterogeneous. The passage 1 cells 
purchased from PromoCell are derived from a pool of umbilical cords and therefore are 
representative of a number of individuals, hence providing some degree of control over the 
natural variability of HUVECs. Additionally, prior to despatch from the manufacturer all 
HUVECs are screened for their morphology, adherence, viability, and expression of the 
endothelial marker proteins VWF and CD31. It is well-known in the Carter lab and has been 
reported by other groups that the rate and extent of WPB exocytosis from HUVECs varies 
due to the inherent heterogeneity of individual cultures and is also affected by passage 
number and confluency states (Nightingale et al. 2009, Howell et al. 2004). When repeating 
biochemical assays and ICC protocols this was controlled for by ensuring that HUVECs were 
plated at similar densities and used at the same passage number. Even so, I observed 
considerable variability in the secretory response of ionomycin-stimulated HUVECs. The  
Antigen Manufacturer 
Catalogue 
Number 
Host 
Species 
Optimum Dilution 
for ICC 
Optimum Dilution for 
Western Blotting 
SYT I Synaptic Systems 105 011 Mouse 1:200* 1:200 
SYT III abcam
®
 ab81538 Rabbit N/D** N/D 
SYT III Synaptic Systems 105 133 Rabbit 1:200 1:200 
SYT V abcam
®
 ab116452 Rabbit N/D 1:200 
SYT VI abcam
®
 ab24250 Rabbit 1:200  1:200 
SYT VII  Synaptic Systems 105 172 Rabbit 1:200 1:200 
SYT VII Santa Cruz Sc-15418 Goat N/D N/D 
SYT VIII Acris Antibodies AP54128PU-N Rabbit  N/D 1:200 
SYT XI Santa Cruz Sc-101299 Mouse N/D 1:200 
SYT XVII abcam
®
 ab76274 Rabbit N/D 1:500 
 
Table 2.1. The details of the α-SYT antibodies. 
* Unless otherwise stated, the optimum dilutions of the SYT antibodies for ICC were 
determined in HEK cells expressing fluorescent constructs of the SYT proteins.  
** N/D = Not Determined. The antibody failed to recognize its antigen under any of the 
conditions tested. 
 
 
Antigen Manufacturer 
Catalogue 
Number 
Host 
Species 
Optimum Dilution 
for ICC 
Optimum Dilution for 
Western Blotting 
VWF DAKO A0082 Rabbit 1:10000 N/A* 
VWF Serotec AHP062 Sheep 1:10000 N/A 
VWF Serotec MCA127 Mouse 1:100 N/A 
Actin Sigma-Aldrich A5060 Rabbit N/A 1:1000 
Tubulin Sigma-Aldrich T9026 Mouse N/A 1:5000 
LAMP1 DSHB** H4B4 Mouse 1:100 N/A 
CD63 DSHB H5C6 Mouse 1:200 N/A 
EEA-1 
BD Transduction 
Laboratories 
610456/7 Mouse 1:100 N/A 
TGN-46 Serotec AHP500 Sheep 1:300 N/A 
PDI Stressgen SPA-891 Mouse 1:100 N/A 
tfR Invitrogen 13-6800 Mouse 1:200 N/A 
VAMP3 Synaptic Systems 104 102 Rabbit 1:200 N/A 
GFP Molecular Probes A-11122 Rabbit 1:300 Variable 
GFP Biogenesis 4745-1051 Sheep 1:250 Variable 
Rab27a 
BD Transduction 
Laboratories 
610595/6 Mouse 1:100 N/A 
tPA abcam
®
 ab28219 Rabbit 1:250 N/A 
PECAM DSHB PSB1 Mouse 1:20 N/A 
 
Table 2.2. The details of the non-SYT commercial antibodies.  
* N/A = Not Applicable. Western blotting or ICC was not performed for this antigen.  
** DSHB = Developmental Studies Hybridoma Bank 
 
 
 
 
extent of the basal release of VWF from unstimulated cells ranged from 0.2 - 2.5% of the 
total VWF within the cells whereas the equivalent figure for proregion was generally around 
1%. The extent of the stimulated secretion of VWF in response to 1 µM ionomycin exposure 
ranged from 8 – 30% of the total VWF within the cells and that of proregion ranged from 35 - 
65%. When assaying HUVECs cultured in 24- rather than 6-well plates this value could be as 
high as 85% total secreted protein. 
 HUVECs were cultured in HUVEC growth media (HGM) consisting of medium 199 
(Invitrogen, Paisly, UK) supplemented with 20% fetal calf serum (Biosera, Ringmer, UK), 50 
µg/ml gentamicin (Invitrogen), 10 U/ml heparin (Invitrogen) and 30 µg/ml endothelial cell 
growth supplement (ECGS) (Upstate, Dundee, UK). Cells were grown at 37°C under 5% 
CO2 on 14-cm dishes, 6-well plates, 24-well plates, or 9-mm ethanol-sterilized glass 
coverslips. All culture dishes were purchased from Thermo Scientific (Langenselbold, 
Germany) and were coated with 1% porcine gelatin (Sigma-Aldrich, St. Louis, USA) prior to 
use. For passaging, confluent HUVECs were washed once with Dulbecco’s 1x sterile PBS 
(Invitrogen) followed by a short incubation with 2.5 mL of 0.25% trypsin-EDTA 
(Invitrogen). When the HUVECs had fully detached from the growth surface, the trypsin was 
inactivated by the addition of 9.5 mL of HGM. The required quantity of the cell suspension 
was added to fresh HGM which was then re-plated onto new gelatin-coated growth surfaces. 
For experiments, HUVECs were grown to confluency and used at either passage 4 or 5.  
 
2.2.2 The Culture of HEK-293 Cells:  
 
Human Embryonic Kidney-293 (HEK-293) cells were cultured in Minimal Essential 
Medium (MEM) Alpha Medium 1x (Invitrogen) supplemented with 10% fetal calf serum 
(Biosera, Ringmer, UK) and 50 µg/ml gentamycin (Invitrogen). Cells were grown at 37°C 
under 5% CO2 on 14-cm dishes, 6-well plates, or 9-mm ethanol-sterilized glass coverslips. 
There was no need to pre-coat growth surfaces with gelatin. HEK cells were split using the 
same protocol as for HUVECs (2.2.1 The Culture of HUVECs) with the exception that MEM 
Alpha medium was used in place of HGM. HEK cells were maintained at approximately 80% 
confluency and were used up to passage 25.   
 
2.2.3 The Nucleofection™ Protocol: 
 
Nucleofection™ is a form of transfection which allows the direct transfer of DNA 
into cell nuclei and generally results in excellent transfection efficiency (between 40-70%) 
and cell viability (around 95%) (Hamm et al. 2002, Maasho et al. 2003). For the transfection 
of HUVECs with DNA constructs and siRNA, the Amaxa Nucleofection™ system was used 
according to the manufacturer’s instructions (Lonza Biologics Plc, Slough, UK). Briefly, 
confluent HUVECs were washed once with Dulbecco’s 1x sterile PBS, incubated with 2.5 
mL of 0.25% trypsin-EDTA until they had fully detached from the growth surface, and 9.5 
mL of HGM was added to the trypsinzed cells. The required quantity of cell suspension was 
then centrifuged for 3 minutes at 1000 RCF. The HGM was removed and the cell pellet was 
re-suspended in 100 µL of HUVEC OLD Nucleofector™ Solution containing 2-4 µg of 
target DNA. The solution was transferred to a supplied curvette and transfected using 
programme U-01 of the Nucleofector™ device. Immediately following transfection, the cell 
suspension was transferred to fresh HGM pre-warmed to 37°C and then plated onto gelatin-
coated growth surfaces. Cells were used for experiments 8 – 48 hours following transfection 
depending on the expression properties of the transfected construct.  
The Nucleofection™ procedure for HEK cells was identical to that for HUVECs with 
the exceptions that MEM Alpha medium was used in place of HGM, Cell Line 
Nucleofector™ Solution V was used in place of HUVEC OLD Nucleofector™ Solution, the 
cells were transfected with programme Q-01 rather than U-01, and growth surfaces were not 
pre-coated with gelatin.  
 
2.2.4 The Knock-Down of SYT mRNA: 
 
For the knock-down of SYT mRNA in HUVECs, ON-TARGETplus SMARTpool 
siRNA was purchased from Dharmacon (Thermo Scientific, St. Leon-Rot, Germany) and 
prepared in 5 x siRNA resuspension buffer (Dharmacon) according to the manufacturer’s 
instructions. HUVECs were transfected with 200 – 400 pMol of SYT siRNA using the 
Amaxa Nucleofection™ system as detailed above (2.2.3 The Nucleofection™ Protocol). As a 
control, HUVECs were transfected with non-targeting siRNA (ON-TARGETplus Non-
targeting Control Pool #D-001810, Dharmacon, Thermo Scientific, St. Leon-Rot, Germany). 
The extent of protein knock-down for each SYT was determined by Western blotting and 
quantified using ImageJ software (National Institutes of Health, Bethesda, Maryland, USA).  
 
2.3 Reverse-Transcription PCR:  
Reverse-transcription polymerase chain reaction (RT-PCR) was used to detect the 
expression of SYT mRNA transcripts in HUVECs and HEK cells. For each of the 17 
members of the SYT family, two sets of unmodified DNA primers were purchased from 
eurofins (Ebersberg, Germany). These primers were designed to span two exons flanking an 
intron as shown in Figure 2.1 using the SYT gene sequences provided in the Ensembl 
database (http://www.ensembl.org/index.html). The purpose of this was to discriminate 
between coding mRNA and any contaminating genomic DNA as the sizes of amplified 
fragments would be considerably different. The sequences of the primers are shown in Table 
2.3. Template RNA for RT-PCR was extracted from confluent HUVECs and HEK cells using 
the RNeasy
® Mini Kit (Qiagen, Manchester, UK) according to the manufacturer’s 
instructions. The quantity and purity of extracted RNA was determined by measuring its 
absorbance at 280 and 260 nm using a Nandrop-1000
® 
device (Wilmington, DE, USA).  
Purified RNA was stored at -20°C and thawed on ice. RT-PCR was performed using a 
SuperScript™ One-Step kit (Invitrogen, Paisley, UK) according to the manufacturer’s 
instructions. Briefly, 1 µg of RNA was added to the reaction mix and cDNA was synthesized 
using one cycle of heating to 55°C for 20 minutes following by an increase to 94°C for two 
minutes. Subsequent PCR amplification of HUVEC cDNA was achieved using 40 cycles of 
denaturation (94°C for 15 seconds), followed by annealing (55°C for 30 seconds) and 
extension (72°C for 1 minute). PCR was performed using a Mastercycler
®
 machine 
(eppendorf, Stevenage).The products of PCR were run on a 1.5% agarose gel and visualized 
by ethidium-bromide staining. All bands of interest were sent for sequencing to confirm their 
identities (GATC Biotech, Cologne, Germany). 
 
2.4 Western Blotting: 
 
2.4.1 Lysate Extraction: 
 
2.4.1.1 Conventional Lysate Extraction: 
 
 Lysates were extracted from confluent HUVECs and HEK cells grown on either 14-
cm dishes or 6-well plates. For lysate extraction from 14-cm dishes, the cells were trypsinized 
as described (2.2.1 The Culture of HUVECs) and the cell suspension was centrifuged for 
three minutes at 1000 RCF. The cell pellet was re-suspended in PBS and centrifuged again 
for three minutes at 1000 RCF. The supernatant was removed, and 2 x Laemmli sample 
 
 
 
 
 
 
 
 
 
Table 2.3. The sequences of the primers used to identify SYT family 
members. 
SYT 
Primer Set One Primer Set Two 
Forward Primer Reverse Primer Forward Primer Reverse Primer 
I 
GCCATAGTCGC
AGTCCTTTT 
ATCCTTGAGGGCC
TGATCTT 
ACAGTGGATTTTG
GCCATGT 
CCACCCACATCCA
TCTTCTT 
II 
GAAGGGGAGG
AGGAGAAAGA 
TTCCGATGGACTTT
GGTCTC 
TCACTGTCTGCAT
CCTGGAG 
AATCTGCTCGAAG
GGGATCT 
III 
GATCTACCTGC
TGCCTGACC 
CGAGAAGCGGTCA
AAGTCAT 
ATAATGAGGCGCT
GGTGTTC 
CACTAGCTGATGC
CAGTGCT 
IV 
GGCCTTGCACT
TCACAATTT 
GTAACTCACCCCG
TCCTGAA 
TTCAGGACGGGGT
GAGTTAC 
TTTGGCATGGTAC
AGGTTCA 
V 
CTCAGGCCTCC
TCATCTTCA 
TTCTGGCTGCACCT
TGTCTA 
CCCTATGAGCTCC
GTGGAC 
TTTTAGCCTCCAGG
ACGATG 
VI 
TTGAGGCCTCT
GACCTGTCT 
GCCTTGAGGTTCC
GACACT 
TGAGGCCATCATC
TTTGACA 
TTACCTCCACCAA
GGAGTGC 
VII 
GCGCAGTGAGA
AGAAGGCTA 
ATCTCGCTGGTGA
GGGAGT 
AGGTGTCCATCCC
CCTTAAC 
GATGTCCATGGCT
TTGAGGT 
VIII 
GAAGAAGCCCA
GGGACAAG 
GCTTCCAAAGTCG
AACTCCA 
GCTTCTCTCTCCGG
TACGTG 
AGGAAGGTGAAGG
CCTCATT 
IX 
ACTTAATCGGC
CAAGTGGTG 
CAGCCGTTGGAAG
ATAGCAC 
CCCGAGAACATTG
ACCAAAT 
GGCTTCCGAGGAT
ATGACAA 
X 
TGACATGATTG
GGGAAGTGA 
AGCCGTCGGTAGG
TAACAAA 
ACATCCCTCCAGA
GAACGTG 
GCCAGTGCGTTAT
TGGTTTT 
XI 
CAGCACAGGCA
AGGTACAAC 
ATCCATCTTCGGC
AAGTGTC 
GACACTTGCCGAA
GATGGAT 
GGTCAGTGGGGAT
GTCGTAG 
XII 
CCGTTCCCCAA
TTACGACTA 
CCCCAGTTCACTG
ATGCTCT 
TCCTGCTCTCCCTC
AGCTAC 
CGGCTGTCTTCTTT
TTGCTC 
XIII 
AAGAGGCAGGT
CACAGAGGA 
CAAACAATTCTGC
CTTCTGACA 
TCCTGGTGGTGCT
GATTAAA 
TGATCATCTCGTTC
CACACG 
XIV 
CTTGGGAAACA
AGGCAGAAA 
ACAGATGGGGAGA
ACCACTG 
TTCAAGGGAAAAT
GTCATTGC 
GGCATTATAAAGC
AGGCCAAT 
XV 
GTGCTCTTCCCC
TTGAAGAA 
ACAATGCCTCTGT
CCTCCTG 
GACCTCCAGTTCT
GCCTCAG 
GCCTTGAAGCTGA
AGGTCTC 
XVI 
AGCAAAGAAGT
GGCCTTCAA 
TTTGGTTTCTGCTC
CAATCC 
GGACTCTGCCCAA
AATTCAA 
TGAAGGCCACTTC
TTTGCTT 
XVII 
AGCGACGATGT
GGACTCTCT 
CTTCTGGTCTGGC
AGGAGAC 
GTCTCCTGCCAGA
CCAGAAG 
GTGGCGGGAGAAC
TTATCAA 
Figure 2.1. The strategy used to design the SYT primers.  
Primers were selected to span two exons flanking an intron. During splicing, the 
intronic sequence is removed, allowing discrimination between coding mRNA and 
contaminating genomic DNA.  
 
buffer (50% w/v glycerol, 15% SDS, 400mM Tris pH 6.8, 0.01% bromophenol blue) 
supplemented with 5% β-mercaptoethanol and a protease inhibitor cocktail (1:100 dilution, 
Sigma-Aldrich) was added to the pellet at a 1:10 weight/volume ratio followed by heating to 
95°C for 5 minutes.  Samples were frozen at  -20°C if necessary. For lysate extraction from 
6-well plates, the media was removed from each well followed by a brief PBS wash. 400 µL 
of 2 x Laemmli sample buffer supplemented with 5% β-mercaptoethanol and a cocktail of 
protease inhibitors was added to each well. Lysates were collected by scraping into 1.5 mL 
eppendorfs and transferred to a heat block set at 95°C for 5 minutes. The samples were 
homogenized by shearing with a 23G needle, centrifuged at 13,000 RPM for 1 minute, and 
frozen at -20°C if necessary.  
 
2.4.1.2 TX-114 Lysate Partitioning: 
 
TX-114 partitioning is a technique used to enrich a solubilized whole-cell sample with 
membrane proteins using the mild detergent TX-114. Following the heating of a lysate 
sample from 0°C, TX-114 separates into an aqueous phase containing hydrophilic proteins 
and a detergent phase which contains amphiphilic integral membrane proteins (Bordier, 
1981). Here, cells were lysed in cold TX-114 lysis buffer (consisting of 1% TX-114 buffer 
(10% stock, Sigma-Aldrich), 1 mM EDTA, and 1:100 protease inhibitors) and the lysate was 
mixed by rotation at 4°C for 1 hour. The sample was then spun for 10 minutes at 13,000 
RPM at 4°C. The supernatant was removed, heated to 37°C for 1 minute with mild agitation, 
and then centrifuged for 1 minute at 13,000 RPM. The pellet was washed with cold PBS, 
incubated on ice for 5 minutes, and heated to 37°C with mild agitation. The sample was then 
centrifuged for 1 minute at 13,000 RPM, the supernatant was removed, and 10 µL of 10 
mg/ml bovine haemoglobin (Sigma-Aldrich) was added to the TX-114 layer which now 
contains the membrane proteins. 400 µL of methanol, 200 µL of chloroform, and 300 µL of 
dH20 were added sequentially to the sample which was then spun for 3 minutes at 13,000 
RPM. The top phase containing the extracted proteins was transferred to 300 µL of methanol. 
The mixture was then spun for 5 minutes at 13,000 RPM and the supernatant was removed. 
Finally, the pellet was incubated with 2 x Laemmli sample buffer, heated to 95°C for 5 
minutes, and frozen at - 20°C if necessary.  
 
2.4.2 Immunoblotting: 
 
 Lysates were diluted to a 1:1 ratio in 2 x Laemmli sample buffer, loaded onto home-
made 10% acrylamide gels, and separated by running for 40 minutes at 200 volts on a Mini-
Protean
®
 II Cell electrophoresis device (Biorad, Hemel Hempstead, UK). The separated 
proteins were transferred to 0.2 µm nitrocellulose membranes (Whatman
®
, Maidstone, UK) 
at 12 volts for 1 hour. The extent of protein transfer was visualized by a brief incubation with 
0.2% Ponceau S (Sigma-Aldrich), which was then removed by washing with PBS. The blots 
were blocked with 5% milk (Marvel, Premier Foods) for 30 minutes followed by 2 x PBS 
washes and 2 x dH20 washes. For immunoblotting, blots were incubated with primary 
antibodies diluted in PBS/Tween (PBS supplemented with 0.3% Tween-20) for one hour. The 
optimized dilutions of the primary antibodies are shown in Tables 2.1 and 2.2. When initially 
optimizing an antibody for Western blotting it was necessary to use the Miniblotter-28
®
 
device (Immunetics, Cambridge, MA), which allows the simultaneous screening of multiple 
antibodies at various concentrations. The Miniblotter-28
®
 was used according to the 
manufacturer’s instructions and blots were rinsed extensively with PBS/Tween to prevent any 
over-spill between wells prior to their removal from the device. Following incubation with 
the primary antibodies, blots underwent 5 x 5 minute PBS washes and were then incubated in 
the dark for 25 minutes with dye-coupled secondary antibodies diluted in blocking buffer 
(PBS-Tween containing 5% milk) to 1:5000. All secondary antibodies for Western blotting 
were purchased from LI-COR Biosciences (Cambridge, United Kingdom). Blots then 
underwent 5 x 5 minute PBS/Tween washes in the dark followed by 2 x PBS washes and 2 x 
dH20 washes. Finally, the blots were visualized using a LI-COR Odyssey Infrared Imaging 
System (LI-COR Biosciences, Cambridge, United Kingdom). 
 
2.5 Immunocytochemistry: 
 
 2.5.1 Fixation Methods: 
 
  2.5.1.1 Methanol Fixation: 
 
 HUVECs or HEK cells were grown to confluency on 9-mm glass coverslips. The 
media was removed and the cells were fixed for 5 minutes at -20°C with ice-cold methanol. 
The coverslips were then washed once with PBS and incubated with permeabilisation 
solution (PGAS, 0.2% w/v gelatin, 0.02% w/v saponin, 0.02% w/v NaN3, made up in PBS) 
for at least 5 minutes prior to staining.  
   2.5.1.2 PFA/Saponin Fixation: 
 
 HUVECs or HEK cells were grown to confluency on 9-mm glass coverslips. The 
media was removed and the cells were fixed with 3% paraformaldehyde (PFA) in PBS for 20 
minutes. Cells were then permeabilised and quenched by incubation for 15 minutes with 50 
mM NH4CL and 0.2% saponin made up in PBS. Cells were incubated with PGAS for at least 
5 minutes prior to staining.  
 
  2.5.1.3 TX-100 Fixation: 
 
HUVECs or HEK cells were grown to confluency on 9-mm glass coverslips. The 
media was removed and the cells were fixed with 3% PFA in PBS for 20 minutes. Cells were 
then quenched by incubation for 15 minutes with 50 mM NH4CL made up in PBS, followed 
by a 5 minute permabilisation with 0.03% TX-100 in PBS. Cells were incubated with PGAS 
for at least 5 minutes prior to staining.  
 
2.5.2 Immunostaining: 
 
Individual 9-mm glass coverslips were incubated cell-side down in a humidified 
chamber with 50 µL of a solution containing the primary antibodies diluted in PGAS. The 
optimum dilutions of the primary antibodies used for immunocytochemistry (ICC) are shown 
in Tables 2.1 and 2.2. Following the 1 hour primary incubation, the coverslips were removed 
and washed 3 times with PGAS. The coverslips were then incubated in the dark for 45 
minutes with 50 µL of flurophore-conjugated secondary antibodies diluted in PGAS. 
Secondary antibodies were purchased from Jackson ImmunoResearch (West Grove PA, 
USA) and were used at dilutions of 1:200 (for Rhodamine Red™-X and Cy™-5) and 1:150 
(for Cy™-2). The coverslips were then washed three times with PGAS and three times with 
PBS. They were dipped twice in dH20 prior to mounting with Mowiol (Polysciences Inc., PA, 
USA) onto glass microscope slides (Thermo Scientific, Waltham, MA, USA). Mounted 
coverslips were viewed using a Leica SP2 Scanning Spectral Confocal Microscope (Milton 
Keynes, UK) equipped with a 100x/1.40 NA oil immersion objective lens.  Images were 
prepared in Adobe Photoshop CS4 (San Jose, CA, USA).  
 
2.6 Molecular Biology: 
 
 Fluorescent constructs containing DNA encoding the Aequorea Victoria green 
fluorescent protein (GFP) were constructed for each member of the SYT family which is 
known to be expressed in HUVECs and were used to determine the subcellular localization of 
the endothelial SYTs. GFP is a non-toxic, stable protein which does not affect the growth or 
function of transfected cells (Chalfie et al. 2004). Therefore, GFP fusion proteins are 
excellent tools for determining the subcellular localization of endogenous proteins when 
conventional techniques such as ICC fail.  
  
2.6.1 Conventional Ligation-Dependent Cloning: 
 
 To generate the SYTI-EGFP construct, conventional cloning methods were used as 
illustrated in Figure 2.2. Initially, HUVEC mRNA was extracted from a confluent 14-cm dish 
using the RNeasy
® 
Mini Kit (Qiagen, Manchester, UK) according to the manufacturer’s 
instructions. HUVEC cDNA was synthesized from the purified mRNA using the Quanitect
®
 
Reverse-Transcription Kit (Qiagen, Manchester, UK) according to the manufacturer’s 
instructions. Primers were designed which encompassed the cDNA sequence for SYT I and 
incorporated sites for the restriction enzymes HindIII and AgeI. The sequences of the primers 
were as follows: 5’-AGTTTAAGCTTATGGTGAGCGA-3’ (forward primer) and 5’-
GCCGTCAAGAAGGGACCGGTTTTA-3’ (reverse primer), where the sequences in bold 
show the positions of the restriction sites for HindIII (forward) and AgeI (reverse). PCR was 
performed using the KOD Hot Start DNA Polymerase kit (Merck, Feltham, UK) according to 
the manufacturer’s instructions. The cycling conditions were as follows: heating to 50°C for 
30 minutes followed by an increase to 94°C for 2 minutes followed by 40 x [94°C for 15 
seconds, 55°C for 30 minutes, and 70°C for 1 minute] followed by a final step of heating to 
72°C for 5 minutes. The PCR product was run on a 1.5% agarose gel and purified using the 
GenElute™ Gel Extraction Kit (Sigma-Aldrich) according to the manufacturer’s instructions. 
Both the purified PCR fragment and 2 µL of a Clontech pEGFP-N1 vector (BD Biosciences 
Clontech, Saint-Germain-en-Laye, France) were digested using the restriction enzymes 
HindIII (Roche, Welwyn Garden City, UK) and AgeI (New England Biolabs (NEB), Hitchin, 
UK) at 37°C for 3 hours in the presence of the appropriate NEB buffer and BSA. Digested 
products were run on a 1.5% agarose gel and purified using the GenElute™ Gel Extraction 
Kit (Sigma-Aldrich) according to the manufacturer’s instructions. The vector and SYT I  
 
 
 
Figure 2.2. The strategy used to produce the SYTI-EGFP construct.  
The cDNA sequence for SYT I was amplified from a pool of HUVEC 
cDNA using primers containing restriction sites for AgeI and HindIII and 
then digested using these same enzymes. Meanwhile, the EGFP-N1 vector 
was digested with HindIII and AgeI and both the insert and vector were 
combined by ligation to produce the SYTI-EGFP vector.  
 
 
 
 
 
 
 
 
 
insert were then incubated together in a 1:1 ratio in the presence of 0.25 µL of T4 DNA ligase 
(New England Biolabs, Hitchin, UK) and 0.25 µL of its accompanying buffer at room 
temperature for 2 ½ hours. The ligated product was used to transform competent bacteria 
according to the protocol detailed below (2.6.4 The Transformation of Competent Bacteria). 
The purified construct was sequenced to confirm its identity. The SYTI-mCherry construct 
was produced using this same protocol with the exception that a pmCherry-N1 parent vector 
(BD Biosciences Clontech, Saint-Germain-en-Laye, France) was used in place of the pEGFP-
N1 parent vector. 
 
2.6.2 Ligation-Independent Cloning (LIC): 
 
2.6.2.1 The Theory of the LIC Method: 
 
Ligation-independent cloning (LIC) is a relatively novel technique for cloning PCR 
fragments which eliminates the need for restriction enzymes and DNA ligase (Aslanidis and 
Jong, 1990). For the LIC method, PCR primers are designed which contain a 12-nucleotide 
dTMP-free sequence at their 5’-ends and therefore yield products which do not contain 
dAMP at their 3’-ends. The final 12 nucleotides of the amplified product can be removed by 
digestion using the (3’- 5’) exonuclease activity of T4 DNA polymerase in the presence of 
dATP. This leaves 5’ single-stranded ends on the amplified PCR fragments. The LIC parent 
vector contains a specific TMP-lacking sequence which can also be digested with T4 DNA 
polymerase in the presence of dTTP. This leads to the generation of single-stranded 
sequences in the vector which are complementary to the single- stranded tails of the PCR 
product, allowing spontaneous circularization between the product and the vector. This 
approach inhibits the re-ligation of the parent vector which is often a cause of failure with 
conventional cloning methods.  A schematic showing the theory behind the LIC method is 
provided in Figure 2.3. 
  
2.6.2.2 The LIC Protocol: 
 
For the generation of SYT-EGFP constructs the LIC method was used unless 
otherwise stated. The parent LIC-EGFP vector was digested using the restriction enzyme 
XmaI (New England Biolabs (NEB), Hitchin, UK) and NEB buffer 4 at 37°C for 3 hours. 
The digested product was run on a 1.5% agarose gel and purified using the GenElute™ Gel  
 
 
 
 
Figure 2.3. The theory behind the LIC method.  
Template DNA in the form of SYT image clones was amplified using 
specific LIC primers. The PCR products were digested using the 
exonuclease activity of T4 DNA polymerase leaving 5’ single-stranded 
ends. Meanwhile, the parent LIC vector was opened by XmaI digestion 
followed by further digestion with T4 DNA polymerase. The vector and 
PCR product now contain complementary single-stranded ends which will 
anneal spontaneously under the appropriate conditions. Further details are 
provided in the text.  
 
 
 
 
 Table 2.4. The sequences of the primers used for the LIC method.  
The sequences of the primers for each member of the SYT family known 
to be expressed in HUVECs are shown. Note that SYT I was cloned using 
conventional cloning techniques and therefore is not included in the table.  
 
Extraction kit according to the manufacturer’s instructions. LIC primers were designed for 
each SYT isoform known to be expressed in HUVECs with the exception of SYT I according 
to the theory detailed above (2.6.2.1 The Theory of the LIC Method). The sequences of the 
LIC primers are shown in Table 2.4. Image clones containing the SYT cDNA sequences were 
purchased from Source Bioscience (Nottingham, UK) and amplified using the KOD Hot Start 
DNA Polymerase kit (Merck, Feltham, UK) according to the manufacturer’s instructions. The 
cycling conditions were as follows: 1 heating step to 95°C for 5 minutes followed by 10 x 
[95°C for 15 seconds, 52°C for 15 seconds, and 70°C for 3 minutes] followed by 30 x [95°C 
for 15 seconds, 58°C for 15 seconds, and 70°C for 3 minutes] followed by a final step of 
heating to 70°C for 5 minutes. The PCR products were purified using the GenElute™ PCR 
Clean-up Kit according to the manufacturer’s instructions. Following vector digestion by 
XmaI and insert amplification by PCR, the T4 digestion reactions were set up. For the vector, 
4 pMol of purified vector were added to 4 µL of T4 DNA polymerase buffer (Promega 
Madison, WI, USA), 4 µL of 25 mM dTTP, 2 µL of 100 mM DTT, 6 µL of T4 DNA 
polymerase (New England Biolabs, Hitchin, UK), and the mixture was made up to 40 µL 
with dH20. For the insert, 2 pMol of purified PCR fragment were added to 2 µL of T4 DNA 
polymerase buffer, 2 µL of 25 mM dATP, 1 µL of 100 mM DTT, 3 µL of T4 DNA 
polymerase, and the mixture was made up to 20 µL with dH20. The reactions were incubated 
at room temperature for 30 minutes followed by incubation with either 2.2 µL (insert) or 4.4 
SYT Forward Primer Reverse Primer 
III 
GCAGGGGCGCAACAGACCCCGGTATGTC
AGGAGACTACGAGGA 
CCACCAGGCCGGCCAGCACCCGGTCCCTC
GGAGTTCTCTTTCTCTG 
V 
GCAGGGGCGCAACAGACCCCGGTATGTT
CCCGGAGCCCCCAAC 
CCACCAGGCCGGCCAGCACCCGGTCCGGG
CGCAGGCAGCAGCCTCAC 
VI 
GCAGGGGCGCAACAGACCCCGGTATGC
CCTGGAGGAACAAGGA 
CCACCAGGCCGGCCAGCACCCGGTCCCAA
CCGAGGGTTTCCCTC 
VII 
GCAGGGGCGCAACAGACCCCGGTATGT
ACCGGGACCCGGAGGCGG 
CCACCAGGCCGGCCAGCACCCGGTCCGGC
CTTCAGCTGGTGCCAC 
VIII 
GCAGGGGCGCAACAGACCCCGGTATGCT
CCACCTGCATGGCTG 
CCACCAGGCCGGCCAGCACCCGGTCCGGA
GTGGGGCAAGGGCAGGC 
XI 
GCAGGGGCGCAACAGACCCCGGTATGG
CTGAGATCACCAATAT 
CCACCAGGCCGGCCAGCACCCGGTCCGTA
CTCGCTCAGACTGTGCC 
XVII 
GCAGGGGCGCAACAGACCCCGGTATGG
CGTACATCCAGTTGGA 
CCACCAGGCCGGCCAGCACCCGGTCCGGT
CACCTCCAGGGAGGCAG 
µL (vector) of 50 mM EDTA for 20 minutes at 75°C. The individual reactions were then 
purified using the GenElute™ PCR Clean-up kit according to the manufacturer’s instructions 
with the exception that the products were eluted with 30 µL of dH20 instead of elution buffer. 
Then, 1 µL of insert and 2 µL of vector were combined and left at room temperature for 15 
minutes followed by the addition of 2 µL of 100 mM EDTA. The mixture was then heated to 
75°C for 3 minutes. The tubes were removed from the heat block, wrapped in tin foil, and 
allowed to cool slowly for 1 hour at room temperature. The samples now contain SYT-EGFP 
LIC constructs and were used to transform competent bacteria as described (2.6.4 The 
Transformation of Competent Bacteria). All constructs were purified by maxiprepping (see 
2.6.7 Maxiprepping) and sequenced to confirm their identities.   
 
2.6.3 Site-Directed Mutagenesis: 
 
Site-directed mutagenesis was performed using the Stratagene QuikChange
® 
Site-
Directed Mutagenesis Kit according to the manufacturer’s instructions (Agilent Technologies 
UK Limited, Cheshire, UK). High-purity primers were designed with the aid of an on-line 
primer design tool (http://labtools.stratagene.com/QC). To generate the SYT V calcium-
insensitive mutant the following primers were used: 5’-ggtcatggcggtgtacagcttcgaccgcttctct-3’ 
(forward primer) and 5’-agagaagcggtcgaagctgtacaccgccatgacc-3’ (reverse primer). To 
generate the dominant-negative cytoplasmic SYT V mutants the following primers were 
used: 5’-gcaggggcgcaacagaccccggtatgtgctgtttctgtctctacc-3’ (forward primer) and 5’-
ccaccaggccggccagcacccggtccgggcgcaggcagcagcctcac-3’ (reverse primer).  To generate the 
SYT VII calcium-insensitive mutant the following primers were used: 5’- tctacctccaagtcctg- 
agctatgaccgcttcagcc-3’ (forward primer) and 5’-ggctgaagcggtcatagctcaggacttggaggtaga-3’ 
(reverse primer). To generate the dominant-negative cytoplasmic SYT VII mutants the 
following primers were used: 5’-gcaggggcgcaacagaccccggtatgtgtcagcgcaaactgggcaaa-3’ 
(forward primer) and 5’-ccaccaggccggccagcacccggtccggccttcagctggtgccac-3’ (reverse 
primer).  
 
2.6.4 The Transformation of Competent Bacteria: 
 
DH5α competent bacteria (Invitrogen, Paisly, UK) were incubated on ice with a 
variable quantity of target DNA for 30 minutes. They were then heat-shocked at 42°C for 45 
seconds and immediately placed on ice for 2 minutes. 1 mL of SOC media (NIMR, London, 
UK) was added and the mixture was incubated at 37°C with shaking at 1,000 RPM for 1 
hour. Tubes were then spun for 1 minute at 13,000 RPM, the majority of the supernatant was 
removed, and the bacterial cell pellet was re-suspended in the remaining SOC media 
(approximately 100 µL). The suspension was plated onto pre-dried agar plates containing the 
appropriate antibiotic using aseptic technique. Plates were incubated overnight at 37°C. 
 
 2.6.5 Liquid Cultures: 
 
 To grow transformed bacteria in small liquid cultures (2.5 mL), individual colonies 
were picked from agar plates using ethanol-sterilized tweezers and aseptic technique. 
Colonies were incubated overnight with 2.5 mL of L-broth (NIMR, London, UK) containing 
the appropriate antibiotic at 37°C and with vigorous shaking. Liquid cultures were then 
processed for miniprepping as described below (2.6.6 Miniprepping). To grow transformed 
bacteria in large liquid cultures (250 mL), 50 µL of bacterial suspension from a small liquid 
culture were incubated with 250 mL of L-broth containing the appropriate antibiotic at 37°C 
and with vigorous shaking. Samples were then processed for maxiprepping as described 
below (2.6.7 Maxiprepping). 
 
 2.6.6 Miniprepping: 
 
 The alkaline lysis method was used to isolate plasmid DNA from transformed bacteria 
according to the theory and protocol detailed in Brinboim and Dolly (1979) with minor 
modifications. This method will be referred to herein as ‘miniprepping.’ Briefly, 1.5 mL of 
bacterial suspension from a small liquid culture was centrifuged at 13,000 RPM for 30 
seconds. The supernatant was removed and the pellet was re-suspended in 250 µL of cold 
STE (100 mM Tris-HCL pH 8, 100 mM NaCl, 1 mM EDTA). The solution was centrifuged 
at 13,000 RPM for 30 seconds and the supernatant was removed. The bacterial pellet was re-
suspended in 100 µL of Solution I (50 mM glucose, 25 mM Tris-HCL pH 8, and 10 mM 
EDTA) and 200 µL of freshly-prepared Solution II (200 mM NaOH, 1% SDS). The mixture 
was incubated at room temperature for 10 minutes. 150 µL of Solution III (60 mL 5M KAc, 
11.5 mL HAc, made up to 100 mL in dH20) was then added and the mixture was incubated 
on ice for 10 minutes. The samples were then spun at 13,000 RPM for 5 minutes. The 
supernatant was removed and transferred to a fresh 1.5 mL eppendorf. 2 volumes of 100% 
ethanol were added and the samples were incubated at -20°C for 1 hour, followed by 
centrifugation for 5 minutes at 13,000 RPM. The supernatant was removed and the cell pellet 
was washed with 500 µL of 70% ethanol. The samples were centrifuged one final time at 
13,000 RPM for 5 minutes and the supernatant was removed. The pellets were allowed to dry 
at room temperature and were then dissolved in 30 µL of TE buffer (10 mM Tris-HCL pH 9, 
1 mM EDTA).  
 
 2.6.7 Maxiprepping: 
 
 ‘Maxiprepping’ is a technique which allows the isolation of large amounts of pure 
plasmid DNA from a large liquid culture and was performed according to the protocol 
detailed in Molecular Cloning 3
rd
 Edition (Sambrook and Russell, 2001). Briefly, the 
bacterial suspension from a large liquid culture (2.6.5 Liquid Cultures) was pelleted at 3,000 
RPM for 10 minutes at 4°C in a Beckman JS 4.2 centrifuge (Beckman Coulter, High 
Wycombe, UK). The bacterial pellet was re-suspended in 25 mL of ice-cold STE and the 
bacteria were pelleted once again at 3,000 RPM for 10 minutes at 4°C in a Beckman JS 4.2 
centrifuge. The supernatant was removed and the pellet was re-suspended in 10 mL of 
Solution I. 1 mL of 10 mg/ml lysosyme (Sigma-Aldrich, St. Louis, USA) made up in 
Solution I was added and the mixture was incubated at room temperature for 10 minutes. 20 
mL of freshly-prepared Solution II were added and the mixture was incubated at room 
temperature for 10 minutes. Lastly, 15 mL of ice-cold Solution III were added and the 
mixture was incubated on ice for 10 minutes followed by centrifugation at 4,200 RPM for 15 
minutes at 4°C. The supernatant was filtered through home-made glass wool filters and 27 
mL of isopropanol were added. The mixture was then incubated at room temperature for 10 
minutes and centrifuged at 4,200 RPM for 30 minutes at 22°C. The pellet was washed with 
70% ethanol and allowed to dry at room temperature. Dry pellets were then dissolved in 6 
mL TE buffer and the weight of the DNA solution was calculated. For each 1 g of solution, 
1.1 g of solid CsCl (Invitrogen) were added and the sample was mixed until homogenous. At 
this point, 120 µL of ethidium bromide (Biorad, Hemel Hempstead, UK) were added and the 
samples were incubated in the dark for 15 minutes. The tubes were centrifuged at 3,000 RPM 
for 15 minutes at 22°C. The red supernatant was transferred to 2 x 3.9 mL QuickSeal tubes 
(Beckman Coulter, High Wycombe, UK) which were then spun in a TLN-100 ultracentrifuge 
(Beckman Coulter, High Wycombe, UK) at 100,000 RPM overnight at 22°C. The thin band 
of plasmid DNA was removed from the QuickSeal tubes, placed in a 15 mL centrifuge tube, 
and 6 mL of water-saturated N-butanol were added. The solution was shaken vigorously to 
encourage phase separation. The top organic layer was removed from the tube and an 
additional 6 mL of N-butanol were added. This procedure was repeated until no ethidum 
bromide remained in solution. The aqueous phase was transferred to a fresh 15 mL tube and 
made up to 5 mL with dH20. 10 mL of 100% ethanol were added and the tubes were 
incubated on ice for 15 minutes. The samples were spun at 3,000 RPM for 15 minutes at 4°C. 
The pelleted plasmid DNA was then washed with 70% ethanol and allowed to dry at room 
temperature. Finally, the plasmid DNA was dissolved in TE buffer and made up to 2 mg/ml.  
 
2.7 The Enzyme-Linked Immunosorbent Assay (ELISA) Protocol:  
 
 2.7.1 Sample Collection: 
 
 HUVECs were transfected with either a DNA construct or with SYT siRNA 
according to the protocol detailed previously (2.2.3 The Nucleofection™ Protocol). At the 
same time, control cells were transfected with either a non-functional cytoplasmic construct 
or with non-targeting siRNA. Cells were seeded onto 6-well plates in such a way as to ensure 
that equal numbers of wells were designated as ‘stimulated’ and ‘unstimulated’ and each 
condition was replicated at least three times. A schematic of the experimental design for 
media collections is shown in Figure 2.4. Transfected HUVECs were grown to confluency 
and were used 8 – 48 hours following transfection depending on the expression properties of 
the construct. To initiate sample collection, 1 mL of release media (consisting of bicarbonate 
free M199 (Gibco
®
 Life Technologies, Invitrogen, Paisley, UK) and 20 mM HEPES, pH 7.4), 
was added to each well and the HUVECs were allowed to acclimatize to the media for 50 
minutes at 37°C. This was then removed and replaced with fresh release media. After 10 
minutes, the media was collected in 1.5 mL eppendorfs and replaced with 1 mL of fresh 
media containing either 1 µM ionomycin calcium salt (Sigma-Aldrich, St. Louis, USA) or an 
equivalent volume of 100% ethanol to act as the control non-stimulating solution. After 10 
minutes, the release media was collected into 1.5 mL eppendorfs. The samples were spun for 
three minutes at 13,000 RPM to remove cellular debris and the supernatants were transferred 
to fresh 1.5 mL eppendorfs. The cell lysates were then collected by incubating the wells with 
1 mL/well of lysis buffer (made up of release media, protease inhibitors (1:100 dilution) and 
1% TX-100) on ice for five minutes. Lysates were collected by scraping and samples were 
spun for 5 minutes at 13,000 RPM to remove cellular debris. The supernatants were 
transferred to fresh 1.5 mL eppendorfs and if necessary frozen at  -20°C.  
  
 
 
 
 
Figure 2.4. The experimental design for media collections.  
The experimental set-up for 6-well plates is shown on the left and that for 24-well 
plates is shown on the right. For the 6-well plates, equal numbers of wells were 
designated as ‘unstimulated’ and ‘stimulated.’ Unstimulated wells were exposed to 
the ethanol control solution whereas stimulated wells were exposed to 1 µM 
ionomycin. Each condition was replicated three times. For the 24-well plates, 
HUVECs were exposed to varying concentrations of ionomycin. The number within 
each well indicates the applied dose of ionomycin (µM). Each condition was done in 
duplicate, and the shaded wells were excess. 
 
 
 
 
 
 
 
2.7.2 VWF ELISAs: 
 
 VWF ELISAs were used to determine the quantity of VWF secreted by stimulated 
and unstimulated cells in the presence or absence of either an over-expressed protein or SYT 
siRNA. 96-well plates (Thermo Scientific, Rochester, NY, USA) were coated with a rabbit 
anti-VWF antibody (DAKO, Catalogue Number A0082) diluted to 1:600 in PBS. After an 
overnight incubation in the dark, the anti-VWF antibody was removed and the wells were 
blocked for 1 hour with 300 µL of Tween-ELISA buffer (TWEB; 0.2% w/v gelatin, 1 mM 
EDTA, 0.1% Tween-20, made up in PBS). Following blocking, the TWEB was removed and 
100 µL of sample was added to each well. Lysates were diluted 1:8 with lysis buffer prior to 
loading. A standard curve was constructed using a known concentration of VWF (derived 
from HEK-474 cells over-expressing VWF) serially diluted in a 1:1 ratio 11 times in either 
release media or lysis buffer. For each plate, a blank containing un-modified release media or 
lysis buffer was included at the end of the standard curve. The standard curve and the 
samples were placed on a titramax-100 (Heidolph Instruments, Saffron Walden Essex) for 1 
hour at 750 RPM, after which point the samples were removed and the wells were washed 3 
times with TWEB. To each well, 100 µL of HRP-conjugated rabbit anti-VWF (DAKO, 
Catalogue Number P0226) diluted to 1:1000 in TWEB were added. Samples were again 
placed on the titramax-100 for 1 hour at 750 RPM, after which point they were removed and 
each well was washed three times with TWEB and three times with PBS. To develop the 
reaction, 100 µL of CPT buffer (100 mM citric acid, 0.2 M Na2HPO4, 0.1% TX-100) 
supplemented with one 1,2-phenyldiamine dihydrochloride (OPD) tablet (Sigma-Aldrich) 
and 8 µL of 30% hydrogen peroxide (Sigma-Aldrich) were added to each well. The plates 
were immediately placed in a VersaMax plate reader (Molecular Devices, Sunnyvale, CA, 
USA). Data was analysed using Softmax Pro 4.8 software (Molecular Devices, Sunnyvale, 
CA, USA), and the quantity of VWF in each sample was determined from the standard curve. 
 
2.7.3 Proregion ELISAs: 
 
Proregion ELISAs were used to determine the quantity of proregion secreted by 
stimulated and unstimulated cells in the presence or absence of either an over-expressed 
protein or SYT siRNA. 96-well plates (Thermo Scientific, Rochester, NY, USA) were coated 
with the CLB proregion-35 antibody (a kind gift from Professor M.J.A van Mourik (Sanquin 
Research, Amsterdam)) diluted to 1:1000 in PBS. After an overnight incubation in the dark, 
the proregion-35 antibody was removed and the wells were blocked for 1 hour with 300 µL 
of TWEB. Following blocking, the TWEB was removed and 100 µL of sample was added to 
each well.  Lysates were diluted 1:8 with lysis buffer prior to loading.  A standard curve was 
constructed using a known concentration of proregion (derived from HEK-475 cells over-
expressing proregion) serially diluted in a 1:1 ratio 11 times in either release media or lysis 
buffer. For each plate, a blank containing un-modified release media or lysis buffer was 
included at the end of the standard curve. The standard curve and the samples were placed on 
a titramax-100 for 1 hour at 750 RPM, after which point the samples were removed and the 
wells were washed 3 times with TWEB. To each well, 100 µL of an affinity-purified 
antibody specific to the C-terminus of proregion (Hewlett et al. 2011) diluted to 1:1000 in 
TWEB were added. Samples were again placed on the titramax-100 for 1 hour at 750 RPM, 
after which point they were removed and each well was washed three times with TWEB. To 
each well, 100 µL of HRP-conjugated anti-rabbit antibody (Stratech Scientific Ltd, Catalogue 
Number 711-035-152) diluted to 1:500 in TWEB were added. After a 1 hour incubation on 
the titramax-100 at 750 RPM the samples were removed and the wells were washed 3 times 
with TWEB and three times with PBS. To develop the reaction, 100 µL of CPT buffer 
supplemented with 1 OPD tablet (Sigma-Alrich) and 8 µL of 30% hydrogen peroxide 
(Sigma-Aldrich) were added to each well. The plates were immediately placed in a VersaMax 
plate reader (Molecular Devices, Sunnyvale, CA, USA). Data was analysed using Softmax 
Pro 4.8 software (Molecular Devices, Sunnyvale, CA, USA), and the quantity of proregion in 
each sample was determined from the standard curve. 
 
2.7.4 Dose-Response ELISAs: 
 
HUVECs were transfected with either a DNA construct or with SYT siRNA 
according to the protocol detailed previously (2.2.3 The Nucleofection™ Protocol). At the 
same time, control cells were transfected with either a cytoplasmic control construct or with 
non-targeting siRNA. Cells were seeded onto 24-well plates and allowed to grow to 
confluency for 48 hours. To initiate sample collection, 300 µL of release media (consisting of 
bicarbonate free M199 (Gibco
®
 Life Technologies, Invitrogen, Paisley, UK) and 20 mM 
HEPES, pH 7.4), were added to each well and the HUVECs were allowed to acclimatize to 
the media for 50 minutes at 37°C. The release media was removed and the HUVECs were 
incubated for a further 10 minutes in 300 µL of fresh release media. This was discarded and 
the cells were then exposed to 300 µL of release media containing varying concentrations of 
ionomycin calcium salt (Sigma-Aldrich) for 10 minutes according to the schematic shown in 
Figure 2.4. Each concentration was performed in duplicate on each plate. The 0 µM solution 
contained 0.6 µL of 100% ethanol and served as a non-stimulating ethanol control. After a 10 
minute stimulation, the release media from each well was collected in 1.5 mL eppendorfs. 
The samples were spun for three minutes at 13,000 RPM to remove cellular debris. The cell 
lysates were collected by incubating the wells with 300 µL/well of lysis buffer (made up of 
release media, protease inhibitors (1:100 dilution) and 1% TX-100) on ice for five minutes. 
Lysates were collected by scraping and samples were spun for 5 minutes at 13,000 RPM to 
remove cellular debris. The media and lysates were immediately processed for proregion 
ELISAs according to the protocol detailed previously (2.7.3 Proregion ELISAs). 
 
2.8 Data Analysis: 
 
 The data was plotted using Origin 8 software (OriginLab
®
, Northampton, MA, USA) 
and is presented as mean ± standard deviation. Statistical analysis was by nonparametric 
student’s t test using GraphPad Prism Version 5.0 (GraphPad Software Inc, La Jolla, CA, 
USA). Data was considered to be statistically significant when it generated a p-value < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
The Expression and Endogenous Localization of the SYTs in HUVECs 
 
3.1 Chapter Overview: 
 
 The SYTs are the most extensively-characterized family of calcium sensors and have 
well-established roles in the regulation of the Ca
2+
-dependent exocytosis of secretory 
organelles from a variety of cell types (reviewed in Sudhof, 2002). Therefore, I propose that 
the exocytosis of WPBs from endothelial cells is regulated by one or more members of this 
family. In order to investigate this hypothesis it was initially necessary to determine which of 
the 17 SYTs are expressed in HUVECs as to date nothing is known regarding the expression 
profile of this family in endothelial cells.  Firstly, an RT-PCR expression screen was 
performed using isoform-specific primers and HUVEC mRNA as detailed in ‘2.3 Reverse-
Transcription PCR.’ Once it had been established which members of the SYT family are 
found at the mRNA level in our model endothelial cells, Western blotting was performed 
with the aim to verify that these SYTs are also present as proteins in HUVEC lysate. Lastly, 
attempts were made to determine the endogenous subcellular localization of those SYTs 
which are expressed in endothelial cells.  
 
3.2 The Expression of SYT mRNA in HUVECs:  
 
 3.2.1 The Strategy: 
 
For each of the seventeen SYT genes two sets of primers were designed with each set 
recognizing a different section of cDNA sequence. The purpose of this was primarily to allow 
the verification of results by repeating reactions using different primer sets. Additionally, the 
use of multiple primer sets ensured that, should one set fail to recognize its target sequence 
and therefore yield a false-negative result, the other set should in theory rectify this and 
produce a positive result providing that the target sequence is present in the reaction mix.  
 In addition to HUVEC RNA, RNA derived from HEK-293 cells was included as a 
template for PCR. In my experience HEK cells express a wide range of the SYTs and 
therefore the inclusion of RNA from this cell line provides a mechanism for validating the 
functionality of the primers. All bands produced by RT-PCR were sequenced to verify their 
identities. In cases whereby neither HUVEC nor HEK RNA yielded a positive result for the 
presence of a SYT image clones were purchased and used as the template for PCR to confirm 
the functionality of the primers. Lastly, for each SYT a negative control was included in the 
PCR screen. This consisted of the entire PCR with the exception of the template RNA, the 
purpose of which was to control for the presence of contaminating environmental nucleic 
acids. This strategy is detailed in full in Figure 3.1.  
 
 3.2.2 RT-PCR Analysis of SYT Expression in HUVECs: 
 
 An RT-PCR screen for the presence of SYT mRNA in HUVECs was performed 
according to the strategy detailed in Figure 3.1. The principal findings of this are shown in 
Figure 3.2.  As can be seen, I have demonstrated that HUVECs express eight members of the 
SYT family: SYTs I, III, V, VI, VII, VIII, XI, and XVII. Of these, SYTs VIII, XI, and XVII 
are Ca
2+
-independent. HEK cells express SYTs I, II, III, V, VI, VII, VIII, IX, XII, XIII, XIV, 
XV, and XVI (data not shown) and therefore have proved to be a useful positive control cell 
line. I have been unable to demonstrate the presence of SYT IV mRNA in either HUVECs or 
HEK cells. Before concluding that SYT IV is not expressed in either of these cell types it was 
essential to demonstrate that the primers are capable of recognizing SYT IV transcripts when 
they are known to be present in a sample. Therefore, an image clone of the SYT IV gene was 
purchased and this was used as a template for RT-PCR. The results of this are shown in 
Figure 3.3. As can be seen, the SYT IV primers are indeed capable of recognizing and 
amplifying the SYT IV transcript and furthermore it is clear that SYT IV is not expressed by 
either HUVECs or HEK cells.  
This work has provided a comprehensive expression screen of SYT mRNA in both 
HUVECs and HEK cells, the results of which are summarized in Figure 3.4. The eight 
endothelial-expressed SYTs have now been identified as strong potential candidates for the 
role of the calcium sensor regulating WPB release from endothelial cells. The presence of 
SYT XVII mRNA in HUVECs is of particular interest as to my knowledge this represents 
one of the first observations of the endogenous expression of this member of the SYT family 
in any cell type.  
 
3.3 The Expression of SYT Protein in HUVECs: 
 
3.3.1 The Strategy: 
 
 
 
 
 
 Figure 3.1. The Strategy for Determining the Expression of SYT mRNA in HUVECs. 
The rationale behind the RT-PCR screen is shown. The use of two primer sets for each gene 
provides a means of validating results and also guards against false-negatives. The use of 
HEK RNA provides a positive control for a number of the SYTs. This strategy ensures that 
the primers are tested against their target template to verify their efficiency. Any bands 
obtained by PCR were sequenced to confirm their identity. See text for details. 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.2. The Expression of the SYTs in HUVECs 
Representative agarose gels showing the expression of the Ca
2+
-dependent and Ca
2+
-
independent SYTs in HUVECs  by RT-PCR are provided. HUVEC (Hu) and HEK (HK) RNA 
was probed with primers against the SYT cDNA sequences.  A negative control (-Ct) lacking 
template RNA was included in each case to control for environmental contamination. The 
sizes of the marker (M) are indicated (in bps). BL: Blank Lane. The arrows indicate products 
which represent SYT mRNA. These bands were sequence-verified to confirm their identities.  
 
 
 
 
 It is now known that HUVECs express eight members of the SYT family at the 
mRNA level, three of which are Ca
2+
-independent. However, these mRNA transcripts may 
not necessarily be translated to yield functional proteins and therefore it was essential to 
determine if these SYTs are also present at the protein level in HUVECs. For this purpose, 
commercial α-SYT antibodies were purchased (the details of which are available in Table 
2.1). Initially, it was necessary to screen the antibodies to determine their optimum working 
concentrations using the Miniblotter
® device as detailed in ‘2.4.2 Immunoblotting.’ Once the 
optimum dilutions of the primary antibodies had been determined Western blotting was 
performed to test for the presence of each endothelial-expressed SYT in HUVEC lysate.  
Lastly, in order to demonstrate that each α-SYT primary antibody is capable of detecting its 
target protein, SYT-EGFP fusion proteins produced as described in ‘2.6.2.2 The LIC 
Protocol’ were expressed in HEK-293 cells. This cell line produces large quantities of over-
expressed protein and therefore is a convenient tool for demonstrating the functionality of 
antibodies for both Western blotting and ICC. Lysates from SYT-EGFP-transfected HEK 
cells were extracted and subjected to Western blotting. Should the antibody in question 
recognize its target protein then the α-SYT antibody and an α-GFP antibody will both 
recognize the over-expressed SYT-EGFP construct. This strategy therefore allows the 
demonstration that each commercial α-SYT antibody is capable of detecting its target protein 
when it is known to be present in a lysate sample.  
This approach was used to screen for the presence of each SYT which is known to be 
present at the mRNA level in HUVECs and the results are summarized in the following 
sections. For SYT I, the strategy detailed above is presented in full. However, in the interest 
of brevity for the remaining seven SYT family members only the essential data is provided. 
Figure 3.3. SYT IV is not expressed by 
HUVECs or HEK cells.  
 SYT IV was amplified from varying 
dilutions of a sequence-validated Image 
Clone as indicated. A strong single band 
of the anticipated size appears on the gel. 
This band is absent when HUVEC and 
HEK RNA are used as templates. The 
sizes of the marker are shown on the left.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. The expression of the SYT family in HUVECs and HEK cells.  
HUVECs express eight members of the SYT family: SYTs I, III, V, VI, VII, VIII, XI, 
and XVII. HEK cells express thirteen members of the SYT family: SYTs I, II, III, V, 
VI, VII, VIII, IX, XII, XIII, XIV, XV and XVI. The SYTs shown in orange are Ca
2+
-
dependent. Those shown in blue are Ca
2+
-independent.  
3.3.2 The Expression of the Ca
2+
-dependent SYTs at the Protein Level in 
HUVECs: 
 
The first ten members of the SYT family (SYTs I – X) are for the most part Ca2+-
dependent, having the ability to bind free Ca
2+
 ions via specific negatively-charged residues 
in their C2 domains (von Poser et al. 1997). The exceptions to this are SYTs IV and VIII 
which lack the essential aspartate residues required for calcium binding. The primary sensor 
mediating the Ca
2+
-induced exocytosis of WPBs from endothelial cells will logically by Ca
2+
-
dependent and therefore my efforts initially focused on demonstrating the expression of the 
Ca
2+
-dependent SYT proteins in HUVECs. 
 
3.3.2.1 SYT I:  
 
 A primary antibody against the C-terminal portion of SYT I was purchased from 
Synaptic Systems. This reagent was raised in mice against amino acids 80 to 421 of the rat 
SYT I sequence and shows reactivity with human protein. Initially, it was necessary to screen 
the antibody using the Miniblotter
®
 device to determine its optimum working concentration. 
A range of dilutions of the primary antibody were tested and the results of this initial screen 
are shown in Figure 3.5. A primary band of approximately 55 kDa has been identified. Based 
on these results it was decided to perform all subsequent Western blots using the SYT I 
antibody at a dilution of 1:200. An example of such a blot is shown in Figure 3.6, and as can 
be seen a single band of approximately 55 kDa has been detected, replicating the results 
shown in Figure 3.5. The detection of only one band suggests that HUVECs express one 
isoform of the SYT I protein.  
This work indicates that SYT I is indeed found in HUVECs at the protein level. 
However, it was necessary to demonstrate that the commercial antibody is capable of 
recognizing SYT I when it is known to be present in a lysate sample. Therefore, a fluorescent 
construct of SYT I (SYTI-EGFP) was expressed in HEK-293 cells. Lysate from these cells 
was extracted and used for Western blotting with the SYT I primary antibody. The blots were 
also probed with an α-GFP antibody. The results of this are shown in Figure 3.7. As can be 
seen, a clear band appearing at approximately 95 kDa has been detected by both the SYT I 
and GFP antibodies, suggesting that the SYT I antibody is indeed capable of recognizing its 
target antigen. No additional bands have been detected by the SYT I antibody which are not 
also identified by the GFP antibody, suggesting that the recognition of SYT I is relatively  
  
 
 
 
                  
 
 
                               
 
 
 
 
 
 
Figure 3.5. The optimum dilution of the SYT I 
antibody is 1:200. 
A representative Western blot produced by 
probing HUVEC lysate with the SYT I primary 
antibody at varying concentrations is shown. Each 
condition is shown in duplicate as indicated. The 
sizes of the protein marker are shown on the left 
of the figure (kDa). The red arrow indicates the 
appearance of a band which is thought to 
represent the SYT I protein.    
Figure 3.6 The SYT I protein is present in 
HUVECs. 
A representative Western blot produced by 
probing HUVEC (Hu) lysate with the SYT I 
primary antibody at a concentration of 1:200 is 
shown. The sizes of the marker (M) are shown 
on the left. Notice the appearance of a strong 
band at approximately 55 kDa which is thought 
to represent the SYT I protein.    
 Figure 3.7. The α-SYT I antibody recognizes SYTI-EGFP in HEK lysate. 
SYTI-EGFP-expressing HEK lysate was run on the Miniblotter
®
 device. Lanes have 
been probed with either the SYT I primary antibody (red) or with the α-GFP antibody 
(green) at varying dilutions as indicated. An actin transfer control has been included 
and the sizes of the molecular marker (M) (kDa) are shown on the left of the figure. 
The arrow indicates a band (the SYTI-EGFP construct) which is clearly seen in both 
the SYT I- and GFP-probed lanes.  
specific. However, care must be taken with this interpretation as this method is not an 
absolute test of antibody specificity. It is possible that α-SYT antibodies cross-react with 
other members of the SYT family. 
 
 3.3.2.2 SYT III:  
 
A primary antibody against SYT III was purchased from Synaptic Systems. This 
reagent was raised in rabbits against a recombinant peptide corresponding to amino acids 86 
to 169 of the human SYT III protein.   The optimum dilution of this antibody was determined 
to be 1:200 (data not shown) and the results of Western blotting with the α-SYT III antibody 
used at this dilution are shown in Figure 3.8. As can be seen, a series of bands has been 
detected by the SYT III primary antibody, the strongest of which appears at approximately 63 
kDa. This corresponds with the expected size of the largest SYT III isoform. Additional 
bands are visible at 45 and 50 kDa. It is possible that a number of splice variants of SYT III 
are expressed simultaneously within HUVECs, or alternatively these multiple bands may 
represent breakdown products of the original protein (see Discussion). Following the Western 
blotting of lysates derived from HEK-293 cells expressing SYTIII-EGFP, both the α-GFP 
and α-SYT III antibodies recognized an identical band of approximately 100 kD (data not 
shown). Therefore the α-SYT III commercial antibody is capable of recognizing its target 
protein when it is known to be present in a lysate sample. 
 
 
 
 
 
Figure 3.8. The SYT III protein is present 
in HUVECs. 
HUVEC (Hu) lysate was probed with the α-
SYT III antibody at a dilution of 1:200. The 
sizes of the marker are shown on the left of 
the figure (kDa). The top arrow indicates the 
most prominent band appearing at 63 kDa 
which is thought to represent the 
endogenous SYT III protein.  The bottom 
arrow shows the actin transfer control.  
3.3.2.3 SYT V:  
 
A primary antibody generated in rabbits from a synthetic peptide spanning resides 127 
to 167 of the human SYT V sequence was purchased from abcam
®
. The optimum dilution of 
this antibody for Western blotting was determined to be 1:200 (data not shown). A 
representative blot of HUVEC lysate probed with the α-SYT V antibody is shown in Figure 
3.9. A clear band which appears at approximately 45 kDa has been identified and this 
corresponds with the expected size of the SYT V protein.  A number of other bands of larger 
sizes were also observed (see discussion). However only the 45 kDa band was lost following 
siRNA depletion of SYT V (see Chapter 6), indicating that this band most likely represents 
endogenous SYT V. The blotting of lysates derived from HEK cells over-expressing SYTV-
EGFP demonstrated that this commercial antibody is capable of detecting its target protein 
when it is known to be present in a lysate sample (data not shown). 
   
 
 
 
 
3.3.2.4 SYT VI:  
 
 A primary antibody against SYT VI was purchased from abcam
®
. This reagent was 
raised in rabbits against a recombinant protein corresponding to amino acids 85 to 510 of the 
human SYT VI sequence. Its optimum dilution was determined to be 1:200 (data not shown). 
The results of probing HUVEC lysate with the SYT VI antibody at this concentration are 
shown in Figure 3.10. As can be seen, a number of bands have been detected, the most 
prominent of which appear at approximately 55, 60, and 70 kDa. Multiple isoforms of the 
SYT VI protein are known to exist (Fukuda and Mikoshiba, 1999) and equally numerous 
reports have published conflicting observations regarding the molecular mass of the SYT VI 
Figure 3.9. The SYT V protein is present 
in HUVECs. 
HUVEC (Hu) lysate was probed with the α-
SYT V antibody at a dilution of 1:200. The 
sizes of the marker (M) are shown on the 
left. A tubulin transfer control is included (in 
red). Note the strong band appearing at 
approximately 45 kDa which is thought to 
represent SYT V.  
 
protein as it appears on Western blots (see Discussion). Therefore, as the data presented here 
suggests it is likely that SYT VI exists as a series of splice variants in HUVECs. 
 
    
 
3.3.2.5 SYT VII:  
 
A commercial α-SYT VII antibody was purchased from Synaptic Systems. This 
reagent was raised in rabbits against a recombinant peptide corresponding to amino acids 46 
to 133 of the rat SYT VII sequence and is reported to recognize human protein. The optimum 
dilution of this antibody was determined to be 1:200 (data not shown), and a representative 
example of HUVEC lysate probed with the α-SYT VII antibody at this concentration is 
shown in Figure 3.11. Surprisingly, the SYT VII antibody displayed unusual cross-reactivity 
with the protein marker. However, despite this a major band of approximately 65 kDa is 
consistently seen on SYTVII-probed Western blots. This is considerably larger than the 
predicted mass of 45 kDa for the SYT VII protein.  However, it is likely that post-
translational modifications affect the observed size of the protein and equally it is possible 
that a larger isoform of SYT VII is expressed in HUVECs than that which is commonly 
reported in other cell types (see Discussion). In Figure 3.11, a number of additional bands are 
visible and these may represent either minor isoforms of the SYT VII protein or possibly 
proteolytic products of a larger variant. However it was my concern that these bands may be 
a by-product of the unusual cross-reactivity of the primary antibody with the marker protein. 
Therefore, a control blot was run which included HUVEC lysate but no marker protein 
(Figure 3.11, panel ii). An identical staining pattern to that seen when the marker is present  
Figure 3.10. The SYT VI protein is present in 
HUVECs. 
HUVEC (Hu) lysate was probed with the α-SYT 
VI antibody at a dilution of 1:200. The sizes of the 
marker (M) (kDa) are shown on the left of the 
image. A number of bands have been identified by 
the α-SYT VI antibody as indicated by the arrows 
on the right.  
 
 
 
 
 
was produced and so the bands observed on α-SYTVII-probed blots are not artifacts of 
marker reactivity but instead may represent the presence of the SYT VII protein in HUVECs. 
In support of this, Western blotting lysates derived from HEK cells expressing SYTVII-YFP 
demonstrated that the commercial antibody is capable of detecting its target protein when it is 
known to be present in a lysate sample (data not shown). 
 
3.3.3 The Expression of the Ca
2+
-independent SYTs at the Protein Level in 
HUVECs: 
 
I have now established which Ca
2+
-dependent SYTs are expressed in HUVECs at 
both the mRNA and protein levels and therefore I moved on to address the expression of the 
Ca
2+
-independent SYTs. Although these proteins cannot bind Ca
2+
 directly they are known to 
play a modulatory role in the regulation of secretory events (Sudhof, 2002) and therefore are 
potential candidates for the role of the protein sensor regulating WPB exocytosis. 
 
  3.3.3.1 SYT VIII:  
 
 An antibody against SYT VIII was purchased from Acris Antibodies. This reagent 
was raised in rabbits against a recombinant peptide corresponding to amino acids 67 to 96 of 
Figure 3.11. The SYT VII protein is found in 
HUVECs.  
HUVEC lysate was probed with the α-SYT VII 
antibody at a dilution of 1:200. The black arrows 
indicate a major band appearing at approximately 65 
kDa while the red arrows indicate the actin transfer 
controls. The sizes of the protein marker are 
indicated on the left (kDa). In Panel (i) notice the 
intense cross-reactivity of the SYT VII antibody 
with the marker protein. Panel (ii) shows a blot 
which has been run in an identical manner to that 
shown in Panel (i) with the exception that the 
marker has been omitted. The bands are identical to 
those seen in Panel (i), suggesting that the reactivity 
of the SYT VII antibody with the marker protein 
does not affect the staining pattern produced.  
the human SYT VIII protein. The optimum dilution of this antibody was determined to be 
1:200 (data not shown) and the results of a representative experiment probing HUVEC lysate 
for SYT VIII are shown in Figure 3.12. As can be seen, the SYT VIII antibody has detected 
three bands, one of which is dominant and appears at approximately 75 kDa. The smaller, 
fainter bands are seen at approximately 80 and 45 kDa. It is possible that these bands 
represent three different isoforms of the SYT VIII protein, and indeed numerous variants of 
SYT VIII have been reported to exist (see Discussion).  
 
 
 
 
 
 
3.3.3.2 SYT XI:  
 
A mouse monoclonal primary antibody raised against recombinant human SYT XI 
protein was purchased from Santa Cruz. When attempting to determine the optimum dilution 
of the SYT XI antibody I was unable to detect any reactivity in HUVEC lysate regardless of 
the concentration tested (shown in Figure 3.13, Panel (i)). Before any firm conclusions could 
be drawn as to the presence or absence of the SYT XI protein in HUVECs it was essential to 
demonstrate that the primary antibody is capable of detecting its target protein when it is 
known to be present in a lysate sample. Therefore, HUVECs were transfected with a SYTXI-
EGFP construct and the resulting lysate was probed with the α-SYT XI antibody. No bands 
were generated to indicate the recognition of over-expressed SYT XI protein (data not 
shown) suggesting that the SYT XI antibody does not recognize its target antigen. However, 
it may also indicate that a high concentration of SYT XI is required for successful detection. 
To test this possibility HEK-293 cells were transfected with the SYTXI-EGFP construct and 
allowed to grow to confluency. The resulting lysates were probed with either the SYT XI 
Figure 3.12. The SYT VIII protein is 
present in HUVECs.  
HUVEC (Hu) lysate was probed with 
the α-SYT VIII antibody at a dilution 
of 1:200. The sizes of the marker are 
shown on the left of the image. The 
tubulin transfer control appears in red. 
The major band representing the SYT 
VIII protein is indicated by an arrow.  
 
primary antibody or with an α-GFP antibody. The results of this are shown in Figure 3.13 
panel (ii), and as can be seen both antibodies have recognized a band of approximately 75 
kDa. Therefore, this work suggests that the α-SYT XI commercial antibody is capable of 
recognizing its target antigen but requires high levels of expression for successful detection.  
As a final attempt to detect the presence of endogenous SYT XI protein in HUVECs 
TX-114 lysate partitioning was performed. This method allows the enrichment of integral 
membrane proteins in a lysate sample and therefore yields a more concentrated source of 
SYT protein than conventional lysate extraction techniques. The results of Western blotting 
following TX-114 partitioning are shown in Figure 3.13, panel (iii). As can be seen, despite 
its ability to concentrate membrane proteins in a lysate sample this method has not allowed 
the detection of the endogenous SYT XI protein in HUVECs.  
This work has been inconclusive as I have been unable to demonstrate the presence of 
the endogenous SYT XI protein in HUVECs. However, I have shown that the commercial 
antibody is unable to detect SYT XI when it is specifically up-regulated in HUVECs and so is 
clearly ineffective. At this stage it is impossible to draw any conclusions as to the expression 
of the SYT XI protein in endothelial cells. 
 
3.3.3.3 SYT XVII:  
 
 A primary antibody against SYT XVII was purchased from abcam
®
. This reagent was 
raised in rabbits against a synthetic peptide corresponding to the human SYT XVII protein 
sequence. The optimum dilution of this reagent was determined to be 1:500 (data not shown) 
and the results of probing HUVEC lysate with the α-SYT XVII antibody at this concentration 
are shown in Figure 3.14. A single strong band has been detected at approximately 60 kDa. 
The estimated size of the SYT XVII protein is 54 kDa and so it is likely that SYT XVII 
undergoes post-translational modifications in HUVECs (see Discussion). The over-
expression of SYTXVII-EGFP in HEK-293 cells demonstrated that the primary α-SYT XVII 
antibody is indeed capable of detecting its target protein when it is known to be present in a 
lysate sample (data not shown).  
 
3.4. Determining the Distribution of Endogenous SYT Protein in HUVECs: 
 
As it has now been established that a number of the SYT family members are 
expressed in HUVECs at both the mRNA and protein levels I attempted to determine the  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. The SYT XI antibody does not detect SYT XI protein in HUVEC Lysate. 
The SYT XI antibody does not detect SYT XI protein in HUVEC lysate despite repeated 
attempts to optimize the lysate extraction protocol. It does identify SYTXI-EGFP when 
over-expressed in HEK cells but not in HUVECs. In Panel (i) HUVEC lysate has been 
probed with varying dilutions of the SYT XI primary antibody as indicated at the base of the 
figure. An actin transfer control has also been included. No bands have appeared for the SYT 
XI protein. The sizes of the molecular marker are shown on the left of the image (kDa). In 
Panel (ii) a Western blot produced by probing HEK lysate over-expressing SYTXI-EGFP 
with primary antibodies against either SYT XI (red; 1:200) or GFP (green; 1:1000), is 
shown. The sizes of the marker (M) are shown on the left of the figure (kDa). In Panel (iii) 
the results of Western blotting for the endogenous SYT XI protein in HUVEC lysate derived 
from a TX-114 extraction procedure are shown. No bands have been detected representing 
the SYT XI protein. The strong band appearing at approximately 50 kDa is the tubulin 
transfer control. The blotting of HUVEC lysate produced as detailed in ‘2.4.1.1 
Conventional Lysate Extraction’ is shown on the right (labeled ‘Standard Extractions’). The 
sizes of the molecular marker (M) are shown on the left (kDa).  
 
 
 
  
      
 
distribution of endogenous SYT protein in HUVECs by ICC. As with Western blotting it was 
initially necessary to optimize this procedure for the detection of endothelial SYT protein. 
Therefore, for each SYT family member a number of cell fixation methods were trialed along 
with a range of dilutions of the primary α-SYT antibody. Unfortunately, this approach was on 
the whole unsuccessful and I failed to determine the endogenous distribution of the majority 
of the SYTs. Representative examples of PFA/Saponin-fixed HUVECs stained with the SYT 
antibodies at dilutions of 1:100 are shown in Figure 3.15. As can be seen, only a uniform 
background staining pattern has been produced for the SYTs which likely represents either 
the non-specific binding of the primary antibodies or auto-fluorescence from intracellular 
structures. In contrast, the VWF stain has clearly identified numerous rod-shaped WPBs. 
Similar results were obtained with methanol and TX-100-fixed HUVECs and with all SYT 
antibody dilutions tested (data not shown).  
Two possibilities explain this failure to detect endogenous SYT protein in HUVECs. 
Firstly, it is possible that the proteins are in fact not present in HUVECs although this is in 
disagreement with the Western blot data presented previously. It is more likely that the 
commercial antibodies used here are unable to recognize endothelial SYT proteins and in 
order to test this possibility I constructed SYT-EGFP fusion vectors and over-expressed these 
in HUVECs and HEK cells.  The transfected cells were fixed and stained with the 
commercial α-SYT antibodies and with an antibody against GFP. Should the SYT antibodies 
be capable of detecting their target proteins then they should co-stain the over-expressed 
fluorescent constructs with the α-GFP antibody. The results of this for each SYT are shown 
in Figure 3.16. As can be seen, the antibodies against SYTs I, III, VI, and VII are capable of 
Figure 3.14. The SYT XVII protein is 
present in HUVECs.  
HUVEC (Hu) lysate was probed with the α-
SYT XVII antibody at a dilution of 1:500. 
The tubulin transfer control appears in the 
red channel. The sizes of the marker are 
shown on the left. The top arrow indicates 
the appearance of a band thought to represent 
the SYT XVII protein at 60 kDa.  
  
 
 
 
 
 
 
 
 
 
 Figure 3.15. The SYT antibodies do not detect endogenous SYT protein in HUVECs.  
PFA/Saponin-fixed HUVECs were stained with antibodies against SYTs I, III, V, VII, VIII, 
and XVII (green, all used at 1:100) as indicated and counter-stained for VWF (red). Areas 
indicated by the white boxes are shown in grey-scale to the right of the colour images. Scale 
bars are 20 µm.  
recognizing their over-expressed antigens whereas the antibodies against SYTs V, VIII, XI, 
and XVII do not recognize even highly-expressed protein. A more detailed example of this 
for the α-SYT VII antibody is shown in Figure 3.17. In this case, the antibody is capable of 
detecting SYTVII-YFP when it is over-expressed in HEK cells but not in HUVECs. As HEK 
cells synthesize unusually high quantities of foreign protein this suggests that the α-SYT VII 
antibody only recognizes its target antigen by ICC when it is present in a highly-concentrated 
form. HUVECs do not produce sufficient quantities of the SYT VII protein for its recognition 
by ICC even when it is specifically up-regulated by over-expression. Therefore, my inability 
to detect endogenous SYT protein in HUVECs by ICC is most likely the result of an 
insufficient expression level of these proteins in endothelial cells. 
There were two exceptions to the general failure of the commercial antibodies to 
recognize endogenous SYT proteins in HUVECs. Firstly, when optimizing the ICC protocol 
for the SYT VI protein numerous vesicular structures were seen to be stained by the α-SYT 
VI antibody. It was shown that this commercial antibody is capable of high-fidelity 
recognition of its target antigen as it clearly detected over-expressed SYTVI-EGFP in HEK 
cells (Figure 3.16). Therefore I suspected that these vesicular structures were the result of the 
specific recognition of the SYT VI protein by the α-SYT VI antibody. In order to determine 
the identity of these subcellular compartments I performed a full localization screen using 
markers of various organelles. The results of this screen will not be shown in full but it will 
suffice to say that the vesicular organelles detected by the SYT VI antibody were shown to be 
early endosomes as they stained positively for the marker protein EEA-1. An example of the 
co-staining between EEA-1 and SYT VI is shown in Figure 3.18. Hence, endogenous SYT 
VI can be found as a component of the early endosomes in HUVECs.  
Lastly, while optimizing the ICC protocol for the SYT XI protein large globular 
masses were observed following the staining of HUVECs with the α-SYT XI antibody. An 
example of this is shown in Figure 3.19. As can be seen, these aggregates were numerous and 
concentrated around the perinuclear area. No explanation could be offered as to the 
provenance of these masses. It is possible that they were the result of impurities in the 
fixation solutions although I would consider this unlikely as they appeared in HUVECs fixed 
by both the PFA/Saponin and TX-100 methods.  Additionally, these globular masses are not 
seen in the VWF stain, suggesting that they are specific for the SYT XI antibody. Therefore, 
it is possible that SYT XI localizes to large vesicles in the perinuclear area and it may be that 
these vesicles are components of either the endoplasmic reticulum or the Golgi apparatus. 
 Figure 3.16. The commercial α-SYT antibodies do not reliably detect over-
expressed SYT protein in HEK cells. 
HEK cells transfected with fluorescent SYT constructs were co-stained with α-SYT 
antibodies as indicated (red) and an α-GFP antibody (green). Co-localization between 
the two was visible in only half of cases (SYTs I, III, VI, VII). Scale bars are 20 µm. 
  
 
 
 
 
 
 
 
 
Figure 3.17. The SYT VII antibody recognizes SYTVII-YFP when it is expressed in HEK 
cells but not in HUVECs. 
Representative images of HUVECs (Panel (i), Top) and HEK cells (Panel (ii), Bottom) over-
expressing SYTVII-YFP and stained with antibodies against GFP and SYT VII are shown. In 
Panel (i) the merged image is shown on the left and grey-scales of the two stains are shown on the 
right. Note the central cell which is strongly expressing the SYTVII-YFP construct. However, as is 
clear from the red channel the SYT VII primary antibody is unable to distinguish this cell from the 
rest of the monolayer, demonstrating that the antibody does not recognize the SYTVII-YFP 
construct.  In Panel (ii) the merged image is shown on the left and an enlarged section of the cell as 
indicated by the white rectangle is shown on the right. Note the evidence of co-localization as seen 
by the appearance of yellow in the merged image. Therefore the SYT VII antibody is able to 
recognize the SYTVII-YFP construct when it is over-expressed in HEK cells but not in HUVECs. 
 
i 
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Figure 3.18. Endogenous SYT VI is a component of the early endosomes.  
A HUVEC stained for EEA-1 (red) and SYT VI (green) is shown. The merged image is shown 
on the left. An enlarged section of the cell as indicated by the white rectangle is shown on the 
right. Note the clear co-localization between these two proteins. The blue arrows in the enlarged 
panels on the right identify numerous examples of this co-staining.  
 
 
Figure 3.19. Globular structures 
are seen in HUVECs following 
staining for SYT XI.  
The results of staining TX-100-
fixed HUVECs with the VWF (red) 
and SYT XI (green) antibodies are 
shown. The merged image is shown 
on the left. An enlarged section of 
the cell as indicated by the white 
rectangle is shown on the right.  
Note the large aggregates in the 
perinuclear area which have 
appeared following the SYT XI 
stain. 
 
3.5 Discussion and Conclusions: 
 
 3.5.1 SYT I: 
 
I have shown that SYT I exists as both an mRNA transcript and as a protein of 55 kDa 
in HUVECs. This is slightly larger than the predicted mass of 47.5 kDa for the SYT I protein, 
although it is likely that cell-specific post-translational modifications affect the observed size 
of the protein. Indeed, SYT I was originally identified as a protein of 65 kDa on synaptic 
vesicles (Matthew et al. 1981) and so clearly its predicted size does not necessarily correlate 
with experimental observations. The 55-kDa band detected here is specifically diminished 
following the treatment of HUVECs with SYT I siRNA (see Chapter 8), providing supporting 
evidence that it is representative of the SYT I protein. 
A hazy, diffuse background stain was produced following ICC attempting to 
determine the distribution of SYT I in HUVECs (see Figure 1.15). A control screen 
examining the effects of omitting either the SYT I primary antibody or the α-mouse CY-2 
secondary antibody revealed that these reagents do not generate a significant degree of 
background auto-fluorescence (data available in Appendix 3.0). Therefore a subcellular 
localization screen using markers of various intracellular structures was performed with the 
aim to identify any co-localization between the vague SYT I stain and specific cell structures. 
No co-localization was identified between SYT I and any of the organelle markers screened 
(data not shown). Therefore I conclude that the diffuse stain generated by the α-SYT I 
antibody results from non-specific binding and thus is not representative of the distribution of 
SYT I in HUVECs. The antibody was able to recognize SYTI-EGFP following its over-
expression in HEK cells (Figure 3.16). This suggests that either SYT I is present at too low a 
concentration in HUVECs to allow its successful recognition by the commercial antibody or 
that the endogenous protein is found in a complex with other molecules, rendering it 
inaccessible to its antibody. 
The specific recognition of endogenous SYT I by ICC could be facilitated by the 
stimulation of HUVECs with agonists which induce an activated, pro-thrombotic state. 
Indeed, it is known that the expression of a number of secretory proteins such as t-PA, IL-8, 
and exotaxin-3 is up-regulated by the pre-conditioning of HUVECs with pro-inflammatory 
reagents such as TNF-α and IL-1β (Huber et al. 2002, Utgaard et al. 1998, Oynebraten et al. 
2004). It would be of interest to determine the effect of stimulation on the expression of the 
SYT family members in HUVECs as it is likely that their expression may be up-regulated, 
and this in turn might allow their successful detection by ICC.  
 
3.5.2 SYT III: 
 
This work has demonstrated that SYT III is present in HUVECs as an mRNA 
transcript and as a protein thereby adding endothelial cells to the growing list of secretory 
cells which express this Ca
2+
-dependent member of the SYT family. Western blotting 
revealed that SYT III is present in HUVECs as a major variant of 63 kDa in keeping with 
previous observations (Falkowski et al. 2011). However, weaker bands of 45 and 50 kDa 
were also detected following the immunoblotting of HUVEC lysate. These may be a 
consequence of the cross-reactivity of the α-SYT III primary antibody or they may represent 
the presence of numerous SYT III splice variants in HUVECs. Indeed, SYT III has been 
reported to exist as a 78-kDa isoform in the goldfish retia (Berntson and Morgans, 2003) and 
as a number of isoforms of 46, 66, and 80 kDa in rodent brain homogenates (Brown et al. 
2000, Grimberg et al. 2002). Additionally, following the Western blotting of HEK-293 
lysates a single band of 80 kDa representing the SYT III protein was detected (data not 
shown), suggesting that the numerous bands identified on blots of HUVEC lysate are specific 
for this cell type rather than being a result of non-specific binding by the primary antibody. 
Therefore it is likely that within endothelial cells SYT III exists as a number of splice variants 
or alternatively undergoes extensive post-translational modifications.  
ICC aiming to determine the subcellular distribution of the SYT III protein in 
HUVECs was unsuccessful despite numerous attempts to optimize the protocol for the 
detection of this protein. However, the commercial α-SYT III antibody was able to identify 
SYTIII-EGFP following its over-expression in HEK cells (Figure 3.16). Therefore it is likely 
that the concentration of SYT III in HUVECs is too low to allow its recognition by its 
antibody. Alternatively, in HUVECs the SYT III protein may exist in a form which is 
inaccessible to the antibody. For example it may be present as part of a larger complex and 
indeed analysis of the crystal structure of the SYT III C2AB domain has led to the suggestion 
that the protein binds to the trans-SNARE complex in resting cells (Vrijic et al. 2010). 
 
3.5.3 SYT V: 
 
I have demonstrated that SYT V mRNA is present in HUVECs and that the 
endogenous protein can be visualized by Western blotting as a band of 43 kDa. This band 
was diminished following SYTV-siRNA treatment of HUVECs (see Chapter 6). A second 
band was observed at approximately 80 kDa and it is possible that this represents dimeric 
SYT V. Indeed it is known that over-expressed SYT V forms SDS-resistant aggregates in 
other cell types (Iezzi et al. 2004, Saegusa et al. 2002). Hence, it is likely that SYT V forms 
aggregates in HUVECs and the band seen following Western blotting represents an SDS-
resistant SYT V dimer. Additionally, I have obtained similar results following the blotting of 
lysates derived from HEK cells over-expressing SYTV-EGFP (data not shown). Here, bands 
were detected of 43 kDa (representing monomeric endogenous SYT V), 70 kDa (representing 
over-expressed SYTV-EGFP) and 80 kDa (thought to represent dimeric endogenous SYT V).  
ICC attempting to identify the subcellular distribution of endogenous SYT V in 
HUVECs was unsuccessful and this was most likely the result of an inability of the 
commercial α-SYT V antibody to recognize the endogenous protein. Indeed, the antibody 
failed to identify the SYTV-EGFP construct following its over-expression in HEK cells 
(Figure 3.16) and so is clearly unable to detect the SYT V protein when it is known to be 
present at high concentrations in a lysate sample. 
 
 3.5.4 SYT VI:  
 
The Western blotting of HUVEC lysate suggested that SYT VI exists as a series of 
splice variants within endothelial cells, with bands representing the SYT VI protein seen at 
55, 60, and 70 kDa. SYT VI is unique among the SYTs in that it can exist as both a 
transmembrane and cytosolic protein (Craxton and Goedert, 1999). The molecular weight of 
the SYT VI isoforms has been reported to be 58 kDa for the full-length protein in PC12 cells 
(Fukuda and Mikoshiba, 1999), 50 kDa for the ΔTM variants (Fukuda and Mikoshiba, 1999), 
and 66 kDa in sperm cell lysate (Michaut et al. 2001). Therefore, it is likely that numerous 
variants of SYT VI are expressed simultaneously within HUVECs and cell-specific post-
translational modifications may further influence their observed molecular weights. Indeed, 
the simultaneous presence of four separate splice variants of the protein has been reported in 
the mouse cerebellum (Fukuda and Mikoshiba, 1999). Therefore, as the data presented here 
and in previous studies suggests it is possible that SYT VI exists as a series of splice variants 
in HUVECs.  
ICC with a commercial antibody suggested that endogenous SYT VI can be found 
predominantly as a component of the early endosomes and is absent from other subcellular 
structures. In order to more accurately determine the subcellular distribution of endogenous 
SYT VI in HUVECs I performed preliminary co-localization analysis of this protein with 
markers of the various subcellular organelles. The Pearson’s correlation coefficient generated 
for SYT VI and EEA-1 (0.14 ± 0.043) suggested that no significant co-localization exists 
between these two proteins. This is in contrast to the conclusions derived from visual analysis 
of the data. However, the intense background fluorescence generated by the α-SYT VI 
antibody makes accurately determining the subcellular distribution of SYT VI challenging. 
Additionally, the major SYT VI splice variant expressed within HUVECs may well be the 
cytoplasmic ΔTM variant and therefore this background fluorescence may be the result of the 
cytosolic protein. At this point, the true distribution of endogenous SYT VI in HUVECs is 
unclear and requires further investigation. Ideally, the identity of its various splice variants in 
HUVECs should be determined as this would allow sensible predictions to be made as to the 
likely distribution of the SYT VI proteins(s) in endothelial cells.  
 
 3.5.5 SYT VII: 
 
RT-PCR has demonstrated that SYT VII mRNA is expressed in HUVECs. This in 
itself is unsurprising as SYT VII is believed to be ubiquitously expressed. However, there are 
a number of isoforms of the SYT VII gene and my preliminary investigations have shown 
that SYTVII-α and SYTVII-β are specifically expressed in HUVECs (data available to view 
in Appendix 2.0). Similar to the findings reported in other cell types (Fukuda et al. 2002) 
SYTVII-α is the major isoform found within HUVECs whereas the larger variant SYTVII-β 
is also present but to a much lesser extent. It is important to consider that different isoforms 
of SYT VII have different and often antagonistic functions and therefore the ratio of 
expression of the various isoforms can alter the observed function of SYT VII (Gauthier et al. 
2008). It would be of interest to determine if and how the ratio of expression of these two 
isoforms varies, particularly in response to antagonistic stimulation of the endothelium. For 
example, it may be that the ratio of expression shifts following its exposure to inflammatory 
versus vaso-protective stimuli, thus altering the calcium sensitivity of WPB exocytosis. It is 
likely that additional isoforms of SYT VII are present in HUVECs and it would be of interest 
to determine the full extent of SYT VII gene splicing in the future using variant-specific 
PCR.  
Western blotting has demonstrated that a 65-kDa protein representing SYT VII is 
present in HUVEC lysate, and indeed this is the precise size for SYTVII-α (Fukuda et al. 
2002). An additional band of 100 kDa was identified and this may represent either SYTVII-β 
or perhaps a larger uncharacterized transcript. As the SYT VII protein is now known to be 
present in HUVECs ICC was attempted with the aim to determine the distribution of the 
endogenous protein within our model endothelial cells. Unfortunately this was unsuccessful 
with no recognition of the SYT VII protein achieved despite considerable attempts to 
optimize the ICC protocol. It was later shown that the commercial α-SYT VII antibody was 
able to detect SYTVII-YFP following its over-expression in HEK cells but not in HUVECs, 
demonstrating that the reagent requires a concentrated source of antigen for recognition. 
Hence, the endogenous ICC failed due to limitations in the efficiency of the primary 
antibody. 
 
3.5.6 SYT VIII: 
 
Western blotting has demonstrated that the SYT VIII protein is expressed in 
endothelial cells as two major isoforms of 75 and 80 kDa and furthermore bands representing 
these two proteins are specifically diminished following the knock-down of SYT VIII in 
HUVECs (see Chapter 7). This result was not entirely surprising as previous studies have 
reported the existence of numerous isoforms of SYT VIII. Indeed, it has been reported in 
mouse sperm cells as a protein of 70 kDa (Hutt et al. 2002), in the rat renal cortex as a protein 
of 52 kDa (Kishore et al. 1998), and in PC12 cells as isoforms with molecular weights of 40 
and 50 kDa (Monterrat et al. 2006). Therefore it is probable that the SYT VIII exists either as 
a series of splice variants or as one protein which undergoes extensive post-translational 
modifications affecting its observed molecular weight. Interestingly, when the SYTVIII-
EGFP construct was over-expressed in HEK-293 cells and the resulting lysates were 
subjected to Western blotting two bands of 80 and 90 kDa were identified by both the α-GFP 
and α-SYT VIII antibodies (data not shown). This suggests that the over-expressed protein 
undergoes post-translational modifications leading to the generation of two pools of protein 
with different molecular weights. Specific PCR would be needed to determine the number 
and identity of the splice variants of the SYT VIII gene which are expressed in our model 
endothelial cells. 
ICC attempting to determine the localization of endogenous SYT VIII in HUVECs 
was unsuccessful and indeed the commercial antibody failed to detect over-expressed 
SYTVIII-EGFP in HEK-293 cells (Figure 3.16). This implies that the antibody is unable to 
recognize its antigen under the conditions used in our laboratory even when it is present at 
high concentrations in a cell culture. 
 
 3.5.7 SYT XI:  
 
 I have shown by RT-PCR that SYT XI is present in HUVECs as an mRNA 
transcript.  Unfortunately my attempts to demonstrate the expression of the SYT XI protein in 
HUVECs were unsuccessful. This was despite using a variety of lysate extraction techniques 
including TX-114 partitioning which provides a more concentrated source of membrane 
proteins. However the commercial α-SYT XI antibody failed to detect over-expressed 
SYTXI-EGFP in transfected HUVEC lysate and therefore is unable to recognize SYT XI 
when it was known to be present in an endothelial lysate sample. In contrast, the antibody did 
recognize SYTXI-EGFP in transfected HEK cells, demonstrating that it requires a highly 
concentrated source of antigen for successful recognition. In the likely event that SYT XI 
protein is present endogenously within HUVECs its concentration would be too low to allow 
detection by the antibody.  
ICC examining the distribution of the endogenous SYT XI protein in HUVECs was 
on the whole unsuccessful although unusual intracellular aggregates were identified. Initially, 
I presumed that these aggregates were a by-product of fixation or possibly a consequence of 
cell debris. However, over-expression studies revealed that these unusual aggregates are also 
seen in HUVECs and HEK cells following their transfection with SYTXI-EGFP (data not 
shown). It is possible that these aggregates may be a result of the time-dependent aggregation 
of the SYT XI protein. They may also be representative of subcellular vesicles although my 
attempts to identify them using an organelle marker screen were unsuccessful. 
 
3.5.8 SYT XVII: 
 
SYT XVII was shown to be present in HUVECs as an mRNA transcript and to my 
knowledge this is the first observation of the endogenous expression of SYT XVII in any cell 
type. SYT XVII is also thought to be present in HUVECs as a protein of 60 kDa. The 
predicted size of the human SYT XVII protein according to the Uniprot database is 54 kDa 
(http://www.uniprot.org/uniprot, entry Q9BSW7) and so it is likely that either a splice variant 
of the SYT XVII gene is expressed in HUVECs or the protein undergoes post-translational 
modifications which lead to discrepancies between its observed and predicted molecular 
weights. As I have shown, both of these eventualities are commonplace in the SYT family 
and as no other studies have attempted to determine the number of isoforms of SYT XVII in 
existence or their approximate sizes at this point I cannot comment on which possibility is 
more likely. ICC aiming to determine the distribution of endogenous SYT XVII in HUVECs 
was unsuccessful due to the failure of the commercial antibody to recognize the SYT XVII 
protein even when it was over-expressed in HEK-293 cells (Figure 3.16). This was 
unfortunate as this would have been the first determination of the distribution of endogenous 
SYT XVII in any cell type. 
 
 3.5.9 Conclusions: 
 
I have demonstrated that our model endothelial cells express SYTs I, III, V, VI, VII, 
VIII, XI, and XVII at both the mRNA and protein levels. Therefore these eight members of 
the SYT family are strong candidates for the role of the Ca
2+
 sensor regulating WPB 
exocytosis. Although SYTs VIII, XI, and XVII do not bind Ca
2+
 ions directly they are likely 
to play a modulatory role in the regulation of secretory events (Sudhof, 2002). The expression 
of SYT XVII in HUVECs is noteworthy as to my knowledge this represents the first 
observation of the expression of this member of the SYT family in a specific cell type.  
My attempts to determine the endogenous distribution of these proteins in HUVECs 
by ICC have been on the whole unsuccessful. It is likely that the SYTs are either not 
expressed at a sufficient level in HUVECs to allow their recognition by commercial 
antibodies or they are present as a complex with other proteins and so are inaccessible. In any 
case, as endogenous ICC is clearly inefficient the subcellular localization of the endothelial 
SYTs will be determined by the over-expression of fluorescent SYT constructs. The 
remainder of this report will focus on characterizing the subcellular distributions and 
functional roles of the endothelial SYTs with the aim to determine if one or more members of 
this family are involved in regulating the Ca
2+
-driven exocytosis of WPBs from HUVECs. 
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Chapter Four 
Determining the Subcellular Localization of the Endothelial SYTs 
 
4.1 Chapter Overview:  
 
Thus far, I have demonstrated that a number of the SYTs are expressed in our model 
endothelial cells and although the presence of SYT protein in HUVECs has been 
demonstrated by Western blotting attempts to determine the subcellular distribution of 
endogenous SYTs by ICC have been unsuccessful. It appears that in most cases the 
endogenous protein is not present in sufficient quantities to allow recognition by the 
commercial antibodies. Therefore, in order to determine the subcellular distribution of the 
SYTs I constructed fluorescent constructs of each family member which has been shown to 
be expressed in HUVECs. To achieve this I initially attempted a conventional method as 
described in ‘2.6.1 Conventional Ligation-Dependent Cloning.’ However, with the exception 
of the production of the SYTI-mCherry and SYTI-EGFP vectors this approach was 
unsuccessful. Despite repeated attempts to optimize the protocol by, for example, altering the 
ratio of vector to insert during the ligation reaction, increasing the quantity of template DNA 
for PCR, purchasing image clones of the SYTs, and varying the concentration of Mg
2+
 in the 
reactions I was repeatedly unable to produce SYT constructs through conventional means. 
Therefore, I used the ligation-independent (LIC) method as described in ‘2.6.2 Ligation-
Independent Cloning.’ This approach proved successful and EGFP fusion vectors for SYTs 
III, V, VI, VII, VIII, XI, and XVII were created and sequence-verified.  
 In order to determine the subcellular localization of the SYTs in endothelial cells the 
fluorescent constructs were expressed in HUVECs. ICC was performed with the aim to 
determine to which subcellular organelles the fluorescent proteins are trafficked. For each 
transfection, HUVECs were stained for either GFP or mCherry to emphasize the localization 
of the construct and for markers of various subcellular organelles. The marker proteins used 
in this study are listed in Table 4.1 and shown in Figure 4.1. They included VWF (a marker 
of WPBs), LAMP1 (for lysosomes), CD63 (for multivesicular bodies, WPBs, and 
lysosomes), PECAM (a marker for plasma membrane), TGN-46 (for the trans Golgi 
network), PDI (for the endoplasmic reticulum (ER)), EEA-1 (for the early endosomes) and 
the transferrin receptor (tfR; for the recycling endosomes). In some cases, HUVECs were 
also stained for Rab27a (to distinguish between mature and immature WPBs), VAMP3 (a  
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Figure 4.1.  Antigens associated with compartments of the secretory pathway 
The image shows the major subcellular compartments (black text) of the secretory pathway in 
endothelial cells and the antigens (red text) used to identify them. ER; endoplasmic 
reticulum (PDI), Golgi Apparatus, comprising cis, medial and trans (TGN-46) 
compartments, immWPBs; immature Weibel-Palade bodies (VWF), WPBs; mature Weibel-
Palade bodies (VWF, Rab27A), CSO; constitutive secretory organelles (tPA), PM; plasma 
membrane (PECAM), EE; Early Endosomes (EEA-1), RE; Recycling Endosomes (tfR), 
LE\MVBs; late endosomes\multivesicular bodies (CD63), Lys; Lysosomes (LAMP1, 
CD63). 
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Table 4.1. Various antigens were used to identify subcellular compartments.  
The abbreviated and full name of the marker proteins used throughout this study and 
the subcellular structure(s) which they identify are listed.  
 
SNARE protein resident on WPBs) and tPA (to identify small constitutively-secreted 
vesicles). Because the subcellular distribution of an over-expressed protein can vary 
depending on the growth time after transfection, HUVECs were cultured for 6 - 48 hours 
depending on the SYT prior to fixation. This approach allowed me to determine the 
subcellular localization of over-expressed SYTs and by extrapolation to identify the likely 
distribution of the endogenous protein in HUVECs. 
 
4.2 Results: 
 
4.2.1 SYT I:  
 
HUVECs were transfected with SYTI-mCherry and cultured for 24 or 48 hours prior 
to fixation. Figure 4.2 shows a HUVEC double-stained for mCherry and endogenous VWF.  
SYTI-mCherry did not label WPBs at either 24 or 48 hours. Instead it appeared to localize to 
the plasma membrane and to VWF-negative vesicular structures. The plasma membrane 
localization of SYTI-mCherry was confirmed by co-staining with PECAM (Figure 4.3). At 
48 hours post-transfection SYTI-mCherry was less strongly-associated with the plasma 
membrane and more strongly-associated with the vesicle-like structures (Figure 4.3 bottom 
Marker Protein Full Name Organelle / Structure 
VWF von Willebrand Factor WPBs 
LAMP1 
Lysosomal-Associated 
Membrane Protein 1 
Lysosomes 
CD63 N/A 
Multivesicular Bodies, 
WPBs, Lysosomes 
PECAM 
Platelet Endothelial Cell 
Adhesion Molecule 
Plasma Membrane 
TGN-46 Trans Golgi Network-46 trans Golgi Network 
PDI Protein Disulfide Isomerase Endoplasmic Reticulum 
EEA-1 Early Endosome Antigen-1 Early Endosomes 
tfR Transferrin Receptor Recycling Endosomes 
Rab27a N/A Mature WPBs 
VAMP3 
Vesicle-Associated 
Membrane Protein 3 
WPBs 
tPA 
Tissue Plasminogen 
Activator 
Constitutively-Secreted 
Small Vesicles 
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panel). To determine the identity of these structures HUVECs were stained 48 hours 
following transfection with antibodies directed against different compartments of the 
endocytic and recycling pathways.  Immunolabeling with markers of the early and recycling 
endosomes showed little evidence of co-localization at either time point (Figure 4.4), 
indicating that SYTI-mCherry is largely absent from these compartments.  Next, HUVECs 
were stained for markers of the multivesicular bodies and lysosomes (Figure 4.5).  As can be 
seen, SYTI-mCherry co-localized with a subset of CD63-positive organelles and strongly 
with LAMP1-positive structures.  In contrast immunolabeling for the ER and TGN showed 
no evidence of SYTI-mCherry localization to these compartments (Figure 4.6). Together, the 
data shows that SYTI-mCherry localizes to the plasma membrane at early time-points 
following transfection and is present predominantly in multivesicular bodies and lysosomes 
at more extended times. 
 
4.2.2 SYT III: 
 
SYTIII-EGFP expression peaked early after transfection (8-12 hours) and showed 
prominent perinuclear localization, labeling of vesicular structures, and what appeared to be a 
plasma membrane distribution (Figure 4.7). At 24 hours, the number of expressing cells was 
greatly reduced and by 48 hours no cells could be detected expressing the construct.  Based 
on these results an 8 hour time-point was chosen at which to screen the cells with organelle-
specific markers. 
To test whether the SYTIII-EGFP-positive vesicular structures might represent WPBs 
cells were co-stained for VWF (Figure 4.8).  No co-localization was detected between 
SYTIII-EGFP and VWF.  The plasma membrane localization of SYTIII-EGFP was 
confirmed by co-staining with PECAM (Figure 4.9, top panel) and the intense perinuclear 
signal co-localized with TGN-46 (Figure 4.9, bottom panel).  No evidence for co-localization 
of SYTIII-EGFP with the ER marker PDI was found (Figure 4.10).  To determine the identity 
of the SYTIII-EGFP positive vesicle-like structures cells were co-stained with antibodies 
against either EEA-1 (Figure 4.11, top panel), tfR (Figure 4.11 bottom panel), CD63 (Figure 
4.12 top panel) or LAMP1 (Figure 4.12 bottom panel). SYT III-EGFP clearly co-localized 
with EEA-1 but only very weakly with the tfR. However, the tfR staining was at times 
indistinct and so reaching definitive conclusions based on these images is difficult.  SYTIII-
EGFP also co-localized with a subset of CD63-positive organelles and could be detected in 
some but not all of the LAMP1-positive structures (Figure 4.12). 
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Figure 4.2 
Figure 4.2 SYTI-mCherry labels the plasma membrane and VWF-negative vescicle-like 
structures in HUVECs. 
Images show HUVECs expressing SYTI-mCherry (green) and counter-stained with a specific 
antibody to VWF (red) at 24 (top) or 48 hours (bottom) post-transfection. The arrows indicate 
the localization of SYTI-mCherry to the plasma membrane or to VWF-negative vesicular 
structures. Scales bars are 20 μm.  
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      Figure 4.3 
 
 
 
 
 
Figure 4.3. SYTI-mCherry is present on the plasma membrane. 
Images show HUVECs expressing SYTI-mCherry (green) and counter-stained with a specific 
antibody to PECAM (red) at 24 (top) or 48 hours (bottom) post-transfection. The arrows 
indicate SYTI-mCherry-labeled plasma membrane and\or vesicular structures.  Scales bars 
are 20 μm.  
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      Figure 4.4 
 
Figure 4.4. SYTI-mCherry is not detectable in the endosomal system in HUVECs. 
Images show HUVECs expressing SYTI-mCherry (green) and counter-stained (red) with 
specific antibodies to EEA-1 (top) or the tfR (bottom) 48 hours post-transfection.  Scales bars 
are 20 μm.  
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      Figure 4.5 
 
-
Figure 4.5. SYTI-mCherry is found on the multivesciular bodies and lysosomes in 
HUVECs. 
Images show HUVECs expressing SYTI-mCherry (green) and counter-stained (red) with 
specific antibodies to CD63 (top) or LAMP1 (bottom) 48 hours post-transfection.  Scales bars 
are 20 μm.  
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      Figure 4.6 
- 
Figure 4.6 SYTI-mCherry does not co-localize with ER or TGN markers. 
Images show HUVECs expressing SYTI-mCherry (green) and counter-stained (red) with 
specific antibodies to PDI (top) or TGN-46 (bottom) 48 hours post-transfection.  Scales bars 
are 20 μm.  
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Figure 4.7 
 
 
Figure 4.7. Time course of SYTIII-EGFP expression in HUVECs.  
Images show HUVECs expressing SYTIII-EGFP (green) at 4, 8, 12,  
24 and 48 hours post-transfection as indicated. Scales bars are 50 μm.  
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 Figure 4.8 
 
 
Figure 4.8. SYTIII-EGFP does not co-localize with endogenous VWF. 
Images show HUVECs expressing SYTIII-EGFP (green) and counter-stained with a specific 
antibody to VWF (red) 8 hours post-transfection.  Arrows indicate SYTIII-EGFP labeling of 
punctuate VWF-negative vesicular structures.  Scale bar is 30 μm.  
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Figure 4.9 
 
Figure 4.9. SYTIII-EGFP is present at low levels on the plasma membrane and in the 
TGN. 
Images show HUVECs expressing SYTIII-EGFP (green) and counter-stained (red) with a 
specific antibodies to PECAM (top) or TGN-46 (bottom) 8 hours post-transfection.  Arrows 
indicate SYTIII-EGFP-labeling of the plasma membrane (top) or TGN (bottom). Scale bars 
are 20 μm.  
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   Figure 4.10 
 
Figure 4.10 SYTIII-EGFP does not co-localize with the ER marker PDI. 
Images show HUVECs expressing SYTIII-EGFP (green) and counter-stained with a specific 
antibody to PDI (red) 8 hours post-transfection.  There was no evidence for co-localization of 
SYTIII-EGFP with PDI (shown by arrow).  Scale bar is 20 μm.  
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   Figure 4.11 
 
Figure 4.11. SYTIII-EGFP is present in early and possibly recycling endosomes. 
Images show HUVECs expressing SYTIII-EGFP (green) and counter-stained (red) with 
specific antibodies to EEA-1 (top) or tfR (bottom) 8 hours post-transfection.  Arrows indicate 
examples of co-localization between the proteins. Scale bars are 20 μm.  
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    Figure 4.12 
 
Figure 4.12. SYTIII-EGFP is present in a sub-population of multivesicular bodies and 
lysosomes. 
Images show HUVECs expressing SYTIII-EGFP (green) and counter-stained (red) with 
specific antibodies to CD63 (top) or LAMP1 (bottom) 8 hours post-transfection.  Arrows 
indicate examples of co-localization between the proteins. Scales bars are 20 μm.  
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4.2.3 SYT V: 
 
Expressed SYTV-EGFP localised almost exclusively to distinctive rod-like structures 
which co-stained with endogenous VWF and so were confirmed to be WPBs (Figure 4.13).  
Some SYTV-EGFP fluorescence was also detectable on the plasma membrane (Figure 4.14) 
and in the TGN (Figure 4.14, bottom panel) at 24 hours post-transfection (top left in Figure 
4.14). Closer inspection of cells labeled with TGN-46 suggested that SYTV-EGFP is present 
on WPBs as they emerge from this compartment indicating that SYT V may enter the WPB 
membrane at this point in the secretory pathway.  Consistent with a WPB localisation SYTV-
EGFP was detected on rod-shaped CD63- and VWF-positive WPBs but was only 
occasionally seen on smaller, more spherical CD63-positive VWF-negative structures that 
presumably represent the lysosomes and multivesicular bodies (Figure 4.15). No co-
localisation was found between SYTV-EGFP and the organelle markers PDI, EEA-1 (Figure 
4.16), tfR or LAMP1 (Figure 4.17).  
 
4.2.4 SYT VI: 
 
The expression of SYTVI-EGFP resulted in a diffuse pattern of fluorescence that was 
excluded from the nucleus. Co-staining of transfected HUVECs with PECAM or PDI 
indicated that SYTVI-EGFP is present on the plasma membrane and may also be found in the 
ER (Figure 4.18) although the latter was not clear. No evidence for the co-staining of SYTVI-
EGFP with VWF, EEA-1, tfR, CD63 or LAMP1 was detected (Figure 4.18). 
 
4.2.5 SYT VII: 
 
 The SYTVII-YFP construct was a kind gift from Professor Norma Andrews 
(University of Maryland). The expression of SYTVII-YFP in HUVECs resulted in the 
appearance of striking rod-like structures which co-localized with endogenous VWF 
demonstrating that these are representative of WPBs (Figure 4.19). Triple labeling of YFP, 
VWF and the WPB-specific Rab protein Rab27a (Figure 4.20A) or the v-SNARE VAMP3 
(Figure 4.20B) showed that SYTVII-YFP was present on mature WPBs.  Close inspection of 
these images suggested that SYTVII-YFP was also present on some immature Rab27a-
negative WPBs (Figure 4.20A). This suggests that SYTVII-YFP may enter the WPB  
 
17 
 
Figure 4.13 
 
Figure 4.13. SYTV-EGFP is present on WPBs. 
Images show HUVECs expressing SYTV-EGFP (green) and counter-stained with a specific 
antibody to VWF (red) at 24 (top) or 48 (bottom) hours post-transfection.  Arrows show co-
localization between SYTV-EGFP and endogenous VWF.  Scale bars are 20 μm.  
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           Figure 4.14 
 
Figure 4.14 SYTV-EGFP is present on the plasma membrane and TGN at early time-
points. 
Images show HUVECs expressing SYTV-EGFP (green) and counter-stained with specific 
antibodies to PECAM (red) and VWF (blue) at 24 (top left) or 48 hours (top right) post-
transfection.  Bottom: SYTV-EGFP-expressing (green)  HUVECs counter-stained with 
specific antibodies to TGN-46 (red) and VWF (blue) at 24 hours post-transfection.  Arrows 
show the co-localization of SYTV-EGFP with endogenous VWF in the TGN region of the 
cell.  Scale bars are 20 μm.  
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       Figure 4.15 
 
Figure 4.15. SYTV-EGFP is largely absent from multivesicular bodies. 
Images show HUVECs expressing SYTV-EGFP (green) and counter-stained with specific 
antibodies to CD63 (red) and VWF (blue).  Scale bar is 20 μm. Grey scale images from 
region (a) shows SYTV-EGFP (top) and endogenous CD63 (bottom). Red arrows show that 
most small, rounded CD63-positive organelles largely lack SYTV-EGFP. These organelles 
are negative for VWF (not shown).  Only rarely was there some evidence of co-localization 
of SYTV-EGFP and endogenous CD63 in these structures (e.g. white arrow). Grey scale 
panels from region (b) show SYTV-EGFP in rod-shaped CD63-positive WPBs.  
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    Figure 4.16 
 
Figure 4.16. SYTV-EGFP does not co-localize with either PDI or EEA-1. 
Images show HUVECs expressing SYTV-EGFP (green) and counter-stained (red) with 
specific antibodies to PDI (top) or EEA-1 (bottom). Arrows show the lack of co-localization 
of SYTV-EGFP with the ER or early endosomes.  Scale bars are 20 μm.  
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     Figure 4.17 
 
Figure 4.17. SYTV-EGFP does not co-localize with either the tfR or LAMP1. 
Images show HUVECs expressing SYTV-EGFP (green) and counter-stained (red) with 
specific antibodies to tfR (top) or LAMP1 (bottom). Arrows show the lack of co-localization 
of SYTV-EGFP with recycling endosomes or lysosomes.  Scale bars are 20 μm.  
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membrane at the level of TGN. Triple staining for YFP, VWF and CD63 or LAMP1 revealed 
that SYTVII-YFP was also present on lysosomes (Figure 4.21).  No clear evidence for the co-
localization of SYTVII-YFP with the plasma membrane or endosomal system was found 
(Figure 4.22). The co-expression of SYTVII-YFP with mRFP-tPA, a component of 
constitutive secretory granules in HUVECs (Knipe et al 2010), showed that SYTVII-YFP 
was absent from these organelles and therefore does not enter the constitutive pathway (data 
not shown). 
 
4.2.6 SYT VIII:  
 
The expression of SYTVIII-EGFP in HUVECs resulted in the appearance of a 
perinuclear fluorescence signal and the labeling of a subset of striking rod-like structures. 
These co-stained with α-VWF antibodies demonstrating that they are WPBs (Figure 4.23).  
Closer inspection of these images suggested that SYTVIII-EGFP may be present in the WPB 
membrane as the organelle emerges from the TGN region (Figure 4.23) indicating that it 
could be recruited to the granules at the level of Golgi. Triple staining for GFP, VWF and 
CD63 or LAMP1 revealed that SYTVIII-EGFP is absent from the lysosomes although as 
expected CD63-positive WPBs were shown to contain the construct (Figure 4.24).  No 
evidence for the co-localization of SYTVIII-EGFP with the plasma membrane or endosomal 
system was found (Figure 4.25).  
 
4.2.7 SYT XI:  
 
The expression of SYTXI-EGFP in HUVECs resulted in the appearance of a strong 
perinuclear fluorescence signal and a reticular pattern of peripheral fluorescence. The 
perinuclear fluorescence co-localized with TGN-46 (Figure 4.26, bottom) and to some extent 
with PDI (Figure 4.26, top). No evidence for the co-localization of SYTXI-EGFP with WPBs 
(VWF/CD63), the plasma membrane (PECAM), early endosomes (EEA-1), recycling 
endosomes (tfR) or lysosomes (LAMP1/CD63) was identified (Figure 4.27).  
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    Figure 4.18 
 
Figure 4.18. SYTVI-EGFP may be present on the plasma membrane but does not 
clearly co-localize with any other cellular compartment. 
Images show HUVECs expressing SYTVI-EGFP (green) and counter-stained (red) with 
specific antibodies to PDI, TGN-46, VWF, PECAM, EEA-1, tfR, CD63 or LAMP1 as 
indicated. Arrows in the PECAM panel show the putative localization of SYTVI-EGFP to the 
plasma membrane.  Scale bars are 20 μm.  
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     Figure 4.19 
 
Figure 4.19. SYTVII-YFP is present on WPBs. 
The figure shows two examples of HUVECs expressing SYTVII-YFP (green) and counter-
stained with a specific antibody to VWF (red) 48 hours post-transfection.  Arrows show the 
co-localization of SYTVII-YFP with endogenous VWF.  Scale bars are 20 μm.  
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  Figure 4.20A 
 
 
Figure 4.20A. SYTVII-YFP is present on both mature Rab27A-positive and immature 
Rab27A-negative WPBs. 
The image shows HUVECs expressing SYTVII-YFP (green) and counter-stained with 
specific antibodies to endogenous Rab27A (red) and VWF (blue) 48 hours post-transfection  
Scale bar is 20 μm.  The arrows in region (a) show SYTVII-YFP on mature Rab27A-positive 
WPBs while in region (b) SYTVII-YFP can be seen on immature Rab27A-negative WPBs 
emerging from the TGN region of the cell.   
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  Figure 4.20B 
 
 
Figure 4.20B.  SYTVII-YFP co-localizes with VAMP3-positive WPBs 
HUVECs expressing SYTVII-YFP (green) were counter-stained with specific antibodies to 
endogenous VAMP3 (red) and VWF (blue) 48 hours post-transfection.  Scale bar is 20 μm.  
Arrows in region (a) show SYTVII-YFP on VAMP3-positive WPBs. Arrows in region (b) 
show SYTVII-YFP on VAMP3-positive WPBs emerging from the TGN region of the cell.   
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     Figure 4.21 
 
Figure 4.21. SYTVII-YFP co-localizes with CD63- and LAMP1-positive VWF-negative 
organelles. 
HUVECs expressing SYTVII-YFP (green) were counter-stained (red) with specific 
antibodies to endogenous CD63 (top), LAMP1 (bottom) and VWF (blue) 48 hours post-
transfection.  Scale bar is 20 μm.  Arrows show SYTVII-YFP on CD63- or LAMP1-positive 
organelles.   
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Figure 4.22 
 
 
 Figure 4.22.  SYTVII-
YFP does not co-localize 
with PECAM, EEA-1 or 
the tfR. 
Image shows HUVECs 
expressing SYTVII-YFP 
(green) and counter-
stained (red) with specific 
antibodies to endogenous 
PECAM (top), EEA-1 
(middle) or tfR (bottom) 
48 hours post-transfection.  
Scale bar is 20 μm. 
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 Figure 4.23 
 
 
Figure 4.23. SYTVIII-EGFP co-localizes with VWF in WPBs. 
HUVECs expressing SYTVIII-EGFP (green) were counter-stained with a specific antibody to 
endogenous VWF (red) 48 hours post-transfection.  Scale bar is 20 μm.  Arrows in (a) show 
the localization of SYTVIII-EGFP to the WPBs and in (b) show the presence of SYTVIII-
EGFP on WPBs emerging from the TGN region of the cell. 
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           Figure 4.24 
 
 
Figure 4.24. SYTVIII-EGFP is only weakly detected in some multivesicular bodies.  
HUVECs expressing SYTVIII-EGFP (green) were counter-stained with specific antibodies to 
endogenous CD63 (red) or VWF (blue) 48 hours post-transfection  Arrows in region (a) 
indicate a weak co-localization of SYTVIII-EGFP with large CD63-positive (VWF-negative; 
not shown) organelles and in (b) co-localization with CD63-positive WPBs.  Scale bar is 20 
μm. 
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      Figure 4.25 
 
 
Figure 4.25. SYTVIII-EGFP was not detected on the plasma membrane, in the 
endosomal system or in the lysosomes. 
HUVECs expressing SYTVIII-EGFP (green) were counter-stained (red) with specific 
antibodies to endogenous PECAM, EEA-1, tfR and LAMP1 48 hours post-transfection.  
Scale bars are 20 μm. The arrows indicate the absence of co-localization between the 
proteins.  
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        Figure 4.26 
 
Figure 4.26. SYTXI-EGFP is present in the ER and TGN. 
The images show HUVECs expressing SYTXI-EGFP (green) and counter-stained (red) with 
specific antibodies to endogenous PDI (top) and TGN-46 (bottom). Arrows show the 
localization of SYTXI-EGFP to the ER or TGN.  Scale bars are 20 μm.  
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         Figure 4.27 
 
Figure 4.27. SYTXI-EGFP does not co-localize with markers of the WPBs, plasma 
membrane, early endosomes, recycling endosomes, multivesicular bodies or lysosomes. 
HUVECs expressing SYTXI-EGFP (green) were counter-stained (red) with specific 
antibodies to endogenous VWF, PECAM, EEA-1, tfR, CD63 or LAMP1 as indicated. 
Arrows show the lack of co-localization between SYTXI-EGFP and any of the organelle 
markers used.  Scale bars are 20 μm.  
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4.2.8 SYT XVII: 
 
SYT XVII is the most recently discovered member of the SYT family and thus far 
very little work has been done to determine its tissue distribution, subcellular localization, or 
function. To my knowledge, the data presented below is the first attempt to determine the 
subcellular localization of SYT XVII in any cell type.  
SYTXVII-EGFP expression labeled a wide variety of subcellular structures, the most 
striking of which were the WPBs (Figure 4.28). Localization was also apparent in the TGN 
(Figure 4.29), the early and recycling endosomes (Figure 4.30), and the lysosomes and 
multivesicular bodies (Figure 4.31). Surprisingly, no clear evidence of co-localization 
between SYTXVII-EGFP and the plasma membrane was detected and there was no co-
localization with PDI (Figure 4.32).  
 
4.3 Conclusions and Discussion: 
 
 4.3.1 Conclusions: 
 
The primary results of this subcellular localization screen examining the distribution 
of over-expressed fluorescent SYT constructs in HUVECs are summarized in Table 4.2 and 
shown in Figure 4.33. From this work, a series of candidates for the role of the Ca
2+
-sensor 
mediating the exocytosis of WPBs from HUVECs has been identified and therefore the 
findings described in this chapter have determined the direction of my research.  
I have shown that four members of the SYT family (SYTs V, VII, VIII, and XVII) are 
found localized to the WPBs following their over-expression in HUVECs. Logically these 
four proteins were identified as being strong candidates for the role of the calcium sensor 
regulating WPB exocytosis, and within this group two SYTs hold particular promise. First 
and foremost, SYT VII was shown to traffic to both WPBs and lysosomes and a large body of 
published literature has established that SYT VII plays a fundamental role in the regulation of 
the Ca
2+
-mediated exocytosis of large secretory granules in other cell types (for review see 
Andrews and Chakrabarti, 2005). With this in mind, and considering the observed 
distribution of SYTVII-YFP in HUVECs, SYT VII was designated my primary candidate for 
the role of the calcium sensor regulating WPB exocytosis. Therefore my research initially 
focused on investigating the function of this member of the SYT family and this work is 
presented in the following chapter (Chapter 5). 
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   Figure 4.28 
 
 
Figure 4.28. SYTXVII-EGFP localizes to the WPBs in HUVECs 
The image shows a single HUVEC expressing SYTXVII-EGFP (green) and counter-
stained with a specific antibody to endogenous VWF (red). Arrows show co-
localization between SYTXVII-EGFP and WPBs.  Scale bar is 5 μm.  
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     Figure 4.29 
 
 
Figure 4.29 WPB localization of SYTXVII-EGFP 
Image shows a single HUVEC expressing SYTXVII-EGFP (green) and counter-stained with 
specific antibodies to endogenous TGN-46 (red) and VWF (blue). Yellow arrow shows two 
TGN-46 positive WPBs which are emerging from the TGN and contain SYTXVII-EGFP. 
Red arrows show the localization of SYTXVII-EGFP with TGN-46-negative WPBs closely 
associated with the TGN region of the cell.  Scale bar is 20μm.  
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     Figure 4.30 
 
Figure 4.30. SYTXVII-EGFP co-localizes with markers of the endosomal system. 
HUVECs expressing SYTXVII-EGFP (green) were counter-stained (red) with specific 
antibodies to endogenous EEA-1 (top) or tfR (bottom).  Arrows show co-localization of 
SYTXVII-EGFP with the early and recycling endosomes.  Scale bars are 20 μm.  
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         Figure 4.31 
 
Figure 4.31. SYTXVII-EGFP co-localizes with markers of multivesicular bodies and 
lysosomes.  
HUVECs expressing SYTXVII-EGFP (green) were counter-stained (red) with specific 
antibodies to endogenous CD63 (top) or LAMP1 (bottom).  Arrows show the co-staining of 
SYTXVII-EGFP and multivesciular bodies or lysosomes. Scale bars are 20 μm.  
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           Figure 4.32 
  
Figure 4.32. SYTXVII-EGFP is not detectable on the plasma membrane or in the ER 
HUVECs expressing SYTXVII-EGFP (green) were counter-stained (red) with specific 
antibodies to PDI (top) or PECAM (bottom).  The arrows show the lack of co-localization of 
SYTXVII-EGFP with PDI or PECAM.  Scale bars are 20 μm.  
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 A second Ca
2+
-dependent SYT, SYT V, was shown to have a strong and almost-
exclusive WPB distribution in HUVECs and so was identified as a promising candidate for 
the role of the WPB Ca
2+
-sensor. There is currently little known regarding the function of the 
SYT V protein in other cell types and so unlike SYT VII no evidence is available in the 
literature suggesting that SYT V may be involved in mediating WPB exocytosis. However, 
SYT V is expressed in HUVECs and given its strong localization to WPBs following over-
expression it is certainly possible that this protein is involved in the regulation of WPB 
exocytosis. Therefore extensive functional studies were performed with the aim to ascertain 
the function to SYT V in endothelial cells and these are presented in Chapter 6. 
 Two additional members of the SYT family (SYTs VIII and XVII) were shown to 
traffic to WPBs following their over-expression in HUVECs. These two proteins are Ca
2+
-
insensitive and so are not likely to be to be the primary regulators of Ca
2+
-mediated WPB 
exocytosis. It is however entirely feasible that they may function as modulators of exocytosis 
and so were pursued as proteins of interest for the purposes of this investigation. Firstly, 
SYTVIII-EGFP traffics exclusively to WPBs in HUVECs although its distribution pattern 
forty-eight hours following transfection led me to believe that the protein is progressively 
removed from the organelles. Therefore it is possible that the observed localization of the 
construct to WPBs is an artifact of over-expression. Secondly, SYTXVII-EGFP traffics to the 
WPBs following its over-expression in HUVECs but is also found as a component of the 
lysosomes, endosomes, and Golgi network. Two possibilities explain this observation; either 
the trafficking of SYTXVII-EGFP to WPBs is not specific or this member of the SYT family 
plays a fundamental but as-yet unknown role in endothelial cell biology, hence its wide 
distribution.  In any case, the initial experimental evidence suggesting that SYTs VIII and 
XVII are involved in WPB exocytosis is not as strong as for SYTs V and VII. However they 
cannot be excluded on this basis and so functional studies were pursued attempting to 
determine the role of these Ca
2+
-insensitive proteins in HUVECs. This work is presented in 
Chapter 7.  
Finally, four additional SYT family members (SYTs I, III, VI and XI) are found in 
HUVECs but do not localize to WPBs when over-expressed. Therefore these proteins are not 
located in a subcellular position where they could easily regulate the final stage of WPB 
exocytosis. However, it is entirely possible that they are involved in the biosynthesis, 
budding, maturation, or trafficking of WPBs. Therefore, more-limited functional studies were 
attempted aiming to determine the relationship between these SYTs and WPB biology. These 
results will be presented in Chapter 8. 
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Figure 4.33.  The SYTs show an extensive distribution pattern in HUVECs. 
The image summarizes the distribution of fluorescent SYTs (Red Text) associated with the     
major subcellular compartments (Black Text) of the secretory pathway in endothelial cells. 
 
 
 
 
SYT Subcellular Localization 
I 
Plasma Membrane 
Lysosomes 
III Plasma Membrane / Early Endosomes / TGN 
V WPBs / TGN 
VI ER/ Plasma Membrane 
VII 
WPBs 
Lysosomes 
VIII WPBs / TGN 
XI TGN / ER 
XVII 
WPBs 
Lysosomes 
Endosomes 
TGN 
Table 4.2. The SYTs show an extensive distribution pattern in HUVECs.  
The subcellular localization of the endothelial-expressed SYTs is summarized.  
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4.3.2 Discussion: 
 
4.3.2.1 SYT I: 
 
SYT I is a component of synaptic vesicles in neurons (Matthew et al. 1981) and 
LDCVs in PC12 cells (Lynch and Martin, 2007), pancreatic acinar cells (Falkowski et al. 
2011), and mast cells (Baram et al. 2001). Here, the probable distribution of endogenous SYT 
I in HUVECs has been determined by the over-expression of SYTI-mCherry which was 
shown to localize to the plasma membrane and lysosomes at both twenty-four and forty-eight 
hours following transfection. Interestingly, the reported localization of the construct to the 
plasma membrane was considerably stronger at earlier time-points suggesting that SYT I may 
have a short half-life in HUVECs leading to its rapid internalization and degradation. 
Alternatively, this observation may simply be an expression property of the construct and 
therefore not biologically relevant. This distribution of SYT I in HUVECs suggests that it 
may play role in the regulation of WPB exocytosis as SYTs found on opposing membrane are 
able to form oligomers when in close apposition and thus function cooperatively to regulate 
fusion events (Sugita et al. 2001). 
 
4.3.2.2 SYT III: 
 
This work has shown that the SYT III protein is largely absent from the WPBs, 
lysosomes, multivesicular bodies, and the endoplasmic reticulum in HUVECs. However, 
interestingly SYTIII-EGFP was shown to localize strongly to EEA1-positive early 
endosomes and was also detected at low levels on the plasma membrane. This is in keeping 
with published observations showing that SYT III is found endogenously on rab11-positive 
perinuclear endocytic recycling endosomes in RBL-2H3 cells (Grimberg et al. 2002). Here, 
SYT III was shown to be essential for the de novo formation of recycling endosomes at the 
plasma membrane.  Therefore it is highly likely that SYT III is involved in regulating the 
formation of early endosomes in endothelial cells and indeed it would be of interest to 
determine if it can be found co-localized with rab11 in HUVECs. In contrast to published 
observations (Falkowski et al. 2011, Masztalerz et al. 2006), SYT III was not found to co-
localize with LAMP1 in HUVECs. However, following the transfection of HEK cells with 
SYTIII-EGFP the construct was seen to traffic to LAMP1-positive structures (data not 
43 
 
shown), indicating that its absence in these organelles in HUVECs is likely to be a specific 
feature of its over-expression in this cell type.  
 
4.3.2.3 SYT V: 
 
There is currently little known regarding the subcellular distribution of SYT V 
although it has been reported to be a component of secretory granules in pancreatic α-cells 
(Iezzi et al. 2004) and LDCVs in PC12 cells (Saegusa et al. 2002). Here, I have shown that 
SYT V traffics strongly to WPBs when over-expressed in HUVECs and therefore this 
member of the SYT family is in an ideal subcellular position to regulate the exocytosis of 
WPBs. Additionally, a proportion of the construct was observed on the plasma membrane 
and in the Golgi body. It is possible that following the basal release of WPBs from HUVECs 
the SYT V protein is trafficked from the plasma membrane to the Golgi body via the 
recycling pathway where it is loaded onto forming granules. A time-course experiment 
examining the trafficking of the SYT V protein following stimulation would be necessary to 
verify this hypothesis. Additionally, it is known that in other cell types the localization of the 
SYT V protein varies depending on the stimulation state of the cell (Vinet et al. 2008). It 
would be of interest to determine if the observed distribution of SYTV-EGFP is altered 
following HUVEC stimulation with ionomycin or histamine.  
 
4.3.2.4 SYT VI: 
 
The typical subcellular localization of endogenous SYT VI is currently unclear as the 
majority of investigators use over-expressed protein to determine its distribution in their cells 
of interest (Dean et al. 2012, Saegusa et al. 2002, Fukuda and Mikoshiba, 1999). Here, the 
over-expression of the SYTVI-EGFP protein in HUVECs suggests the construct localizes 
predominantly to the plasma membrane and the ER. This is in contrast to my previous 
observation that endogenous SYT VI is found as a component of the early endosomes (see 
Chapter 3). However, it should be noted that the template DNA used to construct the SYTVI-
EGFP vector was derived from a single image clone of SYT VI and so would only represent 
one variant of the protein. It is possible that this variant shows a more restricted distribution 
than has been observed for the endogenous protein(s). Indeed, it is known that different 
variants of the SYT VI protein show unique localization patterns following their over-
expression as full-length SYT VI is trafficked to the ER and Golgi when over-expressed in 
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PC12 and COS cells whereas a transmembrane-lacking variant is found within the cytosol 
and as a component of internal membranes (Fukuda and Mikoshiba, 1999). Interestingly, 
within HEK cells over-expressed SYTVI-EGFP also localizes to the ER and is excluded from 
other structures (data not shown). Therefore, the subcellular localization of SYT VI in 
HUVECs is currently debatable although no evidence has been provided to suggest that the 
protein is found within WPBs. Therefore, SYT VI is not located in a subcellular position 
which would allow its regulation of WPB fusion with the plasma membrane.  
 
4.3.2.5 SYT VII: 
 
The ubiquitously-expressed protein SYT VII appears to have a fundamental role in 
the exocytosis of large secretory granules and has been found as a component of lysosomes in 
fibroblasts (Martinez et al. 2000), phagosomes in macrophages (Czibener et al. 2006), 
LDCVs in T-cells (Fowler et al. 2007), and insulin- and glucagon-containing granules in 
pancreatic cells (Gao et al. 2000, Gustavsson et al. 2009). Here, I have shown that SYTVII-
YFP co-localizes with both VWF and VAMP3 on WPBs and with LAMP1 on lysosomes. In 
HUVECs which express the construct, SYTVII-YFP traffics to virtually every granule. 
However closer inspection reveals that it localizes most strongly to the tips of many WPBs 
and in some cases is also seen concentrated at regular intervals along their length. It is 
tempting to speculate that these regions may represent potential sites of compound fusion 
events between individual granules, or possibly may distinguish sites of fusion between 
WPBs and other cellular structures such as lysosomes and multivesicular bodies. Hence, SYT 
VII may play a specific role in mediating intracellular fusion events between WPBs and other 
organelles.  
SYTVII-YFP was detected on both mature (Rab27a-positive) and immature (Rab27a-
negative) granules, demonstrating that it is likely to be loaded onto WPBs as they form at the 
TGN rather than being recruited from other subcellular structures following granule budding. 
The construct could not be detected in the Golgi body, ER, endosomal system, or as a 
component of the plasma membrane.  Therefore, the specific trafficking of SYTVII-YFP to 
WPBs has implicated this member of the SYT family in the regulation of WPB exocytosis, a 
proposition which is supported by the current literature. Interestingly, the tetraspanin CD63 is 
found as component of the WPB membrane (Vischer and Wagner, 1992) and this protein has 
been reported to bind to and traffic SYT VII to lysosomes in fibroblasts via a palmitoylation-
dependent interaction (Flannery et al. 2010). It is conceivable that a similar mechanism 
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occurs in HUVECs whereby CD63 is responsible for the delivery of SYT VII to WPBs and 
lysosomes. In the future it would be of interest to test this by eliminating the CD63 protein 
and determining the effect on the subcellular distribution of SYT VII. Equally co-
immunoprecipitation experiments may demonstrate a physical interaction between CD63 and 
SYT VII as well as identifying other binding partners of SYT VII in HUVECs. 
 
4.3.2.6 SYT VIII: 
 
The subcellular distribution of endogenous SYT VIII in other cell types is currently 
unknown with the exception that it is found in the acrosomal crescent of murine sperm cells 
(Hutt et al. 2002). Here, I have shown that SYTVIII-EGFP is trafficked exclusively to the 
WPBs and TGN and is excluded from the lysosomes, the plasma membrane, the ER, and the 
endosomal system. However, at forty-eight hours following transfection only a small 
proportion of HUVECs were seen to be expressing the construct and within this population of 
cells only a minority of WPBs were positive for SYTVIII-EGFP. In contrast, at twenty-four 
hours the construct is expressed by a greater proportion of HUVECs and shows a more 
extensive WPB distribution. These discrepancies may simply be the result of an expression 
property of the construct or they may represent the progressive removal of SYTVIII-EGFP 
from WPBs. This would suggest that either SYTVIII-EGFP enters WPBs as a result of a 
default pathway or its presence in the organelles is due to inefficient exclusion at the level of 
the Golgi. However, the lack of trafficking of the construct to other organelles argues against 
this theory.  An additional consideration is that the SYTVIII-EGFP construct, having been 
derived from an image clone, represents only one isoform of the SYT VIII protein. It is 
known that different variants of SYT VIII show unique localization patterns (Monterrat et al. 
2006) and so it would be of interest to produce fusion constructs of the endothelial-specific 
SYT VIII isoforms from pools of HUVEC cDNA to determine their precise subcellular 
distributions. Unfortunately my attempts to do this were unsuccessful but it would be a useful 
avenue for future research.   
 
4.3.2.7 SYT XI: 
 
I have shown that SYTXI-EGFP consistently localizes to the Golgi body in HUVECs. 
This is in-keeping with the published finding that SYTXI-EGFP localizes to the Golgi body 
in PC12 cells (Fukuda and Mikoshiba, 2001). As two unrelated SYTXI-GFP constructs have 
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been shown to localize to the Golgi body in different cell types it is likely that the 
endogenous SYT XI protein is indeed found within this compartment. However, it is also 
possible that the observed distribution of SYT XI is the result of uncontrolled aggregation of 
the over-expressed protein in the TGN. Equally, it is possible that SYT XI lacks a binding 
partner in PC12 and endothelial cells which it requires for transport out of the Golgi. 
However, as the SYT mRNA expression screen has demonstrated that SYT XI mRNA is 
expressed endogenously in HUVECs this option seems unlikely. 
 
4.3.2.8 SYT XVII: 
 
I have shown that SYTXVII-EGFP has a broad distribution pattern in our model 
endothelial cells, localizing to the WPBs, lysosomes, early endosomes, recycling endosomes, 
and the Golgi body. Indeed, the only structures which stain negatively for the over-expressed 
protein are the ER and the plasma membrane. This extensive distribution suggests that either 
the construct is trafficked non-specifically to a number of organelles in HUVECs and 
therefore these observations are an artefact of over-expression or that SYT XVII does in fact 
play a fundamental role in endothelial cell biology. Only one other study has attempted to 
determine the distribution of SYT XVII using a fluorescent construct over-expressed in 
hippocampal neurons and these results were inconclusive (Dean et al. 2012). Therefore given 
the lack of any available literature concerning the distribution of SYT XVII in other cell 
types it is impossible at this point to comment further on my findings.  
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Chapter 5 
 Investigating the Function of SYT VII in HUVECs 
 
5.1 Background Information: 
 
5.1.1 The Regulation of Expression of the SYT VII Gene: 
 
The rat cDNA sequence for SYT VII was first determined in 1995 (Li et al. 1995). 
The human equivalent of the rat SYT VII gene was localized to chromosome 11q13 in 1998 
as a result of an attempt to identify candidate genes responsible for the degenerative eye 
disease Best vitelliform macular dystrophy (Cooper et al. 1998). Initial attempts to 
characterize the tissue distribution of this novel transcript by Northern blotting revealed that 
SYT VII mRNA is found extensively in adult and foetal tissue, with particularly high levels 
reported in the brain, liver, heart, and thymus (Cooper et al. 1998). SYT VII is now known to 
be ubiquitously expressed with its mRNA found in the rodent cerebrum, cerebellum, 
olfactory bulb, intestine, kidney, pancreas, heart, lung, and spleen (Li et al. 1995, Han et al. 
2004).  
The signalling pathways which regulate the expression of the SYT VII gene have 
been partially elucidated in recent years, and indeed SYT VII mRNA levels are known to 
fluctuate in patients suffering from certain medical conditions. For example, in pancreatic 
islets derived from patients suffering from type II diabetes SYT VII mRNA levels are 
decreased (Andersson et al. 2012). Additionally, it is likely that SYT VII mRNA levels 
fluctuate during pregnancy as they have been reported to increase in developing mouse 
follicles following exposure to pregnant mare serum gonadotropin (PMSG) (Choi et al. 
2012).   
It has become clear in recent years that the expression of the SYT VII gene is heavily 
influenced by the dopaminergic signalling pathway. As a consequence SYT VII mRNA 
levels become dysregulated following the onset of Parkinson’s disease and as a result of 
chronic drug use. In the caudoputamen and the striatum, acute cocaine administration results 
in the activation of extracellular signal-regulated kinase (ERK), which leads to the expression 
of the immediate early gene c-fos and ultimately to alterations in the level of SYT VII mRNA 
(Zhang et al. 2004, Zhang and Zu, 2006). The expression of the SYT VII gene is activated by 
the dopamine D1 receptor via the stimulation of adenylyl cyclases and repressed by the D3 
48 
 
receptor via the inhibition of adenylyl cyclases. Interestingly, the SYT VII promoter contains 
cAMP-response element binding (CREB) protein- and AP-1 transcription complex-binding 
consensus sequences, indicating that the expression of SYT VII is likely to be mediated by 
either the CREB or AP-1 transcription complexes following cocaine administration.   
As a consequence of its regulation by the dopaminergic pathway, evidence has been 
provided suggesting that SYT VII may play a role in the pathogenesis of Parkinson’s disease 
(PD). Rats treated with 6-hydroxydopamine to deplete their striatal dopamine levels show an 
almost complete loss of SYT VII mRNA and this can be reversed following treatment with 
either L-dopa or with the D1 agonist SKF82958 (Glavan and Zivin, 2005). Additionally, the 
treatment of hemiparkinsonian rats with L-dopa increases the expression of SYT VII mRNA, 
suggesting that the use of L-dopa as a therapeutic for PD may lead to elevated levels of SYT 
VII mRNA in the striatum. This may partly explain the neurological abnormalities which 
result from chronic L-dopa administration (Glavan, 2008).  
 
5.1.2 The Splice Variants of SYT VII: 
 
At least three isoforms of SYT VII have been reported to exist in human, mouse, and 
rat tissue, and these variants are designated SYTVII-α ,β, and γ (Fukuda et al. 2002). 
SYTVII-α is the major isoform, appearing as a 65-kDa protein on Western blots, and is found 
expressed predominantly in non-neuronal tissues. SYTVII-β and SYTVII-γ are minor 
isoforms and are primarily expressed in neuronal tissue. These two variants contain inserts of 
44 and 116 amino acids respectively in the spacer domain between the transmembrane region 
and the C2 domains.  The three isoforms are present in a ratio of 77:20:3 (α:β:γ) in the mouse 
brain, and therefore SYT VII-γ is relatively uncommon. Indeed, it is rarely detected in tissues 
outside the brain. In PC12 cells, SYTVII-α was reported to co-stain with TGN-38 in the 
perinuclear region and was also seen to reside on endosomes and on dense-core vesicles in 
the tips of neuritis (Fukuda et al. 2002). 
A subsequent study has reported the presence of an additional SYT VII isoform, 
SYTVII-δ, in pancreatic β-cells and INS-1E cells (Gauthier et al. 2008). This novel isoform 
is composed only of exons 1 to 5 of the SYT VII gene and therefore lacks the C2 domains 
necessary for calcium binding. SYTVII-α and -β are also expressed in the pancreas, with the 
ratio of expression being 11:3.8:0.5 (α:β:δ). However, SYTVII-δ was not detected by 
Western blotting and indeed it is possible that this minor isoform is not translated into a 
stable protein. When SYTVII-α is over-expressed in INS-1E cells it is trafficked to the 
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plasma membrane and results in  decreased insulin content of the LDCVs (Gauthier et al. 
2008).  In contrast, capacitance studies revealed that the over-expression of SYTVII-β has no 
effect on insulin secretion. Following the transfection of INS-1E cells with siRNA against the 
various isoforms, it was shown that the loss of SYTVII-α results in a decrease in insulin 
secretion whereas the knock-down of SYTVII-β results in a slight increase in secretion 
(Gauthier et al. 2008). It is possible that SYTVII-β functions as an antagonist of SYTVII-α, 
and therefore the ratio of expression of the various isoforms in a cell may modulate the 
observed overall function of SYT VII. It is important to bear in mind that the precise number 
of SYT VII isoforms has yet to be determined fully, and indeed it is known that rostral brain 
regions express up to six different SYT VII variants (Sugita et al. 2001, Han et al. 2004). 
 
5.1.3 The SYT VII Protein: Structure, Calcium Sensitivity, Oligomerization and 
Internalization: 
 
Structurally, the C2B domain of SYT VII is remarkably similar to that of SYT I, with 
both domains showing 48 % sequence identity. However, a prominent difference is that the 
SYT VII C2B domain binds three Ca
2+
 ions whereas the SYT I C2B domain binds two Ca
2+
 
ions (Xue et al. 2010). These three calcium-binding sites are formed by loops 1-3 of the SYT 
VII C2B domain and the bound ions are coordinated by five aspartate residues, one serine 
residue, and three backbone carbonyl groups. The SYT I C2B domain lacks this crucial serine 
residue and hence only binds two Ca
2+
 ions. Additional differences in the SYT VII C2B 
domain are that only one of two prominent α-helices present in the SYT I C2B domain (the 
HA helix) is seen in the SYT VII protein. These relatively subtle structural differences 
between the two SYTs lead to dramatic functional consequences. The C2 domains are not 
only essential for determining the overall function of the SYT VII protein but are also crucial 
for ensuring its stability. If both C2 domains of SYT VII are mutated to render them 
insensitive to calcium, the expression level of the SYT VII protein is only 20-30 % of that of 
the wild-type protein, suggesting that calcium-binding is essential for the stabilization of the 
protein (Maximov et al. 2008).  
As indicated, SYT VII is a Ca
2+
-sensitive SYT, and like SYTs IX and XI its C2B 
domain shows strong IP4 binding activity demonstrating that this member of the SYT family 
is capable of high-affinity interactions with internal membranes (Ibata et al. 1998). Indeed, 
the Ca
2+
-mediated sensitivity of membrane binding for the SYT VII C2A domain is much 
higher than that for the SYT I C2A domain, with Ca1/2 values of 31 ± 2 µM for the SYT I 
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C2A domain versus 1.7 ± 0.2 µM for the SYT VII C2A (Brandt et al. 2012). This observed 
heightened sensitivity is the result of the slow membrane dissociation rate of the SYT VII 
C2A domain, as although the rate of association with target membranes is 2-fold slower than 
that of the SYT I C2A domain, dissociation rates are 60-fold slower. Dissociation can be 
slowed by treatment with solutes which enhance the hydrophobic effect such as trehalose or 
Na2SO4, and hence it is though that the SYT VII C2A domain first associates with target 
membranes in an electrostatic manner requiring Ca
2+
 ions and anionic membrane lipids and 
then inserts into the membrane through a slow hydrophobic process. Indeed, the SYT VII 
C2A domain forms a stronger interaction with membranes containing higher quantities of the 
anionic lipid phosphatidylserine, demonstrating the importance of electrostatic interactions in 
membrane binding. Additionally, the SYT VII C2A domain maintains its association with 
liposomes following NaCl titration whereas the SYT I C2A domain dissociates rapidly, 
demonstrating the importance of strong non-electrostatic forces in SYT VII membrane 
binding. It is likely that the stronger binding affinity of the SYT VII C2A domain compared 
with the SYT I C2A domain is due to the presence of two phenylalanine residues at positions 
167 and 229 of the SYT VII C2A region. These sites are located at the ends of two Ca
2+
-
binding loops, and in the SYT I C2A domain are occupied by methionine and phenylalanine 
respectively. As phenylalanine shows a stronger affinity for lipid membranes due to its 
inherent hydrophobicity, it is most likely this extra phenylalanine residue which allows the 
SYT VII C2A domain to insert deeper into target membranes.  
 The SYT VII protein shows robust Ca
2+
-dependent oligomerization at the 
cytoplasmic domain with EC50 values of about 155 µM Ca
2+ 
and can also
 
form weak Ca
2+
-
independent oligomers (Fukuda et al. 2000). Indeed, the SYT VII cytoplasmic domain 
displays the strongest Ca
2+
-dependent oligomerization activity in the SYT family (Fukuda et 
al. 2001). This strong multimerization ability is the result of an asparagine residue in the SYT 
VII C2B domain (ASN328). In other SYTs, this site is occupied by threonine. SYT VII 
preferentially forms Ca
2+
-dependent oligomers with SYTs V, VI, and X, can produce weak 
oligomers with SYTs I, II, and IX, and does not interact with the other members of the SYT 
family. For most SYTs, oligomerization of the cytoplasmic domain is only possible if the 
proteins are tethered at the N-terminus. However, the co-expression of both full-length and 
cytoplasmic portions of the SYT VII protein revealed that SYT VII is able to oligomerize 
without anchoring at the N-terminus.  
 The mechanism of oligomerization of the SYT VII protein is different to that of SYT 
I, as both C2 domains contribute to Ca
2+
-dependent hetero- and homo-oligomerization 
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(Fukuda et al. 2001). The SYT VII C2A domain can bind to itself and to the C2A domain of 
SYT VI but not to the SYT VII C2B domain. Likewise the C2B domain of SYT VII can bind 
to itself and to the C2B domain of SYT II but not to the SYT VII C2A domain. Hence, it has 
been proposed that SYT VII has two calcium-binding ‘hands’ and so oligomerizes more 
strongly than other SYT isoforms. Indeed, a chimera consisting of the SYT VII protein 
containing the SYT I C2A domain showed only weak Ca
2+
-dependent oligomerization, and 
hence pairing of the two hands of SYT VII is essential for multimerization (Fukuda et al. 
2002).  
The precise mechanism behind the unique Ca
2+
-mediated oligomerization activity of 
SYT VII has been further studied by site-directed mutagenesis, and it was demonstrated that 
three aspartate residues in loops 1 and 3 of the SYT VII C2 domains (ASP172, ASP303, and 
ASP357) function cooperatively to induce oligomerization (Fukuda et al. 2002). The 
mutation of any of these three residues abolishes the calcium-dependent hetero- and homo-
oligomerization of SYT VII.  
Rotary-shadowing electron microscopy has revealed that SYT VII oligomers are large 
unbranched linear structures of various lengths as opposed to aggregates (Fukuda et al. 
2002). However, in the absence of calcium the free SYT VII molecules do form globular 
structures. A Ca
2+
-independent mutant of SYT VII (D172N/D303N) is unable to form linear 
oligomers and instead remains in a globular form. The Ca
2+
-induced linear oligomer of SYT 
VII may be involved in the opening of the fusion pore. Interestingly, the expression of 
tandem cytoplasmic domains of wild-type SYT VII but not the D172N/D303N mutant in 
PC12 cells was able to inhibit the Ca
2+
-dependent release of neuropeptide Y by 50%. Hence, 
oligomerization is likely to be crucial for the function of SYT VII.  
 The C2B domains of both SYT I and SYT VII contain a WHXL internalization motif 
and hence are likely to interact with the endocytic proteins dynamin and eps15 (Dasgupta and 
Kelly, 2002). However, within the C2B domain of SYT VII a further motif is located within 
the 37 amino acids which constitute the first two β-strands, and this functions to inhibit the 
WHXL internalization signal. Therefore, although the SYT VII C2 domain contains 
internalization signals, in contrast to SYT I the SYT VII protein is not actively internalized in 
PC12, fibroblast, or epithelial cells. Interestingly, the SYT VII C2A domain contains a 
unique non-tryptophan-based internalization signal which is independent of both dynamin 
and AP-2, and indeed if the C2A domain is expressed in isolation it undergoes endocytosis at 
a rate comparable to SYT I (Dasgupta and Kelly, 2002). It has been proposed that SYT VII 
functions to couple exocytosis and endocytosis via these conflicting internalization signals. 
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The theory states that in resting cells SYT VII does not undergo endocytosis as its 
internalization motifs are masked by the C2B inhibitory sequence. However, in response to 
an as-yet unknown stimuli these signals are unmasked and SYT VII is internalized. It is 
possible that internalization requires either phosphorylation or dephosphorylation of SYT VII 
or may require the binding of an accessory protein. The presence of two unique 
internalization signals requiring different signalling mechanisms suggests that SYT VII may 
be directed to different intracellular compartments under different conditions. 
 
5.1.4 The Function of SYT VII: 
 
  5.1.4.1 The SYT VII Knock-Out Mouse: 
 
SYT VII has been highly conserved throughout evolution and is one of only three 
members of the SYT family which is present in both C. elegans and drosophila (Aldolfsen et 
al. 2004). With this in mind, and considering the ubiquitous tissue distribution of SYT VII 
mRNA, it would be reasonable to assume that SYT VII plays a central and essential role in 
the regulation of secretory events. However, the SYT VII 
-/- 
mouse is viable, has a normal 
lifespan, and shows no obvious phenotypic differences to the wild-type mouse (Chakrabarti 
et al. 2003, Maximov et al. 2008). Initially, the only reported abnormality of the SYT VII 
-/-
 
mouse was a slightly limited reproductive potential in later life (Chakrabarti et al. 2003). 
However, more recent work has revealed that SYT VII 
-/- 
mice display a lower body weight, 
reduced body fat content, a higher basal metabolic rate, and an increased rate of lipolysis 
compared with wild-type mice (Lou et al. 2011). Therefore, SYT VII is likely to be involved 
in the regulation of metabolism. 
 
5.1.4.2 SYT VII in the Nervous System: 
 
SYT VII is expressed throughout the nervous system where it is known to be involved 
in the regulation of neurite outgrowth during synaptogenesis and in the secretion of LDCVs 
from PC12 and dopaminergic neurons. However, it is currently unclear what role if any SYT 
VII plays in the regulation of fast synaptic transmission.  
SYT VII is involved in the process of neurite outgrowth during development, as 
superior cervical ganglion neurons derived from SYTVII-deficient mice show defective 
neurite outgrowth and arborisation when explanted onto Matrigel matrices in the presence of 
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Nerve Growth Factor (NGF) (Arrantes and Andrews, 2006). In sympathetic neurons, SYT 
VII is present on VAMP7/LAMP-1-containing lysosomes in the cell body and in neuronal 
processes and is secreted onto the plasma membrane following ionomycin stimulation. The 
inability of neurons from SYTVII-deficient mice to develop correctly may be a result of the 
failure of neuronal lysosome secretion, resulting in a deficit of membrane available to add to 
the tips of growing processes. Indeed, SYT VII is known to be a key regulator of lysosome 
exocytosis in other cell types (Martinez et al. 2000).  
In addition to its role in synaptogenesis and neurite outgrowth, SYT VII is known to 
be involved in regulating the secretion of LDCVs from PC12 cells. In this cell type, SYT VII 
is found on the plasma membrane and is specifically concentrated at active zones where it co-
localizes with the synaptic vesicle protein synaptoporin (Sugita et al. 2001). Peptides against 
the C2A and C2B domains of SYT VII inhibit exocytosis from PC12 cells. Additionally, the 
over-expression of SYT VII in this cell line results in the increased sensitivity of 
catecholamine secretion in response to the divalent cations Ca
2+
, Ba
2+
, and Sr
2+
 (Wang et al. 
2005). Conversely the knock-down of SYT VII in PC12 cells leads to a decrease in the 
sensitivity of secretion. It has been proposed that members of the SYT family function in a 
similar manner to SNARE proteins whereby SYTs located on opposing membranes form 
oligomers which are essential for the opening of the fusion pore (Sugita et al. 2001). It is 
possible that SYT VII localizes to the plasma membrane in PC12 cells and in response to 
Ca
2+
 binding forms oligomers with either SYT I or II on synaptic vesicles, allowing the 
fusion pore to open and in this way regulating exocytosis. 
It is currently unclear if SYT VII plays a role in the regulation of Ca
2+
-mediated fast 
synaptic transmission at axon terminals. In PC12 cells and hippocampal neurons, SYT VII 
has been reported to localize to the plasma membrane and is also enriched at the active zones 
of presynaptic neurons. However, EGFP-SYTVII localizes to lysosomes and LDCVs and not 
to synaptic vesicles (Aldolfson et al. 2004).  Likewise, ICC performed in Drosophila suggests 
that SYT VII does not co-localize with SYT I on synaptic vesicles and instead is found on 
larger granules and within the soma. Therefore, in neurons SYT VII is not in an ideal 
intracellular position to regulate synaptic transmission and instead appears to localize to 
lysosomes and LDCVs.  
In the SYT VII 
-/-
 mouse, the extent of fast synchronous release, slow asynchronous 
release, and short-term plasticity are unaffected, indicating that SYT VII is not involved in 
these aspects of synaptic transmission. SYT VII deletion does not suppress asynchronous 
release in SYT I 
-/-
 mice (Maximov et al. 2008), and equally in SYT I 
-/- 
Drosophila the over-
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expression of SYT VII cannot rescue the loss of fast synaptic transmission or their 
locomotive defects (Aldolfson et al. 2004), indicating that these two members of the SYT 
family perform non-overlapping functions in the regulation of synaptic transmission. 
However, it has been shown that SYT VII regulates the asynchronous release of 
neurotransmitters at the zebrafish neuromuscular, as SYT VII-deficient zebrafish show fewer 
asynchronous release events (Wen et al. 2010).   
In adrenal chromaffin cells, truncated transcripts of SYT VII are expressed and these 
are thought to be involved in the slow phase of synaptic transmission. When adrenal 
chromaffin cells are treated with siRNA against SYT VII, the slow phase of exocytosis is 
decreased by 50% (Schonn et al. 2007). Interestingly, when both SYT I and SYT VII are 
knocked-out in adrenal chromaffin cells, overall exocytosis is reduced by 70% and only very 
slow secretory events persist. However, it is possible that SYT VII plays an indirect role in 
the regulation of slow synaptic transmission by influencing the endocytosis and re-filling of 
synaptic vesicles. Therefore, the likely conclusion from this work is that SYT VII does not 
play a direct role in the regulation of fast synaptic transmission and instead its role in the 
nervous system is in the regulation of LDCV secretion.  
 
5.1.4.3 SYT VII and Endocytosis: 
 
It is known that SYT VII contains numerous internalization signals which allow it to 
interact with endocytic proteins under certain conditions and therefore it is likely that SYT 
VII is involved in the regulation of endocytosis (Dasgupta and Kelly, 2002). Indeed, variants 
of SYT VII which lack the C2 domains increase the rate of recycling of synaptic vesicles 
when over-expressed in neurons (Virmani et al. 2003). By contrast, the over-expression of 
wild-type SYT VII decreases the rate of endocytosis through a mechanism which is 
dependent on the dimerization of SYT VII. Therefore, SYT VII may act as a molecular 
switch, with different splice variants directing vesicles to either a fast or a slow recycling 
pathway depending on their length.  
 
5.1.4.4 SYT VII and the Regulation of Lysosome Exocytosis: 
 
SYT VII is a resident protein on lysosomes and is heavily involved in regulating their 
fusion with the plasma membrane. Initially, SYT VII was reported to localize to lysosomes in 
rat NRK cells, human HEK-293 cells, mouse 3T3 cells, and hamster CHO cells (Martinez et 
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al. 2000). In NRK fibroblasts, the Ca
2+
-dependent secretion of lysosomes could be inhibited 
by their exposure to either antibodies or peptides against the C2A domain of SYT VII. SYT 
VII is now thought to be trafficked to lysosomes via a palmitoylation-dependent interaction 
with the tetraspanin CD63 (Flannery et al. 2010). The palmitoylation sites of SYT VII have 
been identified as three cysteine residues within and directly adjacent to the transmembrane 
domain. If these sites are mutated, SYT VII is retained within the Golgi body whereas CD63 
traffics to lysosomes as expected. Conversely, if the tyrosines in the lysosome targeting motif 
of CD63 are disrupted, both CD63 and SYT VII are trafficked as a complex to the plasma 
membrane. In macrophages, SYT VII is trafficked with CD63 to growing phagosomes from 
lysosomes in a Ca
2+
-dependent process. It is thought that this association with CD63 allows 
SYT VII to be trafficked to both lysosomes and the plasma membrane in response to 
cytoplasmic Ca
2+
 increases. 
 
5.1.4.5 SYT VII and Membrane Repair: 
 
Membrane injury results in the uncontrolled influx of Ca
2+
 across the plasma 
membrane into the cell. This will lead to either apoptosis of the cell or wound healing via the 
Ca
2+
-dependent exocytosis of lysosomes, which occurs at cytosolic Ca
2+
 concentrations of 
between 1- 5 µM (Gerasimenko et al. 2001). SYT VII plays a pivotal role in membrane 
repair by inducing the exocytosis of lysosomes. Indeed, in fibroblasts membrane repair can 
be inhibited by the addition of antibodies against the C2 domains of SYT VII. Additionally, 
murine embryonic fibroblasts (MEFs) derived from mice whose SYT VII gene has been 
disrupted with a neomycin cassette show impaired lysosome exocytosis and plasma 
membrane resealing following wounding (Chakrabarti et al. 2003). Interestingly, these mice 
develop a condition which is similar to the human autoimmune diseases polymyositis and 
dermatomyostitis, characterized by fibrosis of the skin and skeletal muscle, endomysial 
collagen deposition, increased levels of serum creatine kinases, and the invasion of muscle 
fibres by leukocytes. However, there are no obvious defects in the brain, liver, heart, 
pancreas, spleen or kidneys suggesting that the inflammation is restricted to the skeletal 
muscle. This may be due to the fact that skeletal muscle constantly undergoes mechanical 
stress resulting in rupture of the plasma membrane and therefore the loss of the SYT VII 
protein would have a more severe impact in this tissue.  
 
5.1.4.6 SYT VII and Phagocytosis: 
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 SYT VII is involved in the Ca
2+
-dependent process of phagocytosis by regulating the 
delivery of membrane from lysosomes and late endosomes to the forming phagocytic cup. 
Indeed, a progressive inhibition of particle uptake as particle load increases is seen in 
macrophages from SYT VII 
-/-
 mice compared to those derived from wild-type mice 
(Czibener et al. 2006). This effect can be rescued by the over-expression of wild-type but not 
Ca
2+
-insensitive SYT VII. Additionally, the recruitment of LAMP-1 to forming phagosomes 
is inhibited in SYT VII 
-/-
 mice, demonstrating the failure of phagolysosome fusion.   
As a consequence of its role in mediating phagolysosome fusion in phagocytic cells, 
SYT VII is also involved in preventing the replication of pathogens within cells. For 
example, Trypanosoma cruzi G strain (type I) amastigotes are the causative agents of Chagas’ 
disease and induce phagocytosis in mammalian cells with the same efficiency as professional 
phagocytes (Fernandes et al. 2013). The knock-down of either SYT VII or CD63 inhibits 
amastigote internalization, indicating that the delivery of lysosomes to the forming 
phagosome cup is essential for T. cruzi uptake. 
In dendritic cells, the function of SYT VII appears to be unique as it is not involved in 
mediating phagocytosis in this cell type. Dendritic cells are able to undergo phagocytosis, but 
their primary function is to act as antigen-presenting cells. Unlike macrophages, dendritic 
cells undergo a maturation phase following stimulation and it appears that SYT VII is 
involved in this maturation phase rather than in the uptake of antigens. Indeed, no inhibitory 
effects on phagocytosis are seen in cells derived from SYT VII 
-/-
 mice (Becker et al. 2009). 
In dendritic cells, SYT VII is located on the periphery of lysosomes as is the case in 
macrophages. However, SYT VII expression is up-regulated following LPS stimulation and 
the protein is seen to translocate to the plasma membrane. Dendritic cells derived from SYT 
VII 
-/-
 mice show delayed trafficking of MHC class-II molecules to the plasma membrane, 
and therefore it is likely that SYT VII regulates the fusion of MHC class-II-containing 
vesicles with the plasma membrane rather than phagocytosis in this cell type.  
 
5.1.4.7 SYT VII and Bone Formation: 
 
SYT VII is associated with cathepsin-K-containing lysosomes in osteoclasts and bone 
matrix protein-containing vesicles in osteoblasts (Zhao et al. 2008). In SYT VII
 -/-
 mice, 
catepsin K secretion is inhibited as is the formation of the ruffled border in osteoclasts. 
Additionally, bone matrix protein deposition is impaired in SYT VII
 -/-
 osteoblasts. The lack 
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of proper exocytosis from osteoblasts and osteoclasts leads to morphological abnormalities in 
SYT VII 
-/-
 mice. Resorptive pits and ruffled membranes are small and irregular, and calcarial 
primary osteoblasts derived from SYT VII 
-/-
 mice are defective in nodule formation and 
collagen secretion. Additionally, SYT VII-deficient mice are osteopeninc, having a dramatic 
decrease in trabecular bone volume, thickness, and increased trabecular separation. As a 
consequence, bone formation rates are decreased by almost three-fold. Osteoclastogenesis 
however is not affected, indicating that SYT VII is not involved in osteoclast differentiation. 
The transduction of a retrovirus containing SYT VII into osteoclasts and osteoblasts 
completely rescues the defects seen in SYT VII 
-/-
 cells, indicating that they are due entirely 
to the loss of this member of the SYT family.  
 
5.1.4.8 SYT VII and the Secretion of LDCVs from T-cells: 
 
SYT VII has been shown to have an as-yet undefined but essential role in the 
secretion of lytic granules from cytotoxic T-lymphocytes (CTLs) (Fowler et al. 2007). SYT 
VII localizes to granzyme-containing lytic granules following CTL activation. SYTVII 
-/-
 
CTLs show impaired cytotoxicity and indeed SYT VII 
-/-
 animals cannot effectively clear an 
infection by the Listeria monocytogenes pathogen. It is thought that SYT VII is essential for 
the perforin/granzyme-mediated destruction of pathogens by mediating lytic granule 
exocytosis, although its precise role is currently unclear. 
 
5.1.4.9 SYT VII and the Regulation of Insulin and Glucagon Secretion: 
 
It is now well-established that SYT VII is involved in regulating insulin and glucagon 
secretion and therefore plays a significant role in the regulation of metabolism. SYT VII 
mRNA is found in rat islets and BTC3 and RINm5F cell lines whilst the SYT VII protein is 
found on insulin-containing granules in pancreatic β-cells (Gao et al. 2000). The SYT VII 
transcript is also present at high levels in mouse islets and in the INS-1 cell line, and in 
mouse pancreatic β-cells SYT VII is seen to co-localize with insulin (Gustavsson et al. 2007).  
If SYT VII is over-expressed in RINm5F cells, the result is increased insulin secretion (Gao 
et al. 2000). Equally, SYT VII 
-/-
 mice show impaired insulin secretion and glucose 
intolerance (Gustavsson et al. 2007).   
It is now know that the loss of SYT VII in pancreatic islet cells impairs GLUT4 
trafficking following an insulin challenge (Li et al. 2007). GLUT4 is responsible for insulin-
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stimulated glucose uptake, and following stimulation GLUT4 translocates from an 
intracellular compartment to the plasma membrane of fat and skeletal muscle cells in a Ca
2+
-
dependent manner. In SYT VII 
-/-
 mice, GLUT4 is constitutively secreted to the plasma 
membrane of fat and skeletal muscle cells and there is no significant increase in GLUT4 
translocation to the plasma membrane following an insulin challenge. Therefore, in addition 
to regulating Ca
2+
-dependent insulin secretion, SYT VII also functions to translocate GLUT4 
to the plasma membrane of fat and skeletal muscle cells, allowing glucose to be absorbed 
from the bloodstream. 
 SYT VII is found co-localized with glucagon in mouse α-cells, and indeed SYT VII 
is now known to be the principal Ca
2+
-sensor for Ca
2+
-induced glucagon exocytosis from α-
cells in the pancreas (Gustavsson et al. 2009). Indeed, the deletion of SYT VII inhibits 
glucagon secretion from α-cells in an in vivo mouse model. Equally, in an in vitro model 
involving isolated intact pancreatic islets derived from SYT VII
 -/-
 mice an 80% impairment 
in glucagon secretion was reported. Finally, SYT VII-deficient mice show an impaired 
response to insulin-induced hypoglycaemia. Therefore, substantial evidence has been 
provided to demonstrate that SYT VII is heavily involved in the secretion of glucagon from 
α-cells. 
The loss of normal insulin and glucagon secretion in SYT VII 
-/-
 mice has significant 
phenotypic consequences. SYT VII 
-/-
 mice display a lower body weight, lower body fat 
content, higher oxygen consumption,  higher core body temperatures, and a higher basal 
metabolic rate compared with control mice (Lou et al. 2011). They also require an increased 
quantity of lipid for energy production as their respiratory exchange ratio is lower than 
control mice. Indeed, SYT VII 
-/-
 mice display increased lipolysis and an increased capacity 
for fatty acid transport and oxidation. Therefore, it appears that SYT VII 
-/-
  mice employ 
compensatory mechanisms allowing adaptation to a persistent low glucagon level which 
require increased fat consumption leading to a lower overall body weight.  
 
5.1.4.10 SYT VII and Cell Migration: 
 
 SYT VII and SYT V were identified through an RNA-mediated interference screen as 
having positive effects on chemotaxis following chemokine stimulation. Both SYT V- and 
SYT VII-deficient T- and THP-2 cells display less migration following CXCL12 exposure in 
vitro than wild-type cells (Colvin et al. 2010). Equally, chemoattractant-induced Ca
2+
-
dependent lysosome fusion was impaired in SYT VII-deficient neutrophils. Lymphocytes 
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from SYT VII 
-/-
 mice show an accumulation of lysosomes in their uropods (the trailing edges 
of the cell membrane which form during cell migration), and these lysosomes also show 
impaired release. Finally, SYT VII 
-/- 
T-cells are more adherent than those derived from wild-
type animals, with 81.48% of SYT VII 
-/-
 T-cells displaying an adherent phenotype compared 
with 6.14% of wild-type cells. Hence, SYT VII is involved in regulating the adhesive 
properties of cells. It is likely that SYT VII mediates cell migration by inducing the fusion of 
lysosomes with the plasma membrane, allowing the addition of membrane to the leading edge 
of migrating cells in response to chemokine stimulation.  
 
5.1.5 SYT VII and the Fusion Pore: 
 
A popular theory suggests that members of the SYT family regulate exocytic events 
by forming oligomers which influence the formation and physical structure of the fusion pore 
(Tucker and Chapman, 2002). The effect of the SYT VII protein on the opening and dilation 
of fusion pores in chromaffin cells has been analysed using patch amperometry in both wild-
type and SYT VII mutant chromaffin cells (Segovia et al. 2010). Amperometic measurements 
demonstrated that the foot signal which is used to examine the early steps of fusion pore 
formation was unchanged between control, SYT VII 
-/-
, and SYT VII mutant chromaffin 
cells, indicating that SYT VII does not affect the early formation of the fusion pore. 
However, in both SYT VII 
-/-
 and SYT VII mutant cells, the lifetime of the fusion pore was 
significantly extended by up to 3-fold, demonstrating that SYT VII is indeed involved in 
fusion pore structure.  In chromaffin cells expressing a Ca
2+
-insensitive mutant of SYT VII a 
significant increase in kiss-and-run events was reported. It is possible that Ca
2+  
binding to the 
C2A domain of SYT VII is sufficient to initiation the opening of the fusion pore, but in the 
absence of Ca
2+  
binding to the C2B domain the pores become unstable and collapse.  
This work has been extended to demonstrate that SYT VII restricts the expansion of 
the fusion pore. In murine embryonic fibroblasts (MEFs) derived from SYT VII 
-/-
 mice 45% 
of lysosomes undergo complete exocytosis compared with wild-type MEFs from which only 
21% of vesicles undergo full secretion (Jaiswal et al. 2004). Additionally, secretion occurs on 
average 28 seconds earlier than in wild-type mice. Interestingly, it was noted that secreted 
membrane proteins of wild-type mice remain clustered in close proximity to the fusion pore 
following exocytosis, whereas membrane proteins from SYTVII 
-/-
 mice rapidly diffuse away 
from the site of exocytosis. Hence, SYT VII is required to cluster lysosome membrane 
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proteins in the area proximal to the initial site of fusion and also functions to limit the size of 
the fusion pore and increase the time required for its formation.  
 
5.1.6 The Binding Partners of SYT VII: 
 
Currently, it is unclear which proteins SYT VII interacts with in order to form the 
fusion apparatus, and of course the components of this complex will undoubtedly vary 
depending on the cell type in question. In lysates derived from NRK cells, isolated SYT VII 
interacts with the v-SNARE VAMP7 and the t-SNAREs syntaxin-4 and SNAP-23 (Rao et al. 
2004). Specifically, the C2A domain of SYT VII binds SNAP-23 via a mechanism that is 
enhanced by the H3 domain of syntaxin-4. Additionally, the exocytosis of lysosomes from 
NRK cells is inhibited by peptide fragments of syntaxin-4 and VAMP-7 and also following 
SNAP-23 cleavage by Botulinum neurotoxin. However, the specificity of these reported 
interactions has been questioned, as SYT VII can also bind to syntaxin-2, syntaxin-3, and to 
heterodimers consisting of SNAP-25 and syntaxin1a. Equally, SYT I binds to syntaxin-2 and 
syntaxin-3. However, it does not bind to syntaxin-4 and therefore it is likely that the SYT 
VII:syntaxin-4 interaction is more specific. Ultimately, it is probable that SYT VII has a 
number of SNARE binding partners, although work done in NRK cells suggests that a fusion 
complex consisting of SYT VII, syntaxin-4, VAMP7, and SNAP-23 mediates lysosome 
exocytosis.  
 In adrenal chromaffin cells, a 45-kDa isoform of SYT VII was found to be expressed 
and localized to chromogranin A-containing secretory granules (Osborne et al. 2007). It is 
likely that SYT VII is involved in mediating the exocytosis of the slowly releasable pool of 
granules from chromaffin cells whereas SYT I mediates the release of the readily releasable 
pool (RRP) (Schonn et al. 2007). An affinity pulldown screen using highly purified 
chromaffin granules from bovine adrenal medulla demonstrated that SYT VII interacts with 
phosphatidylinositol 4,5-bisphosphate (PIP2) via its C2B domain in the absence of calcium 
and via the C2A and C2B domains in the presence of calcium (Osborne et al. 2007). A 
polylysine stretch consisting of K320, K321, and K325 in the C2B domain has been 
identified as being responsible for mediating PIP2 binding and this interaction is essential for 
the release of catecholamine from chromaffin cells. It may be that by binding PIP2 SYT VII 
is brought into close contact with the vesicle membrane prior to Ca
2+
 binding.  
Finally, it is now known that the function of SYT VII is regulated by SUMOylation, 
either directly or indirectly, and indeed SYT VII interacts with components of the 
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SUMOylation apparatus such as SUMO1 and the deSUMOylating enzyme SENP1 (Dai et al. 
2011). Small ubiquitin-like modifier (SUMO) proteins are reversibly attached to proteins to 
regulate their localization or function in a process called SUMOylation. SUMO1 co-
precipitates with SYT VII in lysates derived from INS-1 cells and human islets, although this 
interaction is transiently lost following glucose stimulation. Binding is enhanced by the 
overexpression of SUMO1 and is disrupted by SENP1 over-expression. This disruption also 
enhances the exocytosis of insulin from INS-1 cells. Hence, SUMOylation may impair 
insulin secretion via a mechanism which involves SYT VII. This effect may be direct, 
resulting from the SUMOylation of SYT VII itself, or may be indirect, resulting from an as-
yet unknown interaction between SYT VII and a SUMOylated binding partner. Equally, it is 
possible that the deSUMOylation of SYT VII is necessary to allow the exocytosis of insulin 
to proceed. 
 
5.1.7 SYT VII and a Potential Role in the Regulation of WPB Exocytosis: 
 
 Based on the evidence provided in the literature I have identified SYT VII as a strong 
candidate for the role of the calcium sensor regulating the release of WPBs from endothelial 
cells. Firstly, SYT VII is known to be involved in the Ca
2+
-mediated exocytosis of large 
secretory granules similar to WPBs from a range of cell types (as discussed, see 5.1.4 The 
Function of the SYT VII Protein). Additionally, WPBs have been detected in the endothelium 
of hagfish, the living ancestor of vertebrates (Yano et al. 2007), and so it is likely that their 
exocytosis will be regulated by an evolutionally-conserved molecule. SYT VII is one of only 
three SYTs found in both C. elegans and drosophila (Aldolfsen et al. 2004), providing further 
evidence that it may be the calcium sensor regulating WPB exocytosis. Finally, SYT VII is a 
binding partner for syntaxin-4 and SNAP-23, and these proteins have been implicated as the 
t-SNAREs responsible for mediating WPB exocytosis with the plasma membrane 
(Matsushita et al. 2003). Therefore, based on the conservation of the SYT VII protein 
throughout evolution, its established role as a Ca
2+
-sensor in a number of cell types, and its 
known ability to interact with components of the WPB fusion apparatus, I propose that SYT 
VII is the most promising candidate for the role of calcium sensor regulating WPB exocytosis 
from HUVECs. Hence, I initially focused my efforts on testing this hypothesis through 
functional studies as will be discussed in the remainder of this chapter.   
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5.2 SYTVII-YFP Over-Expression ELISAs: 
 
Previous observations have shown that SYT VII can be found in HUVECs at both the 
mRNA and protein levels and crucially over-expressed SYTVII-YFP localizes to both the 
WPBs and lysosomes. The trafficking of SYTVII-YFP to the granules supports the 
hypothesis that this member of the SYT family may be involved in regulating the Ca
2+
-
dependent process of WPB exocytosis from endothelial cells. In order to test this theory, the 
SYTVII-YFP construct was transfected into HUVECs with the aim to determine if over-
expressed SYT VII has any effect on the secretion of WPBs from endothelial cells. Briefly, 
HUVECs were transfected with either SYTVII-YFP or with the control cytoplasmic construct 
YFP and allowed to grow to confluency on 6-well plates for 48 hours. Both cultures were 
then stimulated with either 1 µM ionomycin or with a control non-stimulating solution. The 
media and lysates were collected from each well, centrifuged to remove cellular debris, and 
processed for both VWF and proregion ELISAs as described in ‘2.7 The Enzyme-Linked 
Immunosorbent Assay (ELISA) Protocol.’ 
 Initially, VWF ELISAs were carried out with the aim to examine the extent of VWF 
secretion from HUVECs expressing SYTVII-YFP and those expressing YFP. The results of a 
representative experiment are shown in Figure 5.1 (i). As can be seen, no differences in the 
extent of VWF secretion are apparent between cells expressing SYTVII-YFP and those 
expressing the control construct YFP. The samples were then subjected to the more-sensitive 
proregion ELISA and the results of a representative assay can be seen in Figure 5.1 (ii). 
Again, it would appear that the over-expression of SYTVII-YFP does not affect the quantity 
of proregion released from HUVECs. Therefore over-expressed SYT VII does not affect the 
extent of WPB secretion from endothelial cells in response to 1 µM ionomycin exposure. 
However, it is important to note that the expression level of the SYTVII-YFP construct in 
HUVECs is relatively low. It is quite possible that due to this poor transfection efficiency the 
background secretion of protein from non-expressing cells is too high to allow the detection 
of even significant alterations to secretion from transfected cells (see Discussion).   
 
5.3 The Effects of SYTVII-YFP Over-Expression on the Calcium Sensitivity of WPB 
Exocytosis: The Dose-Response Curve  
 
 The over-expression of SYTVII-YFP in HUVECs did not have a significant effect on 
the overall secretion of either VWF or proregion following stimulation with 1 µM ionomycin. 
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Figure 5.1. SYT VII over-expression does not affect the exocytosis of WPBs. 
HUVECs were transfected with either SYTVII-YFP or YFP. Media and lysates were collected 
from cells after forty-eight hours and processed for VWF and proregion ELISAs. Cells 
incubated with a control non-stimulating solution provided the data for basal secretion. Cells 
incubated with 1 µM ionomycin provided the data for stimulated secretion. Panel (i) shows the 
quantity of VWF released as a percentage of the total quantity of VWF in the cells. Panel (ii) 
shows the quantity of proregion released as a percentage of the total quantity of proregion in the 
cells. Black bars represent YFP-transfected cells. Hatched bars represent SYTVII-YFP-
transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
 
 
 
i 
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However these assays only allow the examination of WPB exocytosis in response to a single 
concentration of ionomycin, which in this case is relatively high. It has been reported that a 
key function of members of the SYT family is to influence the sensitivity of secretory events 
to low concentrations of calcium (Gao et al. 2000, Wang et al. 2005), and therefore it is 
possible that SYT VII may modulate the sensitivity of WPB exocytosis in response to low 
concentrations of Ca
2+
 ions. I have developed a dose-response assay as a method for 
determining the effect of the over-expression of constructs on the calcium sensitivity of WPB 
exocytosis, details of which can be found in Appendix 1.0. This assay was used to test the 
hypothesis that SYT VII may function to modulate the calcium sensitivity of WPB exocytosis 
in endothelial cells.   
Briefly, HUVECs transfected with either SYTVII-YFP or with a control cytoplasmic 
construct (YFP) were seeded onto 24-well plates. Cells were allowed to grow to confluency 
for 48 hours, after which point they were stimulated with varying concentrations of 
ionomycin. For each transfection, an ethanol control was included to provide the rate of basal 
secretion. Following the ten-minute stimulation, the media and lysates were collected from 
each well, the samples were spun down to remove cellular debris, and a proregion ELISA 
was performed. HUVECs are heterogeneous and each individual culture will secrete different 
quantities of proregion in response to ionomycin stimulation. Therefore, in order to allow a 
direct comparison between experiments the data from each replicate was normalized to the 
secretion recorded from the YFP-expressing control cells exposed to 1 µM ionomycin. The 
final dose response curve is shown in Figure 5.2. As can be seen, the over-expression of 
SYTVII-YFP in HUVECs results in a small but significant increase in the calcium sensitivity 
of WPB exocytosis. At low concentrations of ionomycin the extent of secretion is 
significantly higher in cells expressing SYTVII-YFP than those expressing the control 
plasmid YFP. However, for 1 µM ionomycin (i.e. the concentration which was used for the 
over-expression ELISAs described previously) the extent of proregion secretion is equivalent 
for both cultures. Therefore, this work suggests that SYT VII does indeed modulate the 
sensitivity of WPB exocytosis as increased proregion secretion is reported from HUVECs 
following their exposure to low concentrations of ionomycin when the SYT VII protein is up-
regulated. 
 
5.4 The Effects of the Knock-Down of SYT VII on WPB Exocytosis: 
 
The use of the dose-response assay has demonstrated that the up-regulation of SYT 
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Figure 5.2. Over-expressed SYT VII modulates the calcium sensitivity of WPB exocytosis.  
Cells transfected with either SYTVII-YFP or the cytoplasmic control construct YFP were 
stimulated with varying concentrations of ionomycin as indicated in the x-axis. The quantity of 
proregion secreted was determine using a proregion ELISA. This procedure was repeated three 
times. For each transfection, the data was normalized to the extent of proregion secreted from YFP-
expressing control cells exposed to 1 µM ionomycin. The data from the three replicates was 
combined and the means of the normalized values were used to plot the final dose-response curves.  
* P-value ‹ 0.05 
 *** P-value ‹ 0.0005 
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VII does indeed have a subtle effect on the calcium sensitivity of WPB secretion. However, 
the overall extent of WPB exocytosis in response to 1 µM ionomycin is not altered in 
HUVECs expressing SYTVII-YFP compared with those expressing YFP. Over-expression 
ELISAs are limited in that they rely on a sufficient expression level of the protein in question 
to overcome the background secretion derived from non-expressing cells. Therefore, it was 
decided to knock-down the SYT VII protein in HUVECs using siRNA with the aim to 
determine if diminished levels of the SYT VII protein have an effect on the exocytosis of 
WPBs from our model endothelial cells.  
 
5.4.1 The Optimization of the Knock-Down Protocol: 
 
Initially, it was necessary to optimize the knock-down protocol for SYT VII siRNA as 
the ideal conditions for achieving an effective knock-down can vary depending on the target 
protein. Firstly, HUVECs were transfected with 400 pMol of either SYT VII siRNA or 
control non-targeting siRNA. After forty-eight hours the lysates were collected and Western 
blots were performed with the aim to determine the quantity of SYT VII protein present in 
each culture. Blots were probed with an α-SYT VII antibody and an α-tubulin antibody. The 
results of this are shown in Figure 5.3. As can be seen, the efficient knock-down of the SYT 
VII protein is achieved using 400 pMol of SYT VII siRNA. In contrast, the level of tubulin in 
each culture remains unchanged indicating that an equivalent quantity of total protein was 
present in each sample. This optimization procedure was repeated using HUVECs transfected 
with either 200 pMol of either SYT VII siRNA or control non-targeting oligos. However, 
these conditions failed to yield efficient knock-down of the SYT VII protein (data not 
shown). Additionally, at time-points less than forty-eight hours no significant knock-down of 
the SYT VII protein was seen (data not shown). Therefore, the optimum knock-down of the 
SYT VII protein is achieved when HUVECs are transfected with 400 pMol of SYT VII 
siRNA and allowed to grow in culture for forty-eight hours. 
In order to determine if the knock-down of SYT VII has any obvious morphological 
effects on the HUVECs or their WPBs, cells were transfected with 400 pMol of either SYT 
VII siRNA or with control siRNA and were processed for ICC forty-eight hours later. A 
mock transfection was also performed whereby cells were transfected with 4 µl of dH20. 
Each culture was stained with antibodies against both VWF and TGN-46. The results of this 
are shown in Figure 5.4. As can be seen, each culture has produced a confluent monolayer  
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which contains high numbers of rod-shaped WPBs. Hence no obvious effects are apparent on 
either HUVEC or WPB morphology following transfection with SYT VII siRNA, suggesting 
that the SYT VII protein does not influence the synthesis or trafficking of WPBs.  
 
5.4.2 SYT VII Knock-down ELISAs:  
 
 As it has now been established that 400 pMol of SYT VII siRNA yields an efficient 
knock-down of the SYT VII protein forty-eight hours following transfection functional 
studies were performed with the aim to determine if the knock-down of SYT VII affects the 
exocytosis of WPBs from HUVECs. Firstly, VWF ELISAs were performed and the results of 
a representative assay are shown in Figure 5.5 (i). As can be seen, no differences in overall 
VWF secretion are apparent between cells transfected with SYT VII siRNA and those  
Figure 5.3. The SYT VII protein is depleted in HUVECs following siRNA 
transfection.  
Cells transfected with 400 pMol of either SYT VII siRNA or the control non-targeting 
oligos (siCTRL) as indicated were grown to confluency for forty-eight hours. Lysates 
from each culture were extracted and Western blotting was performed. The upper blot 
shows the results of probing for SYT VII whereas the lower blot shows the 
corresponding tubulin loading control. As can be seen, efficient knock-down is achieved 
following transfection with 400 pMol SYT VII siRNA. The extent of the knock-down of 
SYT VII in SYT VII siRNA-transfected HUVECs is 74.87% of that seen in control 
siRNA-transfected HUVECs (normalized to the total quantity of protein as determined 
from the tubulin loading control). 
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Figure 5.4. The knock-down of SYT VII does not affect the morphology of either 
HUVECs or their WPBs.  
HUVECs transfected with 400 pMol of either SYT VII siRNA or with control non-targeting 
oligos as indicated were stained with antibodies against both VWF and TGN-46. A mock 
transfection has also been performed (4 µl of dH20). The left-hand panels show the merged 
images, the middle panels show the VWF stain in the red channel, and the right-hand panels 
show the TGN-46 stain in the green channel. All cultures examined have grown to confluency 
and HUVECs appear morphologically normal. Likewise, each culture contains high numbers 
of large, rod-shaped WPBs.  
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transfected with non-targeting control oligos. The collected samples were then processed for 
proregion ELISAs and the results of a representative assay are shown in Figure 5.5 (ii). No 
differences in the total quantity of proregion secreted are visible between HUVECs 
transfected with SYT VII siRNA and those expressing the control oligos. Therefore the 
knock-down of SYT VII does not influence the overall extent of WPB exocytosis from 
HUVECs following their stimulation with 1 µM ionomycin.  
 
5.5 The Effects of SYT VII Knock-Down on the Calcium Sensitivity of WPB Exocytosis: 
The Dose-Response Curve 
 
The dose-response assay revealed that SYT VII over-expression increases the calcium 
sensitivity of WPB exocytosis as increased proregion secretion is reported at lower 
ionomycin concentrations following SYT VII up-regulation. In order to further investigate 
the role of SYT VII in the regulation of WPB exocytosis the dose-response assay was 
repeated using HUVECs transfected with 400 pMol of either SYT VII siRNA or control non-
targeting siRNA. The purpose of this was to determine if the knock-down of SYT VII has an 
effect on the calcium sensitivity of WPB exocytosis in response to ionomycin stimulation.  
Figure 5.6 shows the dose-response curves for HUVECs transfected with SYT VII 
siRNA versus those transfected with control siRNA. As can be seen the knock-down of SYT 
VII in HUVECs does not affect the calcium sensitivity of WPB exocytosis. The dose-
response curves generated from both cultures are remarkably similar with no significant 
differences in the extent of proregion secretion apparent for any of the six ionomycin 
concentrations tested. Therefore, unlike SYT VII over-expression the knock-down of SYT 
VII does not alter the calcium sensitivity of WPB exocytosis from HUVECs.  
 
5.6 Discussion: 
 
As SYTVII-YFP traffics to WPBs when over-expressed in HUVECs it is likely that 
endogenous SYT VII is found as a membrane protein on the granules and so this member of 
the SYT family has been identified as a prime candidate for the role of the calcium sensor 
regulating WPB exocytosis from HUVECs. Indeed, SYT VII is known to play a vital role in a 
number of non-neuronal secretory events such as the regulation of the exocytosis of 
lysosomes from fibroblasts (Martinez et al. 2000), the formation of the phagosomes in  
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Figure 5.5. SYT VII knock-down does not affect the exocytosis of WPBs. 
HUVECs were transfected with either SYTVII siRNA (400 pMol) or control siRNA (400 pMol). 
Media and lysates were collected from cells after forty-eight hours and processed for VWF and 
proregion ELISAs. Cells incubated with a control non-stimulating solution provided the data for 
basal secretion. Cells incubated with 1 µM ionomycin provided the data for stimulated secretion. 
Panel (i) shows the quantity of VWF released as a percentage of the total quantity of VWF in the 
cells. Panel (ii) shows the quantity of proregion released as a percentage of the total quantity of 
proregion in the cells. Black bars represent control siRNA-transfected cells. Hatched bars 
represent SYTVII siRNA-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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Figure 5.6. SYT VII knock-down does not affect the calcium sensitivity of WPB 
exocytosis.  
HUVECs transfected with either SYT VII siRNA or with control non-targeting siRNA were 
stimulated with varying concentrations of ionomycin as indicated in the x-axis. The quantity 
of proregion secreted was determined using a proregion ELISA. This procedure was repeated 
three times. For each assay, the data was normalized to the secretion of proregion recorded 
from control cells exposed to 1 µM ionomycin. Data from the three replicates was combined, 
and the means of the normalized values were used to plot the final dose-response curves.  
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macrophages (Czibener et al. 2006), MHC class II antigen presentation in dendritic cells 
(Becker et al. 2009), bone formation and degradation (Zhao et al. 2008), the release of 
LDCVs from T-cells (Fowler et al. 2007), and the exocytosis of both insulin and glucagon 
from pancreatic cells (Gao et al. 2000, Gustavsson et al. 2007, Gustavsson et al. 2009). 
Therefore SYT VII has an already-established role in mediating the exocytosis of large 
secretory granules similar to WPBs. The functional studies performed here attempting to 
determine the role SYT VII plays within endothelial cells have yielded interesting results. 
Firstly, SYTVII-YFP over-expression ELISAs demonstrated that the up-regulation of the 
SYT VII protein does not affect the absolute release of WPBs following exposure to 1 µM 
ionomycin. However, the dose-response assay revealed that SYTVII-YFP over-expression 
does increase the calcium sensitivity of exocytosis. Although this effect was relatively small, 
it is important to consider that the transfection of SYT DNA into HUVECs is inherently 
inefficient and the majority of the cultured cells will not express the construct. Therefore the 
high signal-to-noise ratio makes the detection of a functional effect following SYT up-
regulation challenging. With this in mind, the observed small effect on calcium sensitivity 
following SYTVII-YFP over-expression seen here is in reality likely to represent a 
considerable shift in the kinetics of WPB exocytosis from transfected cells.  
 SYT VII knock-down studies revealed that the loss of SYT VII in HUVECs does not 
affect either the absolute secretion of WPBs or the calcium sensitivity of their exocytosis. 
These results are in contrast to the over-expression studies and suggest that SYT VII is not 
involved in the regulation of WPB exocytosis. However, it is likely that the extent of knock-
down achieved here was not sufficient to result in a functional effect as it could be the case 
that only a small proportion of the SYT VII protein is required to produce a wild-type 
phenotype. However, it is also possible that redundancy exists amongst the SYTs, masking 
the effects of the knock-down of one family member. In future, double knock-down 
experiments should be performed with particular emphasis on those SYTs which have been 
reported to traffic to WPBs (SYTs V, VII, VIII, and XVII). It is of interest to consider that 
SYT VII preferentially forms oligomers with SYT V (Fukuda et al. 2001), and therefore 
these two molecules are likely to interact within the WPB membrane. Therefore a double 
knock-down involving SYT V and SYT VII may lead to an interesting functional effect.  
  Although the functional studies discussed here have not provided a definitive role for 
the SYT VII protein in endothelial cells, they have certainly identified this member of the 
SYT family as a focal molecule for future studies. Key experiments would focus on live-cell 
imaging with HUVECs over-expressing SYT VII as this would allow the accumulation of 
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kinetic secretory data on a single-cell level and thus overcome the limitations of biochemical 
over-expression studies. Additionally, further analysis of the effect of SYT VII on the 
calcium sensitivity of WPB exocytosis could be achieved by measuring the Ca
2+
 
concentration within living HUVECs using a cell-permeable calcium dye such as fura-2 and 
correlating this with the kinetics of WPB exocytosis. Lastly, live-cell imaging could be used 
in combination with amperometry to determine if the knock-down or over-expression of SYT 
VII influences the formation or stability of the fusion pore. Indeed, it is known that the over-
expression of SYT VII in PC12 cells increases the number of LDCVs which undergo full 
fusion as opposed to kiss-and-run secretory events, suggesting that SYT VII up-regulation 
may decrease the stability of the fusion pore (Sugita et al. 2001). Equally, in chromaffin cells 
the knock-down of SYT VII restricts fusion pore expansion and increases the time required 
for its formation (Segovia et al. 2010). It is likely that SYT VII may be involved in WPB 
fusion pore formation in endothelial cells.  
 Finally, a further avenue for future research which may prove profitable would be to 
obtain a SYT VII
 -/-
 mouse. Endothelial cells from this mouse model could be isolated and 
grown in culture, providing a source of SYT VII 
-/- 
cells which would overcome the 
limitations of the SYT VII siRNA knock-down studies attempted here. The dose-response 
assay could be repeated using these cells to determine if the calcium sensitivity of exocytosis 
is decreased compared with wild-type murine endothelial cells. Additionally, it would be of 
interest to perform ICC to determine if the biosynthesis and morphology of WPBs is affected 
by the complete loss of the SYT VII protein. Lastly, a SYT VII 
-/-
 mouse model would 
provide the opportunity to perform platelet-clotting assays to determine if the loss of SYT VII 
results in a clinical phenotype.  
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Chapter 6 
 Investigating the Function of SYT V in HUVECs 
 
6.1 Background Information: 
 
SYT V was the first non-neuronal member of the SYT family to be described in 1995 
(Hudson and Birnbaum, 1995, Craxton and Geodert, 1995).  This novel SYT was predicted to 
be Ca
2+
-dependent, and examination of its distribution in rat tissue showed it to be present in 
the kidney, lung, heart, adipose tissue, and brain, where it is enriched in synaptic vesicles.  
The full sequence of the human SYT V gene and its genomic location were 
determined in 1997 (Craxton et al. 1997). The human gene encodes a protein which is 386 
amino acids in length and therefore the predicted molecular mass of human SYT V is 42 kDa. 
However it has been identified by Western blotting as a protein of 70 kDa (Iezzi et al. 2004). 
The SYT V gene itself is located on chromosome 19q13.4 in close proximity to the SYT III 
gene, and these two SYTs may indeed be linked. Based on the sequence similarity between 
SYT V and SYTs III, VI, and X these four family members have been proposed to belong to 
the same sub-group of SYTs which primarily functions to regulate non-neuronal exocytosis 
(Saegusa et al. 2002). Members of this group are characterized by an N-terminal cysteine 
cluster which allows dimer formation by disulfide bonding (Saegusa et al. 2002).  
SYT V is expressed in a number of diverse cell types and its physiological function 
has been partly characterized.  It has been reported to be a component of secretory granules in 
glucagon-producing pancreatic α-cells but not in insulin-secreting β-cells (Iezzi et al. 2004, 
Saegusa et al. 2002) and therefore was proposed to be involved in glucagon but not insulin or 
somatostatin secretion. However, the knock-down of SYT V in INS-1E cells reduced 
hormone-stimulated insulin secretion by 79%, and so the true role of SYT V in pancreatic 
hormone exocytosis is currently unclear (Iezzi et al. 2004). In PC12 cells, SYTV-GFP was 
reported to co-localize with SYT I on dense-core vesicles which were able to undergo Ca
2+
-
dependent exocytosis (Saegusa et al. 2002). Additionally, SYT V has been reported to 
localize to axons in hippocampal neurons, where it can be found on both the plasma 
membrane and as a component of dense-core granules (Dean et al. 2012). SYT V mRNA has 
been reported in rat basophilic leukaemia cells, although its function in this cell type is 
currently unknown (Baram et al. 2001). Lastly, SYT V has been linked to the regulation of 
the Ca
2+
-dependent process of phagocytosis. In resting macrophages, SYT V localizes to 
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recycling endosomes and to the plasma membrane where it concentrates in protruding 
filopodia. However, following stimulation, SYT V is rapidly transferred to the phagosomes 
where it remains throughout their maturation and eventual exocytosis (Vinet et al. 2008). The 
knock-down of SYT V results in a 50 % inhibition of phagocytosis, and this effect is 
particularly pronounced under conditions of large particle size and high particle number. 
Hence, it has been suggested that SYT V regulates the focal exocytosis of endosomal 
structures which provide additional membrane surface area for the formation of large 
phagosomes.  
The bulk of the studies done thus far with the aim to characterize the function of SYT 
V have focused on the phagocytosis of Leishmania donovani by macrophages. Leishmania 
parasites are responsible for the potentially fatal visceral disease leishmaniasis in humans and 
are spread via infected female sand flies (Lodge and Descoteaux, 2004). Following infection, 
Leishmania promastigotes are phagocytosed by mononuclear phagocytes, and in order to 
survive and reproduce within human cells the parasite has evolved to inhibit phagosome 
fusion with components of the endosomal and lysosomal systems. The inhibition of these 
fusion events depends on the presence of the crucial virulence factor lipophosphoglycan 
(LPG) which covers the surface of the parasites (Lodge and Descoteaux, 2005). It is thought 
that, following the internalization of the parasite, LPG is transported from the parasite 
membrane to the phagosome membrane and disrupts lipid raft microdomains. This ultimately 
inhibits fusion events between the phagosome and components of the endosomal and 
lysosomal networks. Hence, the accumulation of membrane proteins essential for the 
acidification of the phagosome such as NADPH oxidase is inhibited and this allows the 
parasite to maintain a favourable pH for survival within the host phagosomes.  
It is now known that LPG from Leishmania donovani promastigotes partly inhibits 
phagosome maturation by causing the dissociation of SYT V from phagosome membranes 
(Vinet et al. 2009). Indeed, if a mouse macrophage cell line stably expressing SYTV-GFP is 
infected with L. donovani promastigotes the result is a significant decrease in the quantity of 
SYT V present in the phagosomes of infected cells. The mechanism whereby L. donovani is 
able to remove SYT V from phagosomes depends on the disruption of lipid rafts within the 
phagosome membrane. SYT V can be found on GM1-containing lipid raft microdomains in 
phagosomes and indeed phagosomes internalizing zymosan particles show co-localization 
between SYT V and GM1 (Vinet et al. 2009). However, phagosomes internalizing LPG-
coated particles show co-localization only between GM1 and LPG. Hence, LPG insertion into 
the lipid membrane results in the exclusion of SYT V. 
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The process whereby SYT V is removed from immature phagosomes allows the 
promastigote to survive as the progressive acidification of the organelle fails. Indeed, SYT V 
controls phagolysosome biogenesis by regulating the trafficking of cathepsin D and vesicular 
proton-ATPase (V-ATPase) to the immature phagosomes. The knock-down of SYT V 
impairs cathepsin D and V-ATPase c subunit recruitment by up to 50 % whereas the 
recruitment of LAMP1, EEA-1, and cathepsin B is not affected (Vinet et al. 2009).  The 
impact of this inhibition on the pH of the maturing phagosome is similar to that seen in the 
presence of LPG. Hence, SYT V regulates phagosome maturation, possibly by mediating the 
fusion of immature phagosomes with lysosomes containing cathepsin D and the V-ATPase. 
The insertion of LPG into the lipid rafts disrupts SYT V localization to phagosomes and 
therefore inhibits their acidification. 
Since its discovery in 1995 as a novel non-neuronal SYT the tissue distribution, 
subcellular localization, and possible function of SYT V have been partly characterized. 
Interestingly, a unique role of this SYT seems to be as a regulator of the internal pH of 
organelles via the recruitment of membrane proteins such as acidifying proton pumps. The 
work done thus far to characterize this feature of SYT V has been done entirely on 
phagosomes in macrophages, and therefore it will be of great interest to determine if SYT V 
is responsible for regulating the internal pH of other organelles.  
 
6.2 SYTV-EGFP Over-Expression ELISAs: 
 
I have shown that SYT V is present in HUVECs at both the mRNA and protein levels 
and that over-expressed SYTV-EGFP traffics exclusively to the WPBs. Therefore this 
member of the SYT family is now a prime candidate for the role of the calcium sensor 
regulating the Ca
2+
-mediated exocytosis of WPBs from endothelial cells. In order to 
investigate this hypothesis, functional studies were performed with the aim to identify any 
role SYT V plays in the regulation of WPB secretion from HUVECs. Initially, these 
functional studies involved over-expression ELISAs whereby HUVECs were transfected with 
either the SYTV-EGFP construct or with a control cytosolic construct (YFP). Forty-eight 
hours following transfection, the now-confluent HUVECs were stimulated with either 1 µM 
ionomycin or with a control non-stimulating solution. Both the media and lysates were 
collected and the samples were processed for VWF and proregion ELISAs.  
No significant differences in the extent of the stimulated or basal secretion of 
proregion were apparent between cells expressing SYTV-EGFP and those expressing YFP 
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(data not shown) suggesting that SYT V up-regulation does not affect the quantity of 
proregion secreted from stimulated HUVECs. However, the VWF ELISAs performed on the 
same samples used for the proregion ELISAs yielded conflicting results, as shown in Figure 
6.1. The data generated from the first assay (Figure 6.1 (i)) suggests that SYTV-EGFP over-
expression in HUVECs leads to a significant increase in VWF secretion in response to 
ionomycin exposure compared with YFP-expressing cells. However, Figure 6.1 (ii) shows the 
reverse effect whereby SYTV-EGFP over-expression leads to a significant decrease in VWF 
secretion compared with control cells. Finally, the third assay (Figure 6.1 (iii)) shows no 
significant changes in VWF secretion between cells over-expressing SYTV-EGFP and 
control cells. In my experience, it is unusual for the VWF ELISAs to offer such conflicting 
data when the proregion ELISAs performed on the same samples suggest that the extent of 
secretion remains unchanged between conditions. It is possible that SYTV-EGFP over-
expression causes the deregulation of VWF secretion from HUVECs. However, the reasons 
why the release of VWF but not proregion is affected are currently unclear, but may be 
related to pH changes within the organelle caused by SYTV-EGFP over-expression (see 
Discussion). Therefore, at this point the data suggests that the up-regulation of SYT V may 
affect the exocytosis of WPBs, although it appears that the release of VWF is influenced 
considerably more so than that of smaller WPB-resident proteins such as proregion.  
 
6.3 The Effects of SYTV-EGFP Over-Expression on the Calcium Sensitivity of WPB 
Exocytosis: The Dose-Response Curve  
 
It has been well-documented thus far that over-expressed SYTV-EGFP localizes to 
WPBs in HUVECs and previous functional studies have suggested that SYTV-EGFP over-
expression may influence the secretion of VWF from HUVECs. In order to better define the 
function of SYT V in HUVECs I examined the effects of SYTV-EGFP over-expression on 
the calcium sensitivity of WPB exocytosis using the dose-response curve assay. The 
experiments were performed as described in ‘2.7.4 Dose-Response ELISAs.’ The raw data 
obtained from each replicate was normalized to the quantity of proregion secreted from YFP-
expressing control cells exposed to 1 µM ionomycin. The final dose-response curve is shown  
in Figure 6.2. The two curves provided from cells over-expressing either SYTV-EGFP or 
YFP are broadly similar and show no significant differences in the quantity of proregion 
secreted in response to any of the six different concentrations of ionomycin examined. Hence, 
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Figure 6.1 SYT V up-regulation 
influences the extent of VWF 
secretion from HUVECs. 
 
VWF ELISAs were performed to 
examine the effects of SYTV-EGFP 
over-expression on VWF secretion 
from HUVECs compared with a 
control construct (YFP). The graphs 
show the quantity of VWF released as 
a percentage of the total quantity of 
VWF in the cells. Cells incubated 
with a control non-stimulating 
solution provided the data for the 
basal release of VWF. Cells 
incubated with 1 µM ionomycin 
provided the data for the stimulated 
release of VWF. Black bars represent 
YFP-transfected cells. Hatched bars 
represent SYTV-EGFP-transfected 
cells. Panels (i), (ii), and (iii) show 
the results of three separate assays.  
 
* P-value ‹ 0.05. 
n/s = non-significant (p-value › 0.05) 
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ii 
iii 
79 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. SYTV-EGFP over-expression does not influence the calcium sensitivity 
of WPB exocytosis.  
HUVECs transfected with either SYTV-EGFP or with the cytoplasmic control 
construct YFP were stimulated with varying concentrations of ionomycin as indicated 
in the x-axis. The quantity of proregion secreted was determined using a proregion 
ELISA. This procedure was repeated three times. For each transfection, the data was 
normalized to the extent of proregion secreted from YFP-expressing cells in response to 
1 µM ionomycin. Data from the three replicates was combined, and the means of the 
normalized values were used to plot the final dose-response curves.   
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it would appear that SYTV-EGFP over-expression does not affect the calcium-sensitivity of 
WPB exocytosis from HUVECs. 
 
6.4 The Effects of the Knock-Down of SYT V on WPB Exocytosis: 
 
 The function of the SYT V protein in the regulation of WPB exocytosis is currently 
unclear. In order to further investigate this the SYT V protein was knocked-down in our 
model endothelial cells and functional studies were performed with the aim to determine if 
the loss of SYT V leads to any significant effects on the extent of WPB exocytosis from 
HUVECs. 
 
6.4.1 The Optimization of the Knock-Down Protocol: 
 
The knock-down of SYT V was achieved according to the protocol detailed in ‘2.2.4 
The Knock-Down of SYT mRNA.’ As the knock-down procedure must be optimized for 
each individual protein it was initially necessary to screen the siRNA to determine the ideal 
conditions for the knock-down of SYT V in HUVECs. Figure 6.3 shows the Western blot 
obtained following the blotting of HUVECs transfected with 200 pMol of either SYT V 
siRNA or control siRNA with antibodies against SYT V and tubulin. As can be seen, 
reasonable knock-down of the SYT V protein was achieved when HUVECs were transfected 
with 200 pMol of SYT V siRNA. I made additional attempts to optimize this effect by 
varying the quantity of transfected siRNA and the time for which cells were left in culture 
(data not shown) but I could not improve on that achieved with 200 pMol of SYT V siRNA.  
 Initially, it was necessary to determine if the knock-down of SYT V in HUVECs has 
any visible effect on the morphology and biosynthesis of WPBs. Therefore, ICC was 
performed using HUVECs transfected with 200 pMol of either SYT V siRNA or control non- 
targeting oligos. The results of this are shown in Figure 6.4. As can be seen, no visible 
differences are apparent between the transfected cultures as each has produced a confluent 
monolayer of morphologically-normal HUVECs. Additionally, each culture has generated 
large numbers of rod-shaped WPBs which are dispersed as expected throughout the cells. 
Therefore, SYT V knock-down does not yield any striking effects on the biosynthesis or 
morphology of either HUVECs or their WPBs. 
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6.4.2 SYT V Knock-Down ELISAs: 
 
In order to investigate whether the knock-down of SYT V impacts upon the 
exocytosis of WPBs from HUVECs functional studies were performed in the form of VWF 
and proregion ELISAs. The results of a representative VWF ELISA are shown Figure 6.5 (i). 
As can be seen, SYT V knock-down has no effect on the extent of the overall secretion of 
VWF from HUVECs, suggesting that SYT V does not influence WPB exocytosis.  Proregion 
ELISAs were then performed using the collected samples and the results of a representative 
assay are shown in Figure 6.5 (ii). Again, SYT V knock-down has no effect on the overall 
exocytosis of proregion from transfected HUVECs. Therefore the knock-down of SYT V 
does not influence the extent of WPB exocytosis from endothelial cells. 
Figure 6.3. The SYT V protein is depleted in HUVECs following siRNA 
transfection. 
 Cells were transfected with 200 pMol of either SYT V siRNA or control non-targeting 
oligos (siCTRL) as indicated and were allowed to grow to confluency for forty-eight 
hours. A mock transfection was also performed (4 µL dH2O). Lysates from each 
culture were extracted and Western blotting was carried out probing for SYT V (green) 
and tubulin (red). The sizes of the protein marker are indicated on the left of the blot. 
The knock-down of the SYT V protein is achieved following transfection with 200 
pMol of SYT V siRNA. The tubulin loading control shows that an equivalent quantity 
of total protein was loaded into each well. The extent of the knock-down of SYT V in 
SYT V-siRNA-transfected HUVECs is 41.28% of that seen in control siRNA-
transfected HUVECs (normalized to the total quantity of protein as determined from 
the tubulin loading control). 
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Figure 6.4. The knock-down of SYT V does not affect the morphology of either HUVECs 
or their WPBs.  
HUVECs transfected with 200 pMol of either SYT V siRNA or with control non-targeting 
oligos as indicated were stained with antibodies against both VWF and TGN-46. A mock 
transfection was also included (4 µl of dH20). The left-hand panels show the merged images, the 
middle panels show the VWF stain in the red channel, and the right-hand panels show the TGN-
46 stain in the green channel. All cultures examined have grown to confluency and HUVECs 
appear morphologically normal. Likewise, each culture contains high numbers of large, rod-
shaped WPBs.  
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6.5 SYT V Mutant Proteins and WPB Exocytosis: 
 
The siRNA studies previously described are limited in that they require a strong 
knock-down of the target protein to overcome the residual functional effect of the 
endogenous protein. Therefore, a series of mutants of the SYT V protein were produced with 
the aim to abolish the normal function of endogenous SYT V in HUVECs.  These mutants 
were over-expressed in HUVECs to determine if SYT V does indeed play a role in WPB 
exocytosis.  
 
6.5.1 The SYT V Mutant Proteins: 
 
Three fluorescent mutants of SYT V were generated: a cytoplasmic mutant 
(designated SYTV-EGFPΔTM), a full-length Ca2+-insensitive mutant (designated SYTV-
EGFP D/S), and a cytoplasmic Ca
2+
-insensitive mutant (designated SYTV-EGFPΔTM D/S). 
SYTV-GFPΔTM is a cytoplasmic variant of SYT V and therefore lacks the transmembrane 
domain which normally characterizes members of the SYT family as integral membrane 
proteins (Perin et al. 1990). For the human SYT V protein, this transmembrane region is 
located between amino acids 24 and 45 according to the Uniprot database (entry O00445). In 
order to generate the SYTV-EGFPΔTM mutant, a forward primer was designed which 
eliminated both the transmembrane and N-terminal regions of the SYT V protein. Therefore, 
the final product of cloning will consist only of the linker region and the C2 domains of the 
SYT V protein and so is expected to be a cytoplasmic variant of the full-length protein.  
Secondly, a Ca
2+
-independent variant of full-length SYT V was generated, designated 
SYTV-EGFP D/S. Wild-type SYT V is a Ca
2+
-dependent SYT due to a series of aspartate 
residues in its C2A domain which function to coordinate Ca
2+
 ions prior to secretory events. 
However, the Ca
2+
-independent SYTs such as SYTs IV and XI have a serine residue in place 
of the third aspartate in the Ca
2+
-binding motif of the C2A domain, rendering them unable to 
bind Ca
2+
 ions (von Poser et al. 1997). Therefore, a Ca
2+
-dependent SYT such as SYT V can 
be converted to a putative Ca
2+
-independent protein by mutating this essential aspartate. For 
the SYT V protein, this key residue is ASP197. Hence, in order to generate the SYTV-EGFP 
D/S mutant nucleotides 589, 590, and 591 (i.e. the codon GAC) of the SYT V cDNA 
sequence were mutated to AGC, resulting in an aspartate to serine mutation. This approach is 
illustrated in Figure 6.6. 
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Figure 6.5. SYT V knock-down does not affect the exocytosis of WPBs. 
 HUVECs were transfected with either SYT V siRNA (200 pMol) or control siRNA (200 
pMol). Media and lysates were collected from cells after forty-eight hours and processed for 
VWF and proregion ELISAs. Cells incubated with a control non-stimulating solution 
provided the data for basal secretion. Cells incubated with 1 µM ionomycin provided the 
data for stimulated secretion. Panel (i) shows the quantity of VWF released as a percentage 
of the total quantity of VWF in the cells. Panel (ii) shows the quantity of proregion released 
as a percentage of the total quantity of proregion in the cells. Black bars represent control 
siRNA-transfected cells. Hatched bars represent SYT V siRNA-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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The final SYT V mutant generated for these assays, designated SYTV-EGFPΔTM 
D/S, is a cytoplasmic version of the SYTV-GFP D/S mutant and was intended to act as a 
dominant negative inhibitor of endogenous SYT V. This construct was produced by PCR 
using the forward primer originally designed to generate SYTV-GFPΔTM to eliminate the N-
terminal and transmembrane domains of the SYTV-GFP D/S full-length mutant, thereby 
generating SYTV-GFPΔTM D/S. An image depicting the creation of these three SYT V 
mutants is provided in Figure 6.7 
 
6.5.2 The Over-Expression of the SYT V Mutant Proteins in HUVECs: 
 
 The three newly-synthesized SYT V mutants were used for proregion over-expression 
ELISAs with the aim to determine if non-functional variants of the SYT V protein could 
affect the extent of WPB secretion from HUVECs. The results of a representative assay are 
shown in Figure 6.7. As can be seen, it would appear that none of the three mutants examined 
here affect the quantity of proregion secreted from HUVECs as the levels of secretion are not 
significantly different to that seen from cells expressing the wild-type SYTV-EGFP 
construct. Therefore, the data provided here and from other functional studies performed to 
date suggest that SYT V is not involved in the regulation of WPB secretion from endothelial 
cells. 
 
Figure 6.6. SYT V can be converted to a Ca
2+
-independent SYT by the mutation 
of one essential aspartate residue in the C2A domain.  
A D/S mutation was introduced into SYTV-EGFP to produce SYTV-EGFP D/S. For 
each construct, the cDNA sequence is provided as indicated while the amino acid 
sequence is shown underneath. The mutated nucleotides and their corresponding 
amino acids are emphasized in red.  
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Figure 6.7. Three mutant variants of the SYTV-EGFP construct were created.  
Panel (i) depictes the structure of the SYTV-EGFP D/S mutant compared with the SYTV-
EGFP construct. Panel (ii) depictes the structures of the SYTV-EGFPΔTM and SYTV-
EGFPΔTM D/S constructs.  The numbers of the amino acid residues marking the 
boundaries of each domain of SYT V are shown in black.  
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Figure 6.8. The up-regulation of mutant SYT V proteins does not affect the secretion of 
proregion from HUVECs. 
The results of a representative experiment examining the effects of the over-expression of 
mutants of the SYT V protein on proregion secretion from HUVECs are shown.  Media and 
lysate were collected from cells expressing SYTV-EGFP, SYTV-EGFP D/S, SYTV-
EGFPΔTM, or SYTV-EGFPΔTM D/S and a proregion ELISA was performed. The graph 
shows the quantity of proregion released as a percentage of the total quantity of proregion in 
the cells. Cells incubated with a control non-stimulating solution provided the data for the 
basal release of proregion. Cells incubated with 1 µM ionomycin provided the data for the 
stimulated release of proregion. No significant differences in proregion secretion are apparent 
between cell expressing wild-type SYT V (SYTV-EGFP) and those expressing any of the 
three mutant variants of SYT V.  
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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6.5.3  The Subcellular Localization of the SYT V Mutants: 
 
 It was of interest to identify the subcellular localization of each of the three novel 
SYT V mutants to determine if the trafficking of these proteins is affected by their mutations. 
Therefore HUVECs expressing each of the four constructs were fixed forty-eight hours 
following transfection and processed for ICC. The results of this are shown in Figure 6.9. As 
can be seen, no obvious differences in the subcellular localization of the SYT V variants are 
apparent as each plasmid appears to localize strongly to the WPBs. For the SYTV-EGFP D/S 
mutant this was expected as a single amino-acid substitution is not predicated to be sufficient 
to alter the subcellular localization of this construct compared with wild-type SYTV-EGFP. 
For the SYT V variants which lack the transmembrane domain (SYTV-EGFPΔTM and 
SYTV-EGFPΔTM D/S), it is likely that these protein are trafficking to the WPBs via 
interactions with integral membrane proteins present on the surface of the organelle. It is 
probable that these mutant variants of SYT V are peripheral membrane proteins and associate 
with the WPBs through other membrane proteins (Li et al. 1995). However, notice the 
appearance of diffuse cytoplasmic staining for both SYTV-EGFPΔTM and SYTV-
EGFPΔTM D/S in Figure 6.8 suggesting that a proportion of the protein can be found within 
the cytoplasm. The expression of the three SYT V mutants does not affect the morphology of 
WPBs as HUVECs expressing these plasmids all contain high numbers of rod-shaped WPBs.  
 
6.6 Discussion: 
 
The general function of SYT V has yet to be determined although it is known to 
regulate the exocytosis of LDCVs from PC12 cells (Saegusa et al. 2002), the formation of 
phagosomes in macrophages (Vinet et al. 2008), and plays an as-yet unclear role in insulin 
secretion (Iezzi et al. 2004). The observation that SYTV-EGFP localizes extensively to 
WPBs suggests that endogenous SYT V is located in an ideal position to regulate the Ca
2+
- 
dependent exocytosis of granules from endothelial cells. In order to further investigate the 
function of the SYT V protein in HUVECs, over-expression ELISAs were performed which 
yielded conflicting data. The VWF ELISAs revealed a dysregulation of WPB exocytosis 
following SYTV-EGFP over-expression whereas the proregion ELISAs performed on the 
same samples showed no effect of SYT V up-regulation on proregion secretion. There are a 
number of possibilities which explain these interesting findings. Firstly, it may simply be that  
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Figure 6.9. Mutant SYT V proteins localize to WPBs.  
HUVECs expressing SYTV-EGFP, SYTV-EGFP D/S, SYTV-EGFPΔTM, or SYTV-
EGFPΔTM D/S as indicated on the left of the figure were stained for either VWF or 
GFP. The left-hand panels show the merged images, the middle panels show the VWF 
stain in the red channel, and the right-hand panels show the GFP stain in the green 
channel. In all four cultures the constructs localize to the WPBs. Notice the diffuse 
cytoplasmic staining seen in cells expressing variants of SYT V which lack the 
transmembrane domain (SYTV-EGFPΔTM and SYTV-EGFPΔTM D/S). All four 
constructs showed a similar transfection efficiency (approximately 20%) in HUVECs 
and all showed an optimum expression time of 48 hours.   
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the proregion ELISAs are more accurate than the VWF ELISAs although such conflicting 
results have not been observed in other experimental series. In order to test this possibility it 
is essential that substantially more replicates of the VWF and proregion assays are performed 
to verify that the unusual effects seen here are consistent and reproducible. Secondly, it is 
possible that SYT V may be involved in mediating the formation or structure of the fusion 
pore. In this case, the up-regulation of SYT V in HUVECs may lead to alterations in the size 
of the fusion pore, allowing the release of proregion but not VWF from transfected cells. 
Equally, an increase in the number of kiss-and-run events due to fusion pore instability may 
explain these findings. Live-cell imaging using the SYTV-EGFP construct would be required 
to test these possibilities. Thirdly, it is possible that SYT V over-expression results in 
alterations in the internal pH of granules in transfected cells.  Indeed, SYT V is known to be 
involved in the acidification of phagosomes in macrophages by mediating the recruitment of 
V-ATPase and cathepsin D (Vinet et al. 2009). A dysregulation of the internal pH of the 
WPBs may influence the exocytosis of multimeric VWF more so than the smaller and more 
mobile proregion. However, increases in the internal pH of WPBs would lead to the 
rounding-up of the granules, and the lack of any effect of SYTV-EGFP over-expression on 
the morphology of WPBs argues against this hypothesis. Lastly, it is possible that the over-
expression of SYT V influences not the regulated secretion of VWF but rather its release via 
the constitutive pathway. This would explain the observation that SYTV-EGFP over-
expression affects VWF but not proregion secretion, as proregion is found exclusively within 
WPBs whereas VWF is also found within the constitutive pathway (Arribas and Cutler, 
2000). Future work may focus on testing these alternatives to better characterize the function 
of the SYT V protein in HUVECs.  
 The SYTV-EGFP construct was also used to establish a dose-response curve with the 
aim to determine if the up-regulation of SYT V in HUVECs influences the calcium 
sensitivity of WPB exocytosis. Although recent work has suggested that members of the SYT 
family can function cooperatively to determine the sensitivity of secretory events (Gao et al. 
2000, Wang et al. 2004), the dose-response curve constructed here demonstrated that SYT V 
is not involved in determining the calcium sensitivity of WPB exocytosis. To further 
investigate the function of SYT V in endothelial cells, mutant variants of the SYTV-EGFP 
construct were produced and over-expressed in HUVECs but again no functional effects on 
WPB exocytosis were identified.  However, it is important to consider that all over-
expression studies are limited in that they rely on a high transfection efficiency to overcome 
the background secretion from non-transfected cells. It is possible that these studies did not 
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achieve a sufficient level of expression of the SYTV-EGFP construct to allow the 
identification of a functional effect.  Indeed, the issue of the poor transfection of an unrelated 
SYTV-EGFP construct has been identified as an obstacle in other studies (Iezzi et al. 2004). 
To overcome this problem, knock-down studies were attempted using siRNA specific for 
SYT V. In keeping with the previous observations, no effects on WPB exocytosis were 
reported following the knock-down of SYT V in HUVECs. However, this work was 
compromised as the optimum knock-down of the SYT V protein was low (approximately 
40%). It is likely that the extent of the knock-down of SYT V was not sufficient to abolish 
the function of the endogenous protein as only a small proportion of the total SYT V 
molecules present in HUVECs may be required to achieve a wild-type phenotype. 
Additionally, the quantification of the knock-down was challenging as multiple bands 
representing the SYT V protein were visualized by Western blotting and the commercial 
antibody failed to detect the endogenous protein by ICC. More accurate quantification of 
SYT V knock-down in HUVECs could be achieved by using real-time PCR, and indeed this 
technique could also be useful in further optimizing the knock-down protocol for SYT V 
mRNA. Lastly, it is possible that following the knock-down of SYT V in HUVECs another 
member of the SYT family is able to compensate for its loss, and indeed functional 
redundancy between members of the family has been reported (Lynch and Martin, 2007, 
Nishiki and Augustine, 2004).    
 In conclusion, this work has demonstrated that SYT V, despite its strong localization 
to WPBs in HUVECs, most likely does not play a role in their exocytosis. However, there 
have been many limitations associated with these functional studies, as has been discussed. 
The next step in determining the function of SYT V in HUVECs would be to perform live-
cell imaging experiments using the SYTV-EGFP construct over-expressed in our model 
endothelial cells. This would allow the accumulation of real-time secretory data on a single-
cell level, overcoming the limitations of the over-expression and knock-down studies. 
Additionally, as SYT V plays a role in the regulation of pH within phagosomes it would be of 
interest to determine if SYT V up-regulation influences the internal pH of WPBs through the 
use of pH-sensitive GFP mutants. Finally, the generation and analysis of a SYT V knock-
down mouse would shed more light on the function of SYT V in both endothelial cells and 
other cell types. Such a mouse model is not available at present but its creation would offer a 
wealth of possibilities for future research.  
 
 
Chapter 7 
 Investigating the Functions of SYTs VIII and XVII in HUVECs 
 
7.1 Chapter Overview:  
 
 The Ca
2+
-independent SYTs VIII and XVII are expressed in HUVECs and both can 
be found as components of WPBs when over-expressed. Despite this, for reasons which have 
been discussed neither protein has been identified as an outstanding candidate for the role of 
the calcium sensor regulating WPB exocytosis from endothelial cells. However, as both 
SYTs are found within the WPB membrane a series of functional studies were undertaken 
with the aim to determine if either one of these proteins does indeed play a role in the 
regulated exocytosis of the granules.  
 
7.2 SYT VIII: 
 
7.2.1 Background Information: 
 
 As is the case with many members of the SYT family there has been relatively little 
work done attempting to characterize the distribution and function of SYT VIII. It is known 
that this SYT belongs to a group of paralogues consisting of SYTs I, II, V, and VIII 
(Monterrat et al. 2006) and that it contains several mutations in its C2A domain which render 
it unable to bind  Ca
2+
 ions (von Poser et al. 1997). Further evidence suggesting that SYT 
VIII is a Ca
2+
-insensitive SYT comes from the observation that a fluorescent fragment of 
SYT VIII, SYT8-C2AB-eGFP, does not translocate to internal membranes upon a rise in 
cytosolic calcium levels (Kishore et al. 1998). SYT VIII contains two putative PKA 
phosphorylation sites in its cytoplasmic region and interestingly also contains a histidine-rich 
region consisting of the sequence HRHRHRK which is not seen in other family members 
(Kishore et al. 1998). The titration of these histidine residues could impact the binding of 
SYT VIII to other proteins such as SNARES and therefore changing pH levels could be a 
stimulus for secretory events which are regulated by SYT VIII.  
The relatively limited work done to date examining the distribution of SYT VIII 
suggests that it is broadly expressed in mammals. SYT VIII is found as a 52-kDa protein in 
the rat renal cortex and inner medulla, and RT-PCR has demonstrated the existence of SYT 
VIII mRNA in the rodent kidney, cerebral cortex, liver, lung, and heart (Kishore et al. 1998). 
Indeed, an extensive analysis of the distribution of SYT VIII in the rat kidney showed that the 
protein could be found in the cortex, outer medulla, and inner medulla. SYT VIII expression 
has also been reported in the insulinoma cell line HIT-5HT and in PC12 cells (Monterrat et 
al. 2006). 
 Like many members of the SYT family, SYT VIII exists as a number of isoforms and 
indeed different variants of the protein show different subcellular localizations. ICC and 
subcellular fractionation studies have reported the existence of two isoforms of the SYT VIII 
protein consisting of either 50 or 40 kDa which are distinguished by variations in the N-
terminus of the protein (Monterrat et al. 2006). The 40 kDa variant is a cytosolic protein in 
the brain, in PC12 cells, and in clonal β-MIN6 cells whereas the 50 kDa isoform is found in 
clusters on vesicles and co-localizes with the Golgi SNARE protein Vti1a. In neurons, SYT 
VIII immunoreactivity is confined to the soma and co-stains with synaptophysin, a marker of 
synaptic vesicles (Monterrat et al. 2006).   
 The bulk of the work done thus far to determine the function of SYT VIII has focused 
on its role in the regulation of the secretion of the acrosome from sperm cells. The sperm 
acrosome is a single large secretory granule which is released in response to the increasing 
Ca
2+
 levels generated when the sperm surface membrane contacts receptors in the zona 
pellucida surrounding the egg. SYT VIII has been found at both the mRNA and protein levels 
in mouse spermatogenic cells (Hutt et al. 2002). Fractionation studies have demonstrated that 
SYT VIII is found specifically in the membrane fraction and co-sediments with markers of 
the mouse sperm head such as the sperm-specific β-1,4 galctosyl transferase. Furthermore, 
SYT VIII is localized to the acrosomal crescent and the densitometric analysis of Western 
blots demonstrated that SYT VIII reactivity diminishes by 54% following stimulation of 
sperm cells with the calcium ionophore A23187. SYT VIII is now known to bind to syntaxin 
2, a SNARE protein which is also expressed in sperm cells and localized to the acrosome 
(Hutt et al. 2005). Recombinant fragments of SYT VIII and syntaxin 2 inhibit the acrosomal 
reaction in streptolysin O-permeabilized sperm in a dose-dependent manner. The same effect 
is seen following the addition of antibodies specific for SYT VIII. Therefore, it has been 
proposed that SYT VIII and syntaxin 2 play a role in the regulation of the secretion of the 
acrosome from mouse sperm cells. 
 In conclusion, although little is known concerning the function of SYT VIII, evidence 
to date suggests that it is a broadly-distributed, Ca
2+
-insensitive SYT which plays a 
potentially-vital role in the exocytosis of the acrosome from sperm cells. As with many 
members of the SYT family, the presence of numerous isoforms of the protein, each with 
unique subcellular distributions, makes the study of SYT VIII challenging.   
 
7.2.2 SYTVIII-EGFP Over-Expression ELISAs: 
 
  7.2.2.1 Forty-Eight Hours Following SYTVIII-EGFP Transfection: 
 
 Studies thus far have demonstrated that SYT VIII can be found at both the mRNA and 
protein levels in HUVECs and that over-expressed SYT VIII localizes to WPBs. Hence, SYT 
VIII is a strong candidate for the role of the calcium sensor regulating WPB secretion from 
endothelial cells. In order to investigate this hypothesis over-expression ELISAs were 
performed with the aim to examine the effect of the up-regulation of SYT VIII on WPB 
exocytosis. Briefly, HUVECs were transfected with either SYTVIII-EGFP or with the control 
cytoplasmic construct YFP and were seeded onto 6-well plates. After forty-eight hours the 
now-confluent cells were stimulated with either 1 µM ionomycin or with a control non-
stimulating solution. The media and lysates were collected from the cells and these samples 
were processed for ELISAs as detailed in ‘2.7 The Enzyme-Linked Immunosorbent Assay 
(ELISA) Protocol.’ Both the VWF and proregion ELISAs demonstrated that the over-
expression of SYTVIII-EGFP in HUVECs cultured for forty-eight hours does not affect the 
extent of WPB release compared with cells expressing YFP (data not shown).  
  
7.2.2.2 Twenty-Four Hours Following SYTVIII-EGFP Transfection: 
 
 The ELISAs performed at forty-eight hours following transfection have indicated that 
the up-regulation of SYT VIII in HUVECs does not influence WPB exocytosis. However, the 
subcellular localization screen examining the distribution of SYTVIII-EGFP described in 
Chapter Four has demonstrated that the construct shows a higher expression level across the 
HUVEC monolayer and a more intense perinuclear staining pattern twenty-four hours 
following transfection. I was interested to see if a shorter culture time following transfection 
would influence the results of the VWF and proregion ELISAs. Therefore, HUVECs 
transfected with either SYTVIII-EGFP or YFP were allowed to grow to confluency for 
twenty-four hours after which point the media collections and ELISAs were repeated. 
Interestingly, for both the VWF and proregion assays every replicate showed a clear trend 
towards an increase in the quantity of material secreted from SYTVIII-EGFP-transfected 
HUVECs compared with YFP-expressing cells. Example VWF and proregion assays are 
shown in Figure 7.1. In most cases, however, the difference in secretion between the cultures 
did not reach statistical significance. It is possible that SYTVIII-EGFP over-expression does 
influence the secretion of WPBs from HUVECs although an increased number of replicates 
would be required to confirm this. Additionally, the SYTVIII-EGFP construct has a poor 
transfection efficiency in HUVECs and it may be that its expression level is too low to allow 
significant results to be generated from these assays. 
 
7.2.3 The Effects of the Knock-Down of SYT VIII on WPB Exocytosis: 
 
 As the previous series of functional experiments has proved inconclusive knock-down 
ELISAs were performed to determine if the loss of SYT VIII from HUVECs has a significant 
effect on WPB exocytosis.   
 
7.2.3.1 The Optimization of the Knock-Down Protocol: 
 
As the knock-down procedure must be tailored for individual proteins it was initially 
necessary to determine the optimum conditions for the efficient elimination of the SYT VIII 
protein in endothelial cells. A number of conditions were trialed which will not be discussed 
in detail here. The end-result of this process was that the optimum knock-down of SYT VIII 
is achieved with 400 pMol of siRNA and an incubation time of forty-eight hours. A 
representative Western blot showing the reduction in the level of SYT VIII protein in 
HUVECs treated in this way is shown in Figure 7.2. In keeping with previous observations 
(see Chapter 3), two bands representing the SYT VIII protein have appeared following 
Western blotting. The top band of approximately 80 kDa is diminished to a greater extent 
than the bottom band of 75 kDa. These two bands likely represent two separate isoforms of 
the SYT VIII protein. Therefore it is possible that the larger isoform has a shorter half-life in 
endothelial cells than the smaller variant, thus explaining the discrepancy in knock-down 
efficiency. The implications of this will be considered at a later stage (7.2.4 The Role of SYT 
VIII in Human Endothelial Cells – A Discussion.) 
It was necessary to evaluate the effects of the knock-down of SYT VIII on the 
morphology of the HUVECs and their resident WPBs. Therefore, HUVECs transfected with 
400 pMol of either SYT VIII siRNA or control siRNA were fixed forty-eight hours following 
transfection. ICC was performed with antibodies against VWF and TGN-46. The 
  
 
 
 
 
 
 
 
 
 
 
Figure 7.1. SYT VIII over-expression results in a trend for the increased secretion of 
WPBs from stimulated HUVECs.  
 HUVECs were transfected with either SYTVIII-EGFP or YFP. Media and lysates were 
collected from cells after twenty-four hours and processed for VWF and proregion ELISAs. 
Cells incubated with a control non-stimulating solution provided the data for basal secretion. 
Cells incubated with 1 µM ionomycin provided the data for stimulated secretion. Panel (i) 
shows the quantity of VWF released as a percentage of the total quantity of VWF in the cells. 
Panel (ii) shows the quantity of proregion released as a percentage of the total quantity of 
proregion in the cells. Black bars represent YFP-transfected cells. Hatched bars represent 
SYTVIII-EGFP-transfected cells.  
* P-value ‹ 0.05. 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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results of this are shown in Figure 7.3. As can be seen the cells have formed a confluent 
monolayer and the WPBs are numerous, large, and rod-shaped as expected. Therefore, this 
brief investigation suggests that SYT VIII does not influence either the biosynthesis or 
trafficking of WPBs in endothelial cells. 
 
7.2.3.2 SYT VIII Knock-Down ELISAs: 
 
It has now been established that the reasonable knock-down of SYT VIII can be 
achieved following the transfection of HUVECs with 400 pMol of SYT VIII siRNA and that 
this process has no obvious effects on cell morphology. Therefore, VWF and proregion 
ELISAs were performed with the aim to determine if the loss of the SYT VIII in endothelial 
Figure 7.2. The SYT VIII protein is depleted in HUVECs following siRNA 
transfection.  
HUVECs were transfected with either SYT VIII siRNA (VIII) or the control non-
targeting oligos (C) and grown to confluency for forty-eight hours. Lysates from 
each culture were extracted and Western blotting was performed probing for SYT 
VIII (green) and tubulin (red). Reasonable knock-down of SYT VIII is achieved 
following transfection with 400 pMol of SYT VIII siRNA. The tubulin loading 
control shows that an equivalent quantity of protein was loaded into each well. Two 
isoforms of SYT VIII have been visualized at 80 and 75 kDa, as indicated. The 
larger isoform showed a knock-down of 66% compared with the loading control. 
The smaller isoform showed a knock-down of 31% compared to the loading 
control. The sizes of the marker are indicated on the left (kDa).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3. The knock-down of SYT VIII does not affect the morphology of either 
HUVECs or their WPBs.  
HUVECs transfected with 400 pMol of either SYT VIII siRNA or control non-targeting 
oligos (siCTRL) as indicated were stained with antibodies against both VWF and TGN-
46. A mock transfection was also included (4 µl of dH20). The left-hand panels show 
the merged images, the middle panels show the VWF stain in the red channel, and the 
right-hand panels show the TGN-46 stain in the green channel. All cultures examined 
have grown to confluency and HUVECs appear morphologically normal. Likewise, 
each culture contains high numbers of large, rod-shaped WPBs.  
 
cells has an effect on the exocytosis of WPBs. The results of a representative VWF ELISA 
are shown in Figure 7.4 (i). The knock-down of SYT VIII does not affect the quantity of 
VWF secreted from stimulated HUVECs. The results of a representative proregion ELISA 
are shown in Figure 7.4 (ii). Again, it would appear that the loss of the SYT VIII protein from  
HUVECs does not influence the overall secretion of proregion. These results suggest that, 
despite its subcellular localization, SYT VIII does not play a role in the Ca
2+
-mediated 
exocytosis of WPBs from HUVECs. However, the knock-down effect achieved here was 
relatively weak and so it may be the case that the residual endogenous protein is sufficient to 
maintain a fully functional phenotype following SYT VIII knock-down. Additionally, it 
appears that numerous isoforms of SYT VIII are present simultaneously within HUVECs and 
these are inhibited to varying extents following siRNA transfection. The implication of this 
will be considered further in the following section.    
 
7.2.4 The Role of SYT VIII in Human Endothelial Cells – A Discussion: 
 
  It is known that SYT VIII regulates the secretion of acrosomes from sperm cells via 
an interaction with the SNARE syntaxin-2 (Hutt et al. 2005). However the role of SYT VIII 
in other cell types is currently unclear. Here, I have attempted to determine if SYT VIII plays 
a role in the regulation of WPB exocytosis from endothelial cells. Firstly, I performed over-
expression ELISAs using HUVECs transfected with the SYTVIII-EGFP construct and grown 
in culture for either forty-eight or twenty-four hours. The up-regulation of SYT VIII in 
HUVECs grown for forty-eight hours following transfection had no effect on the secretion of 
either VWF or proregion in response to ionomycin stimulation. In contrast, in HUVECs 
incubated for only twenty-four hours following transfection the over-expression of SYTVIII- 
EGFP resulted in a trend for the increased exocytosis of both VWF and proregion following 
stimulation. However these results did not generally reach statistical significance. A higher 
number of replicates would be required first and foremost to improve the reliability of this 
data. Equally, it would be of interest to repeat these ELISAs with HUVECs incubated for 8 or 
12 hours following transfection. If SYTVIII-EGFP is progressively removed from WPBs as 
they mature and move through the secretory pathway then these shorter time periods may 
yield interesting results. Lastly, as the expression level of the SYTVIII-EGFP construct is 
notably low live-cell imaging would prove invaluable for the collection of data on a single-
cell level. This would also provide an efficient means for rapidly increasing the sample size 
of SYTVIII-EGFP-expressing cells for statistical analysis without the need for time-  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4. SYT VIII knock-down does not affect the exocytosis of WPBs. 
HUVECs were transfected with either SYT VIII siRNA (400 pMol) or control siRNA (400 
pMol). Media and lysates were collected from cells after forty-eight hours and processed for 
VWF and proregion ELISAs. Cells incubated with a control non-stimulating solution provided 
the data for basal secretion. Cells incubated with 1 µM ionomycin provided the data for 
stimulated secretion. Panel (i) shows the quantity of VWF released as a percentage of the total 
quantity of VWF in the cells. Panel (ii) shows the quantity of proregion released as a percentage 
of the total quantity of proregion in the cells. Black bars represent control siRNA-transfected 
cells. Hatched bars represent SYT VIII siRNA-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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consuming biochemical assays.   
As the over-expression ELISAs have proved inconclusive as to the involvement of 
SYT VIII in the regulation of WPB exocytosis I also performed SYT VIII knock-down 
assays. These studies showed that the knock-down of SYT VIII has no effect on the Ca
2+
-
mediated exocytosis of either VWF or proregion from HUVECs. They were however 
complicated by the fact that two variants of the SYT VIII protein are knocked-down to 
different extents following siRNA transfection. Western blotting revealed that the larger 80 
kDa SYT VIII isoform was diminished to a greater extent than the smaller 75 kDa isoform. It 
is possible that the smaller isoform is more stable and has a longer half-life in endothelial 
cells. Alternatively, it may be that the pools of siRNA target the larger isoform with greater 
efficiency than smaller variants. Therefore, at this point it is impossible to say if the lack of 
an effect following SYT VIII siRNA transfection in HUVECs is an accurate observation or is 
simply the result of the inefficient knock-down of certain isoforms leading to a significant 
quantity of endogenous protein remaining in culture. These complications could be over-
come by the generation of a SYT VIII 
-/-
 mouse as this would prove the optimum method for 
definitively eliminating every isoform of the SYT VIII protein in endothelial cell cultures.  
 To conclude, this work has demonstrated that SYT VIII is a WPB-associated protein 
and therefore is a key protein of interest for future work investigating the biosynthesis, 
trafficking and exocytosis of these organelles from endothelial cells. My attempts to assign a 
function for the SYT VIII protein have been complicated by the low transfection efficiency of 
the SYTVIII-EGFP construct and the simultaneous expression of multiple SYT VIII isoforms 
in HUVECs. However, multiple avenues for future research attempting to better define the 
role of the SYT VIII protein in endothelial cells have been identified and these would focus 
on live-cell imaging experiments, the production of a SYT VIII 
-/-
 mouse, and the generation 
of fluorescent constructs of endothelial-specific SYT VIII isoforms.  
 
7.3 SYT XVII: 
 
 7.3.1 Background Information: 
 
 SYT XVII is the most recently characterized member of the SYT family and to date 
no studies have been undertaken attempting to determine its physical properties, tissue 
distribution, subcellular localization, or function. The only exception to this is the observation 
that following an over-expression screen of the SYT family in hippocampal neurons SYT 
XVII localizes to internal vesicles in the axon (Dean et al. 2012). The identity of these axonal 
structures is currently unknown but they are unlikely to be synaptic vesicles. Here, I have 
demonstrated that SYT XVII is present in HUVECs as both an mRNA transcript and as a 
protein of approximately 65 kDa. Surprisingly, over-expressed SYTXVII-EGFP was shown 
to have an extensive distribution in HUVECs, localizing to the lysosomes, TGN, endosomal 
system, and WPBs. The fact that SYTXVII-EGFP localizes to WPBs suggests that this 
member of the SYT family may be involved in the regulation of WPB secretion. Therefore 
functional studies were undertaken with the aim to test this hypothesis. To my knowledge this 
will be the first study focusing on this Ca
2+
-independent member of the SYT family.  
 
7.3.2 SYTXVII-EGFP Over-Expression ELISAs: 
 
Firstly, the effect of the up-regulation of SYT XVII on WPB secretion was examined 
using both VWF and proregion ELISAs performed on samples collected from HUVECs 
expressing either SYTXVII-EGFP or YFP. The results of the VWF ELISAs are shown in 
Figure 7.5. In Figure 7.5 (i), SYTXVII-EGFP over-expression has resulted in a significant 
decrease in the extent of regulated VWF secretion compared with that seen from the control 
YFP-expressing cultures. However, in the assay shown in Figure 7.5 (ii) the opposite effect is 
seen whereby SYTXVII-EGFP over-expression results in an increase in VWF secretion. 
Lastly, Figure 7.5 (iii) shows no significant differences in secretion between SYTXVII-
EGFP-expressing HUVECs and control cells. The reasons for these discrepancies are 
currently unclear although it would appear that SYTXVII-GFP over-expression has resulted 
in the deregulation of VWF secretion.  
As these VWF ELISAs have yielded conflicting results proregion ELISAs were 
carried out on the collected samples in an attempt to further investigate the effects of 
SYTXVII-EGFP over-expression on WPB secretion. Surprisingly, for all three assays no 
significant differences in proregion secretion were identified between cells over-expressing 
SYTXVII-EGFP and YFP (data not shown). Therefore SYTXVII-EGFP over-expression 
does not affect the extent of proregion secretion from HUVECs but does seen to have an as-
yet unclear effect on VWF secretion. Interestingly, this data is similar to that generated from 
the ELISAs examining the effect of the over-expression of SYTV-EGFP in HUVECs.  
 
7.3.3 The Role of SYT XVII in Human Endothelial Cells – A Discussion: 
 
The observations that SYT XVII is expressed in HUVECs and traffics to the WPBs 
when over-expressed imply that this member of the SYT family is a strong candidate for the 
role of the calcium sensor regulating WPB exocytosis at the plasma membrane. Over-
expression ELISAs using the SYTXVII-EGFP construct were performed with the aim to 
investigate this theory. These showed surprising results whereby the up-regulation of the 
SYT XVII protein has a very similar effect to that of SYT V. Indeed, each VWF assay 
performed yielded conflicting results whereas the proregion assays carried out on the same 
samples showed no effect of SYTXVII-EGFP over-expression on WBP exocytosis. The 
reasons for these discrepancies are extensive and include changes in the internal pH of the 
WPBs, dysregulation of the constitutive but not regulated release of VWF, alterations to the 
size and formation of the fusion pore, or simply being the result of differences in the 
accuracies of the two assays. These possibilities also explain the effect of the up-regulation of 
the SYT V protein in HUVECs and have been discussed extensively elsewhere (see 6.6 
Discussion). Therefore they will not be re-evaluated here but it will suffice to say that SYT 
XVII may have an interesting but as-yet unclear role in the regulation of WPB exocytosis. 
Additionally, Ca
2+
-independent SYTs are known to function cooperatively with Ca
2+
-
dependent SYTs to regulate secretory events and therefore it may be the case that SYTs V 
and XVII function as a complex to regulate the exocytosis of WPBs. The over-expression of 
either protein would have implications for the extent of WPB secretion and this may explain 
the strikingly similar effects of over-expression of these two SYTs on VWF secretion. 
Future work must focus on confirming any role that SYT XVII plays in the regulation 
of the Ca
2+
-mediated exocytosis of WPBs from endothelial cells. This would be best achieved 
at this point through the use of knock-down assays, and indeed I attempted the siRNA-
mediated inhibition of SYT XVII in HUVECs but unfortunately could not achieve a knock- 
down effect greater than 50%. Despite this, I did perform knock-down ELISAs using SYT 
XVII siRNA which suggested that the loss of the SYT XVII protein from HUVECs does not 
affect the release of either VWF or proregion (data not shown). Equally ICC implied that the 
knock-down of SYT XVII in HUVECs does not affect the synthesis or trafficking of WPBs 
(data not shown). However, as the extent of knock-down of SYT XVII as measured by 
Western blotting was so poor it is impossible to judge if these negative results are genuine 
observations or are the result of an inefficient knock-down. Therefore this data has not been 
presented. In the future the SYT silencing protocol for the SYT XVII protein should be  
 
 
 
 
 
Figure 7.5 SYT XVII up-regulation 
influences the extent of VWF 
secretion from HUVECs. 
 
VWF ELISAs were performed to 
examine the effects of SYTXVII-EGFP 
over-expression on VWF secretion from 
HUVECs compared with a control 
construct (YFP). The graphs show the 
quantity of VWF released as a 
percentage of the total quantity of VWF 
in the cells. Cells incubated with a 
control non-stimulating solution 
provided the data for the basal release of 
VWF. Cells incubated with 1 µM 
ionomycin provided the data for the 
stimulated release of VWF. Black bars 
represent YFP-transfected cells. Hatched 
bars represent SYTXVII-EGFP-
transfected cells. Panels (i), (ii), and (iii) 
show the results of three separate assays.  
 
* P-value ‹ 0.05. 
** P-value ‹ 0.005. 
n/s = non-significant (p-value › 0.05) 
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optimized and these studies repeated once an acceptable level of knock-down has been 
achieved. Additionally, it would be of great interest to see if the simultaneous knock-down of 
both SYTs V and XVII has an effect on the exocytosis of WPBs from HUVECs, as the 
evidence suggests that these two SYT family members may have a similar role in endothelial 
cell biology. It may be that these two proteins function either cooperatively or redundantly 
and therefore their joint knock-down may yield a striking biological effect.  
This work has been the first of its kind attempting to determine the distribution and 
role of the SYT XVII protein in any cell type, and therefore the results are of general interest 
for those working in the field of SYT biology. However before the function of this member 
of the SYT family can be understood further it is essential to determine the extent of 
expression of the SYT XVII gene in mammalian tissue and the number of SYT XVII 
isoforms which may exist in various cell types. As the subcellular localization screen 
performed here suggests that SYT XVII may have an unexpected fundamental role in 
organelle biogenesis, trafficking, or exocytosis it would be of particular interest to generate a 
SYT XVII 
-/-
 mouse to determine if such a creature shows any striking phenotypic defects.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Eight 
Investigating the Functions of SYTs I, III, VI, and XI in HUVECs 
 
8.1 An Overview: 
 
 
The previous functional studies have focused on establishing a role for those 
endothelial SYTs which are known to localize to WPBs when over-expressed in HUVECs as 
these proteins are in the optimum subcellular location for the regulation of WPB fusion with 
the plasma membrane.  However, there are four additional members of the SYT family which 
are expressed in HUVECs but do not localize to the WPBs. These proteins should not be 
immediately discounted as candidates for the role of the WPB calcium sensor as it has been 
proposed that members of the SYT family can function in a similar manner to SNAREs 
whereby different SYTs located on opposing membranes can form complexes which are 
essential for mediating secretory events. Particularly, the oligomerization of SYTs on closely-
positioned membranes may be crucial for the formation of the fusion pore (Sugita et al. 2001, 
Sudhof, 2002). Hence, the fact that a SYT is not found on the WPB membrane does not 
necessarily imply that it is not involved in the regulation of WPB exocytosis. Indeed, over-
expressed SYTI-mCherry localizes to the plasma membrane and so this SYT may be located 
in an ideal subcellular position to influence WPB secretion. Additionally, these four SYTs 
may be involved in other aspects of WPB biology such as their biosynthesis, maturation, and 
trafficking which although not directly relevant to the aims of this investigation could be 
easily identified by basic biochemical assays. Therefore, I performed limited functional 
studies aiming to identify any role played by SYTs I, III, VI, and XI in the regulation of WPB 
secretion.  
 
8.2 The Function of SYT I in HUVECs: 
 
 8.2.1 Background Information: 
 
  8.2.1.1 Discovery and Initial Characterization: 
 
 SYT I was first identified in 1981 in the rat brain as a vesicular protein of 65 kDa 
present on the outer surface of synaptic vesicles (Matthew et al. 1981). This novel protein, 
initially named p65, was shown to have a wide distribution in neuronal tissue and was 
reported to be present at low levels in non-neuronal secretory tissue. Indeed, it is now known 
that SYT I mRNA is found in the olfactory bulb, hippocampus, amygdala, striatum, 
hypothalamus, pituitary, cerebellum, throughout the cerebral cortex, and at low levels in the 
spinal cord (Berton et al. 1997, Marqueze et al. 1995).  
The sequence of rat SYT I was deduced in 1990 and notably this 421-residue protein 
contains two 116-residue domains which are homologous to the regulatory C2-region of 
protein kinase C (PKC) (Perin et al. 1990). SYT I was therefore predicted to bind Ca
2+
 ions 
and anionic phospholipids via these C2 domains in a similar manner to PKC, and indeed in 
1991 it was shown that SYT I is a putative membrane-bound Ca
2+
-binding protein (Perin et 
al. 1991). A later study demonstrated that isolated SYT I C2 domains are sufficient for high-
affinity Ca
2+
 and anionic phospholipid binding (Davletov and Sudhof, 1993). These domains 
exhibited strong positive cooperatively for Ca
2+
 binding which suggested multiple binding 
sites and also bound Ba
2+
 and Sr
2+
 ions at lower affinities. Further studies mapped the human 
SYT I gene to chromosome 12q21 and demonstrated that this gene is highly conversed 
between humans, rats, and drosophila (Perin et al. 1991).  
 
  8.2.1.2 The Role of SYT I in Synaptic Transmission: 
 
 Early studies demonstrated that SYT I has an essential role in the regulation of fast 
synaptic transmission. SYT I 
-/-
 C. elegans worms exhibit severe behavioural abnormalities 
related to locomotion, feeding, mating, and defecation resulting from reduced synaptic 
function (Nonet et al. 1993). Additionally, SYT I
 -/-
 Drosophila melanogaster flies show a 
high proportion of embryonic lethality and those that do survive exhibit uncoordinated 
muscle contractions and behaviour abnormalities including an inability to jump and mate. 
These mutants show impaired synaptic transmission characterized by diminished evoked 
excitatory junctional potentials whereas the frequency of spontaneous release events 
increases (Littleton et al 1993). Conclusive evidence that SYT I is the major Ca
2+
 sensor for 
fast synaptic neurotransmission came from the generation of SYT I 
-/-
 mice (Geppert et al. 
1994). This mutation is lethal but hippocampal neurons cultured from embryonic SYT I 
-/-
 
homozygous mice show severely impaired synaptic transmission. In keeping with the 
observations generated from the SYT I
 -/-
 Drosophila, fast synchronous release is inhibited 
whereas the frequency of asynchronous release including spontaneous activity increases.  
It is now known that the primary functions of SYT I in synaptic transmission are to 
synchronize fast release events and inhibit asynchronous transmission. Indeed, hippocampal 
neurons derived from SYT I 
-/-
 mice secrete a reduced quantity of glutamate via the fast 
synchronous pathway but an increased quantity through asynchronous events, resulting in no 
overall changes in glutamate release compared with wild-type neurons (Nishiki and 
Augustine, 2004). Additionally, SYT I 
-/-
 AD4 drosophila mutants which have no functional 
SYT I protein show severely inhibited synchronous secretion and increased asynchronous 
release events (Yoshihara and Littleton, 2002). SYT I AD1 drosophila mutants which express 
the SYT I C2A domain show partially recovered synchronous release indicating that the C2A 
domain in isolation is able to stimulate synaptic vesicle fusion.   
 The importance of SYT I in the regulation of the kinetics and sensitivity of fast 
synaptic transmission has been demonstrated by a series of elegant mutagenesis studies. A 
single point mutation (R223Q) in the SYT I protein results in a two-fold decrease in its 
overall Ca
2+
 affinity, and this in turn results in a two-fold decrease in the both the Ca
2+
 
sensitivity and overall probability of release events (Fernandez-Chacon et al. 2001). In 
contrast, a gain-of-function mutation whereby tryptophan residues are introduced into the 
exposed surface loops of the SYT I C2 domain increasing their inherent hydrophobicity and 
membrane affinity resulted in enhanced Ca
2+
 sensitivity and probability of synaptic 
transmission (Rhee et al. 2005). Incidentally in both cases spontaneous release events are not 
affected by these SYT I mutants.  
 
8.2.1.3 The Role of SYT I in the Regulation of Non-Synaptic Secretory 
Events: 
 
 SYT I is found primarily in neuronal cells where it specializes in mediating fast 
synaptic transmission. However it has been shown to be involved in the regulation of non-
neuronal secretory events. For example, SYT I is found in pancreatic acinar cells where it 
localizes to zymogen granules (Falkowski et al. 2011). An anti-SYT I antibody inhibits 
ancini exocytosis by 35% and so SYT I is involved in the regulation of zymogen exocytosis. 
Additionally, SYT I functions reluctantly with SYT IX to control the exocytosis of LDCVs 
from PC12 cells (Lynch and Martin, 2007). Indeed, the regulated exocytosis of LDCVs 
persists fully in cells which lack only one of these two SYT isoforms but is abolished 
completely if both proteins are simultaneously knocked-down in PC12 cells. Interestingly, 
each isoform appears to confer unique kinetic properties to the secretion of LDCVs as the 
over-expression of SYT I leads to faster release kinetics whereas that of SYT IX leads to 
slower release kinetics. Hence, it is likely that the ratio of expression of various SYT 
isoforms may affect the observed kinetics of a secretory event. Interestingly, this study also 
demonstrated that SYT I but not SYT IX mediates compensatory endocytosis in PC12 cells. 
Lastly, when over-expressed in the immortalized mast cell line RBL-2H3 SYT I localizes to 
secretory granules and results in their increased Ca
2+
-dependent secretion (Baram et al. 
2001).  
 
8.2.1.4 Insights into the Regulation and Trafficking of SYT I: 
 
 SYT I is phosphorylated on a single residue (T128) found in the lysine-rich linker 
region between the transmembrane and C2A domains by casein kinase II although the 
functional implications of this are currently unclear (Davletov et al. 1993). However, it is 
known that the trafficking of SYT I is heavily regulated by the palmitoylation of this crucial 
linker region. Indeed, the palmitoylation of five cysteine residues directs SYT I to vesicles in 
rodent cortical and striatal neurons (Kang et al. 2004). In contrast, unpalmitoylated SYT I 
localizes in a diffuse pattern across the axon and increased amounts are found on the plasma 
membrane. It is likely that palmitoylation regulates the internalization of SYT I from the cell 
surface and indeed unpalmitoylated SYT I mutant proteins fail to undergo endocytosis from 
the plasma membrane. 
 The final 29 N-terminal amino acids of SYT I constitute a crucial signalling peptide 
as their transplantation to SYT VII can re-direct this protein from the plasma membrane to 
secretory vesicles (Han et al. 2004). Equally, the N-terminus of SYT VII when transplanted 
to SYT I re-directs this vesicular protein to the plasma membrane. Interestingly, the 
glycosylation of this region is also essential for the correct trafficking of SYT I, with one 
asparagine residue (ASN24) playing a particularly central role. Indeed, a randomized N-
terminal sequence containing ASN24 inserted onto SYT VII is all that is required to re-direct 
this protein to the synaptic vesicles. Additionally, N24Q SYT I mutants fails to undergo 
endocytosis from the plasma membrane indicating that glycosylation is also essential for its 
internalization. As would be expected, hippocampal neurons expressing the N24Q mutant 
show diminished synaptic responses as a result of the mis-sorting of SYT I. These 
observations suggest that glycosylation is crucial for the regulation of both the endocytosis of 
SYT I and its trafficking to synaptic vesicles. The exact sequence surrounding the 
glycosylation site appears to be irrelevant.  
8.2.2 SYTI-EGFP Over-Expression ELISAs: 
 
 It has been established thus far that SYT I is present in HUVECs as both an mRNA 
transcript and as a protein. Additionally, subcellular localization studies have demonstrated 
that fluorescently-tagged SYT I traffics to the plasma membrane and to lysosomes when 
over-expressed. By virtue of its localization to the plasma membrane, it is possible that SYT I 
may be involved in the regulation of WPB exocytosis from HUVECs. In order to test this 
hypothesis, VWF and proregion ELISAs were performed with the aim to establish the effects 
of SYT I over-expression on WBP secretion. Briefly, HUVECs were transfected with either 
SYTI-EGFP or with a control cytoplasmic construct (YFP). Cells were seeded onto 6-well 
plates and allowed to grow to confluency for forty-eight hours. HUVECs were then 
stimulated with either 1 µM ionomycin or with a control non-stimulating solution. Following 
stimulation, both the media and lysates were collected and spun down to remove cellular 
debris. Samples were processed for both VWF and proregion ELISAs according to the 
protocols detailed in ‘2.7 The Enzyme-Linked Immunosorbent Assay (ELISA) Protocol.’ 
Initially, VWF ELISAs were performed on samples collected from both SYTI-EGFP 
and YFP over-expressing cells. The results of this are shown in Figure 8.1. As can be seen 
SYTI-EGFP over-expression does not affect the quantity of either VWF or proregion released 
from stimulated HUVECs, indicating that the up-regulation of SYT I does not influence the 
extent of WPB secretion. 
It has been demonstrated that the subcellular localization of the SYTI-EGFP construct 
varies depending on the time after transfection that HUVECs are fixed and examined (see 
Chapter 4). After forty-eight hours, the SYTI-EGFP construct localizes to lysosomes and to 
the plasma membrane. However, at twenty-four hours following transfection the construct 
shows a much stronger plasma membrane distribution. Therefore, the VWF and proregion 
ELISAs were repeated using HUVECs cultured for twenty-four hours following transfection. 
The results of this did not differ from those seen at forty-eight hours following transfection 
(data not shown).  
 
8.2.3 The Effects of the Knock-Down of SYT I on WPB Exocytosis: 
 
Over-expression ELISAs are limited in that they rely on a sufficient expression level 
of the construct to overcome the background exocytosis of WPBs from non-expressing cells. 
With this in mind, and considering that SYT I has a well-characterized role in the Ca
2+
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 8.1. SYT I up-regulation does not affect the exocytosis of WPBs. 
 HUVECs were transfected with either SYTI-EGFP or YFP. Media and lysates were 
collected from cells after forty-eight hours and processed for VWF and proregion ELISAs. 
Cells incubated with a control non-stimulating solution provided the data for basal secretion. 
Cells incubated with 1 µM ionomycin provided the data for stimulated secretion. Panel (i) 
shows the quantity of VWF released as a percentage of the total quantity of VWF in the 
cells. Panel (ii) shows the quantity of proregion released as a percentage of the total quantity 
of proregion in the cells. No significant differences in the extent of WPB secretion are 
apparent between cells expressing SYTI-EGFP and those expressing YFP. Black bars 
represent YFP-transfected cells. Hatched bars represent SYTI-EGFP-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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dependent secretion of synaptic vesicles from neurons, it was decided to pursue knock-down 
studies using SYT I siRNA. 
 
8.2.3.1 The Optimization of the Knock-Down Protocol: 
 
 
 Initially, it was necessary to optimize the knock-down protocol for SYT I. Therefore, 
HUVECs were transfected with varying quantities of either SYT I siRNA or with non-
targeting control oligos and were allowed to grow to confluency for either twenty-four or 
forty-eight hours. Following each time-point lysates were extracted from the cell cultures and 
Western blotting were performed using an α-SYT I antibody with the aim to determine the 
efficiency of the knock-down procedure. The results of this are shown in Figure 8.2. As can 
be seen, HUVECs transfected with both 200 and 400 pMol of SYT I siRNA show a strong 
knock-down effect forty-eight hours following transfection. By contrast, lysates extracted 
from HUVECs which were left for twenty-four hours following siRNA transfection showed 
no significant reduction in the quantity of cellular SYT I (data not shown). 
 The presence of any gross morphological changes to HUVECs following transfection 
with SYT I siRNA were examined by ICC. HUVECs were transfected with 400 pMol of 
either SYT I siRNA or control siRNA and grown to confluency for forty-eight hours. The 
cultures were then fixed and stained for VWF and LAMP1 with the intention to identify 
alterations to the number and structure of WPBs or to the morphology of HUVECs. The 
results of this are shown in Figure 8.3. As can be seen, no obvious differences are apparent 
between HUVECs transfected with SYT I siRNA and those transfected with either control 
oligos or with dH20. Indeed, all cultures have grown to confluency and contain high number 
of rod-shaped WPBs, suggesting that the knock-down of SYT I does not lead to any visible 
defects in WPB synthesis.  
 
8.2.3.2 SYT I Knock-Down ELISAs: 
 
 As the optimum conditions for the knock-down of SYT I in HUVECs have now been 
established VWF and proregion ELISAs were performed with the aim to determine if the 
knock-down of SYT I in HUVECs affects the exocytosis of WPBs. The results of this are 
shown in Figure 8.4. As can be seen, the knock-down of SYT I does not affect the quantity of 
either VWF or proregion secreted from HUVECs compared with cells transfected with  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control oligos, indicating that the knock-down of SYT I does not influence the secretion of 
WPBs from endothelial cells. 
 
8.3 The Function of SYT III in HUVECs: 
 
8.3.1 Background Information: 
 
 
8.3.1.1 The Physical Properties of SYT III: 
Figure 8.2. The SYT I protein is depleted in HUVECs following siRNA transfection. 
Cells have been transfected with varying quantities of either SYT I siRNA (I) or control non-
targeting oligos (C) as indicated and were allowed to grow to confluency for forty-eight hours. A 
mock transfection was also performed (4 µL dH2O). Lysates were extracted and probed by 
Western blotting for SYT I (upper blot) and actin (lower blot). The sizes of the protein marker are 
indicated on the left (kDa). The extent of the knock-down of SYT I in SYT I-siRNA-transfected 
HUVECs is 83.43% (400 pMol) and 69.31% (200 pMol) of that seen in control siRNA-transfected 
HUVECs (normalized to the total quantity of protein as determined from the actin loading 
control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SYT III was first identified in rat endocrine and neuronal cells and in the hormone-
secreting clonal cell lines AtT-20, MIN6, GH3, PC12, RINm5F, and HIT-T15 (Mizuta et al. 
1994). This member of the SYT family is the only isoform which can bind to negatively-
charged phospholipids in an Mg
2+
-dependent manner via a mechanism which requires the N-
terminus of the C2A domain (Fukuda et al. 1997). Therefore SYT III may have a unique role 
in the regulation of exocytosis by allowing the induction of secretory events by Mg
2+
 ions.   
SYT III, along with SYTs V and X, shows no significant IP4 binding activity in either 
the C2A or C2B domains (Ibata et al. 1998). This lack of IP4 binding is due to the combined  
Figure 8.3. The knock-down of SYT I does not affect the morphology of either 
HUVECs or their WPBs.  
HUVECs transfected with 400 pMol of either SYT I siRNA or with control non-
targeting oligos as indicated were stained with antibodies against both VWF and 
LAMP1. A mock transfection was also included (4 µl of dH20).  The left-hand panels 
show the merged images, the middle panels show the VWF stain in the red channel, and 
the right-hand panels show the LAMP1 stain in the green channel. All cultures 
examined have grown to confluency and HUVECs appear morphologically normal. 
Likewise, each culture contains high numbers of large, rod-shaped WPBs.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 8.4. SYT I knock-down does not affect the exocytosis of WPBs. 
 HUVECs were transfected with either SYT I siRNA (400 pMol) or control siRNA (400 
pMol). Media and lysates were collected from cells after forty-eight hours and processed for 
VWF and proregion ELISAs. Cells incubated with a control non-stimulating solution provided 
the data for basal secretion. Cells incubated with 1 µM ionomycin provided the data for 
stimulated secretion. Panel (i) shows the quantity of VWF released as a percentage of the total 
quantity of VWF in the cells. Panel (ii) shows the quantity of proregion released as a 
percentage of the total quantity of proregion in the cells. Black bars represent control siRNA-
transfected cells. Hatched bars represent SYT I-siRNA-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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effect of several residues (P505, E509, N510, E537, and D540) which are located in the C-
terminal region of the SYT III protein. 
 
  8.3.1.2 The Crystal Structure of the SYT III C2 Domains: 
 
The crystal structure of the SYT III C2AB domain has been determined both with and 
without bound Ca
2+
 ions. These models have shown that the two C2 domains act 
independently of one another, bind three Ca
2+
 ions each, have a wide range of movement in 
solution, and are composed of eight-stranded β-sandwiches with type I C2 topology (Sutton 
et al. 1999, Vrijic et al. 2010). Three conserved loops at the apex of each C2 domain 
compose the Ca
2+
-binding sites. Loop 3 of the C2B Ca
2+
-binding region is linked by 
disulphide bonding to another C2B domain, providing a mechanism for oligomerization 
(Sutton et al. 1999). Interestingly, it is the highly divergent linker region between the C2 
domains of a SYT protein which determines the amount of flexibility the molecule has; the 
SYT III linker region contains a high proportion of glycine residues which impart substantial 
flexibility to the overall protein whereas other SYT isoforms contain proline residues and so 
are more restricted in their range of movement (Sutton et al. 1999). 
Following Ca
2+
 binding, the SYT III molecule undergoes large conformational 
changes which result in the two C2 domains migrating to the same plane as a result of a 
hairpin twist in the 7-residue linker region (Vrijic et al. 2010). This allows their simultaneous 
insertion into target membranes. Additionally, a key lysine residue becomes exposed which 
functions to enhance interactions with anionic phospholipids in the membrane. In contrast, 
the endocytic motif WHXL is buried within the Ca
2+
-bound crystal but not in the free 
structure. 
It is thought that, in the absence of free Ca
2+
 ions, the SYT III protein is found bound 
to the trans-SNARE complex. Subsequent Ca
2+
 binding following stimulation then induces a 
large conformational change in SYT III which stabilizes the SYTIII:SNARE complex and 
allows the insertion of the SYT III moiety into the target membrane (Vrijic et al. 2010). This 
model is similar to that generated for SYT I and suggests a common mechanism of fusion 
pore formation within the SYT family. Additionally, the Ca
2+
-binding loops in the SYT III 
crystal structure resemble the membrane-binding loops of certain viral fusion proteins such as 
glycoprotein E1 of the Semliki forest virus. 
Based on the crystal structures which have been developed for SYT III, a general 
model depicting the regulation of exocytosis by SYTs has been proposed. In theory, Ca
2+
-
binding to SYTs would allow them to insert into target membranes by neutralizing the 
negatively-charged amino acids found within the SYT C2 domains. Additionally, a polybasic 
region located in the C2 domains inserts into the negatively-charged area at the centre of the 
SNARE complex. It is possible that SYTs may function as inhibitors of exocytosis by 
binding to SNAREs in their Ca
2+
-independent state, thereby blocking fusion pore formation. 
However, following calcium binding the SYTs preferentially bind to phospholipids in target 
membranes rather than SNARE molecules and this change in binding affinity allows fusion 
to proceed. 
 
8.3.1.3 The Expression and Function of SYT III in the Nervous System: 
 
SYT III is present throughout the rat CNS in a heterogeneous distribution (Marqueze 
et al. 1995, Butz et al. 1999). Its expression is strongest in the hippocampus and cerebellum 
and weakest in the cerebral cortex and olfactory bulb. It is also found in the spinal cord and 
hindbrain at moderate levels. The expression level of SYT III mRNA increases during 
development from E19 to adulthood in correlation with synaptogenesis (Butz et al. 1999). 
Light microscopy has demonstrated that SYT III is concentrated on the plasma membrane 
surrounding synapses in a similar pattern to neurexins (Butz et al. 1999). Interestingly, in the 
bovine retina SYT III shows a similar distribution to SYT I and indeed SYT III is co-
expressed with SYT I in hippocampal synapses (Ullrich et al. 1994).  
The function of SYT III in the nervous system is current unclear. In PC12 cells, 
SYTIII-GFP localizes to the plasma membrane and its over-expression results in defective 
neurite formation (Saegusa et al. 2002). SYT III appears to play a unique role in the 
regulation of synaptic vesicle exocytosis in the goldfish retina where it is found as a protein 
of 78 kDa (Berntson and Morgans, 2003). In mammalian retinas, SYT I and SYT II are 
localized to photoreceptor and biopolar cell terminals. However, in the goldfish retina SYT 
III is found in small domains of PKC-labelled bipolar cell terminals whereas SYTs I and II 
are absent from ribbon synaptic terminals of photoreceptors.  Based on the observed staining 
pattern SYT III is not found on synaptic vesicles in bipolar cells and hence probably 
functions as a plasma membrane protein. SYT III is also found enriched in the rat retina in 
the inner and outer plexiform layers. 
SYT III levels in the rat hippocampus are reduced following both a single and 
repeated electroconvulsive seizure (an animal model of electroconvulsive therapy) (Elfving et 
al. 2008). Electroconvulsive therapy is the treatment of choice for drug-resistant depressive 
disorders but its mechanism of action is currently unclear. These results suggest that SYT III 
up-regulation may be involved in the development of depression.   
 
8.3.1.4 The Expression and Function of SYT III in Non-Neuronal Cells: 
 
SYTIII is found as an expression transcript in RBL-2H3 cells, a rat tumour cell line of 
mucosal mast cells (Baram et al. 2001). Additionally, SYT III is found in pancreatic acinar 
cells as an mRNA transcript and as a 63-kDa protein which co-localizes with LAMP1 in 
membrane fractions (Falkowski et al. 2011). However, SYT III does not play a role in the 
exocytosis of zymogen granules from acinar cells. SYT III mRNA is present in murine T-
cells and the SYT III protein is found in multivesicular bodies containing the chemokine 
receptor CXCR4 and LAMP1 (Masztalerz et al. 2006). The CXCR4-regulated migration of 
T-cells and their extravasation to fibroblast monolayers can be inhibited by the knock-down 
of SYT III. It is now known that the inhibition of SYT III in T-cells impairs CXCR4 
recycling and therefore leads to reduced levels of the protein on the plasma membrane.  
It has now been established that SYT III is involved in mediating the recycling of 
proteins from the plasma membrane. Indeed, SYT III is an essential factor regulating the 
formation of rab11-positive perinuclear endocytic recycling compartments (Grimberg et al. 
2002). In RBL-2H3 cells, SYT III co-localizes with markers of the early endosomes  such as 
EEA-1, annexin II, transferrin, and syntaxin 7, and also co-localizes with the secretory 
granule markers histamine and serotonin. This distribution pattern was not consistent among 
RBL-2H3 cells suggesting that SYT III cycles between early endosomes and other 
organelles. When SYT III is knocked-down, internalized transferrin does not reach 
perinuclear endocytic recycling compartments but instead is distributed in vesicles 
throughout the cytosol. Additionally, Rab11 which normally traffics to recycling endosomes 
remains cytosolic in SYTIII-deficient cells, suggesting that SYT III regulates the de novo 
formation of recycling endosomes. It is noteworthy to consider that this study reported the 
existence of SYT III as an 80 kDa protein in the rat brain and as a 65 kDa protein in RBL-
2H3 cells, suggesting that SYT III undergoes cell-specific post-translational modifications 
(Grimberg et al. 2002). Additionally, the Western blotting of rat brain homogenates has 
identified proteins representing SYT III with molecular weights of 46 and 66 kDa (Brown et 
al. 2000). 
Lastly, SYT III is known to be involved in the regulation of insulin exocytosis and is 
found co-localized with insulin on secretory granules in rat pancreatic islets and in BtC3, 
MIN6, and RINm5F cells (Mizuta et al. 1997, Gao et al. 2000). The up-regulation of the SYT 
III protein results in increased insulin secretion and an increase in the calcium sensitivity of 
secretory events (Gao et al. 2000). In contrast, antibodies against the SYT III protein inhibit 
insulin secretion from pancreatic β-cells (Mizuta et al. 1997, Brown et al. 2000). It is 
interesting to consider that the level of the SYT III protein is decreased in Goto-Kakizaki rat 
models  of type 2 (non-insulin dependent) diabetes mellitus compared with control rats, 
suggesting that the SYT III may have a physiological role in the development or progression 
of diabetes (Zhang et al. 2002).  
In conclusion, the SYT III protein is found expressed in a number of tissues with 
particular enrichment in certain regions of the brain. The function of SYT III in neuronal 
tissue is currently unclear. However, in non-neuronal tissue SYT III has an established role in 
the regulation of insulin secretion and interestingly appears to be crucial for the formation of 
recycling endosomes. Numerous studies have demonstrated that the SYT III protein is likely 
to undergo extensive post-translational modifications as its reported molecular weight varies 
considerably between cell types.  
 
8.3.2 SYTIII-EGFP Over-Expression ELISAs: 
 
 Over-expressed SYTIII-EGFP localizes to the plasma membrane, TGN, and 
endosomal system in our model endothelial cells (see Chapter 4). Therefore endogenous SYT 
III is probably not located in a subcellular position which would allow it to regulate the 
exocytosis of WPBs and therefore is unlikely to be the calcium sensor responsible for 
governing this process. In order to test this hypothesis over-expression VWF and proregion 
ELISAs were performed using the SYTIII-EGFP construct. Representative assays are shown 
in Figure 8.5. No significant differences in the secretion of either VWF or proregion between 
HUVECs expressing SYTIII-EGFP and those expressing the control construct YFP are 
apparent, indicating that the up-regulation of SYT III does not influence the exocytosis of 
WPBs from HUVECs.  
 
8.4 The Function of SYT VI in HUVECs: 
 
8.4.1 Background Information: 
 
8.4.1.1 The Subcellular Localization and Physical Properties of SYT VI:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 8.5. SYT III up-regulation does not affect the exocytosis of WPBs. 
HUVECs were transfected with either SYTIII-EGFP or YFP. Media and lysates were 
collected from cells after eight hours and processed for VWF and proregion ELISAs. Cells 
incubated with a control non-stimulating solution provided the data for basal secretion. Cells 
incubated with 1 µM ionomycin provided the data for stimulated secretion. Panel (i) shows 
the quantity of VWF released as a percentage of the total quantity of VWF in the cells. Panel 
(ii) shows the quantity of proregion released as a percentage of the total quantity of 
proregion in the cells. No significant differences in the extent of WPB secretion are apparent 
between cells expressing SYTIII-EGFP and those expressing YFP. Black bars represent 
YFP-transfected cells. Hatched bars represent SYTIII-EGFP-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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First identified in the adult mouse cerebellum in 1999, SYT VI is unique among the  
SYT family members in that its major isoform does not contain a transmembrane domain and 
therefore is not an integral membrane protein (Fukuda and Mikoshiba, 1999). Specifically, 
the major splice variant of SYT VI lacks the last 85 amino acids of the N-terminus which 
normally constitute the SYT transmembrane domain and therefore is designated SYTVIΔTM. 
This major isoform accounts for 85% of SYT VI transcripts in the rodent cerebellum, while 
three additional splice variants make up the remaining 15% (Fukuda and Mikoshiba, 1999). 
The two shorter isoforms are produced by alternative splicing of the transmembrane domain 
and ultimately encode the same protein product.  
SYT VI derived from the adult mouse brain is visible on a Western blot as two 
closely-related bands of approximately 50 kDa (Fukuda and Mikoshiba, 1999). Following the 
subcellular fractionation of the mouse olfactory bulb, these two bands are seen in both the 
membrane and soluble fractions and can be eliminated from the membrane fraction by prior 
incubation with 1M NaCl buffer (Butz et al. 1999, Fukuda and Mikoshiba, 1999). The 
appearance of two distinct bands may be due to either the alternative splicing of the 
cytoplasmic domain of SYT VI or may be the result of post-translational modifications to the 
same protein product. Following its over-expression in COS-7 cells, full-length 
transmembrane SYT VI appears as a band of 58 kDa on Western blots (Fukuda and 
Mikoshiba, 1999).  
The tissue distribution and subcellular localization of SYT VI are currently unclear 
and most likely vary depending on the isoform in question. SYT VI is most prominently 
expressed in the thymus (Craxton and Goedert, 1999). Additionally, SYT VI mRNA is found 
at low levels throughout the brain with the highest levels of expression reported in the 
olfactory bulb (Butz et al. 1999). In hippocampal neurons, over-expressed pHluorin-SYTVI 
is found in both axons and dendrites where it localizes to the plasma membrane and internal 
vesicles (Dean et al. 2012). In both PC12 and COS-7 cells, over-expressed SYTVIΔTM 
localizes primarily to the internal and plasma membranes, although a proportion of the 
protein is found in the cytosol. In contrast, the full-length protein is trafficked to the ER and 
to the Golgi (Fukuda and Mikoshiba, 1999). This observation was confirmed in a later study 
which reported the localization of SYTVI-GFP to the ER in PC-12 cells (Saegusa et al 2002). 
These subcellular localization studies have demonstrated that, in spite of its lack of either a 
transmembrane domain or N-terminal palmitoylation sites, SYT VI is able to interact with 
internal membranes. It is now known that this ability is the result of the final 29 amino acids 
of the SYT VI C-terminus, as the removal of these residues by deletion mutagenesis impairs 
the membrane association of SYT VI by 60% (Fukuda and Mikoshiba, 1999). Additionally, it 
is likely that interactions between the C2 domains and negatively-charged phospholipids 
contribute to the ability of SYTVIΔTM to bind to internal membranes.  
Due to its lack of a transmembrane domain, the SYT VI protein displays unique 
physical properties compared with other members of the SYT family. For example, 
SYTVIΔTM is unable to dimerize with SYTs III, V, VI, or X because it lacks the crucial N-
terminal region required for dimerization (Fukuda and Mikoshiba, 1999). It is also unable to 
interact with full-length versions of itself or with any other cysteine-containing SYTs even in 
the presence of high Ca
2+
 concentrations. The only exception to this was a weak interaction 
formed with SYT X. Like many other members of the SYT family, the C2B domain of SYT 
VI does show weak IP4 binding activity (Ibata et al. 1998). 
 
8.4.1.2 SYT VI and Acrosome Exocytosis from Sperm Cells: 
 
The majority of the work examining the subcellular localization and function of SYT 
VI has been performed in human sperm cells and involves the exocytosis of the acrosome. 
The acrosome is a single large secretory granule containing the degradative enzymes 
hyaluronidase and acrosin. Following the binding of receptors on the sperm plasma 
membrane with components of the egg’s zona pellucida, the acrosome membrane fuses with 
the plasma membrane and releases its degradative contents into the hard shell surrounding the 
egg. It is now known that SYT VI is heavily involved in the regulation of this Ca
2+
-dependent 
process.  
The SYT VI protein is present in human sperm cells, appearing as a band of 66 kDa 
on Western blots, and ICC has shown that SYT VI localizes to the outer acrosomal 
membrane (Michaut et al. 2001). Both an anti-SYT VI antibody and a fusion protein 
containing the SYT VI C2 domains are able to inhibit acrosome exocytosis when applied to 
permeabilized sperm cells. However, the phosphorylation of this fusion protein by phorbyl 
esters abolishes its ability to inhibit exocytosis, suggesting that the phosphorylation of SYT 
VI plays a role in the regulation of its function. Indeed, recombinant SYT VI is 
phosphorylated in vitro following its incubation with PKC and PMA. 
 The signalling pathways regulating the SYTVI-induced fusion of the acrosome with 
the plasma membrane have been studied extensively in recent years. It is now know that each 
of the SYT VI C2 domains can block the exocytosis of the acrosome, as when either the C2A 
or C2B domain is expressed individually in spermatozoa exocytosis is inhibited (Roggero et 
al. 2005). However, individual domains expressed in isolation have a 5-fold lower potency 
than both C2 domains expressed together, suggesting that the two domains play a role in the 
initiation of acrosome exocytosis. The ability of the C2 domains of SYT VI to block 
acrosome exocytosis can be inhibited by their prior phosphorylation with purified PKCβII 
(Roggero et al. 2005). Likewise, the inhibitory effect of phosphorylation is abolished by 
incubation with the PKC-inhibitor chelerythrine indicating that, as previously suggested 
(Michaut et al. 2001) PKC is required for the phosphorylation of SYT VI. Indeed, it is now 
known that endogenous SYT VI is phosphorylated in the acrosome region in unstimulated 
sperm cells, and an antibody against phosphorylated SYT VI is able to block acrosome 
exocytosis (Roggero et al. 2005). Interestingly, as the process of acrosome secretion proceeds 
the level of phosphorylated SYT VI decreases and the antibody against phosphorylated SYT 
VI is only inhibitory at early time-points in the acrosome reaction. In contrast, an antibody 
which recognizes both phosphorylated and dephosphorylated SYT VI is inhibitory 
throughout the secretory reaction. Therefore, in resting cells, SYT VI is phosphorylated by 
PKC and this appears to inhibit the fusion of the acrosome with the plasma membrane. 
However, following stimulation, SYT VI is dephosphorylated, allowing the exocytic reaction 
to proceed.  
The sites of phosphorylation in the C2B domain of SYT VI have been identified by 
site-directed mutagenesis as Thr418 and Thr419, which are found in the fourth β-strand of the 
highly-conserved polybasic region (Roggero et al. 2005). The mutation of these two residues 
to glutamine abolishes the inhibitory effect of the recombinant SYT VI peptide. It is 
interesting to consider that the fourth β-strand of the polybasic region is a so-called ‘effector 
region’ and binds to a number of target molecules including inositol polyphosphates, PIP2, 
SNAREs, and AP2. It is also an essential region for mediating oligomerization in other SYT 
family members. Hence, the phosphorylation state of this region would have significant 
implications for the overall function of the SYT VI protein. The phosphorylation site in the 
SYT VI C2A domain has been identified as Thr284. Although this residue is also found 
within a polybasic region, it is unclear what direct functional consequences its 
phosphorylation would have on the activity of the SYT VI protein.  
It has now been established that the dephosphorylation of the SYT C2B domain 
during the early stages of acrosome exocytosis occurs as a result of the actions of calcineurin, 
a Ca
2+
-dependent serine/threonine phosphatase, as an antibody against the α-subunit of 
calcineurin is able to inhibit exocytosis (Bennett et al. 2010). The dephosphorylation of SYT 
VI is vital for successful acrosome fusion, as the calcineurin inhibitor cyclosporin A inhibits 
exocytosis whereas the over-expression of a catalytically-active version of calcineurin 
rescues this effect. This calcineurin variant also dephosphorylates the C2B domain of SYT VI 
in an Mn
2+
-dependent manner in an in vitro model of exocytosis. The dephosphorylation of 
SYT VI by calcineurin must occur within a specific window of time, as shown by the 
observation that if sperm cells are treated with catalytically-active calcineurin before 
ionomycin stimulation then the exocytosis of the acrosome is inhibited. Therefore the 
premature dephosphorylation of SYT VI inhibits exocytosis. The addition of phosphorylated 
SYT VI C2B domain restores acrosome exocytosis, indicating that SYT VI plays an active 
role in the instigation of fusion. Indeed, phosphorylated SYT VI may prevent the premature 
formation of the trans-SNARE complex whilst the dephosphorylation of SYT VI allows the 
assembly of the fusion apparatus.  
Lastly, it has been reported that the dephosphorylation of the SYT VI C2B domain 
modulates a complexin/SYT VI interaction which regulates the exocytosis of the acrosome 
(Roggero et al. 2007). Complexins bind to SNARE complexes by inserting as an antiparallel 
α-helix between the synaptobrevin and syntaxin helices. They can have both inhibitory and 
activating roles in relation to secretory events. It is thought that SYT I can displace 
complexins from the SNARE apparatus in a Ca
2+ 
-dependent manner, allowing the exocytosis 
of docked granules to proceed. It is currently unclear which complexins are expressed in 
human sperm cells, although it is known that antibodies against complexin I and II are able to 
inhibit acrosome exocytosis. The addition of both the C2B domain of SYT VI and an α-
complexin antibody blocks the formation of the trans-SNARE complex in human 
spermatozoa. This can be reversed by adding back complexin. However, as with 
dephosphorylation this effect appears to be time-dependent as the addition of complexin 
blocks exocytosis once the SNAREs have formed the trans-complex. This in-turn is relieved 
by the addition of the SYT VI C2B domain and Ca
2+ 
ions. Therefore, complexins and SYT 
VI form an active complex which regulates acrosome exocytosis, and indeed it is possible 
that SYT VI may function to displace complexins from the fusion apparatus, allowing 
secretion to proceed. This ability is dependent on the dephosphorylation of SYT VI, as the 
addition of either phosphorylated wild-type SYT VI or a phosphomimetic variant blocks the 
ability of SYT VI to displace complexin.  
The data discussed here has presented a model whereby SYT VI regulates the 
exocytosis of the acrosome from sperm cells through a balance between its phosphorylation 
by PKC and dephosphorylation by calcineurin (Michaut et al. 2001, Roggero et al. 2005, 
Roggero et al. 2007, Bennett et al. 2010). This model is summarized in Figure 8.6. Indeed, 
this work has generated the clearest example of how phosphorylation can influence the 
function of a member of the SYT family, and it is likely that other SYTs are regulated in a 
similar manner. 
 
8.4.2 SYTVI-EGFP Over-Expression ELISAs: 
 
In order to test if the up-regulation of SYT VI affects the exocytosis of WPBs from 
HUVECs VWF and proregion ELISAs were performed using samples derived from SYTVI-
EGFP- and YFP-transfected cells. Representative assays are shown in Figure 8.7. As can be 
seen, the expression of SYTVI-EGFP does not affect the secretion of either VWF or 
proregion from HUVECs compared with the expression of YFP. Hence SYT VI is unlikely to 
be involved in the regulation of WPB exocytosis from endothelial cells.  
 
8.5 The Function of Synaptotagmin XI in HUVECs: 
 
8.5.1 Background Information: 
 
 There is currently little known regarding the distribution and function of the 431-
amino acid protein sensor SYT XI. This Ca
2+
-independent member of the SYT family was 
first characterized in 1997 where it was reported to contain two cytoplasmic C2 domains as is 
characteristic of the SYT family. However, due to a mutation to one of the essential Ca
2+
-
coordinating aspartates in the C2A domain it is unable to bind Ca
2+
 ions (van Poser et al. 
1997). Like SYT IV, SYT XI cannot bind phospholipids in a Ca
2+
-dependent manner, and 
therefore is considered to be Ca
2+
-independent. SYT XI is expressed at high levels in the 
brain and at low levels in most other tissues (van Poser et al. 1997). The intracellular 
distribution of SYT XI is currently unclear, although in transfected PC12 cells a fluorescent 
construct containing SYT XI cDNA was shown to localize to the Golgi network (Fukuda and 
Mikoshiba, 2001), and in hippocampal neurons a pH-sensitive variant of SYT XI localizes to 
the dendrites (Dean et al. 2012). A single paper has suggested its function may be as an 
inhibitor of fast pre-synaptic neurotransmission (Wang et al. 2001), although no information 
to support this hypothesis has been provided in recent years.  
Most interest in the SYT XI gene and its protein product stems from the reported 
associations between human psychiatric disorders and the expression and intracellular 
interactions of SYT XI. Indeed, SYT XI is known to interact with parkin, a protein implicated  
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6. SYT VI regulates the exocytosis of the acrosome from sperm cells. 
A model explaining the activity of the SYT VI protein in the regulation of acrosome 
exocytosis from human sperm cells is shown. In the resting cell, SYT VI is phosphorylated by 
PKC and acts as an inhibitor of exocytosis. However following the stimulation of the 
spermatozoa by contact with the zona pellucida the concentration of Ca
2+
 in the cytoplasm 
increases, resulting in the activation of calcineurin and the dephosphorylation of SYT VI. 
Dephosphorylated SYT VI is able to displace complexin from the ternary SNARE complex, 
allowing the formation of the trans-SNARE complex and the fusion of the acrosome 
membrane with the plasma membrane.  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7. SYT VI up-regulation does not affect the exocytosis of WPBs. 
HUVECs were transfected with either SYTVI-EGFP or YFP. Media and lysates were collected 
from cells after forty-eight hours and processed for VWF and proregion ELISAs. Cells 
incubated with a control non-stimulating solution provided the data for basal secretion. Cells 
incubated with 1 µM ionomycin provided the data for stimulated secretion. Panel (i) shows the 
quantity of VWF released as a percentage of the total quantity of VWF in the cells. Panel (ii) 
shows the quantity of proregion released as a percentage of the total quantity of proregion in the 
cells. No significant differences in the extent of WPB secretion are apparent between cells 
expressing SYTVI-EGFP and those expressing YFP. Black bars represent YFP-transfected cells. 
Hatched bars represent SYTVI-EGFP-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual experiments 
performed on separate vials of HUVECs. 
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in the pathogenesis of Parkinson’s disease. Parkin is a ubiquitin ligase and is involved in the 
targeting of misfolded proteins for destruction via the proteasome complex. Mutations in the 
parkin gene can lead to autosomal recessive Parkinson’s disease. It has been demonstrated by 
co-immunoprecipitation and yeast two-hybrid analysis that parkin can bind to SYT XI via its 
C2A and C2B domains (Huynh et al. 2003). This interaction results in the ubiquitination of 
SYT XI, and indeed mutations in the parkin gene can lead to a reduced binding affinity for 
and decreased ubiquitination of SYT XI. In both PC12 cells and cells of the human substantia 
nigra, SYT XI and parkin were found co-localized at the nuclear membrane and perinuclear 
area. Interestingly, ICC of brain sections from patients suffering from sporadic Parkinson’s 
disease showed that SYT XI is localized to Lewy bodies. It has been suggested that SYT XI 
may be involved in synaptic vesicle trafficking due to the link between its accumulation in 
Lewy bodies and the subsequent dysregulation of dopaminergic neurons in the substantia 
nigra (Huynh et al. 2003).  
The human SYT XI gene is located on chromosome 1q21-22 and consists of 4 exons 
(Yokota et al. 2003). Immediately upstream of the SYT XI gene there exists a tandem repeat 
of a 33 base-pair sequence which has promoter-like activity (Yokota et al. 2003).  The 
transfection of constructs containing different numbers of tandem repeats placed immediately 
upstream of the reporter gene firefly luciferase into COS-1 cells demonstrated that the 
promoter-like activity of this region increases in a linear fashion with the increasing number 
of repeats.  This region upstream of the SYT XI gene has been loosely linked to familial 
schizophrenia, as within a sample of 60 Japanese schizophrenia patients two showed 
polymorphisms in this region whereas no polymorphisms were reported in a pool of 68 
healthy individuals (Yokota et al. 2003). Recently, this work has been extended and it has 
been demonstrated that the overexpression of SYT XI is associated with the development of 
schizophrenia (Inoue et al. 2007). This was shown using a larger sample size of 227 Japanese 
schizophrenic patients versus 198 healthy controls. As previously reported, an increasing 
number of tandem repeats in the region upstream of the SYT XI gene leads to the increased 
transcription of the gene. This is most likely due to a stronger interaction with the 
transcription factor Sp 1. Additionally, a SNP (T/C) in the SYT XI 5’ un-translated region 
has been identified which is now known to influence the level of transcription of SYT XI 
independently of the number of tandem repeats in the upstream region (Inoue et al. 2007). 
This SNP is located within the binding sequence for the transcription factor YY1, and indeed 
gel mobility shift assays revealed that YY1 binds to the cytosine genotype of the SNP with a 
four-fold higher affinity than the thymine genotype. However, no significant association was 
found between this SNP and the development of schizophrenia. 
Therefore, the true function of the SYT XI protein and its intracellular localization in 
healthy tissue are not known. However, current interest in this protein stems from its possible 
links with psychiatric disorders such as Parkinson’s disease and schizophrenia. It is 
noteworthy that the closest relative of SYT XI, SYT IV, has also been associated with the 
development of psychiatric diseases (Ferguson et al. 2001). 
 
8.5.2 SYTXI-EGFP Over-Expression ELISAs: 
 
 In order to investigate the possibility that SYT XI may be involved in the secretion of 
WPBs from HUVECs over-expression VWF ELISAs were performed using the SYTXI-
EGFP construct. The results of a representative assay are shown in Figure 8.8. As can be 
seen, no significant differences are apparent between the quantity of VWF secreted from cells 
expressing SYTXI-EGFP compared with those expressing the control construct YFP. 
Therefore, at this point it would appear that SYTXI-EGFP over-expression does not affect the 
quantity of VWF released from HUVECs following ionomycin stimulation.  
.  
8.6 The Roles of SYTs I, III, VI, and XI in Human Endothelial Cells: A Discussion 
 
8.6.1 The Role of SYT I: 
 
SYT I is the most well-characterized member of the SYT family and has a proven 
fundamental role in the regulation of fast synaptic transmission in neurons. Here, I have 
shown that SYT I is expressed in endothelial cells as both an mRNA transcript and as a 
protein. Additionally, over-expressed SYTI-mCherry localizes to the plasma membrane and 
lysosomes in HUVECs. The fact that SYT I localizes to the plasma membrane when up-
regulated in HUVECs led me to believe that this member of the SYT family is involved in 
mediating WPB exocytosis as it has been suggested that different members of the SYT family 
located on closely-positioned but opposing membranes can form oligomers which contribute 
to the formation of the fusion pore in a similar manner to SNARE proteins (Sujita et al. 2001, 
Sudhof 2002, Gerber and Sudhof, 2002). Therefore, endothelial SYT I may be located in an 
ideal subcellular position to allow it to regulate WPB fusion as a plasma membrane SYT. 
However, functional studies involving both over-expression and knock-down ELISAs 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
suggested that SYT I plays no role in mediating the exocytosis of WPBs as no effect on the 
secretion of either VWF or proregion was seen following the up-regulation or inhibition of 
SYT I in HUVECs. This observation was not entirely surprising as SYT I is a low-affinity 
calcium sensor which is specialized for fast synaptic transmission. This is contrast to the 
relatively slow release kinetics of large dense-core vesicles such as WPBs. Additionally, SYT 
I is primarily expressed in neuronal cells where its role in synaptic transmission has been well 
Figure 8.8. SYT XI up-regulation does not affect the exocytosis of WPBs. 
The results of a representative experiment examining the effects of SYTXI-EGFP over-
expression on VWF secretion are shown.  Media and lysate were collected from cells 
expressing either SYTXI-EGFP or a cytoplasmic control construct (YFP) and a VWF 
ELISA was performed. The graph shows the quantity of VWF released as a percentage of 
the total quantity of VWF in the cells. Cells incubated with a control non-stimulating 
solution provided the data for the basal release of VWF. Cells incubated with 1 µM 
ionomycin provided the data for the stimulated release of VWF. Black bars represent 
YFP-transfected cells. Hatched bars represent SYTXI-EGFP-transfected cells.  
n/s = non-significant (p-value › 0.05) 
n = 3 replicates from one vial of HUVECs; data is representative of 3 individual 
experiments performed on separate vials of HUVECs. 
 
 
established. In contrast its role in non-neuronal secretory tissue is more unclear. With this in 
mind and considering the functional studies performed here I will discount this member of 
the SYT family as a potential candidate for the role of the calcium sensor regulating WPB 
release at the plasma membrane. However, definitive proof would be provided by repeating 
these biochemical assays using endothelial cells isolated from SYT I 
-/-
 embryonic mice as 
these reagents are widely available.  
 
8.6.2 The Role of SYT III: 
 
 The absence of SYT III from WPBs implies that this member of the SYT family is not 
involved in mediating the Ca
2+
-dependent exocytosis of these organelles. Over-expression 
ELISAs using the SYTIII-EGFP construct confirmed this theory as the up-regulation of SYT 
III does not affect the release of either VWF or proregion from stimulated HUVECs. 
Therefore this member of the SYT family will be discounted as a possible candidate for the 
role of the calcium sensor mediating WPB exocytosis. However, as mentioned (Chapter 4) 
the work done here suggests that SYT III may play an essential role in the formation of 
recycling endosomes in HUVECs. Future work could focus on testing this hypothesis with 
knock-down and mutagenesis studies. Specifically, it would be of interest to determine the 
effect of the loss of a functional SYT III protein on the distribution of rab11 and the 
morphology of endocytic granules in HUVECs. The generation of a SYT III 
-/-
 mouse would 
also prove indispensable for the investigation of the true function of this member of the SYT 
family in endothelial cells and in other cell types, particularly in neurons.  
  
8.6.3 The Role of SYT VI: 
 
The work presented in the previous chapters has demonstrated that SYT VI is found 
as both an mRNA transcript and as a protein in human endothelial cells. The subcellular 
localization of SYT VI in HUVECs is currently unclear as the endogenous protein is found 
predominately as a component of the early endosomes whereas over-expression studies using 
the SYTVI-EGFP construct indicated that over-expressed SYT VI localizes to the 
endoplasmic reticulum and plasma membrane. However, what is clear is that SYT VI is not 
found as a component of the WPBs and therefore is unlikely to be involved in the regulation 
of their Ca
2+
-mediated fusion with the plasma membrane. This hypothesis was strengthened 
by the observation that the over-expression of SYTVI-EGFP in HUVECs does not affect the 
secretion of either VWF or proregion from transfected cells compared with YFP-expressing 
control cells. Therefore, this work will conclude that SYT VI is not involved in the regulation 
of WPB exocytosis from HUVECs but rather plays another role in endothelial cell biology. It 
would be of interest to determine precisely which isoforms of SYT VI are expressed in 
HUVECs using variant-specific PCR in the future. Once the number and identity of the 
isoforms expressed in HUVECs have been established, a series of SYTVI-EGFP vectors 
could be generated from HUVEC cDNA. These reagents could be used to determine the true 
extent of the subcellular localization of the SYT VI protein(s) as it is likely that each isoform 
displays a unique distribution pattern. Future work to determine the role of SYT VI in 
HUVECs could involve knock-down or mutagenesis studies, and as a long-term project a 
SYTVI-KO mouse would prove insightful as to the function of this poorly-characterized SYT 
in many different cell types. However, this is of course beyond the scope of this project.  
  
8.6.4 The Role of SYT XI: 
 
 SYT XI is a ubiquitously-expressed Ca
2+
-insensitive member of the SYT family. 
Although the SYT XI gene has been loosely linked with the development of human 
psychiatric disorders the function of the SYT XI protein is currently unknown. Here, I have 
demonstrated that SYT XI mRNA is present in HUVECs and have attempted to determine 
the subcellular localization and function of this SYT isoform in our model endothelial cells.   
  Over-expression VWF ELISAs have demonstrated that SYT XI up-regulation in 
HUVECs does not affect WPB exocytosis in response to stimulation by 1 µM ionomycin. 
This was not entirely unexpected as due to its Golgi distribution the SYT XI protein is not in 
a subcellular location which would allow it to regulate the fusion of WPBs with the plasma 
membrane. However SYT XI may be involved in mediating the biosynthesis of WPBs at the 
Golgi although ICC revealed that WPBs in SYTXI-EGFP transfected cells appear 
morphologically normal. Therefore, SYT XI most likely plays an as-yet unidentified role in 
endothelial cell biology and may be involved in either the formation of subcellular vesicles or 
the fusion of recycling vesicles returning cargo to the TGN.  
 Future work attempting to determine the role of this Ca
2+
-insensitive member of the 
SYT family could focus on mutagenesis or knock-down studies. I took the decision not to 
pursue these avenues for the purposes of this investigation. Equally, live-cell imaging using 
over-expressed SYTXI-EGFP would provide a definitive answer to the question as to 
whether or not SYT XI is involved in WPB exocytosis, as over-expression ELISAs are 
always limited by the transfection efficiency of the over-expressed construct. Finally, it 
would be of general interest to generate a SYT XI knock-out mouse to determine if this 
animal shows any obvious phenotypic abnormalities, particularly a higher susceptibility to 
developing symptoms resembling human psychiatric disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9 
Final Discussion 
 
Over the course of my project I have attempted to determine the identity of the 
calcium sensor responsible for mediating the Ca
2+
-induced exocytosis of WPBs from human 
endothelial cells. It is my hypothesis that this process is regulated by one or more members of 
the SYT family as this group of proteins has been shown to have an extensive and 
fundamental role in the regulation of secretory events from a vast range of cell types. In this 
thesis, I have provided evidence demonstrating that SYTs I, III, V, VI, VII, VIII, XI, and 
XVII can be found as mRNA transcripts in our model endothelial cells. I have also shown 
that the majority of these SYTs are found as proteins in HUVECs. Unfortunately, for the 
most part my attempts to determine the endogenous distribution of the endothelial-expressed 
SYTs by ICC were unsuccessful. Therefore I constructed a series of fluorescent fusion 
proteins which were over-expressed in HUVECs with the aim to determine the subcellular 
distribution of the SYTs in our model endothelial cells. The results of this work are 
summarized in full in Table 4.2. Of particular note, I detected the presence of SYTs V, VII, 
VIII, and XVII on WPBs and as a result of these observations the majority of the functional 
studies described here focused on characterizing the role of these four members of the SYT 
family in endothelial cells. Indeed, my principal molecule of interest was SYT VII as this 
highly-conserved protein has a well-established role in regulating the Ca
2+
-mediated 
exocytosis of large secretory organelles from a range of cell types (Andrews and Chakrabarti, 
2005). Through the use of a novel dose-response assay I was able to demonstrate that SYT 
VII does indeed play a role in the regulation of WPB exocytosis by mediating the calcium 
sensitivity of secretion. Additionally, over-expression ELISAs suggested a more unclear role 
for SYTs V and XVII in the regulation of VWF secretion from HUVECs which warrants 
further investigation. Lastly, it is noteworthy that I have demonstrated the expression and 
surprisingly extensive distribution of SYT XVII in endothelial cells as to my knowledge this 
will be the first study attempting to characterize the tissue distribution, subcellular 
localization, and function of this newest member of the SYT family.  
As would be expected I encountered a number of challenges over the course of this 
project. Firstly, as documented I have been unable to determine the endogenous distribution 
of the SYTs in HUVECs as commercial antibodies are unable to recognize SYT protein by 
ICC under the conditions used in our laboratory. It is possible that members of the SYT 
family are expressed in endothelial cells at a level which falls below the detection criteria of 
the antibodies or it may be that the particular SYT isoforms expressed in HUVECs are not 
recognized by the commercial antibodies, most of which have been developed using one 
common variant of their target protein. Another possibility is that in resting HUVECs the 
SYTs exist as a complex with other molecular mediators of exocytosis and are therefore 
inaccessible to their antibodies. It should be noted that this inability to detect endogenous 
SYTs by ICC is commonplace in the literature and therefore the majority of investigators opt 
for the over-expression of fluorescent fusion proteins to determine the distribution of the 
SYTs in their cells of interest. This was the path I took although it would also have been 
possible to personally design and manufacture variant-specific antibodies once the full 
sequences of the endothelial-expressed SYTs had been established. However, due to the 
number of proteins under investigation in this report I have been unable to attempt this in the 
time available. In the future it would be of particular interest to design non-commercial 
antibodies against SYTs V, VII, VIII, and XVII to confirm that these proteins do indeed 
localize endogenously to the WPBs as has been strongly suggested by the over-expression 
studies performed here.  
 A particularly time-consuming obstacle to my progress was my failure to generate 
SYT-EGFP fusion vectors using conventional cloning techniques dependent on enzyme-
driven ligation. Despite repeated attempts to troubleshoot the cloning protocol I was 
consistently unable to clone SYT cDNA into parent EGFP vectors. This inhibited my 
progress for some time as without these reagents I was unable to determine the distribution of 
the endothelial-expressed SYTs. Therefore I attempted a novel ligation-independent cloning 
(LIC) method which by-passed the need for restriction and ligation enzymes. This method 
proved extremely effective and I was able to generate SYT-EGFP fusion vectors. These new 
tools enabled me to determine the distribution of the SYTs in HUVECs which in turn allowed 
the identification of strong candidates for the role of the calcium sensor regulating WPB 
release on which I based my functional studies.  Of course, care must be taken with the 
interpretation of these observations as the distribution of over-expressed SYT protein may not 
necessarily be representative of that of the endogenous protein. However, in most cases my 
findings have been consistent with published studies examining the distribution of SYTs in 
other cell types. Additionally, this systematic screening approach involving the expression of 
GFP-tagged protein has proved successful for determining the distribution of Rab proteins in 
PC12 cells (Tsuboi and Fukuda, 2006) and HUVECs (Zografou et al. 2012). 
 An essential component of the functional studies performed here was the use of 
siRNA to eliminate SYT mRNA from HUVECs with the aim to determine the effects of the 
knock-down of individual SYTs on WPB exocytosis. However, in most cases the 
quantification of the knock-down effect was challenging as I was unable to use ICC to 
demonstrate the loss of endogenous protein in fixed cells. Instead, I relied on Western 
blotting which was in turn complicated by the difficulty in visualizing SYT protein by 
immunoblotting and by the simultaneous expression of multiple SYT variants in HUVEC 
lysate. It would have been possible to use real-time PCR (Q-PCR) to determine the exact 
extent of mRNA knock-down in HUVECs. However, this method would not provide a 
reliable estimate of the extent of protein knock-down as it is likely that each SYT variant has 
a different degree of stability in endothelial cells. In order to determine the absolute effect of 
the knock-down of the SYT family members on WPB exocytosis it would be essential to 
produce or obtain SYT 
-/- 
mice, as only this approach would allow the complete elimination 
of all variants of each SYT from endothelial cells. These reagents are available for a small 
number of the SYT family members and I have trialed methods for isolating and culturing 
endothelial cells derived from murine lung tissue. The long-term goal of this was to establish 
a colony of SYT VII 
-/-
 mice which would provide a source of SYT VII 
-/- 
endothelial cells for 
future experiments. In the immediate future it would be of interest to perform double knock-
out experiments as members of the SYT family are known to function both cooperatively and 
redundantly to regulate secretory events (Lynch and Martin, 2007, Nishiki and Augustine, 
2004). It would be of particular interest to selectively eliminate combinations of the WPB-
localized SYTs to determine if this additive approach yields a greater functional effect than 
the single knock-outs performed here.  
 The majority of the functional studies described in this report relied upon the over-
expression of SYT-EGFP constructs and therefore have limitations of their own. In most 
cases the transfection efficiency of the construct was poor with the majority of transfected 
HUVECs failing to express the ectopic DNA. A possible solution to this would have been to 
differentiate between expressing and non-expressing HUVECs through cell sorting by flow 
cytometry using an α-GFP antibody. However, it would be of greater importance and more 
efficient to perform live-cell imaging experiments using HUVECs over-expressing the SYT-
EGFP constructs. This would allow the accumulation of real-time kinetic data on a single-cell 
level and would provide an accurate measure of the effect of the up-regulation of the SYT 
family members on both the rate and extent of WPB exocytosis from HUVECs. However, in 
order to perform these assays it was essential to create either red-fluorescent versions of my 
EGFP-tagged SYT constructs or develop a red-fluorescent pH-sensitive marker of WPBs. To 
this aim I have attempted to create a construct consisting of the WPB-resident protein 
proregion coupled to the novel pH-sensitive red fluorescent proteins Fuji and pH Tomato 
(both a kind gift from Professor Robert E. Campbell of the University of Alberta) with the 
aim to use these reagents to selectively mark WPBs in transfected cells. However this has 
been unsuccessful thus far.  
As a final point, all of the secretion assays performed here have utilized the non-
physiological reagent ionomycin to induce WPB exocytosis. The mechanism of action of 
ionomycin in endothelial cells is currently unclear although it is known to induce a reversible 
biphasic increase in the cytoplasmic Ca
2+
 concentration, with the initial spike resulting from 
the release of Ca
2+ 
ions from intracellular stores and the second, more-sustained increase 
resulting from the influx of Ca
2+ 
across the plasma membrane in response to store depletion 
(Morgan and Jacob, 1994). Indeed, rather than induce uncontrolled Ca
2+
 influx across the 
plasma membrane ionomycin mimics the endogenous signaling pathways initiated by 
physiological agonists such as histamine (Morgan and Jacob, 1994). However, ionomycin 
does induce a stronger secretory response from HUVECs than histamine and so it is possible 
that it triggers the release of a reserve pool of WPBs which is not accessible to physiological 
agonists (Erent et al. 2007). It may also be the case that ionomycin exposure results in the 
loss of the spatial control of WPB exocytosis as a more global response to stimulation would 
be induced compared to that initiated by receptor-based signaling pathways. These 
considerations may be relevant to the work described here as the WPB-localized SYTs may 
specifically label distinct subpopulations of granules. For example, a cursory examination of 
the subcellular distribution of over-expressed SYTVIII-EGFP in HUVECs suggests that this 
construct might preferentially localize to rounder granules and so may influence WPB 
morphology, perhaps through the recruitment of other membrane proteins during granule 
formation at the TGN. The rigorous analysis of the distribution of over-expressed SYTs in 
HUVECs may identify certain WPBs which are labeled by specific SYTs, such as those 
which form the RRP or those which contain certain subsets of cargo proteins. Equally, more 
detailed investigations into the morphology of WPBs in HUVECs which have been treated 
with SYT siRNA may reveal subtle changes in granule size and shape. Therefore it would be 
of interest, firstly, to repeat the secretion assays performed here with a physiological agonist 
such as histamine to determine the reproducibility of the ionomycin-induced stimulation data, 
and secondly to perform an analysis of the spatial distribution of the SYTs in HUVECs and 
the specific features of the granules to which they preferentially localize.   
  It is my hope that this work will prove of general interest to those working in the field 
of regulated exocytosis and its control by the SYT family. Additionally, my observations 
have provided a solid foundation on which future investigations aiming to further 
characterize the role of the SYT family in the control of WPB exocytosis can be based. 
However, it is essential to consider that WPB exocytosis may well be regulated by a family 
of calcium sensors entirely separate to the SYTs, and other possible candidates for the role of 
the Ca
2+
 sensor include but are not limited to the annexins, the Doc2 proteins, MCTPs, 
copines, the VP115 family, and the ferlins (for reviews describing these protein families see 
Burgoyne and Morgan, 1998, Sudhof 2002, and Pang and Sudhof, 2010). Indeed, I have 
demonstrated by PCR that HUVECs express Doc2A and Doc2B (data not shown) in addition 
to the eight SYTs described here. However, the SYT family is the most well-characterized 
group of calcium sensors with a fundamental role in the regulation of Ca
2+
-mediated 
exocytosis, and given the extensive expression of the SYTs in HUVECs I have limited my 
investigations to this collection of Ca
2+
-binding proteins.  
 In conclusion, over the course of this thesis I have described my attempts to determine 
the identity of the Ca
2+
 sensor regulating WPB exocytosis from human endothelial cells. 
WPBs are specialized secretory organelles which have considerable clinical relevance, being 
implicated in the pathology of atherosclerosis, thrombosis, and malaria. Additionally, in 
recent years exciting new links between WPB exocytosis and the development of multiple 
sclerosis, the recruitment of stem cells, and the metastasis of cancerous cells have been 
proposed. With this in mind it is essential to fully understand the mechanisms of WPB 
exocytosis with the aim that this process may be manipulated in the future for the benefit of 
human health. Finally, WPBs provide an excellent general model of regulated exocytosis and 
therefore insights into how this process is controlled at the molecular level can be applied to 
other secretory systems in order to better understand this fundamental aspect of cell biology.  
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Appendix 1.0: The Creation of the Dose-Response Curve of Proregion Secretion Against 
Ionomycin Concentration: 
 
1.0 Designing a suitable assay: 
 
 In order to determine if the calcium sensitivity of WPB exocytosis is affected by the 
over-expression or knock-down of individual SYTs it was necessary to construct a dose-
response curve describing the exocytosis of proregion in response to varying concentrations 
of agonists. For this assay I used a proregion ELISA and un-transfected HUVECs stimulated 
with increasing concentrations of the calcium ionophore ionomycin. Ionomycin elicits the 
rapid, sustained, and reliable secretion of WPBs from HUVECs, and therefore will provide 
the sensitivity required for these experiments.  
Initially, it was necessary to determine the optimum design of this assay. I had the 
option of using either 6-well or 24-well plates for culturing HUVECs prior to stimulation. 
The Carter lab routinely uses 6-well plates for ELISA assays. However, the 6-well plates 
would prevent the examination of a large number of different conditions due to the limited 
number of available wells and hence would make the construction of a complete dose-
response curve challenging. The alternative culture method, the 24-well plate, has not been 
used in the Carter lab before for ELISA assays and therefore I initially proceeded by 
determining the accuracy and reproducibility of secretion data obtained from cells cultivated 
on 24-well plates as opposed to 6-well plates. Hence, a low (0.05 µM), medium (1.0 µM), 
and high (5 µM) concentration of ionomycin was applied to confluent HUVECs grown in 
wells on either a 6-well or a 24-well plate. The same volume of cells was seeded into each 
well relative to the surface area available for growth. The results of this preliminary 
experiment are shown in Figure One. As can be seen, a clear dose-dependent secretory 
response is obvious from cells grown in both the 6- and 24-well plate. However, cells grown 
in the 24-well plate show greater absolute quantities of proregion secreted compared with 
those from the 6-well plate. Hence, due to the fact that the 24-well plate yielded higher 
quantities of secreted proregion and also allows considerably more conditions to be screened 
in a single experiment it was decided to use the 24-well plate format for all subsequent 
assays.  
 
 
 
2.0 Creating the dose-response curve:  
 
Once the technicalities of the experimental design had been established I then 
proceeded to construct an expanded dose-response curve using un-transfected HUVECs 
grown in 24-well plates. An equal volume of cell suspension was seeded into each well 48 
hours prior to stimulation. Cells were stimulated with ionomycin at a concentration of 0 µM, 
0.01 µM, 0.03 µM, 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM, or 20 µM. Following stimulation, 
media was collected from each well and the quantity of secreted proregion was determined by 
a proregion ELISA. The raw data from a representative experiment is shown in Table 1. The 
data is expressed as arbitrary units relative to the quantity of proregion in a known standard. 
To obtain a sufficient range of ionomycin concentrations the experiments were carried out 
over two separate 24-well plates. This experimental design was useful because in order to 
ensure that the same number of cells were present in each well, two conditions (0.3 µM and 1 
µM) were represented on both plates. The proregion ELISA was repeated using lysates 
extracted from stimulated cells in these wells. The quantity of proregion contained within 
these cells grown on different plates but representing the same conditions was shown to be 
not significantly different (3.25 versus 3.03 for 0.3 µM, p-value ≥ 0.05; 2.51 versus 2.50 for 1 
µM, p-value ≥ 0.05). The full dose-response curve representing the combined results of three 
individual experiments is shown in Figure Two. As individual endothelial cell cultures are 
heterogeneous and the absolute quantity of proregion secreted varied between cultures, the 
results have been normalized to the quantity of proregion secreted at 10 µM ionomycin. It is 
interesting to note that maximal secretion occurred at 3 µM, and decreased between 10 and 
20 µM. It may be that higher concentrations of ionomycin lead to an excessive calcium influx 
into the cell resulting in apoptosis. This would explain the decreased quantity of proregion 
secreted at ionomycin concentrations higher than 3 µM.  
Therefore, this assay has allowed me to construct a reproducible dose-response curve 
for proregion secretion against increasing ionomycin concentrations. It is now possible to 
manipulate the expression profile of the various SYTs within HUVECs to determine the 
effect on calcium sensitivity. 
 
 
 
 
 
 Ionomycin Concentration (µM) 
 
Mean of Three Replicates 
(Arbitrary Units of 
Proregion Secretion) 
Standard 
Deviation 
Ethanol Control (0) 3.067 0.06565 
0.01 6.86 0.06928 
0.03 10.73 0.01882 
0.1 14.90 0.28143 
0.3 22.29 0.61789 
1 32.80 1.57206 
3 56.49 9.16858 
10 42.79 2.3362 
 
- Table One, showing the raw data obtained from a representative assay of 
proregion secretion versus increasing concentrations of ionomycin.  Data is 
expressed as arbitrary units relative to the quantity of proregion in a known 
standard. 
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- Figure One showing the secretory dose-response seen following the 
application of varying concentrations of ionomycin to cells grown in wells 
on either a 6-well or 24-well plate, as indicated. The x-axis represents 
arbitrary units of secreted proregion compared to a known standard, as 
determined by the plate reader. Note the significantly higher quantity of 
proregion secreted from cells cultured in a 24-well plate compared with 
those cultured in a 6-well plate.  
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- Figure Two, showing the dose-response curve of proregion secretion 
against increasing concentrations of ionomycin. Results from three 
individual experiments have been normalized to the maximum secretion 
obtained at 10 µM. The lowest value represents the basal secretion seen 
when an ethanol control is used in place of ionomycin.   
 
 
 
 
 
 
Appendix 2.0: The Determination of the Expression of SYT VII Isoforms in HUVECs: 
 
 
 
 
 
The agarose gel above shows the RT‐PCR of HUVEC mRNA using primers specific for the 
highly-spliced spacer region of SYT VII. The major isoform of SYTVII, SYTVII‐α, is visible 
at approximately 300 bp and the minor isoform, SYTVII‐β, is present at approximately 450 
bp. Although faint, this top band is typical of published work describing the SYTVII‐β 
isoform which is expressed at much lower levels compared with SYTVII‐α (Fukuda et al. 
2002). Hence, preliminary investigations suggest that HUVECs express SYTVII-α and –β. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3.0: Screening the α-SYT I antibody for non-specific binding, auto-
fluorescence, and the bleed-through effect.  
 
 
 
- Figure One, showing the results of screening the α-SYT I antibody for 
background fluorescence, non-specific binding, and the bleed-through 
effect (i.e. the leaking of signal between channels due to saturation of the 
image). Panels a-c show the results of omitting the VWF stain entirely. 
Panels d-f show the results of omitting the SYT I stain entirely. Panels g-i 
show the results of omitting the SYT I primary antibody. Panels j-l show 
the results of omitting the SYT I secondary antibody (α-mouse CY-2). 
Panels a, d, g, and j show the red channels. Panels b, e, h, and k show the 
green channels. Panels c, f, i and l show the merged channels.  
 
